{"version": "v2.0", "data": [{"id": "3708949_1_0", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "3708949_1_1", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "2300 mg in 3 days"}, {"id": "3708949_1_2", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_1_3", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "parenteral"}, {"id": "3708949_1_4", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_1_5", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_1_6", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "congestive heart failure"}, {"id": "3708949_1_7", "context": "After therapy with parenteral amiodarone (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.", "question": "adverse event. Treatment, parenteral amiodarone (2300 mg in 3 days) and other measures. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_3_8", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Subject, a patient, with a 30-year history of rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_3_9", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Subject, a patient, with a 30-year history of rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_3_10", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Subject, a patient, with a 30-year history of rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "a"}, {"id": "8467620_3_11", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Subject, a patient, with a 30-year history of rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_3_12", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Subject, a patient, with a 30-year history of rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_3_13", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8467620_3_14", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low dose"}, {"id": "8467620_3_15", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "weekly"}, {"id": "8467620_3_16", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_3_17", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_3_18", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "10-month period."}, {"id": "8467620_3_19", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "8467620_3_20", "context": "We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking low dose methotrexate weekly over a 10-month period.", "question": "adverse event. Treatment, low dose methotrexate weekly over a 10-month period. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_6_21", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1422497_6_22", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1422497_6_23", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1422497_6_24", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1422497_6_25", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1422497_6_26", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alum"}, {"id": "1422497_6_27", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_6_28", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_6_29", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "irrigation"}, {"id": "1422497_6_30", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_6_31", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_6_32", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal impairment"}, {"id": "1422497_6_33", "context": "We recommend the cautious use of alum irrigation in patients with renal impairment and monitoring of serum aluminum levels to prevent excessive accumulation and toxicity.", "question": "adverse event. Treatment, alum irrigation. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_3_34", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, a 20-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "20-year-old"}, {"id": "10082597_3_35", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, a 20-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "10082597_3_36", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, a 20-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_3_37", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, a 20-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_3_38", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, a 20-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_3_39", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxaprozin"}, {"id": "10082597_3_40", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_3_41", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_3_42", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_3_43", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_3_44", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_3_45", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "10082597_3_46", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, oxaprozin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_3_47", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, A 44-year-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "44-year-old"}, {"id": "10082597_3_48", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, A 44-year-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "10082597_3_49", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, A 44-year-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_3_50", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, A 44-year-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_3_51", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Subject, A 44-year-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_3_52", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "naproxen"}, {"id": "10082597_3_53", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_3_54", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_3_55", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_3_56", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_3_57", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_3_58", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic low back pain"}, {"id": "10082597_3_59", "context": "RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.", "question": "adverse event. Treatment, naproxen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_1_60", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Subject, middle-aged man who suffered from chronic sinusitis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "middle-aged"}, {"id": "16018164_1_61", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Subject, middle-aged man who suffered from chronic sinusitis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "16018164_1_62", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Subject, middle-aged man who suffered from chronic sinusitis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_1_63", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Subject, middle-aged man who suffered from chronic sinusitis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_1_64", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Subject, middle-aged man who suffered from chronic sinusitis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16018164_1_65", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pseudoephedrine"}, {"id": "16018164_1_66", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_1_67", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily"}, {"id": "16018164_1_68", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ingesting"}, {"id": "16018164_1_69", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_1_70", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "for one year"}, {"id": "16018164_1_71", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic sinusitis"}, {"id": "16018164_1_72", "context": "CASE REPORT: We report a case of intracerebral hemorrhage occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting pseudoephedrine daily for one year.", "question": "adverse event. Treatment, ingesting pseudoephedrine daily for one year. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_1_73", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_1_74", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_1_75", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_1_76", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_1_77", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_1_78", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8467620_1_79", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_1_80", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_1_81", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_1_82", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_1_83", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_1_84", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "8467620_1_85", "context": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_4_86", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14742791_4_87", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14742791_4_88", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14742791_4_89", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14742791_4_90", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14742791_4_91", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pantoprazole"}, {"id": "14742791_4_92", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_4_93", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_4_94", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_4_95", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_4_96", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_4_97", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_4_98", "context": "The Naranjo probability scale suggests a highly probable relationship between AIN and pantoprazole therapy in this patient.", "question": "adverse event. Treatment, pantoprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_11_99", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Subject, fetus. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "fetus"}, {"id": "8442800_11_100", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Subject, fetus. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8442800_11_101", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Subject, fetus. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8442800_11_102", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Subject, fetus. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8442800_11_103", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Subject, fetus. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8442800_11_104", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "8442800_11_105", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_11_106", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8442800_11_107", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8442800_11_108", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_11_109", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8442800_11_110", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_11_111", "context": "In one case, disulfiram was the only potential teratogen exposed to the fetus.", "question": "adverse event. Treatment, disulfiram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_4_112", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Subject, in 2-16% of patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15368548_4_113", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Subject, in 2-16% of patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15368548_4_114", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Subject, in 2-16% of patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "2-16%"}, {"id": "15368548_4_115", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Subject, in 2-16% of patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15368548_4_116", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Subject, in 2-16% of patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15368548_4_117", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "15368548_4_118", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_4_119", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_4_120", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_4_121", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_4_122", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_4_123", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "a variety of pediatric neoplasms"}, {"id": "15368548_4_124", "context": "Pancreatitis has been noted to be a complication in 2-16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms.", "question": "adverse event. Treatment, L-asparaginase for a variety of pediatric neoplasms. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_2_125", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin"}, {"id": "21630612_2_126", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_2_127", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_2_128", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_2_129", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_2_130", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_2_131", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_2_132", "context": "Myopathy, including rhabdomyolysis, is a well-known, albeit rare complication of statin therapy.", "question": "adverse event. Treatment, statin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_1_133", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "18855892_1_134", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_1_135", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_1_136", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_1_137", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_1_138", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_1_139", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_1_140", "context": "Management and successful desensitization in methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12166705_1_141", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Mitomycin-C"}, {"id": "12166705_1_142", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12166705_1_143", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12166705_1_144", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12166705_1_145", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12166705_1_146", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12166705_1_147", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12166705_1_148", "context": "Mitomycin-C induced hemolytic uremic syndrome: a case report.", "question": "adverse event. Treatment, Mitomycin-C. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15588385_1_149", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "15588385_1_150", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_1_151", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_1_152", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_1_153", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_1_154", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_1_155", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hyperthyroidism"}, {"id": "15588385_1_156", "context": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism.", "question": "adverse event. Treatment, propylthiouracil (PTU). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_1_157", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_1_158", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_1_159", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_1_160", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_1_161", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_1_162", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diphenylhydantoin"}, {"id": "748238_1_163", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "chronic"}, {"id": "748238_1_164", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_1_165", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_1_166", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_1_167", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_1_168", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_1_169", "context": "Monoclonal gammopathy and subsequent multiple myeloma in a patient on chronic diphenylhydantoin therapy.", "question": "adverse event. Treatment, chronic diphenylhydantoin therapy.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_3_170", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Subject, a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3359700_3_171", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Subject, a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3359700_3_172", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Subject, a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3359700_3_173", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Subject, a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3359700_3_174", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Subject, a patient with systemic lupus erythematosus and tubulointerstitial renal disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3359700_3_175", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine A"}, {"id": "3359700_3_176", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_3_177", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_3_178", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_3_179", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_3_180", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_3_181", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "systemic lupus erythematosus; tubulointerstitial renal disease"}, {"id": "3359700_3_182", "context": "Unexpected severe reversible cyclosporine A-induced nephrotoxicity in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.", "question": "adverse event. Treatment, cyclosporine A. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_2_183", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "AZ"}, {"id": "9352164_2_184", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_2_185", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_2_186", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_2_187", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_2_188", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_2_189", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_2_190", "context": "As far as we know, this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3693034_1_191", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-fluorocytosine; amphotericin B"}, {"id": "3693034_1_192", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3693034_1_193", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3693034_1_194", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3693034_1_195", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "19 days"}, {"id": "3693034_1_196", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3693034_1_197", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3693034_1_198", "context": "Toxic epidermal necrolysis resulted after 19 days of treatment with 5-fluorocytosine and amphotericin B.", "question": "adverse event. Treatment, 19 days of treatment with 5-fluorocytosine and amphotericin B. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "5-fluorocytosine; amphotericin B"}, {"id": "16018164_4_199", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenylpropanolamine"}, {"id": "16018164_4_200", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_4_201", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_4_202", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_4_203", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_4_204", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_4_205", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_4_206", "context": "Since 1979, over 30 published case reports have documented the relationship between phenylpropanolamine and stroke.", "question": "adverse event. Treatment, phenylpropanolamine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_1_207", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Subject, A 61-year-old woman with no apparent risk factors for liver injury. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "61-year-old"}, {"id": "18523232_1_208", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Subject, A 61-year-old woman with no apparent risk factors for liver injury. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "18523232_1_209", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Subject, A 61-year-old woman with no apparent risk factors for liver injury. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_1_210", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Subject, A 61-year-old woman with no apparent risk factors for liver injury. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_1_211", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Subject, A 61-year-old woman with no apparent risk factors for liver injury. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_1_212", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "itraconazole"}, {"id": "18523232_1_213", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "200 mg"}, {"id": "18523232_1_214", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "18523232_1_215", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "orally"}, {"id": "18523232_1_216", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_1_217", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_1_218", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "onychomycosis"}, {"id": "18523232_1_219", "context": "CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.", "question": "adverse event. Treatment, long-term course of pulse itraconazole therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_4_220", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Subject, a case of chronic renal failure in a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_4_221", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Subject, a case of chronic renal failure in a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_4_222", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Subject, a case of chronic renal failure in a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_4_223", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Subject, a case of chronic renal failure in a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_4_224", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Subject, a case of chronic renal failure in a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "chronic renal failure"}, {"id": "9352164_4_225", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "AZ"}, {"id": "9352164_4_226", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_4_227", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_4_228", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_4_229", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_4_230", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_4_231", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_4_232", "context": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication.", "question": "adverse event. Treatment, AZ. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_1_233", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, a pregnant patient with myotonic dystrophy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16192734_1_234", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, a pregnant patient with myotonic dystrophy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16192734_1_235", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, a pregnant patient with myotonic dystrophy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16192734_1_236", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, a pregnant patient with myotonic dystrophy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16192734_1_237", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, a pregnant patient with myotonic dystrophy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "myotonic dystrophy"}, {"id": "16192734_1_238", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ritodrine hydrochloride"}, {"id": "16192734_1_239", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_1_240", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_1_241", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "16192734_1_242", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_1_243", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_1_244", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_1_245", "context": "Rhabdomyolysis caused by tocolysis with oral ritodrine hydrochloride in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, tocolysis with oral ritodrine hydrochloride. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "536470_2_246", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, a patient with a renal tubular defect. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "536470_2_247", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, a patient with a renal tubular defect. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "536470_2_248", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, a patient with a renal tubular defect. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "536470_2_249", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, a patient with a renal tubular defect. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "536470_2_250", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, a patient with a renal tubular defect. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal tubular defect"}, {"id": "536470_2_251", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulindac; warfarin"}, {"id": "536470_2_252", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "536470_2_253", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "536470_2_254", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "536470_2_255", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "536470_2_256", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "536470_2_257", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "536470_2_258", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac; had been anticoagulated with warfarin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; sulindac"}, {"id": "536470_2_259", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "536470_2_260", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "536470_2_261", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "536470_2_262", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "536470_2_263", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "536470_2_264", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "536470_2_265", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "536470_2_266", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, warfarin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "536470_2_267", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, normal male volunteers. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "536470_2_268", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, normal male volunteers. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "536470_2_269", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, normal male volunteers. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "536470_2_270", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, normal male volunteers. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "536470_2_271", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Subject, normal male volunteers. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "536470_2_272", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulindac"}, {"id": "536470_2_273", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "536470_2_274", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "536470_2_275", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "536470_2_276", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "536470_2_277", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "536470_2_278", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "536470_2_279", "context": "While sulindac failed to affect significantly warfarin-induced hypoprothrombinemia in normal male volunteers, it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin.", "question": "adverse event. Treatment, sulindac. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_7_280", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8912599_7_281", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_7_282", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_7_283", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_7_284", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_7_285", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_7_286", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriatic plaques"}, {"id": "8912599_7_287", "context": "Painful erosion of psoriatic plaques is a less common sign of methotrexate toxicity that may precede evidence of bone marrow suppression.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_2_288", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Subject, an acromegalic patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16728538_2_289", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Subject, an acromegalic patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16728538_2_290", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Subject, an acromegalic patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16728538_2_291", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Subject, an acromegalic patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16728538_2_292", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Subject, an acromegalic patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16728538_2_293", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegvisomant; octreotide"}, {"id": "16728538_2_294", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_2_295", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_2_296", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_2_297", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_2_298", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_2_299", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acromegalic"}, {"id": "16728538_2_300", "context": "Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.", "question": "adverse event. Treatment, combined treatment with pegvisomant and octreotide long-acting repeatable. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "pegvisomant; octreotide"}, {"id": "7978578_2_301", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Subject, a patient in a promethazine-induced coma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7978578_2_302", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Subject, a patient in a promethazine-induced coma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7978578_2_303", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Subject, a patient in a promethazine-induced coma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7978578_2_304", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Subject, a patient in a promethazine-induced coma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7978578_2_305", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Subject, a patient in a promethazine-induced coma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7978578_2_306", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "flumazenil; promethazine"}, {"id": "7978578_2_307", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7978578_2_308", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7978578_2_309", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7978578_2_310", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7978578_2_311", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7978578_2_312", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "coma"}, {"id": "7978578_2_313", "context": "We report the first case of a patient in a promethazine-induced coma responding to treatment with flumazenil.", "question": "potential therapeutic event. Treatment, treatment with flumazenil. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18425523_3_314", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Subject, patients 1 and 3; in patient 2. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18425523_3_315", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Subject, patients 1 and 3; in patient 2. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18425523_3_316", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Subject, patients 1 and 3; in patient 2. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18425523_3_317", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Subject, patients 1 and 3; in patient 2. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18425523_3_318", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Subject, patients 1 and 3; in patient 2. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18425523_3_319", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ranibizumab; ranibizumab"}, {"id": "18425523_3_320", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_3_321", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_3_322", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18425523_3_323", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "1 month after the second; 1 month after the first"}, {"id": "18425523_3_324", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_3_325", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_3_326", "context": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.", "question": "adverse event. Treatment, 1 month after the second ranibizumab injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_5_327", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zuclopenthixol"}, {"id": "12022905_5_328", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_5_329", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_5_330", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_5_331", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_5_332", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_5_333", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_5_334", "context": "Priapism associated with zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_3_335", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "12488741_3_336", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_3_337", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12488741_3_338", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12488741_3_339", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_3_340", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12488741_3_341", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_3_342", "context": "Reversible MR imaging and MR spectroscopy abnormalities in association with metronidazole therapy.", "question": "adverse event. Treatment, metronidazole therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_3_343", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "15857283_3_344", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_3_345", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_3_346", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_3_347", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_3_348", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_3_349", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_3_350", "context": "PURPOSE: The aim of this study was to report on the possible development of corneal endothelial deposits resulting from the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_3_351", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Subject, a child undergoing his second hematopoietic stem cell transplant (HSCT). Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "19318596_3_352", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Subject, a child undergoing his second hematopoietic stem cell transplant (HSCT). Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "his"}, {"id": "19318596_3_353", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Subject, a child undergoing his second hematopoietic stem cell transplant (HSCT). Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_3_354", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Subject, a child undergoing his second hematopoietic stem cell transplant (HSCT). Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_3_355", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Subject, a child undergoing his second hematopoietic stem cell transplant (HSCT). Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_3_356", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcineurin"}, {"id": "19318596_3_357", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_3_358", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_3_359", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_3_360", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_3_361", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_3_362", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hematopoietic stem cell transplant"}, {"id": "19318596_3_363", "context": "OBJECTIVE: To report a case of calcineurin-induced pain syndrome (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).", "question": "adverse event. Treatment, calcineurin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_4_364", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Subject, a male patient with psoriasis and hypertension. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14684937_4_365", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Subject, a male patient with psoriasis and hypertension. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "14684937_4_366", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Subject, a male patient with psoriasis and hypertension. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14684937_4_367", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Subject, a male patient with psoriasis and hypertension. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14684937_4_368", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Subject, a male patient with psoriasis and hypertension. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14684937_4_369", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacalcitol; thiazide"}, {"id": "14684937_4_370", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_4_371", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_4_372", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ointment"}, {"id": "14684937_4_373", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_4_374", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_4_375", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriasis; hypertension"}, {"id": "14684937_4_376", "context": "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and hypercalcemia.", "question": "adverse event. Treatment, tacalcitol ointment and thiazide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "tacalcitol; thiazide"}, {"id": "16341621_3_377", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium hydroxylapatite"}, {"id": "16341621_3_378", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_3_379", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_3_380", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "16341621_3_381", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_3_382", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_3_383", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_3_384", "context": "To our knowledge, this is the first granulomatous reaction described after calcium hydroxylapatite injection.", "question": "adverse event. Treatment, calcium hydroxylapatite injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_3_385", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX; non-steroidal, anti-inflammatory drugs"}, {"id": "15595320_3_386", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_3_387", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_3_388", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_3_389", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_3_390", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_3_391", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_3_392", "context": "Previous studies have demonstrated the interaction of MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.", "question": "adverse event. Treatment, MTX and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3868420_1_393", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Subject, a patient with alveolar hydatid disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3868420_1_394", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Subject, a patient with alveolar hydatid disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3868420_1_395", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Subject, a patient with alveolar hydatid disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3868420_1_396", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Subject, a patient with alveolar hydatid disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3868420_1_397", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Subject, a patient with alveolar hydatid disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3868420_1_398", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mebendazole"}, {"id": "3868420_1_399", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3868420_1_400", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3868420_1_401", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3868420_1_402", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3868420_1_403", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3868420_1_404", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "alveolar hydatid disease"}, {"id": "3868420_1_405", "context": "We present a case report of a patient with alveolar hydatid disease, whose treatment with mebendazole was brief due to side effects of alopecia and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.", "question": "adverse event. Treatment, mebendazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_1_406", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Subject, approximately 0.67% of patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3174043_1_407", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Subject, approximately 0.67% of patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3174043_1_408", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Subject, approximately 0.67% of patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "0.67%"}, {"id": "3174043_1_409", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Subject, approximately 0.67% of patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3174043_1_410", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Subject, approximately 0.67% of patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3174043_1_411", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Niacin"}, {"id": "3174043_1_412", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "3174043_1_413", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_1_414", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_1_415", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_1_416", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_1_417", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_1_418", "context": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67% of patients taking high doses of the drug.", "question": "adverse event. Treatment, Niacin; high doses. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6854698_1_419", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Subject, tuberculosis patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6854698_1_420", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Subject, tuberculosis patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6854698_1_421", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Subject, tuberculosis patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6854698_1_422", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Subject, tuberculosis patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6854698_1_423", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Subject, tuberculosis patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6854698_1_424", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isoniazid"}, {"id": "6854698_1_425", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6854698_1_426", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6854698_1_427", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6854698_1_428", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6854698_1_429", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6854698_1_430", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "tuberculosis"}, {"id": "6854698_1_431", "context": "When tuberculosis patients on isoniazid eat certain varieties of fish they may develop a histamine reaction.", "question": "adverse event. Treatment, isoniazid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_2_432", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zuclopenthixol"}, {"id": "12022905_2_433", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_2_434", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_2_435", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_2_436", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_2_437", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_2_438", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_2_439", "context": "CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.", "question": "adverse event. Treatment, zuclopenthixol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14766993_2_440", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "14766993_2_441", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14766993_2_442", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14766993_2_443", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14766993_2_444", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14766993_2_445", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14766993_2_446", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "several thromboembolic events"}, {"id": "14766993_2_447", "context": "To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events.", "question": "adverse event. Treatment, warfarin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17167851_1_448", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyproterone acetate"}, {"id": "17167851_1_449", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17167851_1_450", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17167851_1_451", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17167851_1_452", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17167851_1_453", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17167851_1_454", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17167851_1_455", "context": "Hepatotoxicity induced by cyproterone acetate: a report of three cases.", "question": "adverse event. Treatment, cyproterone acetate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14561622_1_456", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "14561622_1_457", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_1_458", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_1_459", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "14561622_1_460", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_1_461", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_1_462", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_1_463", "context": "Neurotoxicity of intrathecal methotrexate: MR imaging findings.", "question": "adverse event. Treatment, intrathecal methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_2_464", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Isonicotinic acid hydrazide"}, {"id": "11804071_2_465", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_2_466", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_2_467", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_2_468", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_2_469", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_2_470", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_2_471", "context": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.", "question": "adverse event. Treatment, Isonicotinic acid hydrazide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_5_472", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Subject, one case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_5_473", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Subject, one case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_5_474", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Subject, one case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "one"}, {"id": "18523232_5_475", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Subject, one case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_5_476", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Subject, one case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_5_477", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "itraconazole"}, {"id": "18523232_5_478", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_5_479", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_5_480", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_5_481", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_5_482", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_5_483", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "onychomycosis"}, {"id": "18523232_5_484", "context": "Only one case of severe symptomatic hepatitis occurring after pulse therapy with itraconazole for onychomycosis and requiring transplantation has been reported previously.", "question": "adverse event. Treatment, pulse therapy with itraconazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_3_485", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trazodone"}, {"id": "4066620_3_486", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_3_487", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_3_488", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_3_489", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_3_490", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_3_491", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_3_492", "context": "The elicitation of a movement disorder by trazodone: case report.", "question": "adverse event. Treatment, trazodone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6572542_2_493", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CCNU"}, {"id": "6572542_2_494", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "6572542_2_495", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_2_496", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_2_497", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_2_498", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_2_499", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myeloid leukemia"}, {"id": "6572542_2_500", "context": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia.", "question": "adverse event. Treatment, high doses of CCNU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_2_501", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Subject, dihydropyrimidine dehydrogenase (DPD) deficiency. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_2_502", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Subject, dihydropyrimidine dehydrogenase (DPD) deficiency. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_2_503", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Subject, dihydropyrimidine dehydrogenase (DPD) deficiency. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9007910_2_504", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Subject, dihydropyrimidine dehydrogenase (DPD) deficiency. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_2_505", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Subject, dihydropyrimidine dehydrogenase (DPD) deficiency. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "dihydropyrimidine dehydrogenase (DPD) deficiency"}, {"id": "9007910_2_506", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-fluorouracil"}, {"id": "9007910_2_507", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_2_508", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_2_509", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "9007910_2_510", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_2_511", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_2_512", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cancer"}, {"id": "9007910_2_513", "context": "PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially lethal adverse reactions following 5-fluorouracil (5-FU)-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU)-based chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_3_514", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "verapamil"}, {"id": "6697887_3_515", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_3_516", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_3_517", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6697887_3_518", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_3_519", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_3_520", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_3_521", "context": "We report a case of sustained hypotension after administration of parenteral verapamil.", "question": "adverse event. Treatment, administration of parenteral verapamil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10212021_4_522", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Methadone"}, {"id": "10212021_4_523", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10212021_4_524", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10212021_4_525", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10212021_4_526", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10212021_4_527", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10212021_4_528", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "human immunodeficiency viral infection"}, {"id": "10212021_4_529", "context": "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse.", "question": "potential therapeutic event. Treatment, Methadone. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21515865_9_530", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCG; phytonadione"}, {"id": "21515865_9_531", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_9_532", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_9_533", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_9_534", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "a week earlier; after his fourth treatment"}, {"id": "21515865_9_535", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_9_536", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_9_537", "context": "Each time he arrived at the anticoagulation clinic after his BCG therapy, his INR was supratherapeutic, except after his fourth treatment (INR of 2.5), which can be explained by residual effects from the phytonadione he received a week earlier.", "question": "adverse event. Treatment, BCG; phytonadione. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "BCG; phytonadione"}, {"id": "22677303_3_538", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A 70-year-old man. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "70-year-old"}, {"id": "22677303_3_539", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A 70-year-old man. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "22677303_3_540", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A 70-year-old man. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22677303_3_541", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A 70-year-old man. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22677303_3_542", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A 70-year-old man. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22677303_3_543", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin"}, {"id": "22677303_3_544", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_3_545", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22677303_3_546", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22677303_3_547", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_3_548", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22677303_3_549", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "atrial fibrillation"}, {"id": "22677303_3_550", "context": "A 70-year-old man had been treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1703754_1_551", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Subject, a child with systemic lupus erythematosus. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "1703754_1_552", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Subject, a child with systemic lupus erythematosus. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1703754_1_553", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Subject, a child with systemic lupus erythematosus. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1703754_1_554", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Subject, a child with systemic lupus erythematosus. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1703754_1_555", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Subject, a child with systemic lupus erythematosus. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1703754_1_556", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisolone; azathioprine"}, {"id": "1703754_1_557", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1703754_1_558", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1703754_1_559", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1703754_1_560", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1703754_1_561", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1703754_1_562", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "systemic lupus erythematosus"}, {"id": "1703754_1_563", "context": "This is a case report of fatal cryptococcal meningitis in a child with systemic lupus erythematosus being treated with prednisolone and azathioprine.", "question": "adverse event. Treatment, prednisolone and azathioprine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "prednisolone; azathioprine"}, {"id": "9352164_1_564", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Subject, a patient with chronic renal failure. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_1_565", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Subject, a patient with chronic renal failure. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9352164_1_566", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Subject, a patient with chronic renal failure. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_1_567", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Subject, a patient with chronic renal failure. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_1_568", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Subject, a patient with chronic renal failure. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "chronic renal failure"}, {"id": "9352164_1_569", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acetazolamide"}, {"id": "9352164_1_570", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_1_571", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_1_572", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_1_573", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_1_574", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_1_575", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_1_576", "context": "Acute hemorrhagic gastritis associated with acetazolamide intoxication in a patient with chronic renal failure.", "question": "adverse event. Treatment, acetazolamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_2_577", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trazodone"}, {"id": "4066620_2_578", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4066620_2_579", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_2_580", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_2_581", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_2_582", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_2_583", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4066620_2_584", "context": "Although the movement disorder could not with certainty be attributed to trazodone alone, the drug at least acted as an eliciting agent.", "question": "adverse event. Treatment, trazodone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_2_585", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "itraconazole"}, {"id": "18523232_2_586", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "Prolonged exposure"}, {"id": "18523232_2_587", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_2_588", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "continuously or intermittently"}, {"id": "18523232_2_589", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_2_590", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_2_591", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_2_592", "context": "CONCLUSIONS: Prolonged exposure to itraconazole, administered either continuously or intermittently, may precipitate severe and irreversible hepatotoxic events.", "question": "adverse event. Treatment, Prolonged exposure to itraconazole, administered either continuously or intermittently. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "507889_1_593", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Subject, two patients with mycosis fungoides. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "507889_1_594", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Subject, two patients with mycosis fungoides. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "507889_1_595", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Subject, two patients with mycosis fungoides. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "507889_1_596", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Subject, two patients with mycosis fungoides. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "507889_1_597", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Subject, two patients with mycosis fungoides. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "507889_1_598", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "psoralens"}, {"id": "507889_1_599", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "507889_1_600", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "507889_1_601", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "507889_1_602", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "507889_1_603", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "507889_1_604", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "mycosis fungoides"}, {"id": "507889_1_605", "context": "In two patients with mycosis fungoides, a squamous cell carcinoma developed during therapy with psoralens plus long-wave ultraviolet radiation (PUVA).", "question": "adverse event. Treatment, psoralens plus long-wave ultraviolet radiation (PUVA). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_1_606", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Subject, a patient with acute promyelocytic leukemia.. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15663666_1_607", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Subject, a patient with acute promyelocytic leukemia.. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15663666_1_608", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Subject, a patient with acute promyelocytic leukemia.. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15663666_1_609", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Subject, a patient with acute promyelocytic leukemia.. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15663666_1_610", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Subject, a patient with acute promyelocytic leukemia.. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15663666_1_611", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "all-trans retinoic acid"}, {"id": "15663666_1_612", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_1_613", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15663666_1_614", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15663666_1_615", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_1_616", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15663666_1_617", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute promyelocytic leukemia"}, {"id": "15663666_1_618", "context": "Scrotal ulceration induced by all-trans retinoic acid in a patient with acute promyelocytic leukemia.", "question": "adverse event. Treatment, all-trans retinoic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_1_619", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Subject, A 61 year-old male patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "61 year-old"}, {"id": "6693840_1_620", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Subject, A 61 year-old male patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "6693840_1_621", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Subject, A 61 year-old male patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6693840_1_622", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Subject, A 61 year-old male patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6693840_1_623", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Subject, A 61 year-old male patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6693840_1_624", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline"}, {"id": "6693840_1_625", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_1_626", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_1_627", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_1_628", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_1_629", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_1_630", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_1_631", "context": "A 61 year-old male patient developed gynecomastia after starting theophylline.", "question": "adverse event. Treatment, theophylline. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_3_632", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dextran-40"}, {"id": "2483959_3_633", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_3_634", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_3_635", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_3_636", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_3_637", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_3_638", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_3_639", "context": "Several possible explanations of the mechanism of renal failure associated with the use of dextran-40 are discussed.", "question": "adverse event. Treatment, dextran-40. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_2_640", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Subject, a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20349794_2_641", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Subject, a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20349794_2_642", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Subject, a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20349794_2_643", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Subject, a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20349794_2_644", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Subject, a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20349794_2_645", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin"}, {"id": "20349794_2_646", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_2_647", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_2_648", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_2_649", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_2_650", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_2_651", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "advanced-stage large cell neuroendocrine carcinoma of the cervix"}, {"id": "20349794_2_652", "context": "We present a case of the syndrome of inappropriate antidiuretic hormone (SIADH) secondary to cisplatin therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.", "question": "adverse event. Treatment, cisplatin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_5_653", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Subject, An 80-year-old white female. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "80-year-old"}, {"id": "18675768_5_654", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Subject, An 80-year-old white female. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "female"}, {"id": "18675768_5_655", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Subject, An 80-year-old white female. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18675768_5_656", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Subject, An 80-year-old white female. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "white"}, {"id": "18675768_5_657", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Subject, An 80-year-old white female. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "mild cognitive impairment"}, {"id": "18675768_5_658", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "propafenone"}, {"id": "18675768_5_659", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "900 mg/d"}, {"id": "18675768_5_660", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18675768_5_661", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18675768_5_662", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_5_663", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ">10 years"}, {"id": "18675768_5_664", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "paroxysmal atrial fibrillation"}, {"id": "18675768_5_665", "context": "An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking propafenone 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.", "question": "potential therapeutic event. Treatment, propafenone 900 mg/d for >10 years. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20925534_12_666", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Subject, 109 patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_12_667", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Subject, 109 patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_12_668", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Subject, 109 patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "109"}, {"id": "20925534_12_669", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Subject, 109 patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_12_670", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Subject, 109 patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_12_671", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole; placebo"}, {"id": "20925534_12_672", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_12_673", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_12_674", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_12_675", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_12_676", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_12_677", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_12_678", "context": "A total of 109 patients had a cardiovascular event, with event rates of 4.9% with omeprazole and 5.7% with placebo (hazard ratio with omeprazole, 0.99; 95% CI, 0.68 to 1.44; P = 0.96); high-risk subgroups did not show significant heterogeneity.", "question": "adverse event. Treatment, 4.9% with omeprazole and 5.7% with placebo. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_10_679", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zomepirac"}, {"id": "6731466_10_680", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_10_681", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_10_682", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_10_683", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_10_684", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_10_685", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_10_686", "context": "The mechanism of anaphylactoid reaction to zomepirac in this case, therefore, remains unclear.", "question": "adverse event. Treatment, zomepirac. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_1_687", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "18203308_1_688", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_1_689", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_1_690", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_1_691", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_1_692", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_1_693", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_1_694", "context": "New onset of CD may be considered as an immune-mediated injury induced by etanercept.", "question": "adverse event. Treatment, etanercept. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_2_695", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin"}, {"id": "11109149_2_696", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_2_697", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_2_698", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_2_699", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_2_700", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_2_701", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_2_702", "context": "This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.", "question": "adverse event. Treatment, bleomycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24918555_1_703", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Subject, patients with severe recalcitrant nodular acne. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "24918555_1_704", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Subject, patients with severe recalcitrant nodular acne. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "24918555_1_705", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Subject, patients with severe recalcitrant nodular acne. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24918555_1_706", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Subject, patients with severe recalcitrant nodular acne. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24918555_1_707", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Subject, patients with severe recalcitrant nodular acne. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24918555_1_708", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "isotretinoin-Lidose"}, {"id": "24918555_1_709", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24918555_1_710", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24918555_1_711", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24918555_1_712", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24918555_1_713", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24918555_1_714", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe recalcitrant nodular acne"}, {"id": "24918555_1_715", "context": "Results of a Phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-Lidose in patients with severe recalcitrant nodular acne.", "question": "potential therapeutic event. Treatment, isotretinoin-Lidose. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16490518_4_716", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "corticosteroid"}, {"id": "16490518_4_717", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_4_718", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_4_719", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16490518_4_720", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_4_721", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_4_722", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_4_723", "context": "This treatment has the potential to cause severe vision loss as a result of intractable corticosteroid-induced glaucoma.", "question": "adverse event. Treatment, corticosteroid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3708949_4_724", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Subject, this patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_4_725", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Subject, this patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_4_726", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Subject, this patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_4_727", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Subject, this patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_4_728", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Subject, this patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_4_729", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "3708949_4_730", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_4_731", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_4_732", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "parenteral"}, {"id": "3708949_4_733", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_4_734", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_4_735", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_4_736", "context": "Therefore, parenteral amiodarone was implicated as the cause of acute hepatitis in this patient.", "question": "adverse event. Treatment, parenteral amiodarone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_5_737", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "11485141_5_738", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_5_739", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_5_740", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_5_741", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Twenty-four hours"}, {"id": "11485141_5_742", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_5_743", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_5_744", "context": "Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.", "question": "adverse event. Treatment, administration of gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_11_745", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "omeprazole; placebo"}, {"id": "20925534_11_746", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_11_747", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_11_748", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_11_749", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_11_750", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_11_751", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "upper gastrointestinal bleeding"}, {"id": "20925534_11_752", "context": "The rate of overt upper gastrointestinal bleeding was also reduced with omeprazole as compared with placebo (hazard ratio, 0.13; 95% CI, 0.03 to 0.56; P = 0.001).", "question": "potential therapeutic event. Treatment, omeprazole. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8145359_2_753", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenothiazine"}, {"id": "8145359_2_754", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8145359_2_755", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8145359_2_756", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8145359_2_757", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8145359_2_758", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8145359_2_759", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8145359_2_760", "context": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration.", "question": "adverse event. Treatment, phenothiazine overdose. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6340463_4_761", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Subject, Patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6340463_4_762", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Subject, Patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6340463_4_763", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Subject, Patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6340463_4_764", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Subject, Patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6340463_4_765", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Subject, Patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6340463_4_766", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisone"}, {"id": "6340463_4_767", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6340463_4_768", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6340463_4_769", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6340463_4_770", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6340463_4_771", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6340463_4_772", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "graft-versus-host disease."}, {"id": "6340463_4_773", "context": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long-term prednisone for graft-versus-host disease.", "question": "adverse event. Treatment, long-term prednisone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_1_774", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "12477460_1_775", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_1_776", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_1_777", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_1_778", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_1_779", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_1_780", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_1_781", "context": "Atypical endometriosis may act as a precancerous lesion in the process of tamoxifen-induced malignant transformation of endometriosis.", "question": "adverse event. Treatment, tamoxifen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_1_782", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Subject, A 28 year old white schizophrenic male. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "28 year old"}, {"id": "9562211_1_783", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Subject, A 28 year old white schizophrenic male. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "9562211_1_784", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Subject, A 28 year old white schizophrenic male. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9562211_1_785", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Subject, A 28 year old white schizophrenic male. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": "white"}, {"id": "9562211_1_786", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Subject, A 28 year old white schizophrenic male. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9562211_1_787", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "9562211_1_788", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_1_789", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_1_790", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_1_791", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_1_792", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "about one year"}, {"id": "9562211_1_793", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenic"}, {"id": "9562211_1_794", "context": "A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements.", "question": "adverse event. Treatment, risperidone monotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22047557_8_795", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ivacaftor"}, {"id": "22047557_8_796", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22047557_8_797", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22047557_8_798", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22047557_8_799", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22047557_8_800", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22047557_8_801", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "pulmonary exacerbation"}, {"id": "22047557_8_802", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, ivacaftor. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22047557_8_803", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "placebo"}, {"id": "22047557_8_804", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22047557_8_805", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22047557_8_806", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22047557_8_807", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22047557_8_808", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22047557_8_809", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "22047557_8_810", "context": "Subjects receiving ivacaftor were 55% less likely to have a pulmonary exacerbation than were patients receiving placebo, through week 48 (P<0.001).", "question": "potential therapeutic event. Treatment, placebo. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10759907_2_811", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zolmitriptan"}, {"id": "10759907_2_812", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_2_813", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_2_814", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_2_815", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_2_816", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_2_817", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_2_818", "context": "Spinal cord infarction during use of zolmitriptan: a case report.", "question": "adverse event. Treatment, use of zolmitriptan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_3_819", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Subject, a 29-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "29-year-old"}, {"id": "12854039_3_820", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Subject, a 29-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12854039_3_821", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Subject, a 29-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12854039_3_822", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Subject, a 29-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12854039_3_823", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Subject, a 29-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12854039_3_824", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha-2b"}, {"id": "12854039_3_825", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_3_826", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_3_827", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_3_828", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "22-month"}, {"id": "12854039_3_829", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_3_830", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myelogenous leukemia"}, {"id": "12854039_3_831", "context": "Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of recombinant interferon alpha-2b for chronic myelogenous leukemia.", "question": "adverse event. Treatment, 22-month use of recombinant interferon alpha-2b. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_3_832", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chlorpropamide"}, {"id": "6794018_3_833", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_3_834", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_3_835", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_3_836", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_3_837", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_3_838", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_3_839", "context": "These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent.", "question": "adverse event. Treatment, chlorpropamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_2_840", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Risperidone"}, {"id": "9562211_2_841", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_2_842", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_2_843", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_2_844", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_2_845", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_2_846", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_2_847", "context": "Risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, Risperidone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_2_848", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentazocine"}, {"id": "9737132_2_849", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_2_850", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_2_851", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_2_852", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_2_853", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_2_854", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_2_855", "context": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, pentazocine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_2_856", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine A"}, {"id": "3359700_2_857", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3359700_2_858", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_2_859", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_2_860", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3359700_2_861", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_2_862", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_2_863", "context": "Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity.", "question": "adverse event. Treatment, cyclosporine A. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_2_864", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Niacin"}, {"id": "3174043_2_865", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3174043_2_866", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_2_867", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3174043_2_868", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_2_869", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_2_870", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_2_871", "context": "Niacin maculopathy.", "question": "adverse event. Treatment, Niacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22293514_5_872", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etravirine; clobazam"}, {"id": "22293514_5_873", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22293514_5_874", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22293514_5_875", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22293514_5_876", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22293514_5_877", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22293514_5_878", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22293514_5_879", "context": "We report a case in which a potential drug interaction between clobazam and etravirine may have led to increased concentrations of clobazam and its pharmacologically active metabolite, N-desmethylclobazam, causing neurotoxic symptoms.", "question": "adverse event. Treatment, interaction between clobazam and etravirine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "clobazam; etravirine"}, {"id": "11202801_1_880", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11202801_1_881", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11202801_1_882", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11202801_1_883", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11202801_1_884", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11202801_1_885", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "11202801_1_886", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_1_887", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_1_888", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_1_889", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_1_890", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "long-term"}, {"id": "11202801_1_891", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_1_892", "context": "A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.", "question": "adverse event. Treatment, long-term cyclophosphamide treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_3_893", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18076602_3_894", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18076602_3_895", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18076602_3_896", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18076602_3_897", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18076602_3_898", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "18076602_3_899", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_3_900", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_3_901", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_3_902", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_3_903", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_3_904", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_3_905", "context": "We present a case of cutaneous leucocytoclastic vasculitis in which amphotericin B might presumably be the aetiological factor.", "question": "adverse event. Treatment, amphotericin B. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_5_906", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18364401_5_907", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_5_908", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_5_909", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_5_910", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within days of initiation"}, {"id": "18364401_5_911", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_5_912", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_5_913", "context": "There have been numerous case reports of hyperglycemia with olanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_2_914", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Subject, same patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_2_915", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Subject, same patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_2_916", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Subject, same patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_2_917", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Subject, same patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_2_918", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Subject, same patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_2_919", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antiretroviral drug"}, {"id": "23970584_2_920", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_2_921", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_2_922", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_2_923", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_2_924", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_2_925", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_2_926", "context": "This case report describes two severe antiretroviral drug adverse reactions that occurred in the same patient.", "question": "adverse event. Treatment, antiretroviral drug. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_2_927", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thiethylperazine maleate"}, {"id": "16101941_2_928", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_2_929", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_2_930", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_2_931", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_2_932", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_2_933", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_2_934", "context": "We report the first case presenting with successive anaphylactic reaction and extra-pyramidal syndrome after treatment with thiethylperazine maleate (thiethylperazine).", "question": "adverse event. Treatment, treatment with thiethylperazine maleate (thiethylperazine). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_2_935", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dextran-40"}, {"id": "2483959_2_936", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_2_937", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_2_938", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_2_939", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_2_940", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_2_941", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_2_942", "context": "Renal failure associated with the use of dextran-40.", "question": "adverse event. Treatment, dextran-40. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_1_943", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxaliplatinum; 5-fluorouracil"}, {"id": "11510798_1_944", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_1_945", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_1_946", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "11510798_1_947", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_1_948", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_1_949", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_1_950", "context": "Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil and oxaliplatinum combined chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "5-fluorouracil; oxaliplatinum"}, {"id": "11155197_3_951", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "11155197_3_952", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11155197_3_953", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11155197_3_954", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11155197_3_955", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11155197_3_956", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11155197_3_957", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11155197_3_958", "context": "Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.", "question": "adverse event. Treatment, Type II heparin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_3_959", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "atovaquone"}, {"id": "7485371_3_960", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_3_961", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_3_962", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_3_963", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_3_964", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_3_965", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_3_966", "context": "RESULTS: Similar to previous findings of drug-induced vortex keratopathy, atovaquone vortex keratopathy is presumably caused by its lipophilic properties.", "question": "adverse event. Treatment, atovaquone; its lipophilic properties. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_1_967", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin; methotrexate"}, {"id": "11109149_1_968", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_1_969", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_1_970", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_1_971", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_1_972", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_1_973", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11109149_1_974", "context": "Gangrene of the fingertips after bleomycin and methotrexate.", "question": "adverse event. Treatment, bleomycin and methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "methotrexate; bleomycin"}, {"id": "8404753_9_975", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Subject, children. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "8404753_9_976", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Subject, children. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_9_977", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Subject, children. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_9_978", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Subject, children. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_9_979", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Subject, children. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_9_980", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CBZ"}, {"id": "8404753_9_981", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_9_982", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_9_983", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_9_984", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_9_985", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_9_986", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_9_987", "context": "These cases demonstrate that CBZ can induce simple motor tics in children.", "question": "adverse event. Treatment, CBZ. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3964363_2_988", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "3964363_2_989", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "3964363_2_990", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3964363_2_991", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3964363_2_992", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3964363_2_993", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3964363_2_994", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3964363_2_995", "context": "Esophageal spasm following propranolol overdose relieved by glucagon.", "question": "adverse event. Treatment, propranolol overdose. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9352164_3_996", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Subject, She. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9352164_3_997", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Subject, She. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "9352164_3_998", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Subject, She. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9352164_3_999", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Subject, She. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9352164_3_1000", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Subject, She. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9352164_3_1001", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "AZ"}, {"id": "9352164_3_1002", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9352164_3_1003", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_3_1004", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_3_1005", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_3_1006", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_3_1007", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_3_1008", "context": "She was thus diagnosed as having AZ intoxication.", "question": "adverse event. Treatment, AZ. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_3_1009", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oolong tea; caffeine"}, {"id": "10592946_3_1010", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "massive"}, {"id": "10592946_3_1011", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_3_1012", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ingestion"}, {"id": "10592946_3_1013", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_3_1014", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_3_1015", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_3_1016", "context": "Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.", "question": "adverse event. Treatment, massive ingestion of oolong tea. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_2_1017", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15663666_2_1018", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_2_1019", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15663666_2_1020", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15663666_2_1021", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_2_1022", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15663666_2_1023", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15663666_2_1024", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, antibiotic treatment. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15663666_2_1025", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ATRA"}, {"id": "15663666_2_1026", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15663666_2_1027", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15663666_2_1028", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15663666_2_1029", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15663666_2_1030", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15663666_2_1031", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ulcer"}, {"id": "15663666_2_1032", "context": "The ulcer did not respond to antibiotic treatment and healed shortly after withholding ATRA.", "question": "potential therapeutic event. Treatment, withholding ATRA. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9726762_1_1033", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; Gemfibrozil"}, {"id": "9726762_1_1034", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_1_1035", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_1_1036", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_1_1037", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_1_1038", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_1_1039", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_1_1040", "context": "Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.", "question": "adverse event. Treatment, Gemfibrozil-warfarin drug interaction. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "Gemfibrozil; warfarin"}, {"id": "17665812_2_1041", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "17665812_2_1042", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "non-dose-dependent"}, {"id": "17665812_2_1043", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_2_1044", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_2_1045", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_2_1046", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_2_1047", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_2_1048", "context": "Drug-induced eosinophilia is a non-dose-dependent side effect of clozapine.", "question": "adverse event. Treatment, clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_4_1049", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "atovaquone"}, {"id": "7485371_4_1050", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_4_1051", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_4_1052", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_4_1053", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_4_1054", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_4_1055", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_4_1056", "context": "Vortex keratopathy associated with atovaquone.", "question": "adverse event. Treatment, atovaquone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_1_1057", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thalidomide"}, {"id": "18037876_1_1058", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_1_1059", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_1_1060", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_1_1061", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_1_1062", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_1_1063", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_1_1064", "context": "DIAGNOSIS: Sustained ventricular tachycardia possibly owing to thalidomide treatment.", "question": "adverse event. Treatment, thalidomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "910864_1_1065", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acetohexamide; acetazolamide"}, {"id": "910864_1_1066", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "910864_1_1067", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "910864_1_1068", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "910864_1_1069", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "910864_1_1070", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "910864_1_1071", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "910864_1_1072", "context": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide.", "question": "adverse event. Treatment, acetohexamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_1_1073", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ritalin"}, {"id": "17182354_1_1074", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_1_1075", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_1_1076", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_1_1077", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_1_1078", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_1_1079", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_1_1080", "context": "However, an association of Ritalin with glaucoma has been reported.", "question": "adverse event. Treatment, Ritalin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_1_1081", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha"}, {"id": "12854039_1_1082", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_1_1083", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_1_1084", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_1_1085", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_1_1086", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_1_1087", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_1_1088", "context": "After a two-month interruption of interferon administration, natural interferon alpha was given but followed by another episode of the same neurological manifestations.", "question": "adverse event. Treatment, interferon alpha. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25842648_7_1089", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Subject, cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "25842648_7_1090", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Subject, cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "25842648_7_1091", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Subject, cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "25842648_7_1092", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Subject, cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "25842648_7_1093", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Subject, cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "25842648_7_1094", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "SSRIs; fentanyl"}, {"id": "25842648_7_1095", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25842648_7_1096", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25842648_7_1097", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25842648_7_1098", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25842648_7_1099", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25842648_7_1100", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25842648_7_1101", "context": "This article discusses the clinical manifestations of the serotonin syndrome and highlights reported cases of serotonin syndrome specifically related to an interaction between SSRIs and fentanyl, a commonly used opioid in anesthesia practice.", "question": "adverse event. Treatment, SSRIs and fentanyl. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "SSRIs; fentanyl"}, {"id": "2483959_4_1102", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dextran"}, {"id": "2483959_4_1103", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_4_1104", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_4_1105", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_4_1106", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_4_1107", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_4_1108", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_4_1109", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "adverse event. Treatment, dextran. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_4_1110", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "plasma exchange"}, {"id": "2483959_4_1111", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_4_1112", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2483959_4_1113", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2483959_4_1114", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_4_1115", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2483959_4_1116", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "dextran-associated renal failure"}, {"id": "2483959_4_1117", "context": "While the mechanism of dextran-associated renal failure remains unsolved, plasma exchange seems to be effective therapy.", "question": "potential therapeutic event. Treatment, plasma exchange. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9865241_4_1118", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pamidronate"}, {"id": "9865241_4_1119", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_4_1120", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_4_1121", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_4_1122", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_4_1123", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_4_1124", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hypercalcemia secondary to acute vitamin D intoxication"}, {"id": "9865241_4_1125", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "potential therapeutic event. Treatment, pamidronate. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9865241_4_1126", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vitamin D"}, {"id": "9865241_4_1127", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_4_1128", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_4_1129", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_4_1130", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_4_1131", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_4_1132", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_4_1133", "context": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication.", "question": "adverse event. Treatment, vitamin D. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14614357_1_1134", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acenocoumarol"}, {"id": "14614357_1_1135", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14614357_1_1136", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14614357_1_1137", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14614357_1_1138", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14614357_1_1139", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14614357_1_1140", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14614357_1_1141", "context": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9.", "question": "adverse event. Treatment, acenocoumarol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8589490_3_1142", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CHOP"}, {"id": "8589490_3_1143", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_3_1144", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_3_1145", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_3_1146", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_3_1147", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_3_1148", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_3_1149", "context": "We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy.", "question": "adverse event. Treatment, CHOP. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_2_1150", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "12488741_2_1151", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_2_1152", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12488741_2_1153", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12488741_2_1154", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_2_1155", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12488741_2_1156", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_2_1157", "context": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment.", "question": "adverse event. Treatment, metronidazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_1_1158", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alum"}, {"id": "1422497_1_1159", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_1_1160", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_1_1161", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical; irrigations"}, {"id": "1422497_1_1162", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_1_1163", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_1_1164", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_1_1165", "context": "Encephalopathy and seizures induced by intravesical alum irrigations.", "question": "adverse event. Treatment, intravesical alum irrigations. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_17_1166", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Subject, these patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15522120_17_1167", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Subject, these patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15522120_17_1168", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Subject, these patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15522120_17_1169", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Subject, these patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15522120_17_1170", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Subject, these patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15522120_17_1171", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "SSRI"}, {"id": "15522120_17_1172", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_17_1173", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_17_1174", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_17_1175", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_17_1176", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_17_1177", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_17_1178", "context": "Dermal side reactions to SSRI-drugs in these patients may be due to high activity in the serotonergic system at the dermal and epidermo-dermal junctional area rather than a hypersensitivity to the drug molecule itself.", "question": "adverse event. Treatment, SSRI-drugs. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_3_1179", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Subject, A febrile 36-year-old seaman from Mumbai (Bombay). Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "36-year-old"}, {"id": "12659609_3_1180", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Subject, A febrile 36-year-old seaman from Mumbai (Bombay). Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12659609_3_1181", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Subject, A febrile 36-year-old seaman from Mumbai (Bombay). Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12659609_3_1182", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Subject, A febrile 36-year-old seaman from Mumbai (Bombay). Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "Mumbai (Bombay)"}, {"id": "12659609_3_1183", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Subject, A febrile 36-year-old seaman from Mumbai (Bombay). Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "febrile"}, {"id": "12659609_3_1184", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "chloroquine"}, {"id": "12659609_3_1185", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ">5 times the usual dose"}, {"id": "12659609_3_1186", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12659609_3_1187", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12659609_3_1188", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_3_1189", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12659609_3_1190", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "malaria"}, {"id": "12659609_3_1191", "context": "CASE SUMMARY: A febrile 36-year-old seaman from Mumbai (Bombay) was prescribed >5 times the usual dose of chloroquine for malaria diagnosed empirically onboard ship.", "question": "potential therapeutic event. Treatment, >5 times the usual dose of chloroquine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19266307_2_1192", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Subject, two cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19266307_2_1193", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Subject, two cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19266307_2_1194", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Subject, two cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "19266307_2_1195", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Subject, two cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19266307_2_1196", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Subject, two cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19266307_2_1197", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "epirubicin"}, {"id": "19266307_2_1198", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19266307_2_1199", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19266307_2_1200", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "instillations"}, {"id": "19266307_2_1201", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19266307_2_1202", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19266307_2_1203", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19266307_2_1204", "context": "MATERIALS AND METHODS: We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin.", "question": "adverse event. Treatment, two instillations of epirubicin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_2_1205", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "voriconazole"}, {"id": "18628507_2_1206", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_2_1207", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_2_1208", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_2_1209", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_2_1210", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_2_1211", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_2_1212", "context": "Angio-oedema as an unusual tolerable side effect of voriconazole therapy.", "question": "adverse event. Treatment, voriconazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_8_1213", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Oxycodone; gabapentin"}, {"id": "18262450_8_1214", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_8_1215", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_8_1216", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_8_1217", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_8_1218", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_8_1219", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "pain"}, {"id": "18262450_8_1220", "context": "Oxycodone-gabapentin reduced pain score by 33% from baseline to end of treatment.", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "Oxycodone; gabapentin"}, {"id": "10435399_2_1221", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10435399_2_1222", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10435399_2_1223", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10435399_2_1224", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10435399_2_1225", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10435399_2_1226", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "10435399_2_1227", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10435399_2_1228", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10435399_2_1229", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10435399_2_1230", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10435399_2_1231", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10435399_2_1232", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10435399_2_1233", "context": "OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).", "question": "adverse event. Treatment, clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_5_1234", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Subject, Five of 70 patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_5_1235", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Subject, Five of 70 patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_5_1236", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Subject, Five of 70 patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Five of 70"}, {"id": "11352235_5_1237", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Subject, Five of 70 patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_5_1238", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Subject, Five of 70 patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_5_1239", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "11352235_5_1240", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_5_1241", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_5_1242", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_5_1243", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_5_1244", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_5_1245", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_5_1246", "context": "RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.", "question": "adverse event. Treatment, leflunomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_2_1247", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Subject, a patient with an AVM. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_2_1248", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Subject, a patient with an AVM. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_2_1249", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Subject, a patient with an AVM. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_2_1250", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Subject, a patient with an AVM. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_2_1251", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Subject, a patient with an AVM. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "AVM"}, {"id": "16018164_2_1252", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenylpropanolamine"}, {"id": "16018164_2_1253", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_2_1254", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_2_1255", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_2_1256", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_2_1257", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_2_1258", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_2_1259", "context": "Only one report links phenylpropanolamine consumption to an intracerebral hemorrhage in a patient with an AVM.", "question": "adverse event. Treatment, phenylpropanolamine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_1_1260", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thiethylperazine"}, {"id": "16101941_1_1261", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_1_1262", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_1_1263", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_1_1264", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_1_1265", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_1_1266", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16101941_1_1267", "context": "Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.", "question": "adverse event. Treatment, thiethylperazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8430717_4_1268", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "8430717_4_1269", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_4_1270", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_4_1271", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_4_1272", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_4_1273", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_4_1274", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_4_1275", "context": "PURPOSE: To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir.", "question": "adverse event. Treatment, acyclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_3_1276", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "16317298_3_1277", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_3_1278", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_3_1279", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_3_1280", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_3_1281", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_3_1282", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_3_1283", "context": "Radiation recall from gemcitabine is rare, but can potentially arise in any site that has been previously irradiated.", "question": "adverse event. Treatment, gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_3_1284", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Subject, Most cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15368548_3_1285", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Subject, Most cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15368548_3_1286", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Subject, Most cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15368548_3_1287", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Subject, Most cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15368548_3_1288", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Subject, Most cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15368548_3_1289", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "15368548_3_1290", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_3_1291", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_3_1292", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_3_1293", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_3_1294", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_3_1295", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_3_1296", "context": "Most cases of pancreatitis associated with L-asparaginase toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.", "question": "adverse event. Treatment, L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_6_1297", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Subject, the patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_6_1298", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Subject, the patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "23970584_6_1299", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Subject, the patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_6_1300", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Subject, the patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_6_1301", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Subject, the patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_6_1302", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "23970584_6_1303", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_6_1304", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_6_1305", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_6_1306", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Shortly after"}, {"id": "23970584_6_1307", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_6_1308", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_6_1309", "context": "Shortly after commencing the drug, the patient developed a severe adverse drug reaction manifesting as Drug Reaction (or Rash) with Eosinophilia and Systemic Symptoms (DRESS) syndrome.", "question": "adverse event. Treatment, Shortly after commencing the drug. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9562211_3_1310", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Subject, a potential case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9562211_3_1311", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Subject, a potential case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9562211_3_1312", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Subject, a potential case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9562211_3_1313", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Subject, a potential case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9562211_3_1314", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Subject, a potential case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9562211_3_1315", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "9562211_3_1316", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9562211_3_1317", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9562211_3_1318", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9562211_3_1319", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9562211_3_1320", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9562211_3_1321", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9562211_3_1322", "context": "This report presents a potential case of risperidone-induced tardive dyskinesia.", "question": "adverse event. Treatment, risperidone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_4_1323", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Subject, The patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_4_1324", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Subject, The patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_4_1325", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Subject, The patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_4_1326", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Subject, The patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_4_1327", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Subject, The patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_4_1328", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillin"}, {"id": "16288069_4_1329", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_4_1330", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_4_1331", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "16288069_4_1332", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "one hour"}, {"id": "16288069_4_1333", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_4_1334", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_4_1335", "context": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin.", "question": "adverse event. Treatment, one hour after infusion of the first dose of penicillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_4_1336", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15927910_4_1337", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15927910_4_1338", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15927910_4_1339", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15927910_4_1340", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15927910_4_1341", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentamidine"}, {"id": "15927910_4_1342", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_4_1343", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_4_1344", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_4_1345", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_4_1346", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_4_1347", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_4_1348", "context": "Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature.", "question": "adverse event. Treatment, pentamidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_1_1349", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCNU"}, {"id": "15286697_1_1350", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_1_1351", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_1_1352", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_1_1353", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_1_1354", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_1_1355", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_1_1356", "context": "Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.", "question": "adverse event. Treatment, BCNU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_1_1357", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Subject, patients with normal renal function. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10492493_1_1358", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Subject, patients with normal renal function. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10492493_1_1359", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Subject, patients with normal renal function. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10492493_1_1360", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Subject, patients with normal renal function. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10492493_1_1361", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Subject, patients with normal renal function. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10492493_1_1362", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "losartan"}, {"id": "10492493_1_1363", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_1_1364", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_1_1365", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_1_1366", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_1_1367", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_1_1368", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_1_1369", "context": "CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.", "question": "adverse event. Treatment, losartan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3211830_1_1370", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diltiazem"}, {"id": "3211830_1_1371", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3211830_1_1372", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3211830_1_1373", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3211830_1_1374", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3211830_1_1375", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3211830_1_1376", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3211830_1_1377", "context": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem, a recently introduced calcium antagonist.", "question": "adverse event. Treatment, diltiazem, a recently introduced calcium antagonist. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10492493_4_1378", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "losartan"}, {"id": "10492493_4_1379", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_4_1380", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_4_1381", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_4_1382", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_4_1383", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_4_1384", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_4_1385", "context": "The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.", "question": "adverse event. Treatment, losartan, an angiotensin II receptor antagonist. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18347524_2_1386", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Subject, a young man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "18347524_2_1387", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Subject, a young man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18347524_2_1388", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Subject, a young man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18347524_2_1389", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Subject, a young man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18347524_2_1390", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Subject, a young man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18347524_2_1391", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "18347524_2_1392", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18347524_2_1393", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18347524_2_1394", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "the administration"}, {"id": "18347524_2_1395", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 weeks"}, {"id": "18347524_2_1396", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18347524_2_1397", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "18347524_2_1398", "context": "We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and severe weakness, about 2 weeks after the administration of leflunomide.", "question": "adverse event. Treatment, about 2 weeks after the administration of leflunomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_1_1399", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chloroquine"}, {"id": "12659609_1_1400", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_1_1401", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_1_1402", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_1_1403", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_1_1404", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_1_1405", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "resistant vivax malaria"}, {"id": "12659609_1_1406", "context": "Toxicity related to chloroquine treatment of resistant vivax malaria.", "question": "adverse event. Treatment, chloroquine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8250714_3_1407", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Subject, Patients with vitamin B12 deficiency. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_3_1408", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Subject, Patients with vitamin B12 deficiency. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_3_1409", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Subject, Patients with vitamin B12 deficiency. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_3_1410", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Subject, Patients with vitamin B12 deficiency. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_3_1411", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Subject, Patients with vitamin B12 deficiency. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "vitamin B12 deficiency"}, {"id": "8250714_3_1412", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrous oxide"}, {"id": "8250714_3_1413", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_3_1414", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_3_1415", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_3_1416", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_3_1417", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_3_1418", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_3_1419", "context": "Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15072497_2_1420", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Subject, two patients,. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15072497_2_1421", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Subject, two patients,. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15072497_2_1422", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Subject, two patients,. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15072497_2_1423", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Subject, two patients,. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15072497_2_1424", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Subject, two patients,. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15072497_2_1425", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "colchicine"}, {"id": "15072497_2_1426", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high dose"}, {"id": "15072497_2_1427", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15072497_2_1428", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15072497_2_1429", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15072497_2_1430", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15072497_2_1431", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15072497_2_1432", "context": "However here we reported two patients, presenting with PD during high dose colchicine treatment for familiar mediterranean fever (FMF).", "question": "adverse event. Treatment, high dose colchicine treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_3_1433", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Subject, two patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12786839_3_1434", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Subject, two patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12786839_3_1435", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Subject, two patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "12786839_3_1436", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Subject, two patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12786839_3_1437", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Subject, two patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12786839_3_1438", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "12786839_3_1439", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_3_1440", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_3_1441", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_3_1442", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_3_1443", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_3_1444", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_3_1445", "context": "We report two patients with infectious mononucleosis-like syndrome induced by salazosulfapyridine (SASP).", "question": "adverse event. Treatment, salazosulfapyridine (SASP).. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_2_1446", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carmustine"}, {"id": "1655228_2_1447", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "1655228_2_1448", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_2_1449", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "1655228_2_1450", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_2_1451", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_2_1452", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_2_1453", "context": "Myocardial ischemia associated with high-dose carmustine infusion.", "question": "adverse event. Treatment, high-dose carmustine infusion. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21802143_1_1454", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Subject, a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21802143_1_1455", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Subject, a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21802143_1_1456", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Subject, a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21802143_1_1457", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Subject, a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21802143_1_1458", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Subject, a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "CYP2C19 and CYP3A5 heterozygous mutations"}, {"id": "21802143_1_1459", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrolimus; lansoprazole; voriconazole"}, {"id": "21802143_1_1460", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21802143_1_1461", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21802143_1_1462", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21802143_1_1463", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21802143_1_1464", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21802143_1_1465", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bone marrow transplant"}, {"id": "21802143_1_1466", "context": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.", "question": "adverse event. Treatment, tacrolimus and lansoprazole; voriconazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "tacrolimus; lansoprazole; voriconazole"}, {"id": "12507063_2_1467", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gabapentin"}, {"id": "12507063_2_1468", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12507063_2_1469", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12507063_2_1470", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12507063_2_1471", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12507063_2_1472", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12507063_2_1473", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12507063_2_1474", "context": "Gabapentin withdrawal presenting as status epilepticus.", "question": "adverse event. Treatment, Gabapentin withdrawal. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_1_1475", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "7056119_1_1476", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_1_1477", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_1_1478", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_1_1479", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_1_1480", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_1_1481", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_1_1482", "context": "Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide.", "question": "adverse event. Treatment, amiodarone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_3_1483", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Colchicine"}, {"id": "17619811_3_1484", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_3_1485", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_3_1486", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_3_1487", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_3_1488", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_3_1489", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_3_1490", "context": "Colchicine-induced rhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.", "question": "adverse event. Treatment, Colchicine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4075534_2_1491", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "benzodiazepine"}, {"id": "4075534_2_1492", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4075534_2_1493", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4075534_2_1494", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4075534_2_1495", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4075534_2_1496", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4075534_2_1497", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4075534_2_1498", "context": "Spindle coma in benzodiazepine toxicity: case report.", "question": "adverse event. Treatment, benzodiazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2483959_1_1499", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dextran-40"}, {"id": "2483959_1_1500", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2483959_1_1501", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2483959_1_1502", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2483959_1_1503", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2483959_1_1504", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2483959_1_1505", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2483959_1_1506", "context": "A typical case of dextran-40 associated acute renal failure is presented.", "question": "adverse event. Treatment, dextran-40. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_1_1507", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Subject, he. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15895899_1_1508", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Subject, he. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "he"}, {"id": "15895899_1_1509", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Subject, he. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15895899_1_1510", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Subject, he. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15895899_1_1511", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Subject, he. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15895899_1_1512", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15895899_1_1513", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_1_1514", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_1_1515", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "15895899_1_1516", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_1_1517", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_1_1518", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_1_1519", "context": "After the second infliximab infusion, he was found to have a severe transient neutropenia (0.5 x 10(9)/L).", "question": "adverse event. Treatment, infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7712052_1_1520", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Lithium"}, {"id": "7712052_1_1521", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_1_1522", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7712052_1_1523", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7712052_1_1524", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_1_1525", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7712052_1_1526", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "irritability in post-traumatic stress disorder"}, {"id": "7712052_1_1527", "context": "Lithium for irritability in post-traumatic stress disorder.", "question": "potential therapeutic event. Treatment, Lithium. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14684937_2_1528", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vitamin D3; thiazide diuretics"}, {"id": "14684937_2_1529", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_2_1530", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_2_1531", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ointment"}, {"id": "14684937_2_1532", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_2_1533", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_2_1534", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriasis"}, {"id": "14684937_2_1535", "context": "Iatrogenic hypercalcemia due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.", "question": "adverse event. Treatment, vitamin D3 ointment (1,24(OH)2D3) combined with thiazide diuretics. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "vitamin D3; thiazide diuretics"}, {"id": "6362443_1_1536", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Subject, A case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6362443_1_1537", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Subject, A case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6362443_1_1538", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Subject, A case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6362443_1_1539", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Subject, A case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6362443_1_1540", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Subject, A case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6362443_1_1541", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "6362443_1_1542", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6362443_1_1543", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6362443_1_1544", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6362443_1_1545", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6362443_1_1546", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6362443_1_1547", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6362443_1_1548", "context": "A case of mania associated with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_3_1549", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "progestin"}, {"id": "7748076_3_1550", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_3_1551", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_3_1552", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_3_1553", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_3_1554", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_3_1555", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_3_1556", "context": "RESULTS: Extensive squamous metaplasia was found in endometrial glands following progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16843118_1_1557", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "16843118_1_1558", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16843118_1_1559", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16843118_1_1560", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16843118_1_1561", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16843118_1_1562", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16843118_1_1563", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16843118_1_1564", "context": "Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test.", "question": "adverse event. Treatment, morphine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_1_1565", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Subject, the patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9149614_1_1566", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Subject, the patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9149614_1_1567", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Subject, the patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9149614_1_1568", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Subject, the patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9149614_1_1569", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Subject, the patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9149614_1_1570", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "9149614_1_1571", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_1_1572", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_1_1573", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_1_1574", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Eleven days after"}, {"id": "9149614_1_1575", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_1_1576", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_1_1577", "context": "Eleven days after initiation of therapy with amiodarone, the patient experienced syncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia.", "question": "adverse event. Treatment, Eleven days after initiation of therapy with amiodarone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8579054_3_1578", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Subject, patients with ET. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8579054_3_1579", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Subject, patients with ET. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8579054_3_1580", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Subject, patients with ET. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8579054_3_1581", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Subject, patients with ET. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8579054_3_1582", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Subject, patients with ET. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8579054_3_1583", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxyurea"}, {"id": "8579054_3_1584", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8579054_3_1585", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "Prolonged used"}, {"id": "8579054_3_1586", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8579054_3_1587", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8579054_3_1588", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8579054_3_1589", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ET"}, {"id": "8579054_3_1590", "context": "Prolonged used of hydroxyurea in patients with ET may lead to therapy-associated acute leukemia.", "question": "adverse event. Treatment, hydroxyurea. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "354311_2_1591", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCG vaccination"}, {"id": "354311_2_1592", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "354311_2_1593", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "354311_2_1594", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "354311_2_1595", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "354311_2_1596", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "354311_2_1597", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "354311_2_1598", "context": "Metastatic osteomyelitis following BCG vaccination.", "question": "adverse event. Treatment, BCG vaccination. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1414247_1_1599", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valproic acid"}, {"id": "1414247_1_1600", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1414247_1_1601", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1414247_1_1602", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1414247_1_1603", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1414247_1_1604", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1414247_1_1605", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1414247_1_1606", "context": "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.", "question": "adverse event. Treatment, valproic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_5_1607", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Subject, two patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8912599_5_1608", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Subject, two patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8912599_5_1609", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Subject, two patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "8912599_5_1610", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Subject, two patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8912599_5_1611", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Subject, two patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8912599_5_1612", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8912599_5_1613", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_5_1614", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_5_1615", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_5_1616", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_5_1617", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_5_1618", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "psoriasis"}, {"id": "8912599_5_1619", "context": "We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of methotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9413296_2_1620", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methysergide"}, {"id": "9413296_2_1621", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9413296_2_1622", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9413296_2_1623", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9413296_2_1624", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9413296_2_1625", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9413296_2_1626", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9413296_2_1627", "context": "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features.", "question": "adverse event. Treatment, Methysergide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11099623_1_1628", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Subject, 2 children with cerebral palsy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "11099623_1_1629", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Subject, 2 children with cerebral palsy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11099623_1_1630", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Subject, 2 children with cerebral palsy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "11099623_1_1631", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Subject, 2 children with cerebral palsy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11099623_1_1632", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Subject, 2 children with cerebral palsy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11099623_1_1633", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hyperbaric oxygen"}, {"id": "11099623_1_1634", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11099623_1_1635", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11099623_1_1636", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11099623_1_1637", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11099623_1_1638", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11099623_1_1639", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cerebral palsy"}, {"id": "11099623_1_1640", "context": "We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.", "question": "adverse event. Treatment, treatment with hyperbaric oxygen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "53128_2_1641", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Subject, A patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "53128_2_1642", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Subject, A patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "53128_2_1643", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Subject, A patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "53128_2_1644", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Subject, A patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "53128_2_1645", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Subject, A patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "53128_2_1646", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "anticoagulants"}, {"id": "53128_2_1647", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "53128_2_1648", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "53128_2_1649", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "53128_2_1650", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "53128_2_1651", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "53128_2_1652", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "53128_2_1653", "context": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode.", "question": "adverse event. Treatment, anticoagulants. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_1_1654", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine phosphate"}, {"id": "9671138_1_1655", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_1_1656", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_1_1657", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_1_1658", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_1_1659", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_1_1660", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9671138_1_1661", "context": "CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy.", "question": "adverse event. Treatment, fludarabine phosphate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_3_1662", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Penicillin"}, {"id": "16288069_3_1663", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_3_1664", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_3_1665", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_3_1666", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_3_1667", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_3_1668", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_3_1669", "context": "Penicillin-induced Jarisch-Herxheimer reaction.", "question": "adverse event. Treatment, Penicillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_4_1670", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_4_1671", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_4_1672", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_4_1673", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_4_1674", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_4_1675", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "9550246_4_1676", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_4_1677", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_4_1678", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_4_1679", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_4_1680", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_4_1681", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "9550246_4_1682", "context": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.", "question": "adverse event. Treatment, risperidone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11315123_1_1683", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Subject, a patient with progressive renal impairment. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11315123_1_1684", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Subject, a patient with progressive renal impairment. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11315123_1_1685", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Subject, a patient with progressive renal impairment. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11315123_1_1686", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Subject, a patient with progressive renal impairment. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11315123_1_1687", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Subject, a patient with progressive renal impairment. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "progressive renal impairment"}, {"id": "11315123_1_1688", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cibenzoline"}, {"id": "11315123_1_1689", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "intoxication"}, {"id": "11315123_1_1690", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11315123_1_1691", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11315123_1_1692", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11315123_1_1693", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "chronic"}, {"id": "11315123_1_1694", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11315123_1_1695", "context": "We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.", "question": "adverse event. Treatment, chronic cibenzoline intoxication. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1557089_1_1696", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Subject, a postoperative patient with pre-existent myasthenia gravis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1557089_1_1697", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Subject, a postoperative patient with pre-existent myasthenia gravis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1557089_1_1698", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Subject, a postoperative patient with pre-existent myasthenia gravis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1557089_1_1699", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Subject, a postoperative patient with pre-existent myasthenia gravis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1557089_1_1700", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Subject, a postoperative patient with pre-existent myasthenia gravis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "pre-existent myasthenia gravis"}, {"id": "1557089_1_1701", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "verapamil"}, {"id": "1557089_1_1702", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1557089_1_1703", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1557089_1_1704", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "1557089_1_1705", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1557089_1_1706", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1557089_1_1707", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1557089_1_1708", "context": "In a postoperative patient with pre-existent myasthenia gravis, oral verapamil caused a marked exacerbation in myasthenic weakness.", "question": "adverse event. Treatment, oral verapamil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16288069_1_1709", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16288069_1_1710", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_1_1711", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_1_1712", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_1_1713", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16288069_1_1714", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillin"}, {"id": "16288069_1_1715", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16288069_1_1716", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_1_1717", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16288069_1_1718", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_1_1719", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_1_1720", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16288069_1_1721", "context": "An objective causality assessment suggests that the JHR in our patient was probably related to penicillin.", "question": "adverse event. Treatment, penicillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_2_1722", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Subject, A 34-year-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "34-year-old"}, {"id": "16490518_2_1723", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Subject, A 34-year-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "16490518_2_1724", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Subject, A 34-year-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16490518_2_1725", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Subject, A 34-year-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16490518_2_1726", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Subject, A 34-year-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16490518_2_1727", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone"}, {"id": "16490518_2_1728", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_2_1729", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_2_1730", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravitreal injection"}, {"id": "16490518_2_1731", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_2_1732", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_2_1733", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "diabetic macular edema"}, {"id": "16490518_2_1734", "context": "RESULTS: A 34-year-old man acquired visual field defects and severe vision loss in both eyes after intravitreal injection of triamcinolone for diabetic macular edema.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16537817_1_1735", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone; Simvastatin"}, {"id": "16537817_1_1736", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16537817_1_1737", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16537817_1_1738", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16537817_1_1739", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16537817_1_1740", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16537817_1_1741", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16537817_1_1742", "context": "Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.", "question": "adverse event. Treatment, Simvastatin-amiodarone interaction. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "amiodarone; Simvastatin"}, {"id": "21330680_13_1743", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Subject, A 73-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "73-year-old"}, {"id": "21330680_13_1744", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Subject, A 73-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "21330680_13_1745", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Subject, A 73-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21330680_13_1746", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Subject, A 73-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21330680_13_1747", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Subject, A 73-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21330680_13_1748", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine; smoking"}, {"id": "21330680_13_1749", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dosage"}, {"id": "21330680_13_1750", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_13_1751", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_13_1752", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_13_1753", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_13_1754", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bipolar disorder"}, {"id": "21330680_13_1755", "context": "A 73-year-old woman receiving high-dosage olanzapine for bipolar disorder developed parkinsonism after smoking cessation.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_2_1756", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "16515630_2_1757", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_2_1758", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_2_1759", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_2_1760", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_2_1761", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_2_1762", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_2_1763", "context": "Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.", "question": "adverse event. Treatment, paclitaxel. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_1_1764", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Raltegravir"}, {"id": "23970584_1_1765", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_1_1766", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_1_1767", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_1_1768", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_1_1769", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_1_1770", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_1_1771", "context": "Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.", "question": "adverse event. Treatment, Raltegravir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_1_1772", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Subject, 10-year-old boy with osteosarcoma and normal renal function. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "10-year-old"}, {"id": "19131789_1_1773", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Subject, 10-year-old boy with osteosarcoma and normal renal function. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "19131789_1_1774", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Subject, 10-year-old boy with osteosarcoma and normal renal function. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19131789_1_1775", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Subject, 10-year-old boy with osteosarcoma and normal renal function. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19131789_1_1776", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Subject, 10-year-old boy with osteosarcoma and normal renal function. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19131789_1_1777", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "19131789_1_1778", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose; 12 g/m2"}, {"id": "19131789_1_1779", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_1_1780", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "19131789_1_1781", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 2 hours; 29 hours later"}, {"id": "19131789_1_1782", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "4-hour"}, {"id": "19131789_1_1783", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "osteosarcoma"}, {"id": "19131789_1_1784", "context": "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.", "question": "adverse event. Treatment, 4-hour infusion of high-dose methotrexate (MTX) (12 g/m2). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2012922_1_1785", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Subject, three depressed patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2012922_1_1786", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Subject, three depressed patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2012922_1_1787", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Subject, three depressed patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "2012922_1_1788", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Subject, three depressed patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2012922_1_1789", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Subject, three depressed patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2012922_1_1790", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trazodone"}, {"id": "2012922_1_1791", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2012922_1_1792", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2012922_1_1793", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2012922_1_1794", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2012922_1_1795", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2012922_1_1796", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "depressed"}, {"id": "2012922_1_1797", "context": "Transient trazodone-induced hypomanic symptoms occurred in three depressed patients.", "question": "adverse event. Treatment, trazodone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9886213_4_1798", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9886213_4_1799", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9886213_4_1800", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9886213_4_1801", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9886213_4_1802", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9886213_4_1803", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "praziquantel"}, {"id": "9886213_4_1804", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9886213_4_1805", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9886213_4_1806", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9886213_4_1807", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9886213_4_1808", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9886213_4_1809", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9886213_4_1810", "context": "We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by praziquantel therapy, an event not described previously.", "question": "adverse event. Treatment, praziquantel therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1888256_2_1811", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diltiazem"}, {"id": "1888256_2_1812", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_2_1813", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_2_1814", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_2_1815", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_2_1816", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_2_1817", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_2_1818", "context": "Drug-induced fever should be considered in patients who have unexplained high temperatures during diltiazem therapy.", "question": "adverse event. Treatment, diltiazem therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9443627_1_1819", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "9443627_1_1820", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9443627_1_1821", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9443627_1_1822", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9443627_1_1823", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9443627_1_1824", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9443627_1_1825", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9443627_1_1826", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "adverse event. Treatment, ifosfamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9443627_1_1827", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Hemodialysis"}, {"id": "9443627_1_1828", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9443627_1_1829", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9443627_1_1830", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9443627_1_1831", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9443627_1_1832", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9443627_1_1833", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ifosfamide-related neurotoxicity."}, {"id": "9443627_1_1834", "context": "Hemodialysis was also shown to reverse ifosfamide-related neurotoxicity.", "question": "potential therapeutic event. Treatment, Hemodialysis. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18076602_2_1835", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "18076602_2_1836", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_2_1837", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_2_1838", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_2_1839", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_2_1840", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "55th day"}, {"id": "18076602_2_1841", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_2_1842", "context": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment.", "question": "adverse event. Treatment, 55th day of amphotericin B treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6199475_2_1843", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatinum; vinblastine; bleomycin"}, {"id": "6199475_2_1844", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6199475_2_1845", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6199475_2_1846", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6199475_2_1847", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6199475_2_1848", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6199475_2_1849", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "testicular carcinoma"}, {"id": "6199475_2_1850", "context": "Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "cisplatinum; vinblastine; bleomycin"}, {"id": "3410226_2_1851", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Subject, a 46-yr-old woman with ovarian carcinoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "46-yr-old"}, {"id": "3410226_2_1852", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Subject, a 46-yr-old woman with ovarian carcinoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "3410226_2_1853", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Subject, a 46-yr-old woman with ovarian carcinoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3410226_2_1854", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Subject, a 46-yr-old woman with ovarian carcinoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3410226_2_1855", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Subject, a 46-yr-old woman with ovarian carcinoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3410226_2_1856", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin; cyclophosphamide"}, {"id": "3410226_2_1857", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3410226_2_1858", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3410226_2_1859", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3410226_2_1860", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3410226_2_1861", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3410226_2_1862", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "ovarian carcinoma"}, {"id": "3410226_2_1863", "context": "We report a 46-yr-old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide.", "question": "adverse event. Treatment, cisplatin and cyclophosphamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "cisplatin; cyclophosphamide"}, {"id": "440873_2_1864", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Subject, one child. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "440873_2_1865", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Subject, one child. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_2_1866", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Subject, one child. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "one"}, {"id": "440873_2_1867", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Subject, one child. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_2_1868", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Subject, one child. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_2_1869", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "440873_2_1870", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_2_1871", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_2_1872", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_2_1873", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_2_1874", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "second course"}, {"id": "440873_2_1875", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_2_1876", "context": "In one child, a second course of carbamazepine resulted in a return of the dystonia.", "question": "adverse event. Treatment, a second course of carbamazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_1_1877", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir; lithium"}, {"id": "8726608_1_1878", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_1_1879", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_1_1880", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_1_1881", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_1_1882", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_1_1883", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_1_1884", "context": "Does acyclovir increase serum lithium levels?", "question": "adverse event. Treatment, acyclovir; lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "acyclovir; lithium"}, {"id": "2241449_2_1885", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Sulfadiazine"}, {"id": "2241449_2_1886", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_2_1887", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_2_1888", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_2_1889", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_2_1890", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_2_1891", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_2_1892", "context": "Sulfadiazine crystalluria revisited.", "question": "adverse event. Treatment, Sulfadiazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16472339_1_1893", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16472339_1_1894", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16472339_1_1895", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16472339_1_1896", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16472339_1_1897", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16472339_1_1898", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sumatriptan"}, {"id": "16472339_1_1899", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16472339_1_1900", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16472339_1_1901", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16472339_1_1902", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16472339_1_1903", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16472339_1_1904", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "subarachnoid haemorrhage"}, {"id": "16472339_1_1905", "context": "Administration of sumatriptan in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce symptomatic cerebral vasospasm with potentially dangerous consequences.", "question": "adverse event. Treatment, sumatriptan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_2_1906", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Subject, Six of 13 outpatients with schizophrenia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_2_1907", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Subject, Six of 13 outpatients with schizophrenia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_2_1908", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Subject, Six of 13 outpatients with schizophrenia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Six of 13"}, {"id": "9550246_2_1909", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Subject, Six of 13 outpatients with schizophrenia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_2_1910", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Subject, Six of 13 outpatients with schizophrenia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_2_1911", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "9550246_2_1912", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_2_1913", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_2_1914", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_2_1915", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_2_1916", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "a ten-week"}, {"id": "9550246_2_1917", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "9550246_2_1918", "context": "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia.", "question": "adverse event. Treatment, a ten-week open trial of risperidone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10332990_1_1919", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Subject, a patient with pulmonary hypertension and limited scleroderma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10332990_1_1920", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Subject, a patient with pulmonary hypertension and limited scleroderma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10332990_1_1921", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Subject, a patient with pulmonary hypertension and limited scleroderma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10332990_1_1922", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Subject, a patient with pulmonary hypertension and limited scleroderma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10332990_1_1923", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Subject, a patient with pulmonary hypertension and limited scleroderma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10332990_1_1924", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "epoprostenol"}, {"id": "10332990_1_1925", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10332990_1_1926", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10332990_1_1927", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "acute infusion"}, {"id": "10332990_1_1928", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10332990_1_1929", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10332990_1_1930", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary hypertension and limited scleroderma"}, {"id": "10332990_1_1931", "context": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.", "question": "adverse event. Treatment, acute infusion of epoprostenol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_3_1932", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Decadron"}, {"id": "3003260_3_1933", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_3_1934", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3003260_3_1935", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "3003260_3_1936", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_3_1937", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3003260_3_1938", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cisplatin-induced vomiting"}, {"id": "3003260_3_1939", "context": "Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on cisplatin-induced vomiting.", "question": "potential therapeutic event. Treatment, Decadron. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16087771_1_1940", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pergolide"}, {"id": "16087771_1_1941", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16087771_1_1942", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16087771_1_1943", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16087771_1_1944", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16087771_1_1945", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16087771_1_1946", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Parkinson Disease"}, {"id": "16087771_1_1947", "context": "Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.", "question": "adverse event. Treatment, long-term treatment with the dopamine agonist pergolide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "556126_1_1948", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Subject, An infertile patient with amenorrhea-galactorrhea syndrome. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "556126_1_1949", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Subject, An infertile patient with amenorrhea-galactorrhea syndrome. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "556126_1_1950", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Subject, An infertile patient with amenorrhea-galactorrhea syndrome. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "556126_1_1951", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Subject, An infertile patient with amenorrhea-galactorrhea syndrome. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "556126_1_1952", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Subject, An infertile patient with amenorrhea-galactorrhea syndrome. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "infertile"}, {"id": "556126_1_1953", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Bromocryptine"}, {"id": "556126_1_1954", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "556126_1_1955", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "556126_1_1956", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "556126_1_1957", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "556126_1_1958", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "556126_1_1959", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "amenorrhea-galactorrhea syndrome"}, {"id": "556126_1_1960", "context": "An infertile patient with amenorrhea-galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment.", "question": "adverse event. Treatment, Bromocryptine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8430717_2_1961", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "8430717_2_1962", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8430717_2_1963", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_2_1964", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_2_1965", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "24 to 48 hours after"}, {"id": "8430717_2_1966", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_2_1967", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_2_1968", "context": "CONCLUSIONS: The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.", "question": "adverse event. Treatment, acyclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_5_1969", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mequitazine"}, {"id": "8850251_5_1970", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_5_1971", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_5_1972", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_5_1973", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_5_1974", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_5_1975", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_5_1976", "context": "Two cases of mequitazine-induced photosensitivity reactions.", "question": "adverse event. Treatment, mequitazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9704170_3_1977", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Subject, a patient with decreased calcium-dependent potassium permeability of cell membranes. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_3_1978", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Subject, a patient with decreased calcium-dependent potassium permeability of cell membranes. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_3_1979", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Subject, a patient with decreased calcium-dependent potassium permeability of cell membranes. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_3_1980", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Subject, a patient with decreased calcium-dependent potassium permeability of cell membranes. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_3_1981", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Subject, a patient with decreased calcium-dependent potassium permeability of cell membranes. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "decreased calcium-dependent potassium permeability of cell membranes"}, {"id": "9704170_3_1982", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9704170_3_1983", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_3_1984", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_3_1985", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_3_1986", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_3_1987", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_3_1988", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_3_1989", "context": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.", "question": "adverse event. Treatment, clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_1_1990", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Subject, A 47 year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "47 year-old"}, {"id": "9737132_1_1991", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Subject, A 47 year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "9737132_1_1992", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Subject, A 47 year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9737132_1_1993", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Subject, A 47 year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9737132_1_1994", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Subject, A 47 year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9737132_1_1995", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentazocine"}, {"id": "9737132_1_1996", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_1_1997", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_1_1998", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intramuscular; injections"}, {"id": "9737132_1_1999", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4-year"}, {"id": "9737132_1_2000", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_1_2001", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_1_2002", "context": "A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities.", "question": "adverse event. Treatment, a 4-year history of intramuscular pentazocine injections in the lower extremities. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_5_2003", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10592946_5_2004", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10592946_5_2005", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10592946_5_2006", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10592946_5_2007", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10592946_5_2008", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "caffeine"}, {"id": "10592946_5_2009", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "massive"}, {"id": "10592946_5_2010", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_5_2011", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ingestion"}, {"id": "10592946_5_2012", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_5_2013", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_5_2014", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_5_2015", "context": "The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.", "question": "adverse event. Treatment, massive ingestion of caffeine-containing beverages. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_3_2016", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Subject, A 25-year-old postpartum white woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "25-year-old"}, {"id": "9533061_3_2017", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Subject, A 25-year-old postpartum white woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "9533061_3_2018", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Subject, A 25-year-old postpartum white woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9533061_3_2019", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Subject, A 25-year-old postpartum white woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": "white"}, {"id": "9533061_3_2020", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Subject, A 25-year-old postpartum white woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "postpartum"}, {"id": "9533061_3_2021", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clindamycin"}, {"id": "9533061_3_2022", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_3_2023", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_3_2024", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "vaginal cream"}, {"id": "9533061_3_2025", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "day 6"}, {"id": "9533061_3_2026", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_3_2027", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bacterial vaginosis"}, {"id": "9533061_3_2028", "context": "CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis.", "question": "adverse event. Treatment, clindamycin vaginal cream for bacterial vaginosis. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_1_2029", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Subject, three case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_1_2030", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Subject, three case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_1_2031", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Subject, three case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11236070_1_2032", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Subject, three case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_1_2033", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Subject, three case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_1_2034", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "11236070_1_2035", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_1_2036", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_1_2037", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_1_2038", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_1_2039", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_1_2040", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_1_2041", "context": "Dose-dependent olanzapine-associated leukopenia: three case reports.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_8_2042", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Subject, He. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_8_2043", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Subject, He. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "He"}, {"id": "10682234_8_2044", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Subject, He. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_8_2045", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Subject, He. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_8_2046", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Subject, He. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_8_2047", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "levodopa"}, {"id": "10682234_8_2048", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_8_2049", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_8_2050", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_8_2051", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 weeks"}, {"id": "10682234_8_2052", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_8_2053", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_8_2054", "context": "He became completely premorbid 2 weeks after administration of levodopa.", "question": "adverse event. Treatment, levodopa. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19112808_2_2055", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "darifenacin"}, {"id": "19112808_2_2056", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19112808_2_2057", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19112808_2_2058", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19112808_2_2059", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19112808_2_2060", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19112808_2_2061", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19112808_2_2062", "context": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_6_2063", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Subject, patient; she. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7056119_6_2064", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Subject, patient; she. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "7056119_6_2065", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Subject, patient; she. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7056119_6_2066", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Subject, patient; she. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7056119_6_2067", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Subject, patient; she. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7056119_6_2068", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amiodarone"}, {"id": "7056119_6_2069", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "200 mg/day"}, {"id": "7056119_6_2070", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "six days per week; six months"}, {"id": "7056119_6_2071", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_6_2072", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_6_2073", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_6_2074", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_6_2075", "context": "Amiodarone was the third drug to induce AVT in this patient; she received 200 mg/day six days per week for six months.", "question": "adverse event. Treatment, Amiodarone; 200 mg/day six days per week for six months. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3003260_1_2076", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Subject, A young diamond dealer. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "3003260_1_2077", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Subject, A young diamond dealer. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3003260_1_2078", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Subject, A young diamond dealer. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3003260_1_2079", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Subject, A young diamond dealer. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3003260_1_2080", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Subject, A young diamond dealer. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3003260_1_2081", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Decadron; five-drug antiemetic regimen"}, {"id": "3003260_1_2082", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "four courses"}, {"id": "3003260_1_2083", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3003260_1_2084", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3003260_1_2085", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_1_2086", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3003260_1_2087", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cisplatin-associated nausea"}, {"id": "3003260_1_2088", "context": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.", "question": "adverse event. Treatment, only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "Decadron; five-drug antiemetic regimen"}, {"id": "10492493_3_2089", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10492493_3_2090", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10492493_3_2091", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10492493_3_2092", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10492493_3_2093", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10492493_3_2094", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "losartan"}, {"id": "10492493_3_2095", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_3_2096", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_3_2097", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_3_2098", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_3_2099", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_3_2100", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_3_2101", "context": "OBJECTIVE: To report a case of angioedema associated with losartan administration.", "question": "adverse event. Treatment, losartan administration. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_2_2102", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Subject, a case report. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16341621_2_2103", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Subject, a case report. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16341621_2_2104", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Subject, a case report. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16341621_2_2105", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Subject, a case report. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16341621_2_2106", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Subject, a case report. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16341621_2_2107", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium hydroxylapatite"}, {"id": "16341621_2_2108", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_2_2109", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_2_2110", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "transurethral injection"}, {"id": "16341621_2_2111", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 months"}, {"id": "16341621_2_2112", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_2_2113", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16341621_2_2114", "context": "The authors present a case report of a granulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of calcium hydroxylapatite.", "question": "adverse event. Treatment, 3 months after the transurethral injection of calcium hydroxylapatite. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_1_2115", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15595320_1_2116", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15595320_1_2117", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15595320_1_2118", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15595320_1_2119", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15595320_1_2120", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate; rofecoxib"}, {"id": "15595320_1_2121", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_1_2122", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_1_2123", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_1_2124", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_1_2125", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_1_2126", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "15595320_1_2127", "context": "Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics?", "question": "adverse event. Treatment, methotrexate and rofecoxib. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_4_2128", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aspirin"}, {"id": "18755414_4_2129", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_4_2130", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_4_2131", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_4_2132", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_4_2133", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_4_2134", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_4_2135", "context": "On the other hand, aspirin may have promoted the enlargement of spontaneous hemorrhage from meningioma.", "question": "adverse event. Treatment, aspirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_13_2136", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "20925534_13_2137", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_13_2138", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_13_2139", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_13_2140", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_13_2141", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_13_2142", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_13_2143", "context": "The two groups did not differ significantly in the rate of serious adverse events, though the risk of diarrhea was increased with omeprazole.", "question": "adverse event. Treatment, omeprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_1_2144", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Subject, a patient with severe digitoxin intoxication. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1469187_1_2145", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Subject, a patient with severe digitoxin intoxication. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1469187_1_2146", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Subject, a patient with severe digitoxin intoxication. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1469187_1_2147", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Subject, a patient with severe digitoxin intoxication. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1469187_1_2148", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Subject, a patient with severe digitoxin intoxication. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1469187_1_2149", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Fab fragments of anti-digitalis antibodies"}, {"id": "1469187_1_2150", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_1_2151", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1469187_1_2152", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1469187_1_2153", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_1_2154", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1469187_1_2155", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "digitoxin intoxication"}, {"id": "1469187_1_2156", "context": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies.", "question": "potential therapeutic event. Treatment, Fab fragments of anti-digitalis antibodies. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3410226_1_2157", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide."}, {"id": "3410226_1_2158", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3410226_1_2159", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3410226_1_2160", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3410226_1_2161", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3410226_1_2162", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3410226_1_2163", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3410226_1_2164", "context": "Development of porphyria cutanea tarda after treatment with cyclophosphamide.", "question": "adverse event. Treatment, cyclophosphamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3242521_2_2165", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Subject, a premature infant. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "infant"}, {"id": "3242521_2_2166", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Subject, a premature infant. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3242521_2_2167", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Subject, a premature infant. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3242521_2_2168", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Subject, a premature infant. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3242521_2_2169", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Subject, a premature infant. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "premature"}, {"id": "3242521_2_2170", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nafcillin"}, {"id": "3242521_2_2171", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3242521_2_2172", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3242521_2_2173", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intraventricular"}, {"id": "3242521_2_2174", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3242521_2_2175", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3242521_2_2176", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3242521_2_2177", "context": "We report a premature infant who developed seizures associated with intraventricular administration of nafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.", "question": "adverse event. Treatment, intraventricular administration of nafcillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_4_2178", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zuclopenthixol"}, {"id": "12022905_4_2179", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_4_2180", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_4_2181", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_4_2182", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_4_2183", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_4_2184", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_4_2185", "context": "OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.", "question": "adverse event. Treatment, zuclopenthixol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_1_2186", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "16685112_1_2187", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_1_2188", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_1_2189", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_1_2190", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "five months after"}, {"id": "16685112_1_2191", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_1_2192", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "locally advanced pancreatic cancer"}, {"id": "16685112_1_2193", "context": "CASE REPORT: We hereby report a case of radiation recall dermatitis and myositis occurring on gemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.", "question": "adverse event. Treatment, gemcitabine monotherapy, five months after completing chemoradiation. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6427463_1_2194", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold sodium thiomalate"}, {"id": "6427463_1_2195", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6427463_1_2196", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6427463_1_2197", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6427463_1_2198", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6427463_1_2199", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6427463_1_2200", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6427463_1_2201", "context": "Stroke-like syndrome after gold sodium thiomalate induced vasomotor reaction.", "question": "adverse event. Treatment, gold sodium thiomalate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_3_2202", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "9870779_3_2203", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_3_2204", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_3_2205", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_3_2206", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_3_2207", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_3_2208", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9870779_3_2209", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "adverse event. Treatment, MTX. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_3_2210", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "9870779_3_2211", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_3_2212", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9870779_3_2213", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9870779_3_2214", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_3_2215", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9870779_3_2216", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "leukemia; gestational disease; psoriasis; rheumatoid arthritis"}, {"id": "9870779_3_2217", "context": "MTX-induced hepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.", "question": "potential therapeutic event. Treatment, treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15522120_9_2218", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine; fluoxetine"}, {"id": "15522120_9_2219", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_9_2220", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_9_2221", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_9_2222", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_9_2223", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_9_2224", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_9_2225", "context": "An adverse drug reaction (ADR) induced by fluoxetine was suspected and fluoxetine treatment was discontinued.", "question": "adverse event. Treatment, fluoxetine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_2_2226", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "18203308_2_2227", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_2_2228", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_2_2229", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_2_2230", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_2_2231", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_2_2232", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "active ankylosing spondylitis"}, {"id": "18203308_2_2233", "context": "New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept.", "question": "adverse event. Treatment, etanercept. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_3_2234", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "itraconazole"}, {"id": "18523232_3_2235", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "pulse"}, {"id": "18523232_3_2236", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_3_2237", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_3_2238", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18523232_3_2239", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "long-term"}, {"id": "18523232_3_2240", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "onychomycosis"}, {"id": "18523232_3_2241", "context": "Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.", "question": "adverse event. Treatment, long-term pulse itraconazole treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3824704_1_2242", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "formalin"}, {"id": "3824704_1_2243", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3824704_1_2244", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3824704_1_2245", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical; instillation"}, {"id": "3824704_1_2246", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3824704_1_2247", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3824704_1_2248", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3824704_1_2249", "context": "Fatal outcome of intravesical formalin instillation, with changes mimicking renal tuberculosis.", "question": "adverse event. Treatment, intravesical formalin instillation. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16101941_3_2250", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clemastine fumarate"}, {"id": "16101941_3_2251", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16101941_3_2252", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16101941_3_2253", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16101941_3_2254", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16101941_3_2255", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16101941_3_2256", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "anaphylactic reaction"}, {"id": "16101941_3_2257", "context": "Both reactions were caused due to this anti-emetic drug, but an additive effect of clemastine fumarate, prescribed to treat the anaphylactic reaction, is suggested by the sequence of events.", "question": "adverse event. Treatment, clemastine fumarate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_2_2258", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "16357738_2_2259", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_2_2260", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16357738_2_2261", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16357738_2_2262", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_2_2263", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16357738_2_2264", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "systemic lupus erythematosus with thrombocytopenia"}, {"id": "16357738_2_2265", "context": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine.", "question": "potential therapeutic event. Treatment, cyclosporine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20925534_14_2266", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Subject, patients receiving aspirin and clopidogrel. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "20925534_14_2267", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Subject, patients receiving aspirin and clopidogrel. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20925534_14_2268", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Subject, patients receiving aspirin and clopidogrel. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20925534_14_2269", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Subject, patients receiving aspirin and clopidogrel. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20925534_14_2270", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Subject, patients receiving aspirin and clopidogrel. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20925534_14_2271", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "aspirin; clopidogrel; PPI"}, {"id": "20925534_14_2272", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_14_2273", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_14_2274", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_14_2275", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_14_2276", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_14_2277", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_14_2278", "context": "Among patients receiving aspirin and clopidogrel, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding.", "question": "potential therapeutic event. Treatment, PPI. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "aspirin; clopidogrel; PPI"}, {"id": "11295724_3_2279", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Subject, a pediatric bone marrow transplant recipient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11295724_3_2280", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Subject, a pediatric bone marrow transplant recipient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11295724_3_2281", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Subject, a pediatric bone marrow transplant recipient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11295724_3_2282", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Subject, a pediatric bone marrow transplant recipient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11295724_3_2283", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Subject, a pediatric bone marrow transplant recipient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11295724_3_2284", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Clofazimine"}, {"id": "11295724_3_2285", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11295724_3_2286", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11295724_3_2287", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11295724_3_2288", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11295724_3_2289", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11295724_3_2290", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11295724_3_2291", "context": "Clofazimine enteropathy in a pediatric bone marrow transplant recipient.", "question": "adverse event. Treatment, Clofazimine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11696132_2_2292", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "transdermal scopolamine"}, {"id": "11696132_2_2293", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11696132_2_2294", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11696132_2_2295", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11696132_2_2296", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11696132_2_2297", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11696132_2_2298", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11696132_2_2299", "context": "Anisocoria from transdermal scopolamine.", "question": "adverse event. Treatment, transdermal scopolamine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_4_2300", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Subject, he. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12659609_4_2301", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Subject, he. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "he"}, {"id": "12659609_4_2302", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Subject, he. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12659609_4_2303", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Subject, he. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12659609_4_2304", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Subject, he. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12659609_4_2305", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chloroquine"}, {"id": "12659609_4_2306", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_4_2307", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_4_2308", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_4_2309", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_4_2310", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_4_2311", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_4_2312", "context": "His fever resolved, but he developed symptoms consistent with those of chloroquine toxicity.", "question": "adverse event. Treatment, chloroquine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6199475_1_2313", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Subject, A 36-year-old man; testicular carcinoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "36-year-old"}, {"id": "6199475_1_2314", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Subject, A 36-year-old man; testicular carcinoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "6199475_1_2315", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Subject, A 36-year-old man; testicular carcinoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6199475_1_2316", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Subject, A 36-year-old man; testicular carcinoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6199475_1_2317", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Subject, A 36-year-old man; testicular carcinoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6199475_1_2318", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatinum; vinblastine; bleomycin"}, {"id": "6199475_1_2319", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6199475_1_2320", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6199475_1_2321", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6199475_1_2322", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6199475_1_2323", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6199475_1_2324", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "testicular carcinoma"}, {"id": "6199475_1_2325", "context": "A 36-year-old man being treated with cisplatinum, vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a partial nondominant parietal lobe syndrome.", "question": "adverse event. Treatment, cisplatinum, vinblastine, and bleomycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "cisplatinum; vinblastine; bleomycin"}, {"id": "12410494_2_2326", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12410494_2_2327", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12410494_2_2328", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12410494_2_2329", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12410494_2_2330", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12410494_2_2331", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin; protease inhibitor"}, {"id": "12410494_2_2332", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12410494_2_2333", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12410494_2_2334", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12410494_2_2335", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12410494_2_2336", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12410494_2_2337", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12410494_2_2338", "context": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor, which produced a significant drug-drug interaction.", "question": "adverse event. Treatment, a statin and a protease inhibitor. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "statin; protease inhibitor"}, {"id": "15595320_2_2339", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Subject, RA patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15595320_2_2340", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Subject, RA patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15595320_2_2341", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Subject, RA patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15595320_2_2342", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Subject, RA patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15595320_2_2343", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Subject, RA patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15595320_2_2344", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "15595320_2_2345", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_2_2346", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_2_2347", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_2_2348", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_2_2349", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_2_2350", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "RA"}, {"id": "15595320_2_2351", "context": "Methotrexate (MTX) is a commonly used second line agent for RA, and there have been several recent reports of Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder in MTX-treated RA patients.", "question": "adverse event. Treatment, MTX-treated. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_2_2352", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "azathioprine"}, {"id": "18505911_2_2353", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_2_2354", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_2_2355", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_2_2356", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_2_2357", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_2_2358", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_2_2359", "context": "To describe a case of azathioprine-induced warfarin resistance, present a literature review on warfarin-azathioprine interactions, and provide recommendations on appropriate management of this clinically significant interaction.", "question": "adverse event. Treatment, azathioprine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_4_2360", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel"}, {"id": "16515630_4_2361", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_4_2362", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_4_2363", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_4_2364", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_4_2365", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_4_2366", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_4_2367", "context": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids.", "question": "adverse event. Treatment, paclitaxel therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_2_2368", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Subject, Two patients with adrenal carcinoma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "2830062_2_2369", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Subject, Two patients with adrenal carcinoma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "2830062_2_2370", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Subject, Two patients with adrenal carcinoma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "Two"}, {"id": "2830062_2_2371", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Subject, Two patients with adrenal carcinoma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "2830062_2_2372", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Subject, Two patients with adrenal carcinoma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "2830062_2_2373", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane"}, {"id": "2830062_2_2374", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_2_2375", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2830062_2_2376", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2830062_2_2377", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_2_2378", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2830062_2_2379", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "adrenal carcinoma"}, {"id": "2830062_2_2380", "context": "Two patients with adrenal carcinoma treated with 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy were studied.", "question": "potential therapeutic event. Treatment, 2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane (o,p'-DDD) as adjuvant therapy. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8430717_3_2381", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8430717_3_2382", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8430717_3_2383", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8430717_3_2384", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8430717_3_2385", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8430717_3_2386", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "8430717_3_2387", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8430717_3_2388", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_3_2389", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_3_2390", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_3_2391", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_3_2392", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_3_2393", "context": "METHODS: Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure.", "question": "adverse event. Treatment, acyclovir overdose. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "354311_1_2394", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Subject, 8-year-old girl. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "8-year-old"}, {"id": "354311_1_2395", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Subject, 8-year-old girl. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "354311_1_2396", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Subject, 8-year-old girl. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "354311_1_2397", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Subject, 8-year-old girl. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "354311_1_2398", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Subject, 8-year-old girl. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "354311_1_2399", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCG"}, {"id": "354311_1_2400", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "354311_1_2401", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "354311_1_2402", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "354311_1_2403", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "354311_1_2404", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "354311_1_2405", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "354311_1_2406", "context": "An 8-year-old girl, who had been vaccinated with BCG without subsequent regional reactions, developed osteomyelitis in the left calcaneus 7 months later.", "question": "adverse event. Treatment, BCG. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_3_2407", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "DGTX; FAB"}, {"id": "1469187_3_2408", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_3_2409", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1469187_3_2410", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1469187_3_2411", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_3_2412", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1469187_3_2413", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1469187_3_2414", "context": "Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac DGTX toxicity (total AV-block) persisted.", "question": "adverse event. Treatment, DGTX. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_1_2415", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "7369302_1_2416", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_1_2417", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_1_2418", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_1_2419", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_1_2420", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_1_2421", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_1_2422", "context": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.", "question": "adverse event. Treatment, quinine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1275625_4_2423", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "magnesium sulfate"}, {"id": "1275625_4_2424", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1275625_4_2425", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1275625_4_2426", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1275625_4_2427", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1275625_4_2428", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1275625_4_2429", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "toxemia of pregnancy"}, {"id": "1275625_4_2430", "context": "A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of magnesium sulfate for toxemia of pregnancy.", "question": "adverse event. Treatment, magnesium sulfate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8124920_1_2431", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8124920_1_2432", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "8124920_1_2433", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8124920_1_2434", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8124920_1_2435", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8124920_1_2436", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8124920_1_2437", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "8124920_1_2438", "context": "Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.", "question": "adverse event. Treatment, low-dose methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_3_2439", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Subject, Patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15061230_3_2440", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Subject, Patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15061230_3_2441", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Subject, Patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15061230_3_2442", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Subject, Patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15061230_3_2443", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Subject, Patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15061230_3_2444", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "15061230_3_2445", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_3_2446", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_3_2447", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_3_2448", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_3_2449", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_3_2450", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_3_2451", "context": "Patients should be informed about the risk of osteonecrosis when taking dexamethasone as an antiemetic drug.", "question": "adverse event. Treatment, dexamethasone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_5_2452", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Subject, a patient with inoperable pancreatic cancer. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16317298_5_2453", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Subject, a patient with inoperable pancreatic cancer. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16317298_5_2454", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Subject, a patient with inoperable pancreatic cancer. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16317298_5_2455", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Subject, a patient with inoperable pancreatic cancer. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16317298_5_2456", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Subject, a patient with inoperable pancreatic cancer. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16317298_5_2457", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "16317298_5_2458", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_5_2459", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_5_2460", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_5_2461", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_5_2462", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_5_2463", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "inoperable pancreatic cancer"}, {"id": "16317298_5_2464", "context": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation-recall related to gemcitabine and review literature.", "question": "adverse event. Treatment, gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12836099_2_2465", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Subject, a 14-year-old male. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "14-year-old"}, {"id": "12836099_2_2466", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Subject, a 14-year-old male. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "12836099_2_2467", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Subject, a 14-year-old male. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12836099_2_2468", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Subject, a 14-year-old male. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12836099_2_2469", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Subject, a 14-year-old male. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12836099_2_2470", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisolone"}, {"id": "12836099_2_2471", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12836099_2_2472", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12836099_2_2473", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "12836099_2_2474", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12836099_2_2475", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "6 weeks"}, {"id": "12836099_2_2476", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12836099_2_2477", "context": "We report a case of SJS in a 14-year-old male with nephrotic syndrome, who was treated with oral prednisolone for 6 weeks.", "question": "adverse event. Treatment, oral prednisolone for 6 weeks. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_1_2478", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Subject, A 45-year-old woman with thyrotoxicosis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "45-year-old"}, {"id": "6865827_1_2479", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Subject, A 45-year-old woman with thyrotoxicosis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "6865827_1_2480", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Subject, A 45-year-old woman with thyrotoxicosis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_1_2481", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Subject, A 45-year-old woman with thyrotoxicosis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_1_2482", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Subject, A 45-year-old woman with thyrotoxicosis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_1_2483", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "6865827_1_2484", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_1_2485", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_1_2486", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_1_2487", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_1_2488", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_1_2489", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "thyrotoxicosis"}, {"id": "6865827_1_2490", "context": "A 45-year-old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil.", "question": "adverse event. Treatment, propylthiouracil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_3_2491", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ACTH"}, {"id": "3136101_3_2492", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_3_2493", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_3_2494", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_3_2495", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_3_2496", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_3_2497", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3136101_3_2498", "context": "We wish to call for cautious approach at time of cessation of prolonged ACTH therapy because of possible unexpected and only partially understood hazardous side effects such as hyperkalemia.", "question": "adverse event. Treatment, cessation of prolonged ACTH. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6401771_1_2499", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C; 5-fluorouracil"}, {"id": "6401771_1_2500", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6401771_1_2501", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6401771_1_2502", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6401771_1_2503", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6401771_1_2504", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6401771_1_2505", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "gastric carcinoma"}, {"id": "6401771_1_2506", "context": "Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.", "question": "adverse event. Treatment, long-term mitomycin C and 5-fluorouracil therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "mitomycin C; 5-fluorouracil"}, {"id": "25842648_6_2507", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "selective serotonin reuptake inhibitors (SSRI); fentanyl"}, {"id": "25842648_6_2508", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25842648_6_2509", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25842648_6_2510", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25842648_6_2511", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25842648_6_2512", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25842648_6_2513", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25842648_6_2514", "context": "Although this article focuses on serotonin syndrome as a result of an adverse interaction of selective serotonin reuptake inhibitors (SSRI) and fentanyl, it is important for not only anesthesia professionals, but all clinicians--such as those in emergency medicine and critical care--to be aware of this syndrome and its management.", "question": "adverse event. Treatment, selective serotonin reuptake inhibitors; fentanyl. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "selective serotonin reuptake inhibitors (SSRI); fentanyl"}, {"id": "6794018_1_2515", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Subject, a 61-year-old diabetic patient who presented wit hypoglycaemic coma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "61-year-old"}, {"id": "6794018_1_2516", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Subject, a 61-year-old diabetic patient who presented wit hypoglycaemic coma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6794018_1_2517", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Subject, a 61-year-old diabetic patient who presented wit hypoglycaemic coma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6794018_1_2518", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Subject, a 61-year-old diabetic patient who presented wit hypoglycaemic coma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6794018_1_2519", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Subject, a 61-year-old diabetic patient who presented wit hypoglycaemic coma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "hypoglycaemic coma"}, {"id": "6794018_1_2520", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "glibenclamide"}, {"id": "6794018_1_2521", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_1_2522", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_1_2523", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_1_2524", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_1_2525", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_1_2526", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "diabetic"}, {"id": "6794018_1_2527", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.", "question": "adverse event. Treatment, glibenclamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_10_2528", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Subject, case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22677303_10_2529", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Subject, case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22677303_10_2530", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Subject, case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22677303_10_2531", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Subject, case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22677303_10_2532", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Subject, case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22677303_10_2533", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cloxacillin; warfarin"}, {"id": "22677303_10_2534", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_10_2535", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_10_2536", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_10_2537", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_10_2538", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_10_2539", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_10_2540", "context": "In the presented case, the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity.", "question": "adverse event. Treatment, cloxacillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; cloxacillin"}, {"id": "7783891_2_2541", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sumatriptan"}, {"id": "7783891_2_2542", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_2_2543", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_2_2544", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_2_2545", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_2_2546", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_2_2547", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_2_2548", "context": "Cardiac arrest following use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_4_2549", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Subject, one patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1422497_4_2550", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Subject, one patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1422497_4_2551", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Subject, one patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "one"}, {"id": "1422497_4_2552", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Subject, one patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1422497_4_2553", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Subject, one patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1422497_4_2554", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alum"}, {"id": "1422497_4_2555", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_4_2556", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_4_2557", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_4_2558", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_4_2559", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_4_2560", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_4_2561", "context": "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.", "question": "adverse event. Treatment, receiving continuous bladder irrigations with alum. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_5_2562", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Subject, Nine azotemic patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6671350_5_2563", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Subject, Nine azotemic patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6671350_5_2564", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Subject, Nine azotemic patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Nine"}, {"id": "6671350_5_2565", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Subject, Nine azotemic patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6671350_5_2566", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Subject, Nine azotemic patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "azotemic"}, {"id": "6671350_5_2567", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cephalosporin; moxalactam"}, {"id": "6671350_5_2568", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_5_2569", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_5_2570", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_5_2571", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_5_2572", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_5_2573", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_5_2574", "context": "Nine azotemic patients who developed a coagulopathy associated with the use of either cephalosporin or moxalactam antibiotics are reported.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_10_2575", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Subject, fetuses. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "fetuses"}, {"id": "8442800_10_2576", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Subject, fetuses. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8442800_10_2577", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Subject, fetuses. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8442800_10_2578", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Subject, fetuses. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8442800_10_2579", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Subject, fetuses. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8442800_10_2580", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "8442800_10_2581", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_10_2582", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8442800_10_2583", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8442800_10_2584", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_10_2585", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8442800_10_2586", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_10_2587", "context": "This report suggests that the poor prognosis previously given to fetuses exposed to disulfiram in the first trimester may not be warranted.", "question": "adverse event. Treatment, disulfiram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_6_2588", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "caffeine"}, {"id": "10592946_6_2589", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_6_2590", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_6_2591", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_6_2592", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_6_2593", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_6_2594", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_6_2595", "context": "We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.", "question": "adverse event. Treatment, caffeine toxicity. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18837734_2_2596", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Subject, an 81-year-old-man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "81-year-old"}, {"id": "18837734_2_2597", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Subject, an 81-year-old-man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "18837734_2_2598", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Subject, an 81-year-old-man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18837734_2_2599", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Subject, an 81-year-old-man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18837734_2_2600", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Subject, an 81-year-old-man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18837734_2_2601", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "erlotinib"}, {"id": "18837734_2_2602", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18837734_2_2603", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18837734_2_2604", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18837734_2_2605", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18837734_2_2606", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18837734_2_2607", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18837734_2_2608", "context": "The aim of this paper is to report the case of rosaceiform eruption induced by erlotinib in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.", "question": "adverse event. Treatment, erlotinib; skin scraping. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11295724_1_2609", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Subject, An 11-year-old boy; graft-versus-host disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "11-year-old"}, {"id": "11295724_1_2610", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Subject, An 11-year-old boy; graft-versus-host disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "11295724_1_2611", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Subject, An 11-year-old boy; graft-versus-host disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11295724_1_2612", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Subject, An 11-year-old boy; graft-versus-host disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11295724_1_2613", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Subject, An 11-year-old boy; graft-versus-host disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11295724_1_2614", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clofazimine"}, {"id": "11295724_1_2615", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11295724_1_2616", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11295724_1_2617", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11295724_1_2618", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 years"}, {"id": "11295724_1_2619", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11295724_1_2620", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "graft-versus-host disease"}, {"id": "11295724_1_2621", "context": "An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.", "question": "adverse event. Treatment, clofazimine treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3174043_3_2622", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3174043_3_2623", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3174043_3_2624", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3174043_3_2625", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3174043_3_2626", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3174043_3_2627", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "niacin"}, {"id": "3174043_3_2628", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "3174043_3_2629", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3174043_3_2630", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "3174043_3_2631", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3174043_3_2632", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3174043_3_2633", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3174043_3_2634", "context": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated.", "question": "adverse event. Treatment, high doses of oral niacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_2_2635", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Subject, renal transplanted patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_2_2636", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Subject, renal transplanted patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_2_2637", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Subject, renal transplanted patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14697943_2_2638", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Subject, renal transplanted patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_2_2639", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Subject, renal transplanted patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal transplanted"}, {"id": "14697943_2_2640", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrolimus"}, {"id": "14697943_2_2641", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_2_2642", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_2_2643", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_2_2644", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_2_2645", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_2_2646", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_2_2647", "context": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17387702_2_2648", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Subject, an 11-year-old female treated for mediastinal T-cell lymphoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "11-year-old"}, {"id": "17387702_2_2649", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Subject, an 11-year-old female treated for mediastinal T-cell lymphoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "17387702_2_2650", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Subject, an 11-year-old female treated for mediastinal T-cell lymphoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17387702_2_2651", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Subject, an 11-year-old female treated for mediastinal T-cell lymphoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17387702_2_2652", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Subject, an 11-year-old female treated for mediastinal T-cell lymphoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17387702_2_2653", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate (HDMTX)"}, {"id": "17387702_2_2654", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "17387702_2_2655", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "second cycle"}, {"id": "17387702_2_2656", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17387702_2_2657", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17387702_2_2658", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17387702_2_2659", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "mediastinal T-cell lymphoma"}, {"id": "17387702_2_2660", "context": "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX).", "question": "adverse event. Treatment, following the second cycle of high-dose methotrexate (HDMTX). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11236070_3_2661", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Subject, three cases of patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_3_2662", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Subject, three cases of patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_3_2663", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Subject, three cases of patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11236070_3_2664", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Subject, three cases of patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_3_2665", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Subject, three cases of patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_3_2666", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "11236070_3_2667", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_3_2668", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_3_2669", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_3_2670", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_3_2671", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_3_2672", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_3_2673", "context": "We report three cases of patients who developed leukopenia during olanzapine treatment.", "question": "adverse event. Treatment, olanzapine treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_2_2674", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin; colchicine"}, {"id": "17921794_2_2675", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_2_2676", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_2_2677", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_2_2678", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_2_2679", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_2_2680", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_2_2681", "context": "Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine.", "question": "adverse event. Treatment, the combined use of simvastatin and colchicine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "simvastatin; colchicine"}, {"id": "4063627_1_2682", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Subject, A 35-year-old man with seropositive rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "35-year-old"}, {"id": "4063627_1_2683", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Subject, A 35-year-old man with seropositive rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "4063627_1_2684", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Subject, A 35-year-old man with seropositive rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4063627_1_2685", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Subject, A 35-year-old man with seropositive rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4063627_1_2686", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Subject, A 35-year-old man with seropositive rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4063627_1_2687", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fenclofenac"}, {"id": "4063627_1_2688", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_1_2689", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_1_2690", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_1_2691", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_1_2692", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_1_2693", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "seropositive rheumatoid arthritis"}, {"id": "4063627_1_2694", "context": "A 35-year-old man with seropositive rheumatoid arthritis developed selective IgA deficiency during treatment with fenclofenac.", "question": "adverse event. Treatment, fenclofenac. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15461766_1_2695", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Subject, two newborns with congenital heart anomalies. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "newborns"}, {"id": "15461766_1_2696", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Subject, two newborns with congenital heart anomalies. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15461766_1_2697", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Subject, two newborns with congenital heart anomalies. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "15461766_1_2698", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Subject, two newborns with congenital heart anomalies. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15461766_1_2699", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Subject, two newborns with congenital heart anomalies. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15461766_1_2700", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prostaglandin E1"}, {"id": "15461766_1_2701", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15461766_1_2702", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15461766_1_2703", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15461766_1_2704", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15461766_1_2705", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15461766_1_2706", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "congenital heart anomalies"}, {"id": "15461766_1_2707", "context": "In this report, two newborns with congenital heart anomalies demonstrated the harlequin color change, one whose skin findings showed a course related to the dose of systemic prostaglandin E1, suggesting a possible association.", "question": "adverse event. Treatment, prostaglandin E1. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_4_2708", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Subject, infants. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "infants"}, {"id": "8442800_4_2709", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Subject, infants. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8442800_4_2710", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Subject, infants. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8442800_4_2711", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Subject, infants. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8442800_4_2712", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Subject, infants. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8442800_4_2713", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "8442800_4_2714", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_4_2715", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8442800_4_2716", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8442800_4_2717", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_4_2718", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8442800_4_2719", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8442800_4_2720", "context": "Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies.", "question": "adverse event. Treatment, disulfiram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_3_2721", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15895899_3_2722", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_3_2723", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_3_2724", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_3_2725", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_3_2726", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_3_2727", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15895899_3_2728", "context": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis.", "question": "adverse event. Treatment, infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_4_2729", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "postmenopausal"}, {"id": "12477460_4_2730", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12477460_4_2731", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12477460_4_2732", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12477460_4_2733", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12477460_4_2734", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "12477460_4_2735", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_4_2736", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_4_2737", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_4_2738", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_4_2739", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_4_2740", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "breast cancer"}, {"id": "12477460_4_2741", "context": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer: a case report.", "question": "adverse event. Treatment, tamoxifen therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17123120_1_2742", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Tacrolimus"}, {"id": "17123120_1_2743", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17123120_1_2744", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17123120_1_2745", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17123120_1_2746", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17123120_1_2747", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17123120_1_2748", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nephrotic syndrome"}, {"id": "17123120_1_2749", "context": "Tacrolimus-induced HUS: an unusual cause of acute renal failure in nephrotic syndrome.", "question": "adverse event. Treatment, Tacrolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17090724_2_2750", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Subject, a woman with cryptococcal meningitis and no previous cardiac disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_2_2751", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Subject, a woman with cryptococcal meningitis and no previous cardiac disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "17090724_2_2752", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Subject, a woman with cryptococcal meningitis and no previous cardiac disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_2_2753", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Subject, a woman with cryptococcal meningitis and no previous cardiac disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_2_2754", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Subject, a woman with cryptococcal meningitis and no previous cardiac disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_2_2755", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "17090724_2_2756", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "17090724_2_2757", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_2_2758", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_2_2759", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_2_2760", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_2_2761", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cryptococcal meningitis"}, {"id": "17090724_2_2762", "context": "OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity.", "question": "adverse event. Treatment, an acute overdose of amphotericin B. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3542612_2_2763", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3542612_2_2764", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3542612_2_2765", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3542612_2_2766", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3542612_2_2767", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3542612_2_2768", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "3542612_2_2769", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3542612_2_2770", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3542612_2_2771", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3542612_2_2772", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3542612_2_2773", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3542612_2_2774", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3542612_2_2775", "context": "We report a case of a bullous lichenoid eruption due to the intake of captopril.", "question": "adverse event. Treatment, captopril. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_4_2776", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "steroid"}, {"id": "2830062_4_2777", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "increasing"}, {"id": "2830062_4_2778", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "2830062_4_2779", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "2830062_4_2780", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_4_2781", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "2830062_4_2782", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "The hypoadrenalism"}, {"id": "2830062_4_2783", "context": "The hypoadrenalism was overcome by increasing steroid replacement therapy.", "question": "potential therapeutic event. Treatment, increasing steroid replacement therapy. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16265343_1_2784", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Interferon alpha-2b"}, {"id": "16265343_1_2785", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16265343_1_2786", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16265343_1_2787", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16265343_1_2788", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16265343_1_2789", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16265343_1_2790", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16265343_1_2791", "context": "DIAGNOSIS: Interferon alpha-2b-induced cardiomyopathy.", "question": "adverse event. Treatment, Interferon alpha-2b. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_1_2792", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "systemic tissue plasminogen activator"}, {"id": "8610807_1_2793", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_1_2794", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_1_2795", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_1_2796", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_1_2797", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_1_2798", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_1_2799", "context": "Choroidal hemorrhage associated with systemic tissue plasminogen activator.", "question": "adverse event. Treatment, systemic tissue plasminogen activator. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_1_2800", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17665812_1_2801", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17665812_1_2802", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17665812_1_2803", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17665812_1_2804", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17665812_1_2805", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Clozapine"}, {"id": "17665812_1_2806", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_1_2807", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_1_2808", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_1_2809", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_1_2810", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_1_2811", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic schizophrenia with suicidal tendencies"}, {"id": "17665812_1_2812", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "adverse event. Treatment, Clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17665812_1_2813", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "17665812_1_2814", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "17665812_1_2815", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "17665812_1_2816", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "17665812_1_2817", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Subject, a patient with chronic schizophrenia with suicidal tendencies. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "17665812_1_2818", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quetiapine"}, {"id": "17665812_1_2819", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_1_2820", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17665812_1_2821", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17665812_1_2822", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_1_2823", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17665812_1_2824", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_1_2825", "context": "Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.", "question": "potential therapeutic event. Treatment, quetiapine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18675768_1_2826", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propafenone; citalopram"}, {"id": "18675768_1_2827", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_1_2828", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_1_2829", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_1_2830", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "long-term"}, {"id": "18675768_1_2831", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_1_2832", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_1_2833", "context": "Adverse effects of propafenone after long-term therapy with the addition of citalopram.", "question": "adverse event. Treatment, long-term therapy with the addition of citalopram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "citalopram; propafenone"}, {"id": "7081289_2_2834", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Subject, an adult. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "adult"}, {"id": "7081289_2_2835", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Subject, an adult. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7081289_2_2836", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Subject, an adult. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7081289_2_2837", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Subject, an adult. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7081289_2_2838", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Subject, an adult. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7081289_2_2839", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cimetidine"}, {"id": "7081289_2_2840", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_2_2841", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_2_2842", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_2_2843", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_2_2844", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_2_2845", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_2_2846", "context": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed.", "question": "adverse event. Treatment, cimetidine is discussed. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_3_2847", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Subject, 4 patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16609346_3_2848", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Subject, 4 patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16609346_3_2849", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Subject, 4 patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "4"}, {"id": "16609346_3_2850", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Subject, 4 patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16609346_3_2851", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Subject, 4 patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16609346_3_2852", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin"}, {"id": "16609346_3_2853", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_3_2854", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_3_2855", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_3_2856", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 weeks"}, {"id": "16609346_3_2857", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_3_2858", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_3_2859", "context": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug.", "question": "adverse event. Treatment, within 2 weeks of starting treatment with a statin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_1_2860", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Subject, patient's. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15927910_1_2861", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Subject, patient's. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15927910_1_2862", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Subject, patient's. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15927910_1_2863", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Subject, patient's. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15927910_1_2864", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Subject, patient's. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15927910_1_2865", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentamidine"}, {"id": "15927910_1_2866", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "third dose"}, {"id": "15927910_1_2867", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_1_2868", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_1_2869", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_1_2870", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_1_2871", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_1_2872", "context": "After only the third dose of pentamidine, it was noted that the patient's heart rate had decreased to 48 beats/minute.", "question": "adverse event. Treatment, third dose of pentamidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_2_2873", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Subject, A 44-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "44-year-old"}, {"id": "7056119_2_2874", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Subject, A 44-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "7056119_2_2875", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Subject, A 44-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7056119_2_2876", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Subject, A 44-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7056119_2_2877", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Subject, A 44-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7056119_2_2878", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone; disopyramide; quinidine"}, {"id": "7056119_2_2879", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_2_2880", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_2_2881", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_2_2882", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_2_2883", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_2_2884", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_2_2885", "context": "A 44-year-old woman is described in whom amiodarone, disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, torsade de pointes).", "question": "adverse event. Treatment, amiodarone, disopyramide, and quinidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_9_2886", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Azathioprine"}, {"id": "18505911_9_2887", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_9_2888", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_9_2889", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_9_2890", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_9_2891", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_9_2892", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_9_2893", "context": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale, and a possible causative agent according to the Drug Interaction Probability Scale.", "question": "adverse event. Treatment, Azathioprine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8442800_2_2894", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Subject, patients with a history of alcohol abuse. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8442800_2_2895", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Subject, patients with a history of alcohol abuse. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8442800_2_2896", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Subject, patients with a history of alcohol abuse. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8442800_2_2897", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Subject, patients with a history of alcohol abuse. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8442800_2_2898", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Subject, patients with a history of alcohol abuse. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8442800_2_2899", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Disulfiram"}, {"id": "8442800_2_2900", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8442800_2_2901", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8442800_2_2902", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8442800_2_2903", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8442800_2_2904", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8442800_2_2905", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "history of alcohol abuse"}, {"id": "8442800_2_2906", "context": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse.", "question": "potential therapeutic event. Treatment, Disulfiram. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15507779_2_2907", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Subject, human immunodeficiency virus (HIV)-infected patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15507779_2_2908", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Subject, human immunodeficiency virus (HIV)-infected patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15507779_2_2909", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Subject, human immunodeficiency virus (HIV)-infected patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15507779_2_2910", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Subject, human immunodeficiency virus (HIV)-infected patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15507779_2_2911", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Subject, human immunodeficiency virus (HIV)-infected patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15507779_2_2912", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Nevirapine"}, {"id": "15507779_2_2913", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_2_2914", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15507779_2_2915", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15507779_2_2916", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_2_2917", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15507779_2_2918", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "immunodeficiency virus"}, {"id": "15507779_2_2919", "context": "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis.", "question": "potential therapeutic event. Treatment, Nevirapine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8391300_2_2920", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ergotamine"}, {"id": "8391300_2_2921", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8391300_2_2922", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8391300_2_2923", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8391300_2_2924", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8391300_2_2925", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8391300_2_2926", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8391300_2_2927", "context": "Vasospasm associated with ergotamine is a well-known phenomenon.", "question": "adverse event. Treatment, ergotamine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3359700_1_2928", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine A"}, {"id": "3359700_1_2929", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "3359700_1_2930", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3359700_1_2931", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3359700_1_2932", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "six-week course"}, {"id": "3359700_1_2933", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3359700_1_2934", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3359700_1_2935", "context": "After a six-week course of low-dose cyclosporine A, she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.", "question": "adverse event. Treatment, After a six-week course of low-dose cyclosporine A. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_4_2936", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin; amiodarone; statin"}, {"id": "21630612_4_2937", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_4_2938", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_4_2939", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_4_2940", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "chronic"}, {"id": "21630612_4_2941", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_4_2942", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_4_2943", "context": "We report a case of severe simvastatin-induced rhabdomyolysis triggered by the addition of amiodarone to previously well-tolerated chronic statin therapy.", "question": "adverse event. Treatment, simvastatin; the addition of amiodarone to previously well-tolerated chronic statin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "amiodarone; simvastatin"}, {"id": "23115227_3_2944", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Subject, a 50-year-old transgender female. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "50-year-old"}, {"id": "23115227_3_2945", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Subject, a 50-year-old transgender female. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "transgender female"}, {"id": "23115227_3_2946", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Subject, a 50-year-old transgender female. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23115227_3_2947", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Subject, a 50-year-old transgender female. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23115227_3_2948", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Subject, a 50-year-old transgender female. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23115227_3_2949", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "TRIO"}, {"id": "23115227_3_2950", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23115227_3_2951", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23115227_3_2952", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23115227_3_2953", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23115227_3_2954", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23115227_3_2955", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "HIV infection and recurrent deep vein thrombosis"}, {"id": "23115227_3_2956", "context": "In January 2010, a 50-year-old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen.", "question": "potential therapeutic event. Treatment, TRIO. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10870095_7_2957", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "zafirlukast"}, {"id": "10870095_7_2958", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10870095_7_2959", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10870095_7_2960", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10870095_7_2961", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10870095_7_2962", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10870095_7_2963", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10870095_7_2964", "context": "In vitro inhibition of CYP2C9 by zafirlukast is consistent with clinical studies showing impaired clearance of  S-warfarin and enhanced anti-thrombotic effects, although the in vitro IC(50) value is higher than the usual range of clinically relevant plasma concentrations.", "question": "potential therapeutic event. Treatment, zafirlukast. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18755414_6_2965", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Subject, patients who have asymptomatic meningioma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18755414_6_2966", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Subject, patients who have asymptomatic meningioma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18755414_6_2967", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Subject, patients who have asymptomatic meningioma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18755414_6_2968", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Subject, patients who have asymptomatic meningioma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18755414_6_2969", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Subject, patients who have asymptomatic meningioma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18755414_6_2970", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aspirin"}, {"id": "18755414_6_2971", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_6_2972", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_6_2973", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_6_2974", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_6_2975", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_6_2976", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "asymptomatic meningioma"}, {"id": "18755414_6_2977", "context": "Although it is difficult to solely attribute intratumoral hemorrhage to aspirin, we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.", "question": "adverse event. Treatment, aspirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_3_2978", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IVTA"}, {"id": "18751717_3_2979", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_3_2980", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_3_2981", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18751717_3_2982", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_3_2983", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_3_2984", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_3_2985", "context": "CONCLUSIONS: The fundus picture shown in these cases may be typical of ASPPC after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_3_2986", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "9149614_3_2987", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_3_2988", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_3_2989", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_3_2990", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_3_2991", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_3_2992", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9149614_3_2993", "context": "The probable proarrhythmic action of amiodarone, although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.", "question": "adverse event. Treatment, amiodarone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_4_2994", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "NMSC; imiquimod; infliximab"}, {"id": "21658326_4_2995", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_4_2996", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_4_2997", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_4_2998", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_4_2999", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_4_3000", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "NMSC; psoriasis"}, {"id": "21658326_4_3001", "context": "We present two cases of severe, atypical ASRs which occurred during NMSC treatment with imiquimod in the context of infliximab administration for psoriasis, and consider the grounds supporting a non-fortuitous association.", "question": "adverse event. Treatment, imiquimod in the context of infliximab administration. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "imiquimod; infliximab"}, {"id": "3964363_1_3002", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "3964363_1_3003", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "3964363_1_3004", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3964363_1_3005", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3964363_1_3006", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3964363_1_3007", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3964363_1_3008", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3964363_1_3009", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "adverse event. Treatment, propranolol overdose. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3964363_1_3010", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "glucagon"}, {"id": "3964363_1_3011", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "3964363_1_3012", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "3964363_1_3013", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "3964363_1_3014", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3964363_1_3015", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "3964363_1_3016", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "esophageal spasm preventing extrication of an orogastric lavage tube"}, {"id": "3964363_1_3017", "context": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.", "question": "potential therapeutic event. Treatment, intravenous glucagon. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "4063627_2_3018", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Fenclofenac"}, {"id": "4063627_2_3019", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_2_3020", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_2_3021", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_2_3022", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_2_3023", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_2_3024", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_2_3025", "context": "Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis.", "question": "adverse event. Treatment, Fenclofenac. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_2_3026", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Subject, pediatric population. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "10082597_2_3027", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Subject, pediatric population. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_2_3028", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Subject, pediatric population. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10082597_2_3029", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Subject, pediatric population. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_2_3030", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Subject, pediatric population. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_2_3031", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Naproxen"}, {"id": "10082597_2_3032", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_2_3033", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_2_3034", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_2_3035", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_2_3036", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_2_3037", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_2_3038", "context": "Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.", "question": "adverse event. Treatment, Naproxen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10870095_2_3039", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Zafirlukast"}, {"id": "10870095_2_3040", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10870095_2_3041", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10870095_2_3042", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10870095_2_3043", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10870095_2_3044", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10870095_2_3045", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "allergic and exercise-induced asthma"}, {"id": "10870095_2_3046", "context": "Zafirlukast is a cysteinyl leukotriene antagonist used to treat allergic and exercise-induced asthma.", "question": "potential therapeutic event. Treatment, Zafirlukast is a cysteinyl leukotriene antagonist. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18364401_3_3047", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18364401_3_3048", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_3_3049", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_3_3050", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_3_3051", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_3_3052", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_3_3053", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_3_3054", "context": "Rapidly developing hyperglycemia during treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_1_3055", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Subject, The first patient was a 61-year-old man with a 30-year history of fistulizing CD. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "61-year-old"}, {"id": "10579985_1_3056", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Subject, The first patient was a 61-year-old man with a 30-year history of fistulizing CD. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "10579985_1_3057", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Subject, The first patient was a 61-year-old man with a 30-year history of fistulizing CD. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_1_3058", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Subject, The first patient was a 61-year-old man with a 30-year history of fistulizing CD. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_1_3059", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Subject, The first patient was a 61-year-old man with a 30-year history of fistulizing CD. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_1_3060", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "10579985_1_3061", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_1_3062", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_1_3063", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_1_3064", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "9 months"}, {"id": "10579985_1_3065", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_1_3066", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "fistulizing CD"}, {"id": "10579985_1_3067", "context": "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.", "question": "adverse event. Treatment, 9 months after treatment with infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7761316_2_3068", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Subject, pediatric oncology patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "7761316_2_3069", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Subject, pediatric oncology patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7761316_2_3070", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Subject, pediatric oncology patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7761316_2_3071", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Subject, pediatric oncology patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7761316_2_3072", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Subject, pediatric oncology patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7761316_2_3073", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "7761316_2_3074", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7761316_2_3075", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7761316_2_3076", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7761316_2_3077", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7761316_2_3078", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7761316_2_3079", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "oncology"}, {"id": "7761316_2_3080", "context": "Recognition of a potential drug-induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide.", "question": "adverse event. Treatment, ifosfamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_3_3081", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Subject, a patient with chronic renal failure and ischemic heart disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10225085_3_3082", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Subject, a patient with chronic renal failure and ischemic heart disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10225085_3_3083", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Subject, a patient with chronic renal failure and ischemic heart disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10225085_3_3084", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Subject, a patient with chronic renal failure and ischemic heart disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10225085_3_3085", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Subject, a patient with chronic renal failure and ischemic heart disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10225085_3_3086", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bupivacaine; lidocaine"}, {"id": "10225085_3_3087", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_3_3088", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_3_3089", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "10225085_3_3090", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_3_3091", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_3_3092", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic renal failure and ischemic heart disease"}, {"id": "10225085_3_3093", "context": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, an axillary block with bupivacaine and additional injection of lidocaine in the operative field. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "bupivacaine; lidocaine"}, {"id": "19884751_1_3094", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amikacin"}, {"id": "19884751_1_3095", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_1_3096", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19884751_1_3097", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19884751_1_3098", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_1_3099", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19884751_1_3100", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_1_3101", "context": "Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia.", "question": "adverse event. Treatment, Amikacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_2_3102", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "15368548_2_3103", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_2_3104", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15368548_2_3105", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15368548_2_3106", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_2_3107", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15368548_2_3108", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "L-asparaginase-induced severe necrotizing pancreatitis"}, {"id": "15368548_2_3109", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "potential therapeutic event. Treatment, percutaneous drainage. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15368548_2_3110", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "15368548_2_3111", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_2_3112", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_2_3113", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_2_3114", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_2_3115", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_2_3116", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_2_3117", "context": "L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.", "question": "adverse event. Treatment, L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4014301_4_3118", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Subject, a patient without underlying heart disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4014301_4_3119", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Subject, a patient without underlying heart disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4014301_4_3120", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Subject, a patient without underlying heart disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4014301_4_3121", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Subject, a patient without underlying heart disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4014301_4_3122", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Subject, a patient without underlying heart disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4014301_4_3123", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "4014301_4_3124", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_4_3125", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_4_3126", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_4_3127", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_4_3128", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_4_3129", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_4_3130", "context": "This report describes the first case of insulin-induced cardiac failure in a patient without underlying heart disease.", "question": "adverse event. Treatment, insulin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_4_3131", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_4_3132", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_4_3133", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_4_3134", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_4_3135", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_4_3136", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "11352235_4_3137", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_4_3138", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_4_3139", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_4_3140", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_4_3141", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_4_3142", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "11352235_4_3143", "context": "OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.", "question": "adverse event. Treatment, leflunomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_1_3144", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "INH"}, {"id": "11804071_1_3145", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_1_3146", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_1_3147", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_1_3148", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_1_3149", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_1_3150", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_1_3151", "context": "INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.", "question": "adverse event. Treatment, INH. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19266307_1_3152", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "epirubicin"}, {"id": "19266307_1_3153", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19266307_1_3154", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19266307_1_3155", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "instillations"}, {"id": "19266307_1_3156", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19266307_1_3157", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19266307_1_3158", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19266307_1_3159", "context": "Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.", "question": "adverse event. Treatment, instillations of epirubicin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_5_3160", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ofloxacin"}, {"id": "11724089_5_3161", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_5_3162", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_5_3163", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_5_3164", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_5_3165", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_5_3166", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_5_3167", "context": "Ofloxacin: a probable cause of toxic epidermal necrolysis.", "question": "adverse event. Treatment, Ofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_1_3168", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Subject, 62-year-old woman; advanced ovarian cancer. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "62-year-old"}, {"id": "16515630_1_3169", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Subject, 62-year-old woman; advanced ovarian cancer. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16515630_1_3170", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Subject, 62-year-old woman; advanced ovarian cancer. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16515630_1_3171", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Subject, 62-year-old woman; advanced ovarian cancer. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16515630_1_3172", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Subject, 62-year-old woman; advanced ovarian cancer. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16515630_1_3173", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paclitaxel; carboplatin"}, {"id": "16515630_1_3174", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "six cycles"}, {"id": "16515630_1_3175", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_1_3176", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "16515630_1_3177", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_1_3178", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_1_3179", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "advanced ovarian cancer"}, {"id": "16515630_1_3180", "context": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.", "question": "adverse event. Treatment, six cycles of paclitaxel and carboplatin as combination chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "paclitaxel; carboplatin"}, {"id": "9704170_1_3181", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Subject, A 21-year-old patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "21-year-old"}, {"id": "9704170_1_3182", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Subject, A 21-year-old patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_1_3183", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Subject, A 21-year-old patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_1_3184", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Subject, A 21-year-old patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_1_3185", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Subject, A 21-year-old patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9704170_1_3186", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "9704170_1_3187", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_1_3188", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_1_3189", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_1_3190", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "during his nineteenth week"}, {"id": "9704170_1_3191", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_1_3192", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "drug-resistant schizophrenia"}, {"id": "9704170_1_3193", "context": "A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia.", "question": "adverse event. Treatment, during his nineteenth week of treatment with clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_1_3194", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Subject, a patient with neuroendocrine tumor of the cervix. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20349794_1_3195", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Subject, a patient with neuroendocrine tumor of the cervix. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20349794_1_3196", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Subject, a patient with neuroendocrine tumor of the cervix. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20349794_1_3197", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Subject, a patient with neuroendocrine tumor of the cervix. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20349794_1_3198", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Subject, a patient with neuroendocrine tumor of the cervix. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20349794_1_3199", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cisplatin"}, {"id": "20349794_1_3200", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_1_3201", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20349794_1_3202", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20349794_1_3203", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_1_3204", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20349794_1_3205", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neuroendocrine tumor of the cervix"}, {"id": "20349794_1_3206", "context": "Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.", "question": "adverse event. Treatment, Cisplatin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6610943_1_3207", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vasopressin"}, {"id": "6610943_1_3208", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6610943_1_3209", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6610943_1_3210", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous; infusion"}, {"id": "6610943_1_3211", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6610943_1_3212", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6610943_1_3213", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6610943_1_3214", "context": "Myoglobinuria and acute renal failure associated with intravenous vasopressin infusion.", "question": "adverse event. Treatment, intravenous vasopressin infusion. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18371508_2_3215", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon alpha-2a; ribavirin"}, {"id": "18371508_2_3216", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18371508_2_3217", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18371508_2_3218", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18371508_2_3219", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18371508_2_3220", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18371508_2_3221", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C"}, {"id": "18371508_2_3222", "context": "We report the first case of fulminant adult respiratory distress syndrome (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.", "question": "adverse event. Treatment, pegylated interferon alpha-2a (pegIFNalpha-2a) and ribavirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_1_3223", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "681921_1_3224", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_1_3225", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_1_3226", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_1_3227", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_1_3228", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_1_3229", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_1_3230", "context": "Catatonia associated with disulfiram therapy.", "question": "adverse event. Treatment, disulfiram therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_5_3231", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "TNF-alpha inhibitors; imiquimod"}, {"id": "21658326_5_3232", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_5_3233", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_5_3234", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_5_3235", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_5_3236", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_5_3237", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_5_3238", "context": "To date, no relation has ever been suggested between TNF-alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod.", "question": "adverse event. Treatment, TNF-alpha inhibitors; imiquimod. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "TNF-alpha inhibitors; imiquimod"}, {"id": "10492493_2_3239", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Losartan"}, {"id": "10492493_2_3240", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10492493_2_3241", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10492493_2_3242", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10492493_2_3243", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10492493_2_3244", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10492493_2_3245", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10492493_2_3246", "context": "Losartan-induced angioedema.", "question": "adverse event. Treatment, Losartan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_1_3247", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mequitazine"}, {"id": "8850251_1_3248", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_1_3249", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_1_3250", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_1_3251", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_1_3252", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_1_3253", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_1_3254", "context": "However, dermatologists should be cautious about a photosensitivity reaction induced by mequitazine or other phenothiazine-derivative drugs.", "question": "adverse event. Treatment, mequitazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_10_3255", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Oxycodone; gabapentin"}, {"id": "18262450_10_3256", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_10_3257", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_10_3258", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_10_3259", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_10_3260", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_10_3261", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "pain"}, {"id": "18262450_10_3262", "context": "Oxycodone-gabapentin also significantly improved pain relief vs gabapentin alone (P = 0.003).", "question": "potential therapeutic event. Treatment, Oxycodone-gabapentin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "Oxycodone; gabapentin"}, {"id": "11147747_1_3263", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Subject, the patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_1_3264", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Subject, the patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11147747_1_3265", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Subject, the patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11147747_1_3266", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Subject, the patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_1_3267", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Subject, the patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_1_3268", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium carbonate; beta-blockers"}, {"id": "11147747_1_3269", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_1_3270", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_1_3271", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_1_3272", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_1_3273", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_1_3274", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_1_3275", "context": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.", "question": "adverse event. Treatment, lithium carbonate and beta-blockers. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "beta-blockers; lithium carbonate"}, {"id": "15286697_2_3276", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bis-chloronitrosourea"}, {"id": "15286697_2_3277", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_2_3278", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_2_3279", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_2_3280", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_2_3281", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_2_3282", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_2_3283", "context": "Pulmonary fibrosis is a severe complication associated with bis-chloronitrosourea (BCNU) therapy.", "question": "adverse event. Treatment, bis-chloronitrosourea (BCNU) therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_5_3284", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Subject, 26-year-old female with diffuse large B-cell lymphoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "26-year-old"}, {"id": "15286697_5_3285", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Subject, 26-year-old female with diffuse large B-cell lymphoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "15286697_5_3286", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Subject, 26-year-old female with diffuse large B-cell lymphoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15286697_5_3287", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Subject, 26-year-old female with diffuse large B-cell lymphoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15286697_5_3288", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Subject, 26-year-old female with diffuse large B-cell lymphoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15286697_5_3289", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCNU"}, {"id": "15286697_5_3290", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "600 mg/m2"}, {"id": "15286697_5_3291", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_5_3292", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_5_3293", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "81 days after"}, {"id": "15286697_5_3294", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_5_3295", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "diffuse large B-cell lymphoma"}, {"id": "15286697_5_3296", "context": "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose BCNU (600 mg/m2).", "question": "adverse event. Treatment, high-dose BCNU (600 mg/m2). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6865827_2_3297", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Subject, The patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_2_3298", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Subject, The patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_2_3299", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Subject, The patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_2_3300", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Subject, The patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_2_3301", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Subject, The patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_2_3302", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methimazole; propylthiouracil"}, {"id": "6865827_2_3303", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_2_3304", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_2_3305", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_2_3306", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "10 weeks later"}, {"id": "6865827_2_3307", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_2_3308", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_2_3309", "context": "The patient was given methimazole instead of propylthiouracil but, 10 weeks later, agranulocytosis again occurred.", "question": "adverse event. Treatment, methimazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_6_3310", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Subject, she. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18675768_6_3311", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Subject, she. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "18675768_6_3312", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Subject, she. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18675768_6_3313", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Subject, she. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18675768_6_3314", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Subject, she. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18675768_6_3315", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "citalopram"}, {"id": "18675768_6_3316", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_6_3317", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_6_3318", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_6_3319", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Three months"}, {"id": "18675768_6_3320", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_6_3321", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_6_3322", "context": "Three months after starting citalopram, she experienced episodes of chest tightness and dizziness.", "question": "adverse event. Treatment, citalopram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_2_3323", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Subject, a small number of patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_2_3324", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Subject, a small number of patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_2_3325", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Subject, a small number of patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "a small number"}, {"id": "3171334_2_3326", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Subject, a small number of patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_2_3327", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Subject, a small number of patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_2_3328", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine"}, {"id": "3171334_2_3329", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_2_3330", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_2_3331", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_2_3332", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_2_3333", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_2_3334", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_2_3335", "context": "Although differential diagnostic alternatives can be considered in all described cases it is very likely that vincristine does cause severe visual loss in a small number of patients.", "question": "adverse event. Treatment, vincristine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18042092_3_3336", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "glatiramer acetate"}, {"id": "18042092_3_3337", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18042092_3_3338", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18042092_3_3339", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18042092_3_3340", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18042092_3_3341", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18042092_3_3342", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18042092_3_3343", "context": "This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) glatiramer acetate can induce skin necrosis as a side effect.", "question": "adverse event. Treatment, glatiramer acetate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_4_3344", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "SSRI"}, {"id": "15522120_4_3345", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_4_3346", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_4_3347", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_4_3348", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_4_3349", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_4_3350", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_4_3351", "context": "SSRI-drugs increase serotonin concentrations and are known to have pruritus and other dermal side effects.", "question": "adverse event. Treatment, SSRI-drugs. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22552763_1_3352", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Subject, patients undergoing total hip and total knee arthroplasty. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22552763_1_3353", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Subject, patients undergoing total hip and total knee arthroplasty. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22552763_1_3354", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Subject, patients undergoing total hip and total knee arthroplasty. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22552763_1_3355", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Subject, patients undergoing total hip and total knee arthroplasty. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22552763_1_3356", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Subject, patients undergoing total hip and total knee arthroplasty. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22552763_1_3357", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Dabigatran etexilate; non-steroidal anti-inflammatory drugs; acetylsalicylic acid"}, {"id": "22552763_1_3358", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22552763_1_3359", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22552763_1_3360", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22552763_1_3361", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22552763_1_3362", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22552763_1_3363", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "total hip and total knee arthroplasty"}, {"id": "22552763_1_3364", "context": "Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.", "question": "adverse event. Treatment, Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "non-steroidal anti-inflammatory drugs; acetylsalicylic acid; Dabigatran etexilate"}, {"id": "16393774_7_3365", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Subject, six cases; in MS patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_7_3366", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Subject, six cases; in MS patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_7_3367", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Subject, six cases; in MS patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "six"}, {"id": "16393774_7_3368", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Subject, six cases; in MS patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_7_3369", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Subject, six cases; in MS patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_7_3370", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN-beta"}, {"id": "16393774_7_3371", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_7_3372", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_7_3373", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_7_3374", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_7_3375", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_7_3376", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "MS"}, {"id": "16393774_7_3377", "context": "Our literature review revealed an additional six cases of onset of inflammatory arthritis in MS patients receiving IFN-beta.", "question": "adverse event. Treatment, receiving IFN-beta. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_5_3378", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disopyramide"}, {"id": "7056119_5_3379", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "300 to 600 mg/day"}, {"id": "7056119_5_3380", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_5_3381", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_5_3382", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "24 hours"}, {"id": "7056119_5_3383", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "Two years"}, {"id": "7056119_5_3384", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_5_3385", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "adverse event. Treatment, Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_5_3386", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "isoproterenol"}, {"id": "7056119_5_3387", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_5_3388", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7056119_5_3389", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7056119_5_3390", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_5_3391", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7056119_5_3392", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "arrhythmia"}, {"id": "7056119_5_3393", "context": "Two years later, 24 hours following an increase in the dose of disopyramide from 300 to 600 mg/day, AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.", "question": "potential therapeutic event. Treatment, isoproterenol. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9865241_3_3394", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Subject, The patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9865241_3_3395", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Subject, The patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9865241_3_3396", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Subject, The patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9865241_3_3397", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Subject, The patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9865241_3_3398", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Subject, The patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9865241_3_3399", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "furosemide"}, {"id": "9865241_3_3400", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_3_3401", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_3_3402", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_3_3403", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_3_3404", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_3_3405", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_3_3406", "context": "The patient was initially treated with hydration and furosemide but developed congestive heart failure.", "question": "adverse event. Treatment, furosemide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21729965_4_3407", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21729965_4_3408", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "21729965_4_3409", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21729965_4_3410", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21729965_4_3411", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21729965_4_3412", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antiretroviral; Implanon"}, {"id": "21729965_4_3413", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21729965_4_3414", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21729965_4_3415", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21729965_4_3416", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21729965_4_3417", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21729965_4_3418", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV-positive"}, {"id": "21729965_4_3419", "context": "We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.", "question": "adverse event. Treatment, antiretroviral. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15595320_4_3420", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "15595320_4_3421", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15595320_4_3422", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15595320_4_3423", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15595320_4_3424", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15595320_4_3425", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15595320_4_3426", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15595320_4_3427", "context": "We hypothesize that decreased renal elimination of MTX induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EBV-associated lymphoproliferative disease.", "question": "adverse event. Treatment, MTX. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19212144_2_3428", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Temsirolimus"}, {"id": "19212144_2_3429", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19212144_2_3430", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19212144_2_3431", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19212144_2_3432", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19212144_2_3433", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19212144_2_3434", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19212144_2_3435", "context": "Temsirolimus-induced glomerulopathy.", "question": "adverse event. Treatment, Temsirolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_4_3436", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11485141_4_3437", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11485141_4_3438", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11485141_4_3439", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11485141_4_3440", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11485141_4_3441", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "11485141_4_3442", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_4_3443", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_4_3444", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_4_3445", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_4_3446", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_4_3447", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_4_3448", "context": "OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_2_3449", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7949255_2_3450", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7949255_2_3451", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7949255_2_3452", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7949255_2_3453", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7949255_2_3454", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX; leucovorin rescue"}, {"id": "7949255_2_3455", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "8 gm/m2 by 6 h continuous"}, {"id": "7949255_2_3456", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_2_3457", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "7949255_2_3458", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "5 days after the second course"}, {"id": "7949255_2_3459", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_2_3460", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7949255_2_3461", "context": "This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.", "question": "adverse event. Treatment, the second course of HD-MTX (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "leucovorin rescue; MTX"}, {"id": "16685007_5_3462", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Subject, Adult and adolescent patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "Adult and adolescen"}, {"id": "16685007_5_3463", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Subject, Adult and adolescent patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16685007_5_3464", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Subject, Adult and adolescent patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16685007_5_3465", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Subject, Adult and adolescent patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16685007_5_3466", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Subject, Adult and adolescent patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16685007_5_3467", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "steroid; prednisone"}, {"id": "16685007_5_3468", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_5_3469", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685007_5_3470", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "16685007_5_3471", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_5_3472", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685007_5_3473", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_5_3474", "context": "Adult and adolescent patients (> or = 12 years old; n = 141) with severe, persistent, oral steroid (prednisone)-dependent asthma.", "question": "adverse event. Treatment, oral steroid (prednisone). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17090724_1_3475", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Subject, in children and in adults with preexisting cardiac disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "in children and in adults"}, {"id": "17090724_1_3476", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Subject, in children and in adults with preexisting cardiac disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_1_3477", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Subject, in children and in adults with preexisting cardiac disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_1_3478", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Subject, in children and in adults with preexisting cardiac disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_1_3479", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Subject, in children and in adults with preexisting cardiac disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "preexisting cardiac disease"}, {"id": "17090724_1_3480", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B deoxycholate"}, {"id": "17090724_1_3481", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "conventional dosages"}, {"id": "17090724_1_3482", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_1_3483", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "17090724_1_3484", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_1_3485", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_1_3486", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_1_3487", "context": "DISCUSSION: Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.", "question": "adverse event. Treatment, Amphotericin B deoxycholate; conventional dosages and infusion rates. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_2_3488", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Subject, male 60 yrs of age. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "60 yrs of age"}, {"id": "11510798_2_3489", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Subject, male 60 yrs of age. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "11510798_2_3490", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Subject, male 60 yrs of age. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11510798_2_3491", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Subject, male 60 yrs of age. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11510798_2_3492", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Subject, male 60 yrs of age. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11510798_2_3493", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxaliplatinum; 5-fluorouracil"}, {"id": "11510798_2_3494", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_2_3495", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_2_3496", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_2_3497", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_2_3498", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_2_3499", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "unresectable rectum carcinoma"}, {"id": "11510798_2_3500", "context": "Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "oxaliplatinum; 5-fluorouracil"}, {"id": "18580694_2_3501", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "piperacillin; cefotiam"}, {"id": "18580694_2_3502", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18580694_2_3503", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18580694_2_3504", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18580694_2_3505", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18580694_2_3506", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18580694_2_3507", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18580694_2_3508", "context": "Thus, tardive seizures in our cases are thought to be related to piperacillin and cefotiam.", "question": "adverse event. Treatment, piperacillin and cefotiam. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "piperacillin; cefotiam"}, {"id": "6873616_1_3509", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Subject, A 55-yr-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "55-yr-old"}, {"id": "6873616_1_3510", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Subject, A 55-yr-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "6873616_1_3511", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Subject, A 55-yr-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6873616_1_3512", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Subject, A 55-yr-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6873616_1_3513", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Subject, A 55-yr-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6873616_1_3514", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thiabendazole"}, {"id": "6873616_1_3515", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_1_3516", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_1_3517", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_1_3518", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_1_3519", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_1_3520", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_1_3521", "context": "A 55-yr-old man developed prolonged jaundice and sicca complex after a course of thiabendazole therapy.", "question": "adverse event. Treatment, a course of thiabendazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_3_3522", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methylphenidate"}, {"id": "17182354_3_3523", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_3_3524", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_3_3525", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_3_3526", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_3_3527", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_3_3528", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_3_3529", "context": "Methylphenidate (Ritalin)-associated cataract and glaucoma.", "question": "adverse event. Treatment, Methylphenidate (Ritalin). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12410494_1_3530", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nelfinavir; Simvastatin"}, {"id": "12410494_1_3531", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12410494_1_3532", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12410494_1_3533", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12410494_1_3534", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12410494_1_3535", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12410494_1_3536", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12410494_1_3537", "context": "Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.", "question": "adverse event. Treatment, Simvastatin-nelfinavir interaction. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "nelfinavir; Simvastatin"}, {"id": "17955169_2_3538", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxcarbazepine"}, {"id": "17955169_2_3539", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17955169_2_3540", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17955169_2_3541", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17955169_2_3542", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17955169_2_3543", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17955169_2_3544", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17955169_2_3545", "context": "Uncontrolled headache induced by oxcarbazepine.", "question": "adverse event. Treatment, oxcarbazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_3_3546", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Subject, four cases; kidney transplant recipients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14697943_3_3547", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Subject, four cases; kidney transplant recipients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14697943_3_3548", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Subject, four cases; kidney transplant recipients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "four"}, {"id": "14697943_3_3549", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Subject, four cases; kidney transplant recipients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14697943_3_3550", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Subject, four cases; kidney transplant recipients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "kidney transplant"}, {"id": "14697943_3_3551", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrolimus"}, {"id": "14697943_3_3552", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_3_3553", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_3_3554", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_3_3555", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_3_3556", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_3_3557", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_3_3558", "context": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus.", "question": "adverse event. Treatment, tacrolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7949255_3_3559", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "7949255_3_3560", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "7949255_3_3561", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_3_3562", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7949255_3_3563", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_3_3564", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_3_3565", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "osteogenic sarcoma"}, {"id": "7949255_3_3566", "context": "Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma.", "question": "adverse event. Treatment, the chemotherapy of high-dose methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22372628_1_3567", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Subject, patients with uncontrolled partial-onset seizures. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22372628_1_3568", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Subject, patients with uncontrolled partial-onset seizures. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22372628_1_3569", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Subject, patients with uncontrolled partial-onset seizures. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22372628_1_3570", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Subject, patients with uncontrolled partial-onset seizures. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22372628_1_3571", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Subject, patients with uncontrolled partial-onset seizures. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "22372628_1_3572", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "lacosamide"}, {"id": "22372628_1_3573", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22372628_1_3574", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22372628_1_3575", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22372628_1_3576", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22372628_1_3577", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22372628_1_3578", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "uncontrolled partial-onset seizures"}, {"id": "22372628_1_3579", "context": "Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.", "question": "potential therapeutic event. Treatment, adjunctive lacosamide. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8404753_2_3580", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Subject, adults and children. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "adults; children"}, {"id": "8404753_2_3581", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Subject, adults and children. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_2_3582", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Subject, adults and children. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8404753_2_3583", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Subject, adults and children. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_2_3584", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Subject, adults and children. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_2_3585", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "8404753_2_3586", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_2_3587", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_2_3588", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_2_3589", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_2_3590", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_2_3591", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Tourette's syndrome"}, {"id": "8404753_2_3592", "context": "A variety of movement disorders are known to occur in association with carbamazepine (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.", "question": "adverse event. Treatment, carbamazepine (CBZ) therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_4_3593", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Subject, he; bladder cancer. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "21515865_4_3594", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Subject, he; bladder cancer. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "he"}, {"id": "21515865_4_3595", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Subject, he; bladder cancer. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21515865_4_3596", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Subject, he; bladder cancer. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21515865_4_3597", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Subject, he; bladder cancer. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21515865_4_3598", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "BCG"}, {"id": "21515865_4_3599", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_4_3600", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "weekly"}, {"id": "21515865_4_3601", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "bladder instillations"}, {"id": "21515865_4_3602", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_4_3603", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21515865_4_3604", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "bladder cancer"}, {"id": "21515865_4_3605", "context": "On the day before this visit, he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer.", "question": "potential therapeutic event. Treatment, the third of six serial weekly BCG bladder instillations. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7056119_3_3606", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "quinidine"}, {"id": "7056119_3_3607", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "1.2 g/day"}, {"id": "7056119_3_3608", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7056119_3_3609", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7056119_3_3610", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_3_3611", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "17 years"}, {"id": "7056119_3_3612", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_3_3613", "context": "Following a closed mitral valvotomy, she received quinidine, 1.2 g/day, without interruption for 17 years.", "question": "potential therapeutic event. Treatment, quinidine, 1.2 g/day. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3720318_2_3614", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3720318_2_3615", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3720318_2_3616", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3720318_2_3617", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3720318_2_3618", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3720318_2_3619", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "monooctanoin"}, {"id": "3720318_2_3620", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3720318_2_3621", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3720318_2_3622", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "3720318_2_3623", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3720318_2_3624", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3720318_2_3625", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3720318_2_3626", "context": "We describe a patient in whom noncardiogenic pulmonary edema developed during intrabiliary infusion of monooctanoin.", "question": "adverse event. Treatment, intrabiliary infusion of monooctanoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12166705_2_3627", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Mitomycin-C"}, {"id": "12166705_2_3628", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12166705_2_3629", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12166705_2_3630", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12166705_2_3631", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12166705_2_3632", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12166705_2_3633", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignancies"}, {"id": "12166705_2_3634", "context": "Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.", "question": "adverse event. Treatment, Mitomycin-C. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1414247_2_3635", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Subject, adult patient without a history of metabolic disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "adult"}, {"id": "1414247_2_3636", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Subject, adult patient without a history of metabolic disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1414247_2_3637", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Subject, adult patient without a history of metabolic disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1414247_2_3638", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Subject, adult patient without a history of metabolic disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1414247_2_3639", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Subject, adult patient without a history of metabolic disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1414247_2_3640", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Valproic acid"}, {"id": "1414247_2_3641", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1414247_2_3642", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1414247_2_3643", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1414247_2_3644", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1414247_2_3645", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1414247_2_3646", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1414247_2_3647", "context": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease.", "question": "adverse event. Treatment, Valproic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_4_3648", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Subject, Three patients with no history of asthma or allergy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7355327_4_3649", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Subject, Three patients with no history of asthma or allergy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7355327_4_3650", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Subject, Three patients with no history of asthma or allergy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "7355327_4_3651", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Subject, Three patients with no history of asthma or allergy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7355327_4_3652", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Subject, Three patients with no history of asthma or allergy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7355327_4_3653", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "7355327_4_3654", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_4_3655", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_4_3656", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_4_3657", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_4_3658", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_4_3659", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypertension"}, {"id": "7355327_4_3660", "context": "Three patients with no history of asthma or allergy developed bronchospasm while taking propranolol for hypertension.", "question": "adverse event. Treatment, propranolol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_2_3661", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Subject, two cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_2_3662", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Subject, two cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_2_3663", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Subject, two cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "10573314_2_3664", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Subject, two cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_2_3665", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Subject, two cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_2_3666", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; tolterodine"}, {"id": "10573314_2_3667", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_2_3668", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_2_3669", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_2_3670", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_2_3671", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_2_3672", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_2_3673", "context": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios (INRs).", "question": "adverse event. Treatment, warfarin therapy in which the addition of tolterodine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; tolterodine"}, {"id": "8850251_2_3674", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mequitazine"}, {"id": "8850251_2_3675", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_2_3676", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_2_3677", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "UV exposure"}, {"id": "8850251_2_3678", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_2_3679", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_2_3680", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_2_3681", "context": "In addition, an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.", "question": "adverse event. Treatment, mequitazine directly after UV exposure. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_1_3682", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Acetazolamide; anticonvulsant"}, {"id": "879939_1_3683", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_1_3684", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_1_3685", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_1_3686", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_1_3687", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_1_3688", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_1_3689", "context": "Acetazolamide-accelerated anticonvulsant osteomalacia.", "question": "adverse event. Treatment, Acetazolamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "129501_2_3690", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Subject, Both patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "129501_2_3691", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Subject, Both patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "129501_2_3692", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Subject, Both patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "129501_2_3693", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Subject, Both patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "129501_2_3694", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Subject, Both patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "129501_2_3695", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chymopapain"}, {"id": "129501_2_3696", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "129501_2_3697", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "129501_2_3698", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "129501_2_3699", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "129501_2_3700", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "129501_2_3701", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "129501_2_3702", "context": "Both patients suddenly became hypotensive after injection of chymopapain into a disk.", "question": "adverse event. Treatment, injection of chymopapain into a disk. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_2_3703", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylphenidate"}, {"id": "17182354_2_3704", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_2_3705", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_2_3706", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_2_3707", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_2_3708", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_2_3709", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_2_3710", "context": "Large dose of methylphenidate may cause cataract and glaucoma.", "question": "adverse event. Treatment, methylphenidate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_3_3711", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Subject, a 54-year-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "54-year-old"}, {"id": "7369302_3_3712", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Subject, a 54-year-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "7369302_3_3713", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Subject, a 54-year-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7369302_3_3714", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Subject, a 54-year-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7369302_3_3715", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Subject, a 54-year-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7369302_3_3716", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine sulfate"}, {"id": "7369302_3_3717", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_3_3718", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_3_3719", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_3_3720", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_3_3721", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_3_3722", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "leg cramps"}, {"id": "7369302_3_3723", "context": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "question": "adverse event. Treatment, quinine sulfate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_1_3724", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Carbamazepine"}, {"id": "8404753_1_3725", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_1_3726", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_1_3727", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_1_3728", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_1_3729", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_1_3730", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_1_3731", "context": "Carbamazepine-induced tics.", "question": "adverse event. Treatment, Carbamazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_3_3732", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Subject, Three patients are reported without a history of angina pectoris. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1655228_3_3733", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Subject, Three patients are reported without a history of angina pectoris. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1655228_3_3734", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Subject, Three patients are reported without a history of angina pectoris. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "1655228_3_3735", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Subject, Three patients are reported without a history of angina pectoris. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1655228_3_3736", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Subject, Three patients are reported without a history of angina pectoris. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1655228_3_3737", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCNU"}, {"id": "1655228_3_3738", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_3_3739", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_3_3740", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "1655228_3_3741", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "immediately after"}, {"id": "1655228_3_3742", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_3_3743", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_3_3744", "context": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion.", "question": "adverse event. Treatment, during and immediately after BCNU infusion. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "25298587_1_3745", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clarithromycin; ranolazine"}, {"id": "25298587_1_3746", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "25298587_1_3747", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "25298587_1_3748", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "25298587_1_3749", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "25298587_1_3750", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "25298587_1_3751", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "25298587_1_3752", "context": "A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.", "question": "adverse event. Treatment, ranolazine; clarithromycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "clarithromycin; ranolazine"}, {"id": "16046172_3_3753", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hyaluronate"}, {"id": "16046172_3_3754", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_3_3755", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_3_3756", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "16046172_3_3757", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_3_3758", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_3_3759", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_3_3760", "context": "Septic knee arthritis after intra-articular hyaluronate injection.", "question": "adverse event. Treatment, intra-articular hyaluronate injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_3_3761", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "colchicine; statin"}, {"id": "17921794_3_3762", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_3_3763", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_3_3764", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_3_3765", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_3_3766", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_3_3767", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_3_3768", "context": "The concomitant use, however, of colchicine and statin has been associated with the rapid onset of muscle weakness.", "question": "adverse event. Treatment, colchicine and statin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "colchicine; statin"}, {"id": "15588385_3_3769", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Subject, a patient with propylthiouracil-induced acute hepatic failure. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15588385_3_3770", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Subject, a patient with propylthiouracil-induced acute hepatic failure. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15588385_3_3771", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Subject, a patient with propylthiouracil-induced acute hepatic failure. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15588385_3_3772", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Subject, a patient with propylthiouracil-induced acute hepatic failure. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15588385_3_3773", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Subject, a patient with propylthiouracil-induced acute hepatic failure. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "propylthiouracil-induced acute hepatic failure"}, {"id": "15588385_3_3774", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "15588385_3_3775", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_3_3776", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15588385_3_3777", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15588385_3_3778", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_3_3779", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15588385_3_3780", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hyperthyroidism"}, {"id": "15588385_3_3781", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "potential therapeutic event. Treatment, amiodarone. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15588385_3_3782", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propylthiouracil"}, {"id": "15588385_3_3783", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_3_3784", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_3_3785", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_3_3786", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_3_3787", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_3_3788", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_3_3789", "context": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure.", "question": "adverse event. Treatment, propylthiouracil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21330680_1_3790", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Olanzapine"}, {"id": "21330680_1_3791", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "cessation"}, {"id": "21330680_1_3792", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_1_3793", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_1_3794", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_1_3795", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_1_3796", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_1_3797", "context": "Olanzapine-induced parkinsonism associated with smoking cessation.", "question": "adverse event. Treatment, associated with smoking cessation; Olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_4_3798", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Subject, an 11-year old male with Budd-Chiari syndrome. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "11-year old"}, {"id": "20465622_4_3799", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Subject, an 11-year old male with Budd-Chiari syndrome. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "20465622_4_3800", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Subject, an 11-year old male with Budd-Chiari syndrome. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20465622_4_3801", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Subject, an 11-year old male with Budd-Chiari syndrome. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20465622_4_3802", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Subject, an 11-year old male with Budd-Chiari syndrome. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "Budd-Chiari syndrome"}, {"id": "20465622_4_3803", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrolimus; sirolimus"}, {"id": "20465622_4_3804", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_4_3805", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_4_3806", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_4_3807", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_4_3808", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_4_3809", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_4_3810", "context": "CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound worsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to sirolimus.", "question": "adverse event. Treatment, immunosuppressive therapy was changed from tacrolimus to sirolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10190739_2_3811", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Subject, two patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10190739_2_3812", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Subject, two patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10190739_2_3813", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Subject, two patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "10190739_2_3814", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Subject, two patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10190739_2_3815", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Subject, two patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10190739_2_3816", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "riluzole"}, {"id": "10190739_2_3817", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "100 mg"}, {"id": "10190739_2_3818", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily"}, {"id": "10190739_2_3819", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10190739_2_3820", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10190739_2_3821", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "7 and 4 weeks"}, {"id": "10190739_2_3822", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10190739_2_3823", "context": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.", "question": "adverse event. Treatment, riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_1_3824", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "levodopa"}, {"id": "20628041_1_3825", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_1_3826", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20628041_1_3827", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20628041_1_3828", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_1_3829", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20628041_1_3830", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20628041_1_3831", "context": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.", "question": "adverse event. Treatment, levodopa and enteral nutrition. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_14_3832", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_14_3833", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_14_3834", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_14_3835", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_14_3836", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_14_3837", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tolterodine; warfarin"}, {"id": "10573314_14_3838", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_14_3839", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_14_3840", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_14_3841", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_14_3842", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_14_3843", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_14_3844", "context": "Until further data are available, clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy.", "question": "adverse event. Treatment, tolterodine therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "tolterodine; warfarin"}, {"id": "15522120_13_3845", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Subject, The itch spread to the arms, abdomen and legs and the patient; himself. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15522120_13_3846", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Subject, The itch spread to the arms, abdomen and legs and the patient; himself. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "himself"}, {"id": "15522120_13_3847", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Subject, The itch spread to the arms, abdomen and legs and the patient; himself. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15522120_13_3848", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Subject, The itch spread to the arms, abdomen and legs and the patient; himself. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15522120_13_3849", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Subject, The itch spread to the arms, abdomen and legs and the patient; himself. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "15522120_13_3850", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clemastine"}, {"id": "15522120_13_3851", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_13_3852", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_13_3853", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_13_3854", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_13_3855", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_13_3856", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "itch"}, {"id": "15522120_13_3857", "context": "The itch spread to the arms, abdomen and legs and the patient treated himself with clemastine and the itch disappeared.", "question": "potential therapeutic event. Treatment, clemastine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8391300_3_3858", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Subject, a 36-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "36-year-old"}, {"id": "8391300_3_3859", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Subject, a 36-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "8391300_3_3860", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Subject, a 36-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8391300_3_3861", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Subject, a 36-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8391300_3_3862", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Subject, a 36-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8391300_3_3863", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "erythromycin; ergotamine"}, {"id": "8391300_3_3864", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "normal doses"}, {"id": "8391300_3_3865", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8391300_3_3866", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8391300_3_3867", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8391300_3_3868", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8391300_3_3869", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8391300_3_3870", "context": "In this case report we present a rare drug interaction between erythromycin and ergotamine at normal doses causing lower extremity ischemia in a 36-year-old woman.", "question": "adverse event. Treatment, a rare drug interaction between erythromycin and ergotamine at normal doses. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "erythromycin; ergotamine"}, {"id": "16978752_2_3871", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenothiazines; clozapine"}, {"id": "16978752_2_3872", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_2_3873", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_2_3874", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_2_3875", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_2_3876", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_2_3877", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_2_3878", "context": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine.", "question": "adverse event. Treatment, phenothiazines and clozapine.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_4_3879", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Subject, She. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1695794_4_3880", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Subject, She. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "She"}, {"id": "1695794_4_3881", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Subject, She. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1695794_4_3882", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Subject, She. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1695794_4_3883", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Subject, She. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1695794_4_3884", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "1695794_4_3885", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_4_3886", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1695794_4_3887", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1695794_4_3888", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_4_3889", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1695794_4_3890", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acid-fast bacilli"}, {"id": "1695794_4_3891", "context": "She had been taking rifampin prior to admission for acid-fast bacilli.", "question": "potential therapeutic event. Treatment, rifampin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6572542_3_3892", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CCNU"}, {"id": "6572542_3_3893", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_3_3894", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_3_3895", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_3_3896", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_3_3897", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_3_3898", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_3_3899", "context": "The responsibility of CCNU in the pathogenesis of pulmonary fibrosis seems very likely.", "question": "adverse event. Treatment, CCNU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_1_3900", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_1_3901", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15863610_1_3902", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_1_3903", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_1_3904", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_1_3905", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "raloxifene"}, {"id": "15863610_1_3906", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_1_3907", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_1_3908", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_1_3909", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_1_3910", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_1_3911", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_1_3912", "context": "Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.", "question": "adverse event. Treatment, raloxifene. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_1_3913", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quetiapine"}, {"id": "15516308_1_3914", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_1_3915", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_1_3916", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_1_3917", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_1_3918", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_1_3919", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_1_3920", "context": "Fatal overdoses associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_3_3921", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gemcitabine"}, {"id": "16685112_3_3922", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_3_3923", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_3_3924", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_3_3925", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_3_3926", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_3_3927", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_3_3928", "context": "Gemcitabine-induced rectus abdominus radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_2_3929", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Subject, depressed 55-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "55-year-old"}, {"id": "19754002_2_3930", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Subject, depressed 55-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "19754002_2_3931", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Subject, depressed 55-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19754002_2_3932", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Subject, depressed 55-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19754002_2_3933", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Subject, depressed 55-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19754002_2_3934", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antidepressants; atypical antipsychotic; lithium; pravastatin"}, {"id": "19754002_2_3935", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_2_3936", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_2_3937", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_2_3938", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_2_3939", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_2_3940", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "depressed"}, {"id": "19754002_2_3941", "context": "We report on a serious side effect in a severely depressed 55-year-old woman, who presented an erythematous pigmented skin rash on the whole body under combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin.", "question": "adverse event. Treatment, combination treatment with antidepressants, atypical antipsychotic drugs, the mood stabilizer lithium and the lipid-lowering drug pravastatin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "antidepressants; atypical antipsychotic; lithium; pravastatin"}, {"id": "15588385_4_3942", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Subject, a 20-year-old woman with Basedow-Graves' disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "20-year-old"}, {"id": "15588385_4_3943", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Subject, a 20-year-old woman with Basedow-Graves' disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15588385_4_3944", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Subject, a 20-year-old woman with Basedow-Graves' disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15588385_4_3945", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Subject, a 20-year-old woman with Basedow-Graves' disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15588385_4_3946", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Subject, a 20-year-old woman with Basedow-Graves' disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15588385_4_3947", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "15588385_4_3948", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_4_3949", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_4_3950", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_4_3951", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_4_3952", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_4_3953", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Basedow-Graves' disease"}, {"id": "15588385_4_3954", "context": "We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy.", "question": "adverse event. Treatment, PTU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_2_3955", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Subject, children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "11283125_2_3956", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Subject, children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_2_3957", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Subject, children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_2_3958", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Subject, children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_2_3959", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Subject, children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_2_3960", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cytarabine; methotrexate"}, {"id": "11283125_2_3961", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "11283125_2_3962", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_2_3963", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous"}, {"id": "11283125_2_3964", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_2_3965", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_2_3966", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute lymphoblastic leukemia; stage III and IV lymphoblastic lymphoma"}, {"id": "11283125_2_3967", "context": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.", "question": "potential therapeutic event. Treatment, high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "cytarabine; methotrexate"}, {"id": "6113770_2_3968", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "6113770_2_3969", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6113770_2_3970", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6113770_2_3971", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6113770_2_3972", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6113770_2_3973", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6113770_2_3974", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6113770_2_3975", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6113770_2_3976", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium; phenothiazines"}, {"id": "6113770_2_3977", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6113770_2_3978", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6113770_2_3979", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6113770_2_3980", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6113770_2_3981", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6113770_2_3982", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6113770_2_3983", "context": "The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.", "question": "adverse event. Treatment, lithium; in combination with phenothiazines, primarily thioridazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "lithium; phenothiazines"}, {"id": "1711090_1_3984", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "SMANCS; ADR"}, {"id": "1711090_1_3985", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_1_3986", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1711090_1_3987", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "arterial injection"}, {"id": "1711090_1_3988", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_1_3989", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1711090_1_3990", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hepatocellular carcinoma"}, {"id": "1711090_1_3991", "context": "Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.", "question": "potential therapeutic event. Treatment, Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "ADR; SMANCS"}, {"id": "6693840_2_3992", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline"}, {"id": "6693840_2_3993", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_2_3994", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_2_3995", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_2_3996", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_2_3997", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_2_3998", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_2_3999", "context": "Gynecomastia associated with theophylline.", "question": "adverse event. Treatment, theophylline. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_1_4000", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Subject, multiple sclerosis patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16393774_1_4001", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Subject, multiple sclerosis patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16393774_1_4002", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Subject, multiple sclerosis patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16393774_1_4003", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Subject, multiple sclerosis patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16393774_1_4004", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Subject, multiple sclerosis patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16393774_1_4005", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "interferon-beta"}, {"id": "16393774_1_4006", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_1_4007", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16393774_1_4008", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16393774_1_4009", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_1_4010", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16393774_1_4011", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "multiple sclerosis"}, {"id": "16393774_1_4012", "context": "Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta.", "question": "potential therapeutic event. Treatment, interferon-beta. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "1888256_3_4013", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diltiazem hydrochloride"}, {"id": "1888256_3_4014", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_3_4015", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_3_4016", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_3_4017", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_3_4018", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_3_4019", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_3_4020", "context": "To our knowledge, drug-induced fever has not been reported with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker.", "question": "adverse event. Treatment, drug; with the use of diltiazem hydrochloride, a commonly prescribed calcium channel blocker. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11155197_1_4021", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "11155197_1_4022", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11155197_1_4023", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11155197_1_4024", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11155197_1_4025", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11155197_1_4026", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11155197_1_4027", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11155197_1_4028", "context": "Case studies in heparin-induced thrombocytopenia.", "question": "adverse event. Treatment, heparin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8316494_2_4029", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Subject, a 41 yr old leprosy patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "41 yr old"}, {"id": "8316494_2_4030", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Subject, a 41 yr old leprosy patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8316494_2_4031", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Subject, a 41 yr old leprosy patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8316494_2_4032", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Subject, a 41 yr old leprosy patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8316494_2_4033", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Subject, a 41 yr old leprosy patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8316494_2_4034", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clofazimine"}, {"id": "8316494_2_4035", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8316494_2_4036", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8316494_2_4037", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8316494_2_4038", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8316494_2_4039", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "10 yrs"}, {"id": "8316494_2_4040", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "leprosy"}, {"id": "8316494_2_4041", "context": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain.", "question": "adverse event. Treatment, 10 yrs with clofazimine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_2_4042", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "15061230_2_4043", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_2_4044", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_2_4045", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_2_4046", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_2_4047", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_2_4048", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_2_4049", "context": "Osteonecrosis is a serious side effect of antiemetic treatment with dexamethasone and this serious complication should be incorporated in the current guidelines.", "question": "adverse event. Treatment, antiemetic treatment with dexamethasone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15663666_3_4050", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Subject, a patient with acute promyleocytic leukemia (APL). Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15663666_3_4051", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Subject, a patient with acute promyleocytic leukemia (APL). Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15663666_3_4052", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Subject, a patient with acute promyleocytic leukemia (APL). Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15663666_3_4053", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Subject, a patient with acute promyleocytic leukemia (APL). Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15663666_3_4054", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Subject, a patient with acute promyleocytic leukemia (APL). Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15663666_3_4055", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ATRA"}, {"id": "15663666_3_4056", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "40 mg"}, {"id": "15663666_3_4057", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "15663666_3_4058", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "orally"}, {"id": "15663666_3_4059", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 10 days"}, {"id": "15663666_3_4060", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15663666_3_4061", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute promyleocytic leukemia (APL)"}, {"id": "15663666_3_4062", "context": "We report the development of scrotal ulcer in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily.", "question": "adverse event. Treatment, within 10 days of treatment with ATRA at a dose of 40 mg orally twice daily. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_1_4063", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vitamin D3"}, {"id": "14684937_1_4064", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "20 micro g/g; 10 g"}, {"id": "14684937_1_4065", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "10 g/day"}, {"id": "14684937_1_4066", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "14684937_1_4067", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_1_4068", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_1_4069", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "skin lesions,"}, {"id": "14684937_1_4070", "context": "After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.", "question": "adverse event. Treatment, After initiation of topical vitamin D3 ointment (20 micro g/g of tacalcitol) 10 g/day. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_6_4071", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Vancomycin"}, {"id": "11485141_6_4072", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_6_4073", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_6_4074", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_6_4075", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_6_4076", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_6_4077", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_6_4078", "context": "Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.", "question": "adverse event. Treatment, Vancomycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15623719_1_4079", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "15623719_1_4080", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15623719_1_4081", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15623719_1_4082", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15623719_1_4083", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15623719_1_4084", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15623719_1_4085", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15623719_1_4086", "context": "Vision declined after treatment with methylprednisolone, after which fundus examination became consistent with progressive outer retinal necrosis.", "question": "adverse event. Treatment, methylprednisolone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_3_4087", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Subject, he. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10682234_3_4088", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Subject, he. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "he"}, {"id": "10682234_3_4089", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Subject, he. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10682234_3_4090", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Subject, he. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10682234_3_4091", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Subject, he. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10682234_3_4092", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon"}, {"id": "10682234_3_4093", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_3_4094", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_3_4095", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_3_4096", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Eight days"}, {"id": "10682234_3_4097", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_3_4098", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_3_4099", "context": "Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly.", "question": "adverse event. Treatment, Eight days after the end of interferon treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15895899_2_4100", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "15895899_2_4101", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15895899_2_4102", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15895899_2_4103", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15895899_2_4104", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15895899_2_4105", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15895899_2_4106", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "enteropathic spondyloarthropathy"}, {"id": "15895899_2_4107", "context": "Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy.", "question": "adverse event. Treatment, infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19555801_1_4108", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Aripiprazole"}, {"id": "19555801_1_4109", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19555801_1_4110", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19555801_1_4111", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19555801_1_4112", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19555801_1_4113", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19555801_1_4114", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19555801_1_4115", "context": "Aripiprazole-induced hiccups: a case report.", "question": "adverse event. Treatment, Aripiprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_3_4116", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegvisomant"}, {"id": "16728538_3_4117", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_3_4118", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_3_4119", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_3_4120", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_3_4121", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_3_4122", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_3_4123", "context": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant.", "question": "adverse event. Treatment, pegvisomant. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_4_4124", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Subject, a 58-year-old female patient with Graves' disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "58-year-old"}, {"id": "9777751_4_4125", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Subject, a 58-year-old female patient with Graves' disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "9777751_4_4126", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Subject, a 58-year-old female patient with Graves' disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9777751_4_4127", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Subject, a 58-year-old female patient with Graves' disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9777751_4_4128", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Subject, a 58-year-old female patient with Graves' disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "Graves' disease"}, {"id": "9777751_4_4129", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methimazole"}, {"id": "9777751_4_4130", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_4_4131", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_4_4132", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_4_4133", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_4_4134", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_4_4135", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_4_4136", "context": "We present a case of a 58-year-old female patient with Graves' disease who developed AA in the third exposure to methimazole (MMI).", "question": "adverse event. Treatment, in the third exposure to methimazole (MMI). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685112_2_4137", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "16685112_2_4138", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685112_2_4139", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685112_2_4140", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16685112_2_4141", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685112_2_4142", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685112_2_4143", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685112_2_4144", "context": "CONCLUSIONS: This is the second case report that describes gemcitabine-induced radiation recall in rectus abdominus muscles after gemcitabine-based radiation therapy.", "question": "adverse event. Treatment, gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16046172_2_4145", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Subject, an 80-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "80-year-old"}, {"id": "16046172_2_4146", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Subject, an 80-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16046172_2_4147", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Subject, an 80-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16046172_2_4148", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Subject, an 80-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16046172_2_4149", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Subject, an 80-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16046172_2_4150", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sodium hyaluronate; corticosteroids"}, {"id": "16046172_2_4151", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16046172_2_4152", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "several"}, {"id": "16046172_2_4153", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injections"}, {"id": "16046172_2_4154", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_2_4155", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_2_4156", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_2_4157", "context": "One patient was an 80-year-old woman who was admitted for Staphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and corticosteroids.", "question": "adverse event. Treatment, sodium hyaluronate and corticosteroids. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "sodium hyaluronate; corticosteroids"}, {"id": "6731466_5_4158", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zomepirac"}, {"id": "6731466_5_4159", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_5_4160", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_5_4161", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_5_4162", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_5_4163", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_5_4164", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_5_4165", "context": "Association of zomepirac administration with renal cortical necrosis is not known to have been previously demonstrated.", "question": "adverse event. Treatment, zomepirac. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6427463_2_4166", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold sodium thiomalate"}, {"id": "6427463_2_4167", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6427463_2_4168", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6427463_2_4169", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6427463_2_4170", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6427463_2_4171", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6427463_2_4172", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6427463_2_4173", "context": "Vasomotor reactions after gold sodium thiomalate are well recognized.", "question": "adverse event. Treatment, gold sodium thiomalate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_1_4174", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Moxifloxacin; acetaminophen; warfarin; bacille Calmette-Guerin"}, {"id": "21515865_1_4175", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_1_4176", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_1_4177", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_1_4178", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_1_4179", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_1_4180", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "bladder cancer"}, {"id": "21515865_1_4181", "context": "Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.", "question": "adverse event. Treatment, Moxifloxacin-acetaminophen-warfarin interaction; bacille Calmette-Guerin treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; acetaminophen; Moxifloxacin; bacille Calmette-Guerin"}, {"id": "15571949_1_4182", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Subject, four patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15571949_1_4183", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Subject, four patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15571949_1_4184", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Subject, four patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "four"}, {"id": "15571949_1_4185", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Subject, four patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15571949_1_4186", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Subject, four patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15571949_1_4187", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "busulfan"}, {"id": "15571949_1_4188", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15571949_1_4189", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15571949_1_4190", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15571949_1_4191", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2-45 days after"}, {"id": "15571949_1_4192", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15571949_1_4193", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15571949_1_4194", "context": "In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_1_4195", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Subject, An adolescent male. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "adolescent"}, {"id": "7139589_1_4196", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Subject, An adolescent male. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "7139589_1_4197", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Subject, An adolescent male. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7139589_1_4198", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Subject, An adolescent male. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7139589_1_4199", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Subject, An adolescent male. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7139589_1_4200", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "7139589_1_4201", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_1_4202", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_1_4203", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intramuscular"}, {"id": "7139589_1_4204", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "16 weeks"}, {"id": "7139589_1_4205", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_1_4206", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_1_4207", "context": "An adolescent male developed acute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular L-asparaginase.", "question": "adverse event. Treatment, cessation of intramuscular L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22047557_1_4208", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Subject, patients with cystic fibrosis and the G551D mutation. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "22047557_1_4209", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Subject, patients with cystic fibrosis and the G551D mutation. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "22047557_1_4210", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Subject, patients with cystic fibrosis and the G551D mutation. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "22047557_1_4211", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Subject, patients with cystic fibrosis and the G551D mutation. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "22047557_1_4212", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Subject, patients with cystic fibrosis and the G551D mutation. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "G551D mutation"}, {"id": "22047557_1_4213", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "CFTR potentiato"}, {"id": "22047557_1_4214", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22047557_1_4215", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22047557_1_4216", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22047557_1_4217", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22047557_1_4218", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "22047557_1_4219", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cystic fibrosis"}, {"id": "22047557_1_4220", "context": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.", "question": "potential therapeutic event. Treatment, CFTR potentiator. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17205927_1_4221", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Quinapril"}, {"id": "17205927_1_4222", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "17205927_1_4223", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17205927_1_4224", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17205927_1_4225", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17205927_1_4226", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17205927_1_4227", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17205927_1_4228", "context": "Quinapril is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, transient renal impairment.", "question": "adverse event. Treatment, Quinapril. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9725786_1_4229", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Subject, a renal transplant recipient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9725786_1_4230", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Subject, a renal transplant recipient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9725786_1_4231", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Subject, a renal transplant recipient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9725786_1_4232", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Subject, a renal transplant recipient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9725786_1_4233", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Subject, a renal transplant recipient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9725786_1_4234", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine; prednisone"}, {"id": "9725786_1_4235", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9725786_1_4236", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9725786_1_4237", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9725786_1_4238", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9725786_1_4239", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9725786_1_4240", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal transplant recipient"}, {"id": "9725786_1_4241", "context": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess.", "question": "adverse event. Treatment, maintained on cyclosporine and prednisone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "prednisone; cyclosporine"}, {"id": "15588385_2_4242", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Subject, a patient with PTU-induced fulminant hepatitis. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "15588385_2_4243", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Subject, a patient with PTU-induced fulminant hepatitis. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "15588385_2_4244", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Subject, a patient with PTU-induced fulminant hepatitis. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "15588385_2_4245", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Subject, a patient with PTU-induced fulminant hepatitis. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "15588385_2_4246", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Subject, a patient with PTU-induced fulminant hepatitis. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "PTU-induced fulminant hepatitis"}, {"id": "15588385_2_4247", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "15588385_2_4248", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_2_4249", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15588385_2_4250", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15588385_2_4251", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_2_4252", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15588385_2_4253", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hyperthyroidism"}, {"id": "15588385_2_4254", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "potential therapeutic event. Treatment, amiodarone. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15588385_2_4255", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PTU"}, {"id": "15588385_2_4256", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15588385_2_4257", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15588385_2_4258", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15588385_2_4259", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15588385_2_4260", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15588385_2_4261", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15588385_2_4262", "context": "After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.", "question": "adverse event. Treatment, PTU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12042592_1_4263", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Subject, the patient's mother. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12042592_1_4264", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Subject, the patient's mother. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12042592_1_4265", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Subject, the patient's mother. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12042592_1_4266", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Subject, the patient's mother. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12042592_1_4267", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Subject, the patient's mother. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12042592_1_4268", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metamizole"}, {"id": "12042592_1_4269", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12042592_1_4270", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12042592_1_4271", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12042592_1_4272", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12042592_1_4273", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12042592_1_4274", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12042592_1_4275", "context": "After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.", "question": "adverse event. Treatment, metamizole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_3_4276", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Subject, a patient with a long-standing history of refractory CLL. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9671138_3_4277", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Subject, a patient with a long-standing history of refractory CLL. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9671138_3_4278", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Subject, a patient with a long-standing history of refractory CLL. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9671138_3_4279", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Subject, a patient with a long-standing history of refractory CLL. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9671138_3_4280", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Subject, a patient with a long-standing history of refractory CLL. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9671138_3_4281", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine phosphate"}, {"id": "9671138_3_4282", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_3_4283", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_3_4284", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_3_4285", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_3_4286", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_3_4287", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "refractory CLL"}, {"id": "9671138_3_4288", "context": "We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate.", "question": "adverse event. Treatment, fludarabine phosphate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_1_4289", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Subject, A 77-year-old woman with no history of epilepsy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "77-year-old"}, {"id": "10812579_1_4290", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Subject, A 77-year-old woman with no history of epilepsy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "10812579_1_4291", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Subject, A 77-year-old woman with no history of epilepsy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10812579_1_4292", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Subject, A 77-year-old woman with no history of epilepsy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10812579_1_4293", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Subject, A 77-year-old woman with no history of epilepsy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "no history of epilepsy"}, {"id": "10812579_1_4294", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "10812579_1_4295", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_1_4296", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "continuous"}, {"id": "10812579_1_4297", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "10812579_1_4298", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_1_4299", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_1_4300", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "back pain relating to vertebral metastasis of a malignant lymphoma"}, {"id": "10812579_1_4301", "context": "A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.", "question": "adverse event. Treatment, continuous intravenous morphine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_2_4302", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "corticosteroids"}, {"id": "16685007_2_4303", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_2_4304", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16685007_2_4305", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "Oral"}, {"id": "16685007_2_4306", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_2_4307", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16685007_2_4308", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16685007_2_4309", "context": "Oral corticosteroids (OCS) may be associated with systemic adverse events (AEs), which can be reduced by replacing OCS with inhaled corticosteroids (ICS).", "question": "adverse event. Treatment, Oral corticosteroids (OCS). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15072497_1_4310", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "colchicine"}, {"id": "15072497_1_4311", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15072497_1_4312", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "long-term"}, {"id": "15072497_1_4313", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15072497_1_4314", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15072497_1_4315", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15072497_1_4316", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15072497_1_4317", "context": "Development of Peyronie's disease during long-term colchicine treatment.", "question": "adverse event. Treatment, long-term colchicine treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_6_4318", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Subject, DPD-deficient patients with severe acute 5-FU reactions. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9007910_6_4319", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Subject, DPD-deficient patients with severe acute 5-FU reactions. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9007910_6_4320", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Subject, DPD-deficient patients with severe acute 5-FU reactions. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9007910_6_4321", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Subject, DPD-deficient patients with severe acute 5-FU reactions. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9007910_6_4322", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Subject, DPD-deficient patients with severe acute 5-FU reactions. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "DPD-deficient"}, {"id": "9007910_6_4323", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "thymidine"}, {"id": "9007910_6_4324", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_6_4325", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9007910_6_4326", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9007910_6_4327", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_6_4328", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9007910_6_4329", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "5-FU-induced neurologic symptoms such as encephalopathy and coma; severe acute 5-FU reactions"}, {"id": "9007910_6_4330", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "potential therapeutic event. Treatment, thymidine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9007910_6_4331", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-FU"}, {"id": "9007910_6_4332", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_6_4333", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_6_4334", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_6_4335", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_6_4336", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_6_4337", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9007910_6_4338", "context": "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.", "question": "adverse event. Treatment, 5-FU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16599252_1_4339", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16599252_1_4340", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16599252_1_4341", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16599252_1_4342", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16599252_1_4343", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16599252_1_4344", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aspirin; zafirlukast"}, {"id": "16599252_1_4345", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16599252_1_4346", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16599252_1_4347", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16599252_1_4348", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16599252_1_4349", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16599252_1_4350", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16599252_1_4351", "context": "Adverse reaction in a patient with aspirin-induced asthma treated with zafirlukast.", "question": "adverse event. Treatment, aspirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "zafirlukast; aspirin"}, {"id": "6788011_4_4352", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6788011_4_4353", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6788011_4_4354", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6788011_4_4355", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6788011_4_4356", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6788011_4_4357", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "6788011_4_4358", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6788011_4_4359", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6788011_4_4360", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6788011_4_4361", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6788011_4_4362", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6788011_4_4363", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "6788011_4_4364", "context": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis.", "question": "adverse event. Treatment, therapy with gold. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6731466_6_4365", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nonsteroidal anti-inflammatory; zomepirac"}, {"id": "6731466_6_4366", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_6_4367", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_6_4368", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_6_4369", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_6_4370", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_6_4371", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_6_4372", "context": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti-inflammatory agents, especially zomepirac.", "question": "adverse event. Treatment, nonsteroidal anti-inflammatory agents, especially zomepirac. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12488741_1_4373", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "metronidazole"}, {"id": "12488741_1_4374", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12488741_1_4375", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12488741_1_4376", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12488741_1_4377", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12488741_1_4378", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12488741_1_4379", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12488741_1_4380", "context": "Clinical, spectroscopic, and imaging abnormalities resolved with discontinuation of metronidazole.", "question": "potential therapeutic event. Treatment, metronidazole. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20202988_8_4381", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Subject, two other patients (one after OLTX and one with Crohn's disease). Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "20202988_8_4382", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Subject, two other patients (one after OLTX and one with Crohn's disease). Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "20202988_8_4383", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Subject, two other patients (one after OLTX and one with Crohn's disease). Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "two"}, {"id": "20202988_8_4384", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Subject, two other patients (one after OLTX and one with Crohn's disease). Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20202988_8_4385", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Subject, two other patients (one after OLTX and one with Crohn's disease). Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20202988_8_4386", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "raltegravir; tacrolimus"}, {"id": "20202988_8_4387", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "1 or 2 mg"}, {"id": "20202988_8_4388", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "twice daily"}, {"id": "20202988_8_4389", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20202988_8_4390", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20202988_8_4391", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20202988_8_4392", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "HIV; Crohn's disease; OLTX"}, {"id": "20202988_8_4393", "context": "In two other patients (one after OLTX and one with Crohn's disease), a raltegravir-based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily.", "question": "potential therapeutic event. Treatment, raltegravir; 1 or 2 mg of tacrolimus twice daily.. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "raltegravir; tacrolimus"}, {"id": "16265343_2_4394", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha"}, {"id": "16265343_2_4395", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16265343_2_4396", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16265343_2_4397", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16265343_2_4398", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16265343_2_4399", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16265343_2_4400", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16265343_2_4401", "context": "Reversible cardiomyopathy caused by administration of interferon alpha.", "question": "adverse event. Treatment, administration of interferon alpha. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8696525_1_4402", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Metipranolol"}, {"id": "8696525_1_4403", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8696525_1_4404", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8696525_1_4405", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8696525_1_4406", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8696525_1_4407", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8696525_1_4408", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8696525_1_4409", "context": "Metipranolol associated granulomatous anterior uveitis: not so uncommon as thought.", "question": "adverse event. Treatment, Metipranolol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_13_4410", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tifacogin"}, {"id": "12851279_13_4411", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_13_4412", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12851279_13_4413", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12851279_13_4414", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_13_4415", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12851279_13_4416", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "high INR; low INR"}, {"id": "12851279_13_4417", "context": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts (6.5% tifacogin and 4.8% placebo for high INR; 6.0% tifacogin and 3.3% placebo for low INR).", "question": "adverse event. Treatment, tifacogin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3318771_1_4418", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3318771_1_4419", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3318771_1_4420", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3318771_1_4421", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3318771_1_4422", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3318771_1_4423", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "timolol"}, {"id": "3318771_1_4424", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3318771_1_4425", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3318771_1_4426", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3318771_1_4427", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3318771_1_4428", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3318771_1_4429", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3318771_1_4430", "context": "We also describe a case of timolol-induced ocular pemphigoid.", "question": "adverse event. Treatment, timolol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_1_4431", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Subject, A 70-year-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "70-year-old"}, {"id": "17016002_1_4432", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Subject, A 70-year-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "17016002_1_4433", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Subject, A 70-year-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17016002_1_4434", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Subject, A 70-year-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17016002_1_4435", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Subject, A 70-year-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17016002_1_4436", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "homochlorcyclizine hydrochloride"}, {"id": "17016002_1_4437", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_1_4438", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_1_4439", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_1_4440", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_1_4441", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_1_4442", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "itching"}, {"id": "17016002_1_4443", "context": "A 70-year-old man was admitted to our hospital because of dyspnea after taking an antihistaminic agent (homochlorcyclizine hydrochloride) for itching.", "question": "adverse event. Treatment, an antihistaminic agent (homochlorcyclizine hydrochloride). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10212021_1_4444", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nevirapine"}, {"id": "10212021_1_4445", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10212021_1_4446", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10212021_1_4447", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10212021_1_4448", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10212021_1_4449", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10212021_1_4450", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10212021_1_4451", "context": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine.", "question": "adverse event. Treatment, an antiretroviral regimen including nevirapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_4_4452", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Subject, the patient. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9253492_4_4453", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Subject, the patient. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9253492_4_4454", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Subject, the patient. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9253492_4_4455", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Subject, the patient. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9253492_4_4456", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Subject, the patient. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "9253492_4_4457", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "zonisamide"}, {"id": "9253492_4_4458", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "cessation"}, {"id": "9253492_4_4459", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9253492_4_4460", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9253492_4_4461", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "within 2 weeks"}, {"id": "9253492_4_4462", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9253492_4_4463", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_4_4464", "context": "The oligohidrosis caused by zonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.", "question": "potential therapeutic event. Treatment, zonisamide; cessation of drug administration. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16317298_4_4465", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "16317298_4_4466", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_4_4467", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_4_4468", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_4_4469", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_4_4470", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_4_4471", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "lung and breast cancer"}, {"id": "16317298_4_4472", "context": "Radiation recall related to gemcitabine has been reported in lung and breast cancer.", "question": "adverse event. Treatment, gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10435399_1_4473", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "10435399_1_4474", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10435399_1_4475", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10435399_1_4476", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10435399_1_4477", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10435399_1_4478", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10435399_1_4479", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10435399_1_4480", "context": "It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.", "question": "adverse event. Treatment, clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17827338_2_4481", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Vicriviroc"}, {"id": "17827338_2_4482", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17827338_2_4483", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17827338_2_4484", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17827338_2_4485", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17827338_2_4486", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17827338_2_4487", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "human immunodeficiency virus infection"}, {"id": "17827338_2_4488", "context": "Vicriviroc (SCH 417690), a CCR5 receptor antagonist, is currently under investigation for the treatment of human immunodeficiency virus infection.", "question": "potential therapeutic event. Treatment, Vicriviroc (SCH 417690), a CCR5 receptor antagonist. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9253492_2_4489", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Subject, Children. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "Children"}, {"id": "9253492_2_4490", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Subject, Children. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_2_4491", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Subject, Children. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_2_4492", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Subject, Children. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_2_4493", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Subject, Children. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_2_4494", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zonisamide"}, {"id": "9253492_2_4495", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_2_4496", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_2_4497", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_2_4498", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_2_4499", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_2_4500", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_2_4501", "context": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature.", "question": "adverse event. Treatment, zonisamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11147747_3_4502", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Subject, 2 male patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_3_4503", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Subject, 2 male patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "11147747_3_4504", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Subject, 2 male patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "11147747_3_4505", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Subject, 2 male patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_3_4506", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Subject, 2 male patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_3_4507", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "venlafaxine"}, {"id": "11147747_3_4508", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_3_4509", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_3_4510", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_3_4511", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_3_4512", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_3_4513", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_3_4514", "context": "This concerns 2 male patients who experienced incontinence while taking venlafaxine.", "question": "adverse event. Treatment, venlafaxine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1087773_2_4515", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ethambutol; rifampicin"}, {"id": "1087773_2_4516", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1087773_2_4517", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1087773_2_4518", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1087773_2_4519", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1087773_2_4520", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1087773_2_4521", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1087773_2_4522", "context": "Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.", "question": "adverse event. Treatment, ethambutol and rifampicin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "ethambutol; rifampicin"}, {"id": "15507779_4_4523", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Subject, HIV-infected woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15507779_4_4524", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Subject, HIV-infected woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15507779_4_4525", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Subject, HIV-infected woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15507779_4_4526", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Subject, HIV-infected woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15507779_4_4527", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Subject, HIV-infected woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15507779_4_4528", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nevirapine"}, {"id": "15507779_4_4529", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_4_4530", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15507779_4_4531", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15507779_4_4532", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_4_4533", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15507779_4_4534", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV"}, {"id": "15507779_4_4535", "context": "We report an HIV-infected woman who developed mild leukopenia as the first sign of a nevirapine-related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.", "question": "adverse event. Treatment, nevirapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_2_4536", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Subject, a geriatric patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "geriatric"}, {"id": "18364401_2_4537", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Subject, a geriatric patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_2_4538", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Subject, a geriatric patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_2_4539", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Subject, a geriatric patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_2_4540", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Subject, a geriatric patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_2_4541", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18364401_2_4542", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_2_4543", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_2_4544", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_2_4545", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 days"}, {"id": "18364401_2_4546", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_2_4547", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_2_4548", "context": "OBJECTIVE: To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_15_4549", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Tifacogin"}, {"id": "12851279_15_4550", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_15_4551", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12851279_15_4552", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12851279_15_4553", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_15_4554", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12851279_15_4555", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12851279_15_4556", "context": "Tifacogin administration was associated with an increase in risk of bleeding, irrespective of baseline INR.", "question": "adverse event. Treatment, Tifacogin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6618859_1_4557", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Subject, two epileptic patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6618859_1_4558", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Subject, two epileptic patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6618859_1_4559", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Subject, two epileptic patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "6618859_1_4560", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Subject, two epileptic patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6618859_1_4561", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Subject, two epileptic patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6618859_1_4562", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoresone; phenobarbital; phenytoin"}, {"id": "6618859_1_4563", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "750 mg"}, {"id": "6618859_1_4564", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "daily"}, {"id": "6618859_1_4565", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "6618859_1_4566", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "some months after"}, {"id": "6618859_1_4567", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6618859_1_4568", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "epileptic"}, {"id": "6618859_1_4569", "context": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered.", "question": "adverse event. Treatment, some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "fluoresone; phenobarbital; phenytoin"}, {"id": "6113770_1_4570", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium; haloperidol"}, {"id": "6113770_1_4571", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6113770_1_4572", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6113770_1_4573", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6113770_1_4574", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6113770_1_4575", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6113770_1_4576", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6113770_1_4577", "context": "The authors describe a case of combined lithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of irreversible tardive dyskinesia.", "question": "adverse event. Treatment, combined lithium and haloperidol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "lithium; haloperidol"}, {"id": "17665812_3_4578", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "17665812_3_4579", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17665812_3_4580", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17665812_3_4581", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17665812_3_4582", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17665812_3_4583", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17665812_3_4584", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17665812_3_4585", "context": "Occasionally, despite good therapeutic response, clozapine must be stopped due to dangerous side effects such as agranulocytosis.", "question": "adverse event. Treatment, clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_4_4586", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Subject, two women and one man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7139589_4_4587", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Subject, two women and one man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "women; man"}, {"id": "7139589_4_4588", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Subject, two women and one man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two; one"}, {"id": "7139589_4_4589", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Subject, two women and one man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7139589_4_4590", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Subject, two women and one man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7139589_4_4591", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "7139589_4_4592", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_4_4593", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_4_4594", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "7139589_4_4595", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_4_4596", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_4_4597", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_4_4598", "context": "Three cases of pseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous L-asparaginase.", "question": "adverse event. Treatment, intravenous L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17182354_4_4599", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ritalin"}, {"id": "17182354_4_4600", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17182354_4_4601", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17182354_4_4602", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17182354_4_4603", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17182354_4_4604", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17182354_4_4605", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17182354_4_4606", "context": "We report a case of Ritalin-associated cataract and glaucoma.", "question": "adverse event. Treatment, Ritalin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_3_4607", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amikacin"}, {"id": "19884751_3_4608", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19884751_3_4609", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19884751_3_4610", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19884751_3_4611", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19884751_3_4612", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "short-term"}, {"id": "19884751_3_4613", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19884751_3_4614", "context": "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with Amikacin, resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.", "question": "adverse event. Treatment, short-term therapy with Amikacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1655228_1_4615", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCNU"}, {"id": "1655228_1_4616", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1655228_1_4617", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1655228_1_4618", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1655228_1_4619", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1655228_1_4620", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1655228_1_4621", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1655228_1_4622", "context": "Cardiac toxicity related to BCNU has not been described well.", "question": "adverse event. Treatment, BCNU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12891225_2_4623", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Aprepitant; corticosteroid; 5-hydroxytryptamine(3) (5-HT(3)) antagonist"}, {"id": "12891225_2_4624", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12891225_2_4625", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12891225_2_4626", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12891225_2_4627", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12891225_2_4628", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12891225_2_4629", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "12891225_2_4630", "context": "Aprepitant is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-induced nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.", "question": "potential therapeutic event. Treatment, Aprepitant; added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "Aprepitant; corticosteroid; 5-hydroxytryptamine(3) (5-HT(3)) antagonist"}, {"id": "17123120_2_4631", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tacrolimus"}, {"id": "17123120_2_4632", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17123120_2_4633", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17123120_2_4634", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17123120_2_4635", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17123120_2_4636", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17123120_2_4637", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nephrotic syndrome"}, {"id": "17123120_2_4638", "context": "Thus, tacrolimus-induced HUS is a rare cause of ARF in nephrotic syndrome.", "question": "adverse event. Treatment, tacrolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_3_4639", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15927910_3_4640", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15927910_3_4641", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15927910_3_4642", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15927910_3_4643", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15927910_3_4644", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentamidine"}, {"id": "15927910_3_4645", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_3_4646", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_3_4647", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_3_4648", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_3_4649", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_3_4650", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_3_4651", "context": "Clinicians should be vigilant when monitoring for cardiotoxicity in patients receiving pentamidine throughout the duration of therapy.", "question": "adverse event. Treatment, pentamidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14684937_3_4652", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Subject, The present case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14684937_3_4653", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Subject, The present case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14684937_3_4654", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Subject, The present case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14684937_3_4655", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Subject, The present case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14684937_3_4656", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Subject, The present case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14684937_3_4657", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vitamin D3; thiazide"}, {"id": "14684937_3_4658", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14684937_3_4659", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14684937_3_4660", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ointment"}, {"id": "14684937_3_4661", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14684937_3_4662", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14684937_3_4663", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14684937_3_4664", "context": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously.", "question": "adverse event. Treatment, vitamin D3 ointment and thiazide simultaneously. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "vitamin D3; thiazide"}, {"id": "11352235_1_4665", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "11352235_1_4666", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_1_4667", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_1_4668", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_1_4669", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_1_4670", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_1_4671", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "11352235_1_4672", "context": "CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.", "question": "adverse event. Treatment, leflunomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7071645_2_4673", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Subject, a man with classic rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7071645_2_4674", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Subject, a man with classic rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "7071645_2_4675", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Subject, a man with classic rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7071645_2_4676", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Subject, a man with classic rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7071645_2_4677", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Subject, a man with classic rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7071645_2_4678", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold; penicillamine"}, {"id": "7071645_2_4679", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7071645_2_4680", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7071645_2_4681", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7071645_2_4682", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7071645_2_4683", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7071645_2_4684", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "classic rheumatoid arthritis"}, {"id": "7071645_2_4685", "context": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy.", "question": "adverse event. Treatment, gold or penicillamine therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "24531907_1_4686", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Subject, HIV-infected patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "24531907_1_4687", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Subject, HIV-infected patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "24531907_1_4688", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Subject, HIV-infected patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "24531907_1_4689", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Subject, HIV-infected patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "24531907_1_4690", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Subject, HIV-infected patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "24531907_1_4691", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "etravirine; rifampin"}, {"id": "24531907_1_4692", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "24531907_1_4693", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "24531907_1_4694", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "24531907_1_4695", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "24531907_1_4696", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "24531907_1_4697", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "HIV; tuberculosis"}, {"id": "24531907_1_4698", "context": "Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.", "question": "potential therapeutic event. Treatment, Pharmacokinetics of etravirine; concomitantly treated with rifampin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "etravirine; rifampin"}, {"id": "9352164_5_4699", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "AZ"}, {"id": "9352164_5_4700", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "excessive dose"}, {"id": "9352164_5_4701", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9352164_5_4702", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9352164_5_4703", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9352164_5_4704", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9352164_5_4705", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9352164_5_4706", "context": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.", "question": "adverse event. Treatment, excessive dose of AZ. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8430717_1_4707", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Acyclovir"}, {"id": "8430717_1_4708", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "8430717_1_4709", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8430717_1_4710", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8430717_1_4711", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8430717_1_4712", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8430717_1_4713", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8430717_1_4714", "context": "Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose.", "question": "adverse event. Treatment, Acyclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1680596_2_4715", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1680596_2_4716", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1680596_2_4717", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1680596_2_4718", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1680596_2_4719", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1680596_2_4720", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "1680596_2_4721", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "sulphasalazine"}, {"id": "1680596_2_4722", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1680596_2_4723", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1680596_2_4724", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1680596_2_4725", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1680596_2_4726", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "1680596_2_4727", "context": "Psoriasis-like skin reaction in a patient with rheumatoid arthritis after sulphasalazine therapy.", "question": "adverse event. Treatment, sulphasalazine therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_4_4728", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Subject, 2 patients with Crohn's disease (CD). Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10579985_4_4729", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Subject, 2 patients with Crohn's disease (CD). Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10579985_4_4730", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Subject, 2 patients with Crohn's disease (CD). Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "10579985_4_4731", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Subject, 2 patients with Crohn's disease (CD). Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_4_4732", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Subject, 2 patients with Crohn's disease (CD). Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_4_4733", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "10579985_4_4734", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_4_4735", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_4_4736", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_4_4737", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_4_4738", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_4_4739", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "10579985_4_4740", "context": "We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.", "question": "adverse event. Treatment, treatment with infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_2_4741", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Valproic acid"}, {"id": "17275666_2_4742", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_2_4743", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "17275666_2_4744", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "17275666_2_4745", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_2_4746", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "17275666_2_4747", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "idiopathic generalized epilepsies; juvenile absence epilepsy"}, {"id": "17275666_2_4748", "context": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies, including juvenile absence epilepsy.", "question": "potential therapeutic event. Treatment, Valproic acid. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14561622_3_4749", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "14561622_3_4750", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "14561622_3_4751", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14561622_3_4752", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14561622_3_4753", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14561622_3_4754", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "14561622_3_4755", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_3_4756", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_3_4757", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_3_4758", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_3_4759", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_3_4760", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_3_4761", "context": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia.", "question": "adverse event. Treatment, intrathecal methotrexate neurotoxicity. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_11_4762", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; cloxacillin"}, {"id": "22677303_11_4763", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_11_4764", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_11_4765", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_11_4766", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_11_4767", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_11_4768", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_11_4769", "context": "According to the Drug Interaction Probability Scale, a causal relationship between the warfarin-cloxacillin interaction and increased INR value was rated \"probable\".", "question": "adverse event. Treatment, warfarin; cloxacillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; cloxacillin"}, {"id": "16393774_4_4770", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Subject, two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_4_4771", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Subject, two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "16393774_4_4772", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Subject, two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "16393774_4_4773", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Subject, two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_4_4774", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Subject, two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_4_4775", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN-beta"}, {"id": "16393774_4_4776", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_4_4777", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_4_4778", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_4_4779", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_4_4780", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_4_4781", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "relapsing-remitting multiple sclerosis"}, {"id": "16393774_4_4782", "context": "We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed inflammatory musculoskeletal manifestations, following IFN-beta therapy.", "question": "adverse event. Treatment, IFN-beta. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_1_4783", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Subject, brain-damaged children. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "440873_1_4784", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Subject, brain-damaged children. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_1_4785", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Subject, brain-damaged children. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "440873_1_4786", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Subject, brain-damaged children. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_1_4787", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Subject, brain-damaged children. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "brain-damaged"}, {"id": "440873_1_4788", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "440873_1_4789", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_1_4790", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_1_4791", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_1_4792", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_1_4793", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_1_4794", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_1_4795", "context": "Dystonia associated with carbamazepine administration: experience in brain-damaged children.", "question": "adverse event. Treatment, carbamazepine administration. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_10_4796", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Subject, 51 patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20925534_10_4797", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Subject, 51 patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20925534_10_4798", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Subject, 51 patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "51"}, {"id": "20925534_10_4799", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Subject, 51 patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20925534_10_4800", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Subject, 51 patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20925534_10_4801", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole; placebo"}, {"id": "20925534_10_4802", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_10_4803", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_10_4804", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_10_4805", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "180 days"}, {"id": "20925534_10_4806", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_10_4807", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_10_4808", "context": "In all, 51 patients had a gastrointestinal event; the event rate was 1.1% with omeprazole and 2.9% with placebo at 180 days (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001).", "question": "adverse event. Treatment, 1.1% with omeprazole and 2.9% with placebo. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_1_4809", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Subject, a case. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9865241_1_4810", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Subject, a case. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9865241_1_4811", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Subject, a case. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9865241_1_4812", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Subject, a case. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9865241_1_4813", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Subject, a case. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "9865241_1_4814", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "vitamin D; pamidronate"}, {"id": "9865241_1_4815", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_1_4816", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_1_4817", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_1_4818", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_1_4819", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_1_4820", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hypercalcemia"}, {"id": "9865241_1_4821", "context": "CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20925534_1_4822", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Clopidogrel; omeprazole; Clopidogrel"}, {"id": "20925534_1_4823", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_1_4824", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_1_4825", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_1_4826", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_1_4827", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_1_4828", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "coronary artery disease"}, {"id": "20925534_1_4829", "context": "Clopidogrel with or without omeprazole in coronary artery disease.", "question": "potential therapeutic event. Treatment, Clopidogrel with or without omeprazole. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "Clopidogrel; omeprazole"}, {"id": "11001600_1_4830", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Subject, patients with dementia; elderly patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "11001600_1_4831", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Subject, patients with dementia; elderly patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11001600_1_4832", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Subject, patients with dementia; elderly patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11001600_1_4833", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Subject, patients with dementia; elderly patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11001600_1_4834", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Subject, patients with dementia; elderly patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "dementia"}, {"id": "11001600_1_4835", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "11001600_1_4836", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11001600_1_4837", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11001600_1_4838", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11001600_1_4839", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11001600_1_4840", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11001600_1_4841", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11001600_1_4842", "context": "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.", "question": "adverse event. Treatment, risperidone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18580694_1_4843", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ciprofloxacin"}, {"id": "18580694_1_4844", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18580694_1_4845", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18580694_1_4846", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18580694_1_4847", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18580694_1_4848", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18580694_1_4849", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18580694_1_4850", "context": "In addition, there is a report on prolonged ECT seizure related to ciprofloxacin, which has an epileptogenic property with a similar action to beta-lactam antibiotics.", "question": "adverse event. Treatment, ciprofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10592946_2_4851", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "10592946_2_4852", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_2_4853", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_2_4854", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_2_4855", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_2_4856", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_2_4857", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "delirium"}, {"id": "10592946_2_4858", "context": "After abstinence from oolong tea his delirium resolved.", "question": "adverse event. Treatment, oolong tea. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16901609_1_4859", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diamorphine"}, {"id": "16901609_1_4860", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16901609_1_4861", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16901609_1_4862", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intratheca"}, {"id": "16901609_1_4863", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16901609_1_4864", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16901609_1_4865", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16901609_1_4866", "context": "Anaphylaxis to intrathecal diamorphine.", "question": "adverse event. Treatment, intrathecal diamorphine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_3_4867", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "8726608_3_4868", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "10 mg/kg"}, {"id": "8726608_3_4869", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_3_4870", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_3_4871", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_3_4872", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_3_4873", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_3_4874", "context": "This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in increased serum lithium concentrations.", "question": "adverse event. Treatment, acyclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_12_4875", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sertraline; chocolate"}, {"id": "15522120_12_4876", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_12_4877", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_12_4878", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_12_4879", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "two weeks"}, {"id": "15522120_12_4880", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_12_4881", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_12_4882", "context": "After approximately two weeks of sertraline treatment he noted an intense itching sensation in his scalp after eating a piece of chocolate cake.", "question": "adverse event. Treatment, two weeks of sertraline. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "chocolate; sertraline"}, {"id": "8589490_2_4883", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cytostatic chemotherapeutic agents"}, {"id": "8589490_2_4884", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_2_4885", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_2_4886", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8589490_2_4887", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_2_4888", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_2_4889", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8589490_2_4890", "context": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents.", "question": "adverse event. Treatment, cytostatic chemotherapeutic agents. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_1_4891", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Atovaquone"}, {"id": "7485371_1_4892", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_1_4893", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_1_4894", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_1_4895", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_1_4896", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_1_4897", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_1_4898", "context": "CONCLUSION: Atovaquone should be added to the list of agents causing vortex keratopathy involving the corneal epithelium.", "question": "adverse event. Treatment, Atovaquone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10812579_2_4899", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "naloxone"}, {"id": "10812579_2_4900", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_2_4901", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_2_4902", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "10812579_2_4903", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "a few minutes"}, {"id": "10812579_2_4904", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_2_4905", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_2_4906", "context": "A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.", "question": "adverse event. Treatment, a few minutes after injection of the morphine antagonist naloxone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_1_4907", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Subject, these cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7748076_1_4908", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Subject, these cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7748076_1_4909", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Subject, these cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7748076_1_4910", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Subject, these cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7748076_1_4911", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Subject, these cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7748076_1_4912", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "progestin"}, {"id": "7748076_1_4913", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_1_4914", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_1_4915", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_1_4916", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_1_4917", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_1_4918", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7748076_1_4919", "context": "CONCLUSION: Squamous metaplasia in these cases appears to be a consequence of progestin therapy.", "question": "adverse event. Treatment, progestin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6610943_4_4920", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vasopressin"}, {"id": "6610943_4_4921", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6610943_4_4922", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6610943_4_4923", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6610943_4_4924", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6610943_4_4925", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6610943_4_4926", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "gastrointestinal hemorrhage"}, {"id": "6610943_4_4927", "context": "This association should be considered in the period after vasopressin-treated gastrointestinal hemorrhage.", "question": "adverse event. Treatment, vasopressin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_4_4928", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline"}, {"id": "6693840_4_4929", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_4_4930", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_4_4931", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_4_4932", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_4_4933", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_4_4934", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_4_4935", "context": "The gynecomastia regressed when the theophylline was discontinued.", "question": "adverse event. Treatment, theophylline. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3277077_1_4936", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Subject, this patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3277077_1_4937", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Subject, this patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3277077_1_4938", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Subject, this patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3277077_1_4939", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Subject, this patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3277077_1_4940", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Subject, this patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3277077_1_4941", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxycycline"}, {"id": "3277077_1_4942", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1 g"}, {"id": "3277077_1_4943", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3277077_1_4944", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3277077_1_4945", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3277077_1_4946", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3277077_1_4947", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3277077_1_4948", "context": "Renal hypophosphatemia in this patient was caused by the erroneous intake of 1 g doxycycline.", "question": "adverse event. Treatment, the erroneous intake of 1 g doxycycline.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2297635_1_4949", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Subject, the patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2297635_1_4950", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Subject, the patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2297635_1_4951", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Subject, the patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2297635_1_4952", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Subject, the patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2297635_1_4953", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Subject, the patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2297635_1_4954", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX; Ara-C"}, {"id": "2297635_1_4955", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2297635_1_4956", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2297635_1_4957", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2297635_1_4958", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 weeks."}, {"id": "2297635_1_4959", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2297635_1_4960", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "meningeal tumor"}, {"id": "2297635_1_4961", "context": "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.", "question": "adverse event. Treatment, MTX treatment; subsequent Ara-C treatment; within 3 weeks.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "MTX; Ara-C"}, {"id": "1087773_1_4962", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Subject, a nine-year-old boy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "nine-year-old"}, {"id": "1087773_1_4963", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Subject, a nine-year-old boy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "1087773_1_4964", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Subject, a nine-year-old boy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1087773_1_4965", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Subject, a nine-year-old boy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1087773_1_4966", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Subject, a nine-year-old boy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1087773_1_4967", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifampicin; ethambutol"}, {"id": "1087773_1_4968", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1087773_1_4969", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1087773_1_4970", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1087773_1_4971", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "seven months"}, {"id": "1087773_1_4972", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1087773_1_4973", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "tuberculosis"}, {"id": "1087773_1_4974", "context": "After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.", "question": "adverse event. Treatment, seven months' continuous treatment; with rifampicin and ethambutol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "ethambutol; rifampicin"}, {"id": "16609346_1_4975", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Subject, A few recent individual case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16609346_1_4976", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Subject, A few recent individual case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16609346_1_4977", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Subject, A few recent individual case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16609346_1_4978", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Subject, A few recent individual case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16609346_1_4979", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Subject, A few recent individual case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16609346_1_4980", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "statin"}, {"id": "16609346_1_4981", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_1_4982", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_1_4983", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_1_4984", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_1_4985", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_1_4986", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_1_4987", "context": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment, but this association is not well described.", "question": "adverse event. Treatment, statin treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_2_4988", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "imiquimod"}, {"id": "21658326_2_4989", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_2_4990", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21658326_2_4991", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "Topical"}, {"id": "21658326_2_4992", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_2_4993", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21658326_2_4994", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "non-melanoma skin cancer (NMSC)"}, {"id": "21658326_2_4995", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, Topical imiquimod. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21658326_2_4996", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tumor necrosis factor (TNF)-alpha"}, {"id": "21658326_2_4997", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_2_4998", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21658326_2_4999", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21658326_2_5000", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_2_5001", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21658326_2_5002", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "moderate to severe psoriasis"}, {"id": "21658326_2_5003", "context": "Topical imiquimod and tumor necrosis factor (TNF)-alpha inhibitors have gained wide acceptance as safe and effective treatments for non-melanoma skin cancer (NMSC) and moderate to severe psoriasis, respectively.", "question": "potential therapeutic event. Treatment, tumor necrosis factor (TNF)-alpha. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6731466_1_5004", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zomepirac"}, {"id": "6731466_1_5005", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_1_5006", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_1_5007", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_1_5008", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_1_5009", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_1_5010", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6731466_1_5011", "context": "Focal renal cortical necrosis associated with zomepirac.", "question": "adverse event. Treatment, zomepirac. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_6_5012", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8850251_6_5013", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8850251_6_5014", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8850251_6_5015", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8850251_6_5016", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8850251_6_5017", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mequitazine"}, {"id": "8850251_6_5018", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8850251_6_5019", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_6_5020", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_6_5021", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_6_5022", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_6_5023", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "dermatologic problems"}, {"id": "8850251_6_5024", "context": "We experienced 2 cases of mequitazine-induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems.", "question": "adverse event. Treatment, mequitazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20349794_4_5025", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cisplatin"}, {"id": "20349794_4_5026", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20349794_4_5027", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20349794_4_5028", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20349794_4_5029", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20349794_4_5030", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20349794_4_5031", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "SIADH"}, {"id": "20349794_4_5032", "context": "Carboplatin was substituted for cisplatin, and there were no further episodes of SIADH.", "question": "potential therapeutic event. Treatment, Carboplatin was substituted for cisplatin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16490518_3_5033", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "steroid; triamcinolone acetonide"}, {"id": "16490518_3_5034", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_3_5035", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_3_5036", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravitreal injection"}, {"id": "16490518_3_5037", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_3_5038", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_3_5039", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_3_5040", "context": "Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetonide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16160485_1_5041", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rituximab"}, {"id": "16160485_1_5042", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16160485_1_5043", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16160485_1_5044", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16160485_1_5045", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16160485_1_5046", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16160485_1_5047", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nodular lymphocyte-predominant Hodgkin's lymphoma"}, {"id": "16160485_1_5048", "context": "CD20-negative T-cell-rich B-cell lymphoma as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with rituximab: a molecular analysis using laser capture microdissection.", "question": "adverse event. Treatment, rituximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10717401_2_5049", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Subject, an adult patient with acute lymphoblastic leukemia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "adult"}, {"id": "10717401_2_5050", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Subject, an adult patient with acute lymphoblastic leukemia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10717401_2_5051", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Subject, an adult patient with acute lymphoblastic leukemia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10717401_2_5052", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Subject, an adult patient with acute lymphoblastic leukemia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10717401_2_5053", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Subject, an adult patient with acute lymphoblastic leukemia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10717401_2_5054", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "10717401_2_5055", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10717401_2_5056", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10717401_2_5057", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10717401_2_5058", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10717401_2_5059", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10717401_2_5060", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute lymphoblastic leukemia"}, {"id": "10717401_2_5061", "context": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.", "question": "adverse event. Treatment, consolidation treatment with L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_1_5062", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Subject, a patient with pancreatic cancer. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16317298_1_5063", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Subject, a patient with pancreatic cancer. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16317298_1_5064", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Subject, a patient with pancreatic cancer. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16317298_1_5065", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Subject, a patient with pancreatic cancer. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16317298_1_5066", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Subject, a patient with pancreatic cancer. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16317298_1_5067", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gemcitabine"}, {"id": "16317298_1_5068", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_1_5069", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_1_5070", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_1_5071", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_1_5072", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_1_5073", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pancreatic cancer"}, {"id": "16317298_1_5074", "context": "Gemcitabine-related radiation recall in a patient with pancreatic cancer.", "question": "adverse event. Treatment, Gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_7_5075", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CBZ"}, {"id": "8404753_7_5076", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "the same or higher dose"}, {"id": "8404753_7_5077", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_7_5078", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_7_5079", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_7_5080", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_7_5081", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8404753_7_5082", "context": "After development of the tics in 2, CBZ was continued at the same or higher dose, and the tics abated and then ceased spontaneously < or = 6 months.", "question": "adverse event. Treatment, CBZ. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16978752_4_5083", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16978752_4_5084", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16978752_4_5085", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16978752_4_5086", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16978752_4_5087", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16978752_4_5088", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "16978752_4_5089", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_4_5090", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_4_5091", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_4_5092", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_4_5093", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_4_5094", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_4_5095", "context": "Thus any case of severe neutropenia occurring in a patient receiving olanzapine is alarming to clinicians.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18203308_4_5096", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Subject, 3 AS patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18203308_4_5097", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Subject, 3 AS patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18203308_4_5098", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Subject, 3 AS patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "18203308_4_5099", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Subject, 3 AS patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18203308_4_5100", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Subject, 3 AS patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18203308_4_5101", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "18203308_4_5102", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_4_5103", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_4_5104", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_4_5105", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18203308_4_5106", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_4_5107", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "active AS; AS"}, {"id": "18203308_4_5108", "context": "We describe 3 AS patients treated with etanercept for active AS who developed new onset of CD while AS related symptoms responded well to etanercept.", "question": "adverse event. Treatment, etanercept for active AS. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_5_5109", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oxaliplatinum; 5-fluorouracil"}, {"id": "11510798_5_5110", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_5_5111", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11510798_5_5112", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11510798_5_5113", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_5_5114", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11510798_5_5115", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11510798_5_5116", "context": "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.", "question": "adverse event. Treatment, oxaliplatinum and 5-fluorouracil regimens. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "oxaliplatinum; 5-fluorouracil"}, {"id": "17619811_2_5117", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "colchicine"}, {"id": "17619811_2_5118", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_2_5119", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_2_5120", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_2_5121", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_2_5122", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_2_5123", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_2_5124", "context": "A case of colchicine-induced rhabdomyolysis is reported.", "question": "adverse event. Treatment, colchicine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_4_5125", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Subject, paroxysmal atrial fibrillation. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7056119_4_5126", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Subject, paroxysmal atrial fibrillation. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7056119_4_5127", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Subject, paroxysmal atrial fibrillation. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7056119_4_5128", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Subject, paroxysmal atrial fibrillation. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7056119_4_5129", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Subject, paroxysmal atrial fibrillation. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "paroxysmal atrial fibrillation"}, {"id": "7056119_4_5130", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "the drug"}, {"id": "7056119_4_5131", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1.4 g/day"}, {"id": "7056119_4_5132", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7056119_4_5133", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7056119_4_5134", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "24 hours"}, {"id": "7056119_4_5135", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7056119_4_5136", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7056119_4_5137", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "adverse event. Treatment, the dose of the drug was increased to 1.4 g/day. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7056119_4_5138", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "atropine"}, {"id": "7056119_4_5139", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7056119_4_5140", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7056119_4_5141", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7056119_4_5142", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7056119_4_5143", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7056119_4_5144", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "AVT with syncope"}, {"id": "7056119_4_5145", "context": "Because of a recurrence of paroxysmal atrial fibrillation, the dose of the drug was increased to 1.4 g/day; 24 hours later AVT with syncope developed but responded promptly to atropine.", "question": "potential therapeutic event. Treatment, atropine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17167851_2_5146", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Subject, Three male patients aged 78-83 years. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "78-83 years"}, {"id": "17167851_2_5147", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Subject, Three male patients aged 78-83 years. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "17167851_2_5148", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Subject, Three male patients aged 78-83 years. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Three"}, {"id": "17167851_2_5149", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Subject, Three male patients aged 78-83 years. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17167851_2_5150", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Subject, Three male patients aged 78-83 years. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17167851_2_5151", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CPA"}, {"id": "17167851_2_5152", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17167851_2_5153", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17167851_2_5154", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17167851_2_5155", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17167851_2_5156", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17167851_2_5157", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17167851_2_5158", "context": "Three male patients aged 78-83 years are presented, in whom severe hepatotoxic reactions emerged after CPA administration.", "question": "adverse event. Treatment, CPA. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "172214_2_5159", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "actinomycin-D; mithramycin"}, {"id": "172214_2_5160", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "172214_2_5161", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "172214_2_5162", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "172214_2_5163", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "172214_2_5164", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "172214_2_5165", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "172214_2_5166", "context": "Exacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559).", "question": "adverse event. Treatment, antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin (NSC-24559). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18347524_1_5167", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18347524_1_5168", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18347524_1_5169", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18347524_1_5170", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18347524_1_5171", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18347524_1_5172", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "18347524_1_5173", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18347524_1_5174", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18347524_1_5175", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18347524_1_5176", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18347524_1_5177", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18347524_1_5178", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "18347524_1_5179", "context": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, leflunomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15836666_2_5180", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Subject, a 64-year-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "64-year-old"}, {"id": "15836666_2_5181", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Subject, a 64-year-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "15836666_2_5182", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Subject, a 64-year-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15836666_2_5183", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Subject, a 64-year-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15836666_2_5184", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Subject, a 64-year-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15836666_2_5185", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fentanyl"}, {"id": "15836666_2_5186", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15836666_2_5187", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "chronic"}, {"id": "15836666_2_5188", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "transdermal"}, {"id": "15836666_2_5189", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15836666_2_5190", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15836666_2_5191", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "sciatic pain syndrome"}, {"id": "15836666_2_5192", "context": "We report a case of a 64-year-old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome.", "question": "adverse event. Treatment, a chronic transdermal fentanyl treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6440806_1_5193", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Subject, A 52-year-old; white female. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "52-year-old"}, {"id": "6440806_1_5194", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Subject, A 52-year-old; white female. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "6440806_1_5195", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Subject, A 52-year-old; white female. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6440806_1_5196", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Subject, A 52-year-old; white female. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": "white"}, {"id": "6440806_1_5197", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Subject, A 52-year-old; white female. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6440806_1_5198", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sodium aurothiomalate"}, {"id": "6440806_1_5199", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6440806_1_5200", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6440806_1_5201", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6440806_1_5202", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "8 weeks"}, {"id": "6440806_1_5203", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6440806_1_5204", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "6440806_1_5205", "context": "A 52-year-old, white female developed low-grade fever, cough, and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis.", "question": "adverse event. Treatment, sodium aurothiomalate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_1_5206", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Subject, In both cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12786839_1_5207", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Subject, In both cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12786839_1_5208", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Subject, In both cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "both"}, {"id": "12786839_1_5209", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Subject, In both cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12786839_1_5210", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Subject, In both cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12786839_1_5211", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "SASP"}, {"id": "12786839_1_5212", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_1_5213", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_1_5214", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_1_5215", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_1_5216", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_1_5217", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_1_5218", "context": "In both cases, high fever, skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with SASP.", "question": "adverse event. Treatment, SASP. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_2_5219", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Subject, high-grade chloroquine-resistant Plasmodium vivax. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12659609_2_5220", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Subject, high-grade chloroquine-resistant Plasmodium vivax. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12659609_2_5221", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Subject, high-grade chloroquine-resistant Plasmodium vivax. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12659609_2_5222", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Subject, high-grade chloroquine-resistant Plasmodium vivax. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12659609_2_5223", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Subject, high-grade chloroquine-resistant Plasmodium vivax. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "high-grade chloroquine-resistant Plasmodium vivax"}, {"id": "12659609_2_5224", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chloroquine"}, {"id": "12659609_2_5225", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12659609_2_5226", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_2_5227", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_2_5228", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_2_5229", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_2_5230", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_2_5231", "context": "OBJECTIVE: To report a case of severe chloroquine toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.", "question": "adverse event. Treatment, chloroquine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_4_5232", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Subject, All cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15857283_4_5233", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Subject, All cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15857283_4_5234", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Subject, All cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15857283_4_5235", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Subject, All cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15857283_4_5236", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Subject, All cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15857283_4_5237", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "15857283_4_5238", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_4_5239", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_4_5240", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_4_5241", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_4_5242", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_4_5243", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_4_5244", "context": "RESULTS: All cases developed corneal endothelial deposits after previous use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_2_5245", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Subject, Two infants. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "infants"}, {"id": "3136101_2_5246", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Subject, Two infants. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3136101_2_5247", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Subject, Two infants. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "3136101_2_5248", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Subject, Two infants. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3136101_2_5249", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Subject, Two infants. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3136101_2_5250", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ACTH"}, {"id": "3136101_2_5251", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "cessation"}, {"id": "3136101_2_5252", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_2_5253", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_2_5254", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "shortly after"}, {"id": "3136101_2_5255", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_2_5256", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "infantile spasms"}, {"id": "3136101_2_5257", "context": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms.", "question": "adverse event. Treatment, shortly after cessation of prolonged ACTH therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_2_5258", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "19318596_2_5259", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_2_5260", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_2_5261", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_2_5262", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_2_5263", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_2_5264", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_2_5265", "context": "In this case, CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale.", "question": "adverse event. Treatment, cyclosporine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_1_5266", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone acetonide"}, {"id": "18751717_1_5267", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_1_5268", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_1_5269", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravitreal; injection"}, {"id": "18751717_1_5270", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_1_5271", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_1_5272", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_1_5273", "context": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7139589_2_5274", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "7139589_2_5275", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_2_5276", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_2_5277", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intramuscular"}, {"id": "7139589_2_5278", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_2_5279", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_2_5280", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_2_5281", "context": "Delayed pseudocyst of the pancreas can be a complication of intramuscular L-asparaginase.", "question": "adverse event. Treatment, intramuscular L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7783891_3_5282", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Subject, a 35-year-old woman with occult coronary artery disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "35-year-old"}, {"id": "7783891_3_5283", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Subject, a 35-year-old woman with occult coronary artery disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "7783891_3_5284", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Subject, a 35-year-old woman with occult coronary artery disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7783891_3_5285", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Subject, a 35-year-old woman with occult coronary artery disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7783891_3_5286", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Subject, a 35-year-old woman with occult coronary artery disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "occult coronary artery disease"}, {"id": "7783891_3_5287", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sumatriptan"}, {"id": "7783891_3_5288", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a first-time dose"}, {"id": "7783891_3_5289", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_3_5290", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "subcutaneous"}, {"id": "7783891_3_5291", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within minutes"}, {"id": "7783891_3_5292", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_3_5293", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "migraine"}, {"id": "7783891_3_5294", "context": "I report a 35-year-old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first-time dose of subcutaneous sumatriptan for migraine.", "question": "adverse event. Treatment, within minutes after receiving a first-time dose of subcutaneous sumatriptan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10332990_2_5295", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Epoprostenol; prostacyclin"}, {"id": "10332990_2_5296", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10332990_2_5297", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10332990_2_5298", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10332990_2_5299", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10332990_2_5300", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10332990_2_5301", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "primary pulmonary hypertension"}, {"id": "10332990_2_5302", "context": "Epoprostenol (prostacyclin) is currently approved for treatment of primary pulmonary hypertension; however, it is being evaluated in other forms of pulmonary hypertension, particularly scleroderma.", "question": "potential therapeutic event. Treatment, Epoprostenol (prostacyclin). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11724089_4_5303", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Subject, man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11724089_4_5304", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Subject, man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "11724089_4_5305", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Subject, man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11724089_4_5306", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Subject, man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11724089_4_5307", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Subject, man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11724089_4_5308", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ofloxacin"}, {"id": "11724089_4_5309", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_4_5310", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_4_5311", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "11724089_4_5312", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_4_5313", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_4_5314", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "epididymitis"}, {"id": "11724089_4_5315", "context": "OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.", "question": "adverse event. Treatment, oral ofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12869178_1_5316", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "12869178_1_5317", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12869178_1_5318", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12869178_1_5319", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12869178_1_5320", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12869178_1_5321", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12869178_1_5322", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12869178_1_5323", "context": "Massive pulmonary embolism due to late-onset heparin-induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.", "question": "adverse event. Treatment, heparin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_1_5324", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Subject, increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "11283125_1_5325", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Subject, increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_1_5326", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Subject, increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_1_5327", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Subject, increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_1_5328", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Subject, increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_1_5329", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cytarabine"}, {"id": "11283125_1_5330", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "11283125_1_5331", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_1_5332", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_1_5333", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_1_5334", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_1_5335", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute lymphoblastic leukemia; lymphoblastic lymphoma"}, {"id": "11283125_1_5336", "context": "Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.", "question": "potential therapeutic event. Treatment, high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "11450788_4_5337", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11450788_4_5338", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11450788_4_5339", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11450788_4_5340", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11450788_4_5341", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11450788_4_5342", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "didanosine"}, {"id": "11450788_4_5343", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11450788_4_5344", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11450788_4_5345", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11450788_4_5346", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11450788_4_5347", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11450788_4_5348", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11450788_4_5349", "context": "We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.", "question": "adverse event. Treatment, didanosine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16537817_10_5350", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone; simvastatin"}, {"id": "16537817_10_5351", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16537817_10_5352", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16537817_10_5353", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16537817_10_5354", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16537817_10_5355", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16537817_10_5356", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16537817_10_5357", "context": "An objective causal assessment suggests that rhabdomyolysis, renal failure, and possibly hepatotoxicity were probably related to an amiodarone-simvastatin interaction.", "question": "adverse event. Treatment, an amiodarone-simvastatin interaction. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "amiodarone; simvastatin"}, {"id": "11105373_2_5358", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroquinone"}, {"id": "11105373_2_5359", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11105373_2_5360", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11105373_2_5361", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "cream"}, {"id": "11105373_2_5362", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11105373_2_5363", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11105373_2_5364", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11105373_2_5365", "context": "Nail staining from hydroquinone cream.", "question": "adverse event. Treatment, hydroquinone cream. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_2_5366", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Subject, an epilepsy patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_2_5367", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Subject, an epilepsy patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_2_5368", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Subject, an epilepsy patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_2_5369", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Subject, an epilepsy patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_2_5370", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Subject, an epilepsy patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_2_5371", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diphenylhydantoin"}, {"id": "748238_2_5372", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_2_5373", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_2_5374", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_2_5375", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_2_5376", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "for 20 years"}, {"id": "748238_2_5377", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "epilepsy"}, {"id": "748238_2_5378", "context": "The development of an IgG lambda-type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin (DILANTIN) therapy for 20 years is reported.", "question": "adverse event. Treatment, diphenylhydantoin (DILANTIN) therapy for 20 years. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_2_5379", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Ibuprofen"}, {"id": "10698143_2_5380", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "10698143_2_5381", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_2_5382", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10698143_2_5383", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_2_5384", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_2_5385", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_2_5386", "context": "Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.", "question": "adverse event. Treatment, Ibuprofen overdose. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_5_5387", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Subject, His PD. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "20628041_5_5388", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Subject, His PD. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "His"}, {"id": "20628041_5_5389", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Subject, His PD. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "20628041_5_5390", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Subject, His PD. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "20628041_5_5391", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Subject, His PD. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "20628041_5_5392", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pramipexole; entacapone; levodopa; carbidopa"}, {"id": "20628041_5_5393", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "100 mg; 25 mg; 1.5 tablets"}, {"id": "20628041_5_5394", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "4 times daily"}, {"id": "20628041_5_5395", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "nasogastric tube"}, {"id": "20628041_5_5396", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_5_5397", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20628041_5_5398", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "PD"}, {"id": "20628041_5_5399", "context": "His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube.", "question": "potential therapeutic event. Treatment, pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily; via nasogastric tube. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "pramipexole; entacapone; levodopa; carbidopa"}, {"id": "18675768_15_5400", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propafenone; citalopram"}, {"id": "18675768_15_5401", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_15_5402", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_15_5403", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_15_5404", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_15_5405", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_15_5406", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_15_5407", "context": "CONCLUSIONS: This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone; citalopram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "propafenone; citalopram"}, {"id": "14614357_2_5408", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Subject, a young healthy woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "14614357_2_5409", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Subject, a young healthy woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "14614357_2_5410", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Subject, a young healthy woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14614357_2_5411", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Subject, a young healthy woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14614357_2_5412", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Subject, a young healthy woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14614357_2_5413", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acenocoumarol"}, {"id": "14614357_2_5414", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14614357_2_5415", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14614357_2_5416", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14614357_2_5417", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14614357_2_5418", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14614357_2_5419", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "thromboembolic"}, {"id": "14614357_2_5420", "context": "We report the case of a young healthy woman who presented an early overanticoagulation when receiving acenocoumarol for a first thromboembolic episode.", "question": "adverse event. Treatment, acenocoumarol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3708949_2_5421", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Subject, A patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3708949_2_5422", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Subject, A patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3708949_2_5423", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Subject, A patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3708949_2_5424", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Subject, A patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3708949_2_5425", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Subject, A patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3708949_2_5426", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "3708949_2_5427", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3708949_2_5428", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3708949_2_5429", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3708949_2_5430", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3708949_2_5431", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3708949_2_5432", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3708949_2_5433", "context": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described.", "question": "adverse event. Treatment, parenteral amiodarone administration. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18364401_4_5434", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18364401_4_5435", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_4_5436", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18364401_4_5437", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18364401_4_5438", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_4_5439", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18364401_4_5440", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hyperglycemia (fasting blood glucose 138 mg/dL)"}, {"id": "18364401_4_5441", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "potential therapeutic event. Treatment, olanzapine was stopped. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18364401_4_5442", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18364401_4_5443", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "2.5 mg"}, {"id": "18364401_4_5444", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "twice daily"}, {"id": "18364401_4_5445", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_4_5446", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 days"}, {"id": "18364401_4_5447", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_4_5448", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_4_5449", "context": "Subsequently, he developed hyperglycemia (fasting blood glucose 138 mg/dL) that resolved when olanzapine was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.", "question": "adverse event. Treatment, 2 days of rechallenge with olanzapine 2.5 mg twice daily. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_1_5450", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Subject, HIV-infected patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_1_5451", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Subject, HIV-infected patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_1_5452", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Subject, HIV-infected patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_1_5453", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Subject, HIV-infected patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_1_5454", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Subject, HIV-infected patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_1_5455", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "didanosine"}, {"id": "8151270_1_5456", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_1_5457", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_1_5458", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_1_5459", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_1_5460", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_1_5461", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV"}, {"id": "8151270_1_5462", "context": "Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.", "question": "adverse event. Treatment, didanosine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_4_5463", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ranibizumab"}, {"id": "18425523_4_5464", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_4_5465", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_4_5466", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_4_5467", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_4_5468", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_4_5469", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_4_5470", "context": "Persisent ocular hypertension following intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14968106_4_5471", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Subject, a 31-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "31-year-old"}, {"id": "14968106_4_5472", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Subject, a 31-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "14968106_4_5473", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Subject, a 31-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "14968106_4_5474", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Subject, a 31-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "14968106_4_5475", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Subject, a 31-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "14968106_4_5476", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxorubicin"}, {"id": "14968106_4_5477", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_4_5478", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_4_5479", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "14968106_4_5480", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_4_5481", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_4_5482", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_4_5483", "context": "STUDY DESIGN: Case report of a 31-year-old woman who presented with toxic myelopathy due to intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_4_5484", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Subject, The patient had a background of obsessive compulsive disorder. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18166746_4_5485", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Subject, The patient had a background of obsessive compulsive disorder. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18166746_4_5486", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Subject, The patient had a background of obsessive compulsive disorder. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18166746_4_5487", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Subject, The patient had a background of obsessive compulsive disorder. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18166746_4_5488", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Subject, The patient had a background of obsessive compulsive disorder. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18166746_4_5489", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "paroxetine"}, {"id": "18166746_4_5490", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_4_5491", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18166746_4_5492", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18166746_4_5493", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_4_5494", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18166746_4_5495", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "obsessive compulsive disorder"}, {"id": "18166746_4_5496", "context": "The patient had a background of obsessive compulsive disorder treated with paroxetine.", "question": "potential therapeutic event. Treatment, paroxetine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9704170_2_5497", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Subject, patients with defective calcium-activated K+ channels. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9704170_2_5498", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Subject, patients with defective calcium-activated K+ channels. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9704170_2_5499", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Subject, patients with defective calcium-activated K+ channels. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9704170_2_5500", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Subject, patients with defective calcium-activated K+ channels. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9704170_2_5501", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Subject, patients with defective calcium-activated K+ channels. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "defective calcium-activated K+ channels"}, {"id": "9704170_2_5502", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Clozapine"}, {"id": "9704170_2_5503", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9704170_2_5504", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9704170_2_5505", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9704170_2_5506", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9704170_2_5507", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9704170_2_5508", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9704170_2_5509", "context": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels.", "question": "adverse event. Treatment, Clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_2_5510", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "11485141_2_5511", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_2_5512", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_2_5513", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_2_5514", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_2_5515", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_2_5516", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_2_5517", "context": "CONCLUSIONS: We report the first case of gemcitabine-induced LABD.", "question": "adverse event. Treatment, gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10752888_1_5518", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Nitrofurantoin"}, {"id": "10752888_1_5519", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10752888_1_5520", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10752888_1_5521", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10752888_1_5522", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10752888_1_5523", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10752888_1_5524", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10752888_1_5525", "context": "Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.", "question": "adverse event. Treatment, Nitrofurantoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2012922_2_5526", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Trazodone"}, {"id": "2012922_2_5527", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2012922_2_5528", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2012922_2_5529", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2012922_2_5530", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2012922_2_5531", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2012922_2_5532", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2012922_2_5533", "context": "Trazodone-induced transient hypomanic symptoms and their management.", "question": "adverse event. Treatment, Trazodone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2219619_1_5534", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alum"}, {"id": "2219619_1_5535", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2219619_1_5536", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2219619_1_5537", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravesical; irrigation"}, {"id": "2219619_1_5538", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2219619_1_5539", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2219619_1_5540", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hemorrhagic cystitis"}, {"id": "2219619_1_5541", "context": "Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.", "question": "adverse event. Treatment, continuous intravesical alum irrigation. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18076602_1_5542", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Amphotericin B"}, {"id": "18076602_1_5543", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18076602_1_5544", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18076602_1_5545", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18076602_1_5546", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18076602_1_5547", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18076602_1_5548", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18076602_1_5549", "context": "Amphotericin B-induced cutaneous leucocytoclastic vasculitis: case report.", "question": "adverse event. Treatment, Amphotericin B. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_5_5550", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir; lithium"}, {"id": "8726608_5_5551", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_5_5552", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_5_5553", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_5_5554", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_5_5555", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_5_5556", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_5_5557", "context": "When measured, the serum lithium level had increased 4-fold during acyclovir therapy.", "question": "adverse event. Treatment, acyclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "lithium; acyclovir"}, {"id": "17504225_3_5558", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Subject, a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17504225_3_5559", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Subject, a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "17504225_3_5560", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Subject, a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17504225_3_5561", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Subject, a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17504225_3_5562", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Subject, a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "kidney transplanted"}, {"id": "17504225_3_5563", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clarithromycin; sirolimus"}, {"id": "17504225_3_5564", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_3_5565", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_3_5566", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_3_5567", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_3_5568", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_3_5569", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "pulmonary infection"}, {"id": "17504225_3_5570", "context": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman, suffering from pulmonary infection sustained by a bacterial pathogen, in particular Hemophilus Influenzae.", "question": "adverse event. Treatment, clarithromycin and sirolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "clarithromycin; sirolimus"}, {"id": "12847760_1_5571", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Subject, A 25-year-old man with a history of mid-borderline (BB) Hansen's disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "25-year-old"}, {"id": "12847760_1_5572", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Subject, A 25-year-old man with a history of mid-borderline (BB) Hansen's disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "12847760_1_5573", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Subject, A 25-year-old man with a history of mid-borderline (BB) Hansen's disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12847760_1_5574", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Subject, A 25-year-old man with a history of mid-borderline (BB) Hansen's disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12847760_1_5575", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Subject, A 25-year-old man with a history of mid-borderline (BB) Hansen's disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "mid-borderline (BB) Hansen's disease"}, {"id": "12847760_1_5576", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dapsone; rifampin"}, {"id": "12847760_1_5577", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12847760_1_5578", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12847760_1_5579", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12847760_1_5580", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12847760_1_5581", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12847760_1_5582", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12847760_1_5583", "context": "A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a reversal reaction after starting dapsone and rifampin therapy is presented.", "question": "adverse event. Treatment, dapsone and rifampin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "dapsone; rifampin"}, {"id": "15516308_15_5584", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Subject, cases #1 and #2. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15516308_15_5585", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Subject, cases #1 and #2. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15516308_15_5586", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Subject, cases #1 and #2. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15516308_15_5587", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Subject, cases #1 and #2. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15516308_15_5588", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Subject, cases #1 and #2. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15516308_15_5589", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quetiapine; quetiapine"}, {"id": "15516308_15_5590", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "overdose"}, {"id": "15516308_15_5591", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_15_5592", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_15_5593", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_15_5594", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_15_5595", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_15_5596", "context": "In all cases, drugs in addition to quetiapine were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.", "question": "adverse event. Treatment, quetiapine overdose. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_4_5597", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antiarrhythmic drugs; antiepileptic drugs"}, {"id": "17275666_4_5598", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_4_5599", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_4_5600", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_4_5601", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_4_5602", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_4_5603", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17275666_4_5604", "context": "Similar to antiarrhythmic drugs aggravating particular arrhythmias, antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones.", "question": "adverse event. Treatment, antiepileptic drugs. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16192734_3_5605", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, pregnant patient with myotonic dystrophy.. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16192734_3_5606", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, pregnant patient with myotonic dystrophy.. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "pregnant"}, {"id": "16192734_3_5607", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, pregnant patient with myotonic dystrophy.. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16192734_3_5608", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, pregnant patient with myotonic dystrophy.. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16192734_3_5609", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Subject, pregnant patient with myotonic dystrophy.. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16192734_3_5610", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ritodrine-hydrochloride"}, {"id": "16192734_3_5611", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_3_5612", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_3_5613", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_3_5614", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_3_5615", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_3_5616", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myotonic dystrophy"}, {"id": "16192734_3_5617", "context": "We report here a rare case of ritodrine-hydrochloride-induced rhabdomyolysis in a pregnant patient with myotonic dystrophy.", "question": "adverse event. Treatment, ritodrine-hydrochloride. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7748076_2_5618", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "progestin"}, {"id": "7748076_2_5619", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7748076_2_5620", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7748076_2_5621", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7748076_2_5622", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7748076_2_5623", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7748076_2_5624", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hyperplasia"}, {"id": "7748076_2_5625", "context": "OBJECTIVE: To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia.", "question": "adverse event. Treatment, progestin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_8_5626", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Subject, DPD-deficient patients with cancer. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9007910_8_5627", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Subject, DPD-deficient patients with cancer. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9007910_8_5628", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Subject, DPD-deficient patients with cancer. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9007910_8_5629", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Subject, DPD-deficient patients with cancer. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9007910_8_5630", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Subject, DPD-deficient patients with cancer. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "DPD-deficient"}, {"id": "9007910_8_5631", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "5-FU"}, {"id": "9007910_8_5632", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_8_5633", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9007910_8_5634", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9007910_8_5635", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_8_5636", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9007910_8_5637", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cancer"}, {"id": "9007910_8_5638", "context": "IMPLICATIONS FOR NURSING PRACTICE: Nurses must understand the pharmacology, mechanism of action, clinical presentation, potentially lethal risks, and traumatic psychosocial stresses experienced by DPD-deficient patients with cancer receiving 5-FU therapy in order to develop timely interventions and alternative plans of care.", "question": "potential therapeutic event. Treatment, 5-FU therapy. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8912599_2_5639", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "8912599_2_5640", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_2_5641", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8912599_2_5642", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8912599_2_5643", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_2_5644", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8912599_2_5645", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "psoriasis"}, {"id": "8912599_2_5646", "context": "Methotrexate is an effective but potentially toxic treatment for psoriasis.", "question": "potential therapeutic event. Treatment, Methotrexate. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18203308_3_5647", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "etanercept"}, {"id": "18203308_3_5648", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18203308_3_5649", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18203308_3_5650", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18203308_3_5651", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "11, 12, and 26 months after start"}, {"id": "18203308_3_5652", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18203308_3_5653", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18203308_3_5654", "context": "Typical symptoms of active CD occurred 11, 12, and 26 months after start of etanercept therapy, respectively.", "question": "adverse event. Treatment, etanercept therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "53128_3_5655", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Subject, he. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "53128_3_5656", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Subject, he. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "he"}, {"id": "53128_3_5657", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Subject, he. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "53128_3_5658", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Subject, he. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "53128_3_5659", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Subject, he. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "53128_3_5660", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aspirin"}, {"id": "53128_3_5661", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "53128_3_5662", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "53128_3_5663", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "53128_3_5664", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "53128_3_5665", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "53128_3_5666", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neck pain"}, {"id": "53128_3_5667", "context": "This progressed to tracheal compression with stridor after he had taken some aspirin for relief of the neck pain.", "question": "adverse event. Treatment, aspirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_2_5668", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "toxin; clindamycin phosphate"}, {"id": "9533061_2_5669", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_2_5670", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_2_5671", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "vaginal cream"}, {"id": "9533061_2_5672", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_2_5673", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_2_5674", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_2_5675", "context": "OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_1_5676", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "20234160_1_5677", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_1_5678", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_1_5679", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_1_5680", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_1_5681", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_1_5682", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20234160_1_5683", "context": "Severe vancomycin-induced anaphylactic reaction.", "question": "adverse event. Treatment, vancomycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8876616_2_5684", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Subject, a 74-year-old female patient; a major depression. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "74-year-old"}, {"id": "8876616_2_5685", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Subject, a 74-year-old female patient; a major depression. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "female"}, {"id": "8876616_2_5686", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Subject, a 74-year-old female patient; a major depression. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8876616_2_5687", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Subject, a 74-year-old female patient; a major depression. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8876616_2_5688", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Subject, a 74-year-old female patient; a major depression. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "8876616_2_5689", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "amitriptyline"}, {"id": "8876616_2_5690", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "8876616_2_5691", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8876616_2_5692", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8876616_2_5693", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8876616_2_5694", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8876616_2_5695", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "major depression"}, {"id": "8876616_2_5696", "context": "We report the case of a 74-year-old female patient who received the antide-pressant amitriptyline because of a major depression.", "question": "potential therapeutic event. Treatment, antide-pressant amitriptyline. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16192734_2_5697", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ritodrine hydrochloride."}, {"id": "16192734_2_5698", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16192734_2_5699", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16192734_2_5700", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16192734_2_5701", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16192734_2_5702", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16192734_2_5703", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16192734_2_5704", "context": "Rhabdomyolysis has been recognized as a complication of tocolytic therapy with ritodrine hydrochloride.", "question": "adverse event. Treatment, ritodrine hydrochloride. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_5_5705", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Voriconazole"}, {"id": "18628507_5_5706", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_5_5707", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_5_5708", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_5_5709", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_5_5710", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_5_5711", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_5_5712", "context": "Voriconazole (VRC) has not previously been reported to cause angio-oedema.", "question": "adverse event. Treatment, Voriconazole (VRC). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_3_5713", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Tamoxifen"}, {"id": "12477460_3_5714", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_3_5715", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_3_5716", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_3_5717", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_3_5718", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_3_5719", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12477460_3_5720", "context": "CONCLUSION: Tamoxifen may cause malignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state.", "question": "adverse event. Treatment, Tamoxifen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_5_5721", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Subject, One patient. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10573314_5_5722", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Subject, One patient. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10573314_5_5723", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Subject, One patient. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "One"}, {"id": "10573314_5_5724", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Subject, One patient. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10573314_5_5725", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Subject, One patient. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10573314_5_5726", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "levofloxacin; tolterodine"}, {"id": "10573314_5_5727", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_5_5728", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10573314_5_5729", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10573314_5_5730", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_5_5731", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10573314_5_5732", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "prostatitis"}, {"id": "10573314_5_5733", "context": "One patient had an episode of prostatitis, which was treated with levofloxacin immediately prior to tolterodine initiation.", "question": "potential therapeutic event. Treatment, levofloxacin; tolterodine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "levofloxacin; tolterodine"}, {"id": "16393774_5_5734", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Subject, The first patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_5_5735", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Subject, The first patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_5_5736", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Subject, The first patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_5_5737", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Subject, The first patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_5_5738", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Subject, The first patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_5_5739", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN-beta"}, {"id": "16393774_5_5740", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_5_5741", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_5_5742", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_5_5743", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_5_5744", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_5_5745", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_5_5746", "context": "The first patient developed a monoarthritis 2 weeks after initiation of IFN-beta, which persisted during the 14 months of therapy and resolved with discontinuation of the medication.", "question": "adverse event. Treatment, IFN-beta. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_9_5747", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-alpha"}, {"id": "10682234_9_5748", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_9_5749", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_9_5750", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_9_5751", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_9_5752", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_9_5753", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_9_5754", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_9_5755", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "levodopa"}, {"id": "10682234_9_5756", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_9_5757", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_9_5758", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_9_5759", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_9_5760", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_9_5761", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "neurotoxicity associated with interferon-alpha"}, {"id": "10682234_9_5762", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "potential therapeutic event. Treatment, levodopa treatment. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10682234_9_5763", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-alpha."}, {"id": "10682234_9_5764", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_9_5765", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_9_5766", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_9_5767", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_9_5768", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_9_5769", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_9_5770", "context": "The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18837734_1_5771", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "erlotinib"}, {"id": "18837734_1_5772", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18837734_1_5773", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18837734_1_5774", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18837734_1_5775", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18837734_1_5776", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18837734_1_5777", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18837734_1_5778", "context": "Rosaceiform eruption induced by erlotinib.", "question": "adverse event. Treatment, erlotinib.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_2_5779", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "verapamil"}, {"id": "6697887_2_5780", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_2_5781", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_2_5782", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral; oral"}, {"id": "6697887_2_5783", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_2_5784", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_2_5785", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_2_5786", "context": "The incidence of oral-verapamil-induced hypotension in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.", "question": "adverse event. Treatment, oral-verapamil; in the presence of concomitant beta-adrenergic blockade. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_4_5787", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir; lithium"}, {"id": "8726608_4_5788", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_4_5789", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_4_5790", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "8726608_4_5791", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8726608_4_5792", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_4_5793", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_4_5794", "context": "Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day.", "question": "adverse event. Treatment, intravenous acyclovir is administered concurrently with lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "lithium; acyclovir"}, {"id": "11283125_9_5795", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "HD Ara-C; HD MTX"}, {"id": "11283125_9_5796", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_9_5797", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11283125_9_5798", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11283125_9_5799", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_9_5800", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11283125_9_5801", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11283125_9_5802", "context": "Disappointingly, with the dose schedule used in this protocol, HD Ara-C added to HD MTX, although well tolerated, failed to further decrease the incidence of CNS relapse or to improve the overall DFS.", "question": "adverse event. Treatment, HD Ara-C; HD MTX. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "HD Ara-C; HD MTX"}, {"id": "3732375_1_5803", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "viloxazine; Theophylline"}, {"id": "3732375_1_5804", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3732375_1_5805", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3732375_1_5806", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3732375_1_5807", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3732375_1_5808", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3732375_1_5809", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3732375_1_5810", "context": "Theophylline intoxication following viloxazine induced decrease in clearance.", "question": "adverse event. Treatment, viloxazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "viloxazine; Theophylline"}, {"id": "11197767_3_5811", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zinc"}, {"id": "11197767_3_5812", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "lower concentrations"}, {"id": "11197767_3_5813", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_3_5814", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_3_5815", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_3_5816", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_3_5817", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_3_5818", "context": "Cercarial encystment at concentrations of 25000 microg/l or higher was significantly impaired by all test metals; however, at lower concentrations only zinc demonstrated toxicity.", "question": "adverse event. Treatment, lower concentrations; zinc. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_3_5819", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "brimonidine"}, {"id": "12504711_3_5820", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_3_5821", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_3_5822", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_3_5823", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_3_5824", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_3_5825", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_3_5826", "context": "PURPOSE: We report an unusual paradoxical effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17387702_1_5827", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Subject, a child homozygous for MTHFR C677T polymorphism. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "17387702_1_5828", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Subject, a child homozygous for MTHFR C677T polymorphism. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17387702_1_5829", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Subject, a child homozygous for MTHFR C677T polymorphism. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17387702_1_5830", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Subject, a child homozygous for MTHFR C677T polymorphism. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17387702_1_5831", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Subject, a child homozygous for MTHFR C677T polymorphism. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "homozygous for MTHFR C677T polymorphism"}, {"id": "17387702_1_5832", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "17387702_1_5833", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "17387702_1_5834", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17387702_1_5835", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17387702_1_5836", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17387702_1_5837", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17387702_1_5838", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17387702_1_5839", "context": "Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism.", "question": "adverse event. Treatment, high-dose methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_2_5840", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "19131789_2_5841", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19131789_2_5842", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_2_5843", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "19131789_2_5844", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "2 hours"}, {"id": "19131789_2_5845", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "4-hour"}, {"id": "19131789_2_5846", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_2_5847", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "adverse event. Treatment, 2 hours after the completion of a 4-hour MTX infusion. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_2_5848", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "leucovorin; hemodialysis; charcoal; carboxypeptidase G2"}, {"id": "19131789_2_5849", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "19131789_2_5850", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19131789_2_5851", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "hemoperfusion"}, {"id": "19131789_2_5852", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_2_5853", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19131789_2_5854", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "renal toxicity"}, {"id": "19131789_2_5855", "context": "Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of renal toxicity may be present as early as 2 hours after the completion of a 4-hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.", "question": "potential therapeutic event. Treatment, high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "leucovorin; hemodialysis; charcoal; carboxypeptidase G2"}, {"id": "10646879_2_5856", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Subject, Ten to 15% of patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10646879_2_5857", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Subject, Ten to 15% of patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10646879_2_5858", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Subject, Ten to 15% of patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Ten to 15%"}, {"id": "10646879_2_5859", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Subject, Ten to 15% of patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10646879_2_5860", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Subject, Ten to 15% of patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10646879_2_5861", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "10646879_2_5862", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_2_5863", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10646879_2_5864", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10646879_2_5865", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_2_5866", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10646879_2_5867", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_2_5868", "context": "Ten to 15% of patients treated with ifosfamide develop an encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_3_5869", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11352235_3_5870", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11352235_3_5871", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11352235_3_5872", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11352235_3_5873", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11352235_3_5874", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "leflunomide"}, {"id": "11352235_3_5875", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_3_5876", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_3_5877", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_3_5878", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_3_5879", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_3_5880", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11352235_3_5881", "context": "METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.", "question": "adverse event. Treatment, leflunomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_3_5882", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "681921_3_5883", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_3_5884", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_3_5885", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_3_5886", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_3_5887", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_3_5888", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_3_5889", "context": "This is the first report of a catatonic syndrome occurring in a patient receiving disulfiram treatment.", "question": "adverse event. Treatment, disulfiram treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11096051_2_5890", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "phosphorus; phosphorus"}, {"id": "11096051_2_5891", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11096051_2_5892", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11096051_2_5893", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intravenous; dialysate"}, {"id": "11096051_2_5894", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11096051_2_5895", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11096051_2_5896", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hypophosphatemia"}, {"id": "11096051_2_5897", "context": "Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.", "question": "potential therapeutic event. Treatment, intravenous phosphorus; phosphorus-enriched dialysate. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18569796_4_5898", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alendronate sodium"}, {"id": "18569796_4_5899", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_4_5900", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_4_5901", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_4_5902", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Two weeks following"}, {"id": "18569796_4_5903", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_4_5904", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_4_5905", "context": "Two weeks following rechallenge with alendronate sodium resulted in recurrence of his scleritis.", "question": "adverse event. Treatment, alendronate sodium; Two weeks following. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16901609_2_5906", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diamorphine"}, {"id": "16901609_2_5907", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16901609_2_5908", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16901609_2_5909", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal"}, {"id": "16901609_2_5910", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16901609_2_5911", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16901609_2_5912", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16901609_2_5913", "context": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis.", "question": "adverse event. Treatment, intrathecal diamorphine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_2_5914", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cerivastatin"}, {"id": "15811174_2_5915", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_2_5916", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_2_5917", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_2_5918", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_2_5919", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_2_5920", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_2_5921", "context": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.", "question": "adverse event. Treatment, cerivastatin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_13_5922", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; azathioprine"}, {"id": "18505911_13_5923", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_13_5924", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_13_5925", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_13_5926", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_13_5927", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_13_5928", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_13_5929", "context": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance.", "question": "adverse event. Treatment, azathioprine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_3_5930", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alendronate sodium"}, {"id": "18569796_3_5931", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_3_5932", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_3_5933", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_3_5934", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_3_5935", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_3_5936", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_3_5937", "context": "PURPOSE: To report a case of nodular scleritis following alendronate sodium.", "question": "adverse event. Treatment, alendronate sodium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12869178_2_5938", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Subject, Most cardiac surgical patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12869178_2_5939", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Subject, Most cardiac surgical patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12869178_2_5940", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Subject, Most cardiac surgical patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12869178_2_5941", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Subject, Most cardiac surgical patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12869178_2_5942", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Subject, Most cardiac surgical patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "cardiac surgical"}, {"id": "12869178_2_5943", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "heparin"}, {"id": "12869178_2_5944", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12869178_2_5945", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12869178_2_5946", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12869178_2_5947", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12869178_2_5948", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12869178_2_5949", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12869178_2_5950", "context": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced thrombocytopenia (HIT) postoperatively.", "question": "adverse event. Treatment, heparin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7485371_2_5951", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7485371_2_5952", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7485371_2_5953", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7485371_2_5954", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7485371_2_5955", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7485371_2_5956", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "atovaquone"}, {"id": "7485371_2_5957", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7485371_2_5958", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7485371_2_5959", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7485371_2_5960", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7485371_2_5961", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7485371_2_5962", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7485371_2_5963", "context": "PURPOSE: We studied a case of vortex keratopathy that was associated with the use of atovaquone.", "question": "adverse event. Treatment, atovaquone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16216617_2_5964", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Subject, she. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16216617_2_5965", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Subject, she. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "16216617_2_5966", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Subject, she. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16216617_2_5967", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Subject, she. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16216617_2_5968", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Subject, she. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16216617_2_5969", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenylephrine"}, {"id": "16216617_2_5970", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "maximal dose"}, {"id": "16216617_2_5971", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16216617_2_5972", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16216617_2_5973", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16216617_2_5974", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16216617_2_5975", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16216617_2_5976", "context": "While on a maximal dose of phenylephrine she developed prominent positive U waves, which disappeared with the cessation of the drug.", "question": "adverse event. Treatment, maximal dose of phenylephrine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_4_5977", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Subject, Two patients with ocular inflammation. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18751717_4_5978", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Subject, Two patients with ocular inflammation. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18751717_4_5979", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Subject, Two patients with ocular inflammation. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "18751717_4_5980", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Subject, Two patients with ocular inflammation. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18751717_4_5981", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Subject, Two patients with ocular inflammation. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "ocular inflammation"}, {"id": "18751717_4_5982", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IVTA"}, {"id": "18751717_4_5983", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_4_5984", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_4_5985", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18751717_4_5986", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_4_5987", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_4_5988", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_4_5989", "context": "RESULTS: Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection.", "question": "adverse event. Treatment, IVTA injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_5_5990", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Disopyramide"}, {"id": "1695794_5_5991", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_5_5992", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1695794_5_5993", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1695794_5_5994", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_5_5995", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1695794_5_5996", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "supraventricular tachycardia"}, {"id": "1695794_5_5997", "context": "Disopyramide was started on admission for supraventricular tachycardia.", "question": "potential therapeutic event. Treatment, Disopyramide. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10759907_1_5998", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Subject, A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "50-year-old"}, {"id": "10759907_1_5999", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Subject, A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "10759907_1_6000", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Subject, A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10759907_1_6001", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Subject, A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10759907_1_6002", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Subject, A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10759907_1_6003", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zolmitriptan"}, {"id": "10759907_1_6004", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_1_6005", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_1_6006", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_1_6007", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_1_6008", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_1_6009", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "migraine without aura"}, {"id": "10759907_1_6010", "context": "A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_3_6011", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine; pravastatin; lithium"}, {"id": "19754002_3_6012", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_3_6013", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_3_6014", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_3_6015", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_3_6016", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_3_6017", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_3_6018", "context": "The skin rash effect was most probably due, in first line, to olanzapine, but the cutaneous skin condition was triggered and aggravated by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium medication.", "question": "adverse event. Treatment, olanzapine,; by pravastatin, a 3-hydoxy-3-methylglutaryl-coenzyme A-(HMG-CoA)-reductase inhibitor, and lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "lithium; pravastatin; olanzapine"}, {"id": "7639655_2_6019", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "7639655_2_6020", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_2_6021", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_2_6022", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_2_6023", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_2_6024", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_2_6025", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_2_6026", "context": "CONCLUSION: Anterior ischemic optic neuropathy may complicate treatment with interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_2_6027", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pantoprazole"}, {"id": "14742791_2_6028", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_2_6029", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_2_6030", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_2_6031", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "5 weeks"}, {"id": "14742791_2_6032", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_2_6033", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_2_6034", "context": "After 5 weeks of therapy, she stopped taking pantoprazole due to general malaise.", "question": "adverse event. Treatment, taking pantoprazole; After 5 weeks of therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_5_6035", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "pamidronate"}, {"id": "9865241_5_6036", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_5_6037", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_5_6038", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_5_6039", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_5_6040", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_5_6041", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning"}, {"id": "9865241_5_6042", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "potential therapeutic event. Treatment, pamidronate. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9865241_5_6043", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vitamin D"}, {"id": "9865241_5_6044", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_5_6045", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_5_6046", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_5_6047", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_5_6048", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_5_6049", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_5_6050", "context": "We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11485141_1_6051", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Subject, our patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11485141_1_6052", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Subject, our patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11485141_1_6053", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Subject, our patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11485141_1_6054", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Subject, our patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11485141_1_6055", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Subject, our patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11485141_1_6056", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "11485141_1_6057", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_1_6058", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_1_6059", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_1_6060", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_1_6061", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_1_6062", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_1_6063", "context": "According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.", "question": "adverse event. Treatment, gemcitabine treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_3_6064", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Subject, a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "58-yr-old"}, {"id": "18166746_3_6065", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Subject, a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "woman"}, {"id": "18166746_3_6066", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Subject, a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18166746_3_6067", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Subject, a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18166746_3_6068", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Subject, a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18166746_3_6069", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Methylene blue"}, {"id": "18166746_3_6070", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_3_6071", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18166746_3_6072", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18166746_3_6073", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_3_6074", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18166746_3_6075", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_3_6076", "context": "Methylene blue was administered to a 58-yr-old woman undergoing a parathyroidectomy under general anesthesia.", "question": "potential therapeutic event. Treatment, Methylene blue. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7712052_3_6077", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Subject, veterans with PTSD. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7712052_3_6078", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Subject, veterans with PTSD. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7712052_3_6079", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Subject, veterans with PTSD. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7712052_3_6080", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Subject, veterans with PTSD. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7712052_3_6081", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Subject, veterans with PTSD. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7712052_3_6082", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "7712052_3_6083", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_3_6084", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7712052_3_6085", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7712052_3_6086", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_3_6087", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7712052_3_6088", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "PTSD"}, {"id": "7712052_3_6089", "context": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts.", "question": "adverse event. Treatment, lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_2_6090", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "flucloxacillin"}, {"id": "15773973_2_6091", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_2_6092", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_2_6093", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_2_6094", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_2_6095", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_2_6096", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_2_6097", "context": "It is well-recognized that flucloxacillin may occasionally result in fatal hepatic injury.", "question": "adverse event. Treatment, flucloxacillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2943526_1_6098", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "FUdR"}, {"id": "2943526_1_6099", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2943526_1_6100", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2943526_1_6101", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "hepatic artery infusion"}, {"id": "2943526_1_6102", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2943526_1_6103", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2943526_1_6104", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2943526_1_6105", "context": "Neurologic toxicity associated with hepatic artery infusion HAI of FUdR.", "question": "adverse event. Treatment, hepatic artery infusion HAI of FUdR. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3136101_1_6106", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Subject, infantile spasms. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "infantile"}, {"id": "3136101_1_6107", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Subject, infantile spasms. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3136101_1_6108", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Subject, infantile spasms. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3136101_1_6109", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Subject, infantile spasms. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3136101_1_6110", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Subject, infantile spasms. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3136101_1_6111", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adrenocorticotropic hormone"}, {"id": "3136101_1_6112", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3136101_1_6113", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3136101_1_6114", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3136101_1_6115", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3136101_1_6116", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3136101_1_6117", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "infantile spasms"}, {"id": "3136101_1_6118", "context": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms.", "question": "adverse event. Treatment, adrenocorticotropic hormone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10082597_1_6119", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Subject, two cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10082597_1_6120", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Subject, two cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10082597_1_6121", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Subject, two cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "10082597_1_6122", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Subject, two cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10082597_1_6123", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Subject, two cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10082597_1_6124", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "naproxen; oxaprozin"}, {"id": "10082597_1_6125", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10082597_1_6126", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10082597_1_6127", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10082597_1_6128", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10082597_1_6129", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10082597_1_6130", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10082597_1_6131", "context": "METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.", "question": "adverse event. Treatment, naproxen and oxaprozin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "oxaprozin; naproxen"}, {"id": "18505911_4_6132", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Subject, She. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18505911_4_6133", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Subject, She. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "She"}, {"id": "18505911_4_6134", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Subject, She. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18505911_4_6135", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Subject, She. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18505911_4_6136", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Subject, She. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18505911_4_6137", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin; azathioprine"}, {"id": "18505911_4_6138", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "39 mg; 5.5 mg"}, {"id": "18505911_4_6139", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "weekly; daily"}, {"id": "18505911_4_6140", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18505911_4_6141", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_4_6142", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18505911_4_6143", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_4_6144", "context": "She was treated with an average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy.", "question": "potential therapeutic event. Treatment, average weekly warfarin dose of 39 mg (5.5 mg daily) prior to beginning azathioprine therapy. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9279731_1_6145", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B"}, {"id": "9279731_1_6146", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9279731_1_6147", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9279731_1_6148", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9279731_1_6149", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9279731_1_6150", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9279731_1_6151", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9279731_1_6152", "context": "When the disease recurred conventional amphotericin B was used again, but had to be stopped because of severe side effects.", "question": "adverse event. Treatment, amphotericin B. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3211830_2_6153", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diltiazem"}, {"id": "3211830_2_6154", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3211830_2_6155", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3211830_2_6156", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3211830_2_6157", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3211830_2_6158", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3211830_2_6159", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3211830_2_6160", "context": "Widespread cutaneous vasculitis associated with diltiazem.", "question": "adverse event. Treatment, diltiazem. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9726762_2_6161", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9726762_2_6162", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9726762_2_6163", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9726762_2_6164", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9726762_2_6165", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9726762_2_6166", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; gemfibrozil"}, {"id": "9726762_2_6167", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_2_6168", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_2_6169", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_2_6170", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "4 weeks"}, {"id": "9726762_2_6171", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_2_6172", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_2_6173", "context": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil.", "question": "adverse event. Treatment, on a stable regimen of warfarin; 4 weeks after starting gemfibrozil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_3_6174", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Subject, a 40-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "40-year-old"}, {"id": "15773973_3_6175", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Subject, a 40-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15773973_3_6176", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Subject, a 40-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15773973_3_6177", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Subject, a 40-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15773973_3_6178", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Subject, a 40-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15773973_3_6179", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "flucloxacillin"}, {"id": "15773973_3_6180", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_3_6181", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_3_6182", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "15773973_3_6183", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_3_6184", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "a course"}, {"id": "15773973_3_6185", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_3_6186", "context": "We report the case of a 40-year-old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin.", "question": "adverse event. Treatment, a course of oral flucloxacillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16697705_2_6187", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Subject, This case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16697705_2_6188", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Subject, This case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16697705_2_6189", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Subject, This case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16697705_2_6190", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Subject, This case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16697705_2_6191", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Subject, This case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16697705_2_6192", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Capecitabine"}, {"id": "16697705_2_6193", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16697705_2_6194", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16697705_2_6195", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16697705_2_6196", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16697705_2_6197", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16697705_2_6198", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16697705_2_6199", "context": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.", "question": "adverse event. Treatment, Capecitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7212107_2_6200", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "7212107_2_6201", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7212107_2_6202", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7212107_2_6203", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7212107_2_6204", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7212107_2_6205", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7212107_2_6206", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7212107_2_6207", "context": "These results indicate that lithium may cause biochemical hyperparathyroidism.", "question": "adverse event. Treatment, lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_2_6208", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "10579985_2_6209", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_2_6210", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_2_6211", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10579985_2_6212", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10579985_2_6213", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_2_6214", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "10579985_2_6215", "context": "The relationship between infliximab treatment and lymphoma in Crohn's disease.", "question": "adverse event. Treatment, infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_7_6216", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "raloxifene"}, {"id": "15863610_7_6217", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_7_6218", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_7_6219", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_7_6220", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_7_6221", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_7_6222", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_7_6223", "context": "CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.", "question": "adverse event. Treatment, raloxifene. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19131789_3_6224", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "19131789_3_6225", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "19131789_3_6226", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19131789_3_6227", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19131789_3_6228", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19131789_3_6229", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19131789_3_6230", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19131789_3_6231", "context": "Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.", "question": "adverse event. Treatment, high-dose methotrexate therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8467620_2_6232", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Subject, patients with rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8467620_2_6233", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Subject, patients with rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8467620_2_6234", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Subject, patients with rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8467620_2_6235", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Subject, patients with rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8467620_2_6236", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Subject, patients with rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8467620_2_6237", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8467620_2_6238", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8467620_2_6239", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8467620_2_6240", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8467620_2_6241", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8467620_2_6242", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8467620_2_6243", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "8467620_2_6244", "context": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases, but coincidence cannot be excluded.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14561622_2_6245", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "14561622_2_6246", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14561622_2_6247", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14561622_2_6248", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14561622_2_6249", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14561622_2_6250", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14561622_2_6251", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14561622_2_6252", "context": "We attribute the clinical and radiographic findings to cytotoxic edema secondary to intrathecal methotrexate.", "question": "adverse event. Treatment, intrathecal methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16843118_2_6253", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Morphine"}, {"id": "16843118_2_6254", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16843118_2_6255", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16843118_2_6256", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16843118_2_6257", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16843118_2_6258", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16843118_2_6259", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16843118_2_6260", "context": "Morphine, an opium alkaloid, frequently causes side effects such as hyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.", "question": "adverse event. Treatment, Morphine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20465622_1_6261", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mTOR inhibitors; calcineurin"}, {"id": "20465622_1_6262", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_1_6263", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_1_6264", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "20465622_1_6265", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_1_6266", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_1_6267", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_1_6268", "context": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.", "question": "adverse event. Treatment, oral calcineurin and mTOR inhibitors. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "calcineurin; mTOR inhibitors"}, {"id": "17619811_1_6269", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Subject, A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "79-year-old"}, {"id": "17619811_1_6270", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Subject, A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "17619811_1_6271", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Subject, A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17619811_1_6272", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Subject, A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17619811_1_6273", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Subject, A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "ischemic heart disease; chronic atrial fibrillation; chronic renal failure; hypothyroidism"}, {"id": "17619811_1_6274", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "colchicine"}, {"id": "17619811_1_6275", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_1_6276", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_1_6277", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_1_6278", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "shortly"}, {"id": "17619811_1_6279", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_1_6280", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "gout arthritis"}, {"id": "17619811_1_6281", "context": "A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and leg weakness, shortly after starting treatment with colchicine.", "question": "adverse event. Treatment, treatment with colchicine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_6_6282", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Subject, a child with juvenile absence epilepsy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "17275666_6_6283", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Subject, a child with juvenile absence epilepsy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17275666_6_6284", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Subject, a child with juvenile absence epilepsy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17275666_6_6285", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Subject, a child with juvenile absence epilepsy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17275666_6_6286", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Subject, a child with juvenile absence epilepsy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17275666_6_6287", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valproic acid"}, {"id": "17275666_6_6288", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_6_6289", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_6_6290", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "17275666_6_6291", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_6_6292", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_6_6293", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "juvenile absence epilepsy"}, {"id": "17275666_6_6294", "context": "This report describes a case of paradoxical, intravenous valproic acid-induced seizure exacerbation in a child with juvenile absence epilepsy, documented by video-electroencephalography.", "question": "adverse event. Treatment, intravenous valproic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18277922_1_6295", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Subject, She. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18277922_1_6296", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Subject, She. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "18277922_1_6297", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Subject, She. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18277922_1_6298", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Subject, She. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18277922_1_6299", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Subject, She. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18277922_1_6300", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "18277922_1_6301", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18277922_1_6302", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18277922_1_6303", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18277922_1_6304", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18277922_1_6305", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18277922_1_6306", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18277922_1_6307", "context": "She was treated with acyclovir and subsequently developed VZV antigen-positive zoster.", "question": "adverse event. Treatment, acyclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15857283_1_6308", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rifabutin"}, {"id": "15857283_1_6309", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15857283_1_6310", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15857283_1_6311", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15857283_1_6312", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15857283_1_6313", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15857283_1_6314", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15857283_1_6315", "context": "CONCLUSIONS: In these 3 cases, the unique positive ocular finding was corneal endothelial deposits, which may be related to the use of rifabutin.", "question": "adverse event. Treatment, rifabutin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7978578_1_6316", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "promethazine"}, {"id": "7978578_1_6317", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7978578_1_6318", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7978578_1_6319", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7978578_1_6320", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7978578_1_6321", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7978578_1_6322", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7978578_1_6323", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "adverse event. Treatment, promethazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7978578_1_6324", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "flumazenil"}, {"id": "7978578_1_6325", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7978578_1_6326", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7978578_1_6327", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7978578_1_6328", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7978578_1_6329", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7978578_1_6330", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "promethazine-induced coma"}, {"id": "7978578_1_6331", "context": "Response of a promethazine-induced coma to flumazenil.", "question": "potential therapeutic event. Treatment, flumazenil. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "16978752_1_6332", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Subject, 41 anecdotic cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16978752_1_6333", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Subject, 41 anecdotic cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16978752_1_6334", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Subject, 41 anecdotic cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "41"}, {"id": "16978752_1_6335", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Subject, 41 anecdotic cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16978752_1_6336", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Subject, 41 anecdotic cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16978752_1_6337", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "16978752_1_6338", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_1_6339", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_1_6340", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_1_6341", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_1_6342", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_1_6343", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16978752_1_6344", "context": "First, a review of the literature produced 41 anecdotic cases of neutropenia or agranulocytosis during treatment with olanzapine (Zyprexa) reported in a total of 24 publications.", "question": "adverse event. Treatment, olanzapine (Zyprexa). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8250714_2_6345", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Subject, patients with vitamin B12 deficiency. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_2_6346", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Subject, patients with vitamin B12 deficiency. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_2_6347", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Subject, patients with vitamin B12 deficiency. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8250714_2_6348", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Subject, patients with vitamin B12 deficiency. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_2_6349", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Subject, patients with vitamin B12 deficiency. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "vitamin B12 deficiency"}, {"id": "8250714_2_6350", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrous oxide"}, {"id": "8250714_2_6351", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_2_6352", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_2_6353", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_2_6354", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_2_6355", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_2_6356", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8250714_2_6357", "context": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_3_6358", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antiarrhythmics"}, {"id": "1695794_3_6359", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_3_6360", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1695794_3_6361", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1695794_3_6362", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_3_6363", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1695794_3_6364", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "arrhythmia"}, {"id": "1695794_3_6365", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "adverse event. Treatment, antiarrhythmics. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1695794_3_6366", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "antiarrhythmics"}, {"id": "1695794_3_6367", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1695794_3_6368", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1695794_3_6369", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1695794_3_6370", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1695794_3_6371", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1695794_3_6372", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "arrhythmia"}, {"id": "1695794_3_6373", "context": "Previous therapy with antiarrhythmics had resulted in intolerable adverse effects or no effect on the arrhythmia.", "question": "potential therapeutic event. Treatment, antiarrhythmics. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6239881_1_6374", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "benzoin"}, {"id": "6239881_1_6375", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6239881_1_6376", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6239881_1_6377", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6239881_1_6378", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6239881_1_6379", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6239881_1_6380", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6239881_1_6381", "context": "Allergic contact dermatitis to compound tincture of benzoin.", "question": "adverse event. Treatment, compound tincture of benzoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_3_6382", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Subject, 67-year-old man after a myocardial infarction. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "67-year-old"}, {"id": "8610807_3_6383", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Subject, 67-year-old man after a myocardial infarction. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "8610807_3_6384", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Subject, 67-year-old man after a myocardial infarction. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8610807_3_6385", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Subject, 67-year-old man after a myocardial infarction. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8610807_3_6386", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Subject, 67-year-old man after a myocardial infarction. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8610807_3_6387", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tissue plasminogen activator"}, {"id": "8610807_3_6388", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_3_6389", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_3_6390", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_3_6391", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_3_6392", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_3_6393", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "myocardial infarction"}, {"id": "8610807_3_6394", "context": "PURPOSE: To determine the cause of spontaneous choroidal hemorrhage in a 67-year-old man after a myocardial infarction and administration of tissue plasminogen activator.", "question": "adverse event. Treatment, tissue plasminogen activator. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_4_6395", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Subject, she. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "23970584_4_6396", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Subject, she. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "23970584_4_6397", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Subject, she. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "23970584_4_6398", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Subject, she. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "23970584_4_6399", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Subject, she. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "23970584_4_6400", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone; protease inhibitor"}, {"id": "23970584_4_6401", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_4_6402", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_4_6403", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_4_6404", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_4_6405", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_4_6406", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_4_6407", "context": "Forty-one days later, she developed severe iatrogenic Cushing's syndrome due to the drug-drug interaction between triamcinolone and her boosted protease inhibitor therapy.", "question": "adverse event. Treatment, triamcinolone and her boosted protease inhibitor. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "triamcinolone; protease inhibitor"}, {"id": "11341670_2_6408", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Subject, five female patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11341670_2_6409", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Subject, five female patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "11341670_2_6410", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Subject, five female patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "11341670_2_6411", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Subject, five female patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11341670_2_6412", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Subject, five female patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11341670_2_6413", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole; lansoprazole; pantoprazole"}, {"id": "11341670_2_6414", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "standard doses."}, {"id": "11341670_2_6415", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "7-15 days"}, {"id": "11341670_2_6416", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11341670_2_6417", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11341670_2_6418", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11341670_2_6419", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "peptic acid diseases"}, {"id": "11341670_2_6420", "context": "Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.", "question": "adverse event. Treatment, omeprazole, lansoprazole, or pantoprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_5_6421", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Subject, a child with metastatic osteosarcoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "18855892_5_6422", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Subject, a child with metastatic osteosarcoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_5_6423", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Subject, a child with metastatic osteosarcoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_5_6424", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Subject, a child with metastatic osteosarcoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_5_6425", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Subject, a child with metastatic osteosarcoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_5_6426", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "18855892_5_6427", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_5_6428", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_5_6429", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_5_6430", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_5_6431", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_5_6432", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_5_6433", "context": "We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic/anaphylactoid reaction to methotrexate.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17823522_5_6434", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha"}, {"id": "17823522_5_6435", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_5_6436", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_5_6437", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_5_6438", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_5_6439", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_5_6440", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_5_6441", "context": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus.", "question": "adverse event. Treatment, interferon alpha. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_1_6442", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Alendronate"}, {"id": "18569796_1_6443", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_1_6444", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_1_6445", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_1_6446", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_1_6447", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_1_6448", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_1_6449", "context": "CONCLUSION: Alendronate led to nodular scleritis and rechallenge caused recurrence of scleritis.", "question": "adverse event. Treatment, Alendronate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1469187_2_6450", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Subject, A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX). Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "36-year-old"}, {"id": "1469187_2_6451", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Subject, A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX). Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "1469187_2_6452", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Subject, A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX). Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "1469187_2_6453", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Subject, A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX). Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1469187_2_6454", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Subject, A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX). Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "1469187_2_6455", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "anti-digitalis antibodies"}, {"id": "1469187_2_6456", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1469187_2_6457", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1469187_2_6458", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "i.v.-infusions"}, {"id": "1469187_2_6459", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1469187_2_6460", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1469187_2_6461", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "massive digitoxin (DGTX) intoxication"}, {"id": "1469187_2_6462", "context": "A massive digitoxin (DGTX) intoxication in a 36-year-old man (35 mg DGTX) was treated by prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB).", "question": "potential therapeutic event. Treatment, prolonged and repeated i.v.-infusions of Fab fragments of anti-digitalis antibodies (FAB). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6788011_3_6463", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gold-salt"}, {"id": "6788011_3_6464", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6788011_3_6465", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6788011_3_6466", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6788011_3_6467", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6788011_3_6468", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6788011_3_6469", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6788011_3_6470", "context": "Gold-salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.", "question": "adverse event. Treatment, Gold-salt. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20199429_1_6471", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Subject, three more cases of children with recalcitrant atopic dermatitis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "20199429_1_6472", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Subject, three more cases of children with recalcitrant atopic dermatitis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20199429_1_6473", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Subject, three more cases of children with recalcitrant atopic dermatitis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "20199429_1_6474", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Subject, three more cases of children with recalcitrant atopic dermatitis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20199429_1_6475", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Subject, three more cases of children with recalcitrant atopic dermatitis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20199429_1_6476", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bisabolol"}, {"id": "20199429_1_6477", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20199429_1_6478", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20199429_1_6479", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20199429_1_6480", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20199429_1_6481", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20199429_1_6482", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "recalcitrant atopic dermatitis"}, {"id": "20199429_1_6483", "context": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol- a component of the Aquaphor emollient they were using to treat their atopic dermatitis.", "question": "adverse event. Treatment, bisabolol- a component of the Aquaphor emollient. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16160485_2_6484", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Rituximab"}, {"id": "16160485_2_6485", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16160485_2_6486", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16160485_2_6487", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16160485_2_6488", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16160485_2_6489", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16160485_2_6490", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16160485_2_6491", "context": "Recently, CD20-negative tumors have been described after Rituximab therapy.", "question": "adverse event. Treatment, Rituximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10560960_1_6492", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Subject, A 48-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "48-year-old"}, {"id": "10560960_1_6493", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Subject, A 48-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "10560960_1_6494", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Subject, A 48-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10560960_1_6495", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Subject, A 48-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10560960_1_6496", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Subject, A 48-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10560960_1_6497", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methimazole"}, {"id": "10560960_1_6498", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10560960_1_6499", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10560960_1_6500", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10560960_1_6501", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10560960_1_6502", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10560960_1_6503", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "thyrotoxicosis"}, {"id": "10560960_1_6504", "context": "A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.", "question": "adverse event. Treatment, methimazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_1_6505", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "10646879_1_6506", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_1_6507", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10646879_1_6508", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10646879_1_6509", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_1_6510", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10646879_1_6511", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_1_6512", "context": "Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.", "question": "adverse event. Treatment, ifosfamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_4_6513", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Subject, a women. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15863610_4_6514", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Subject, a women. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "women"}, {"id": "15863610_4_6515", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Subject, a women. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_4_6516", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Subject, a women. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_4_6517", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Subject, a women. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15863610_4_6518", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "raloxifene"}, {"id": "15863610_4_6519", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_4_6520", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_4_6521", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_4_6522", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_4_6523", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_4_6524", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_4_6525", "context": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.", "question": "adverse event. Treatment, while she was taking raloxifene. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22677303_12_6526", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin; cloxacillin"}, {"id": "22677303_12_6527", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22677303_12_6528", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22677303_12_6529", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22677303_12_6530", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22677303_12_6531", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22677303_12_6532", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22677303_12_6533", "context": "Interactions between warfarin and cloxacillin can result in serious adverse reactions.", "question": "adverse event. Treatment, Interactions between warfarin and cloxacillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "warfarin; cloxacillin"}, {"id": "11724089_2_6534", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Subject, three cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11724089_2_6535", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Subject, three cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11724089_2_6536", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Subject, three cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11724089_2_6537", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Subject, three cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11724089_2_6538", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Subject, three cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11724089_2_6539", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ofloxacin"}, {"id": "11724089_2_6540", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_2_6541", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_2_6542", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_2_6543", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_2_6544", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_2_6545", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_2_6546", "context": "However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.", "question": "adverse event. Treatment, ofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_5_6547", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Acetazolamide"}, {"id": "879939_5_6548", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_5_6549", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_5_6550", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_5_6551", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_5_6552", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_5_6553", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "879939_5_6554", "context": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms, including increased renal calcium excretion.", "question": "adverse event. Treatment, Acetazolamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14697943_1_6555", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CyA; tacrolimus"}, {"id": "14697943_1_6556", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14697943_1_6557", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14697943_1_6558", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14697943_1_6559", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14697943_1_6560", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14697943_1_6561", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14697943_1_6562", "context": "In conclusion, RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or tacrolimus), even under monotherapy or with a low steroid dose.", "question": "adverse event. Treatment, anticalcineurinic drug (CyA or tacrolimus). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14742791_5_6563", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "14742791_5_6564", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_5_6565", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_5_6566", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_5_6567", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_5_6568", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_5_6569", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_5_6570", "context": "There have been several reported cases of omeprazole-induced AIN.", "question": "adverse event. Treatment, omeprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9726762_4_6571", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9726762_4_6572", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9726762_4_6573", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9726762_4_6574", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9726762_4_6575", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9726762_4_6576", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "9726762_4_6577", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9726762_4_6578", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9726762_4_6579", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9726762_4_6580", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9726762_4_6581", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9726762_4_6582", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9726762_4_6583", "context": "This interaction may be overlooked by clinicians, which may result in a serious bleeding risk for patients on warfarin.", "question": "adverse event. Treatment, warfarin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_1_6584", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Adriamycin"}, {"id": "1966850_1_6585", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_1_6586", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_1_6587", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_1_6588", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_1_6589", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_1_6590", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1966850_1_6591", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, Adriamycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_1_6592", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cis-platinum"}, {"id": "1966850_1_6593", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_1_6594", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_1_6595", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_1_6596", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_1_6597", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_1_6598", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1966850_1_6599", "context": "Adriamycin-induced cardiomyopathy aggravated by cis-platinum nephrotoxicity requiring dialysis.", "question": "adverse event. Treatment, cis-platinum. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8145359_1_6600", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Subject, An 11-year-old boy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "11-year-old"}, {"id": "8145359_1_6601", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Subject, An 11-year-old boy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "8145359_1_6602", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Subject, An 11-year-old boy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8145359_1_6603", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Subject, An 11-year-old boy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8145359_1_6604", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Subject, An 11-year-old boy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8145359_1_6605", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrimeprazine meleate"}, {"id": "8145359_1_6606", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "relatively high dose"}, {"id": "8145359_1_6607", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8145359_1_6608", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8145359_1_6609", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8145359_1_6610", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8145359_1_6611", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8145359_1_6612", "context": "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.", "question": "adverse event. Treatment, relatively high dose of methotrimeprazine meleate (Levemepromazine). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_1_6613", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Subject, An adult male. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "adult"}, {"id": "11762672_1_6614", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Subject, An adult male. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "11762672_1_6615", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Subject, An adult male. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11762672_1_6616", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Subject, An adult male. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11762672_1_6617", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Subject, An adult male. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11762672_1_6618", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methanol"}, {"id": "11762672_1_6619", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_1_6620", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11762672_1_6621", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ingesting"}, {"id": "11762672_1_6622", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_1_6623", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11762672_1_6624", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_1_6625", "context": "An adult male presented with central blindness after ingesting methanol.", "question": "adverse event. Treatment, ingesting methanol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8523340_1_6626", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gold"}, {"id": "8523340_1_6627", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8523340_1_6628", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8523340_1_6629", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "im"}, {"id": "8523340_1_6630", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 20 weeks"}, {"id": "8523340_1_6631", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8523340_1_6632", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "RA"}, {"id": "8523340_1_6633", "context": "All developed mucocutaneous side effects within 20 weeks of beginning im gold therapy, at a time when RA had improved markedly compared to pretreatment status.", "question": "adverse event. Treatment, im gold therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1868481_2_6634", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Subject, Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1868481_2_6635", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Subject, Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1868481_2_6636", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Subject, Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "1868481_2_6637", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Subject, Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1868481_2_6638", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Subject, Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1868481_2_6639", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "1868481_2_6640", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1868481_2_6641", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1868481_2_6642", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "i.v. pulse"}, {"id": "1868481_2_6643", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1868481_2_6644", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1868481_2_6645", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "idiopathic nephrotic syndrome; endo-extracapillary glomerulonephritis,"}, {"id": "1868481_2_6646", "context": "Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and transient blindness at different times after i.v. pulse methylprednisolone (IVPMP) treatment.", "question": "adverse event. Treatment, i.v. pulse methylprednisolone (IVPMP) treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12836099_1_6647", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Subject, a boy with nephrotic syndrome. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12836099_1_6648", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Subject, a boy with nephrotic syndrome. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "12836099_1_6649", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Subject, a boy with nephrotic syndrome. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12836099_1_6650", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Subject, a boy with nephrotic syndrome. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12836099_1_6651", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Subject, a boy with nephrotic syndrome. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12836099_1_6652", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prednisolone"}, {"id": "12836099_1_6653", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12836099_1_6654", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12836099_1_6655", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12836099_1_6656", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12836099_1_6657", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12836099_1_6658", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "nephrotic syndrome"}, {"id": "12836099_1_6659", "context": "Stevens-Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy.", "question": "adverse event. Treatment, prednisolone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18628507_4_6660", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "VRC"}, {"id": "18628507_4_6661", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_4_6662", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_4_6663", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_4_6664", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_4_6665", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_4_6666", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_4_6667", "context": "To our knowledge, this is the first report of an angio-oedema associated with VRC.", "question": "adverse event. Treatment, VRC. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4014301_1_6668", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Insulin"}, {"id": "4014301_1_6669", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_1_6670", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_1_6671", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_1_6672", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_1_6673", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_1_6674", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_1_6675", "context": "Insulin-induced cardiac failure.", "question": "adverse event. Treatment, Insulin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_10_6676", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clemastine; betametasone"}, {"id": "15522120_10_6677", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_10_6678", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_10_6679", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_10_6680", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_10_6681", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_10_6682", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_10_6683", "context": "The symptoms disappeared with clemastine and betametasone treatment.", "question": "potential therapeutic event. Treatment, clemastine and betametasone. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "betametasone; clemastine"}, {"id": "11724089_6_6684", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ofloxacin"}, {"id": "11724089_6_6685", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_6_6686", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_6_6687", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_6_6688", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_6_6689", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_6_6690", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_6_6691", "context": "This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3917429_1_6692", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "3917429_1_6693", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3917429_1_6694", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3917429_1_6695", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3917429_1_6696", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3917429_1_6697", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3917429_1_6698", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3917429_1_6699", "context": "Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.", "question": "adverse event. Treatment, lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6738830_1_6700", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Subject, A 56-year-old male parkinsonian patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "56-year-old"}, {"id": "6738830_1_6701", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Subject, A 56-year-old male parkinsonian patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "6738830_1_6702", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Subject, A 56-year-old male parkinsonian patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6738830_1_6703", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Subject, A 56-year-old male parkinsonian patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6738830_1_6704", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Subject, A 56-year-old male parkinsonian patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "parkinsonian"}, {"id": "6738830_1_6705", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cinepazide"}, {"id": "6738830_1_6706", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6738830_1_6707", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6738830_1_6708", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral administration"}, {"id": "6738830_1_6709", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6738830_1_6710", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6738830_1_6711", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6738830_1_6712", "context": "A 56-year-old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide, a cerebral vasodilator.", "question": "adverse event. Treatment, the oral administration of cinepazide, a cerebral vasodilator. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "440873_3_6713", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "440873_3_6714", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_3_6715", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_3_6716", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_3_6717", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_3_6718", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_3_6719", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_3_6720", "context": "The currently available clinical and neuropharmacologic data suggest that carbamazepine may be an antagonist of dopamine and that this property is responsible for the production of dystonia.", "question": "adverse event. Treatment, carbamazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12042592_2_6721", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Metamizole"}, {"id": "12042592_2_6722", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12042592_2_6723", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12042592_2_6724", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12042592_2_6725", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12042592_2_6726", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12042592_2_6727", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12042592_2_6728", "context": "Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.", "question": "adverse event. Treatment, Metamizole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_6_6729", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thionamide"}, {"id": "9777751_6_6730", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_6_6731", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_6_6732", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_6_6733", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_6_6734", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_6_6735", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_6_6736", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "adverse event. Treatment, thionamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_6_6737", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hemopoietic colony stimulating factors"}, {"id": "9777751_6_6738", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_6_6739", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9777751_6_6740", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9777751_6_6741", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_6_6742", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9777751_6_6743", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe thionamide-induced hematologic adverse reactions"}, {"id": "9777751_6_6744", "context": "We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions.", "question": "potential therapeutic event. Treatment, hemopoietic colony stimulating factors. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8696525_2_6745", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Subject, Two case reports of bilateral granulomatous anterior uveitis; patients with open angle glaucoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8696525_2_6746", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Subject, Two case reports of bilateral granulomatous anterior uveitis; patients with open angle glaucoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8696525_2_6747", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Subject, Two case reports of bilateral granulomatous anterior uveitis; patients with open angle glaucoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "8696525_2_6748", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Subject, Two case reports of bilateral granulomatous anterior uveitis; patients with open angle glaucoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8696525_2_6749", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Subject, Two case reports of bilateral granulomatous anterior uveitis; patients with open angle glaucoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "bilateral granulomatous anterior uveitis"}, {"id": "8696525_2_6750", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metripranolol"}, {"id": "8696525_2_6751", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "0.6%"}, {"id": "8696525_2_6752", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8696525_2_6753", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "eye drops"}, {"id": "8696525_2_6754", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8696525_2_6755", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8696525_2_6756", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "open angle glaucoma"}, {"id": "8696525_2_6757", "context": "Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6% eye drops.", "question": "adverse event. Treatment, metripranolol 0.6% eye drops. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_2_6758", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "7355327_2_6759", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_2_6760", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_2_6761", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_2_6762", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_2_6763", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_2_6764", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_2_6765", "context": "Regardless of a negative history of asthma, therefore, life-threatening bronchospasm must be considered a possible complication of propranolol therapy.", "question": "adverse event. Treatment, propranolol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11147747_2_6766", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Subject, 2 female patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11147747_2_6767", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Subject, 2 female patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "11147747_2_6768", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Subject, 2 female patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "2"}, {"id": "11147747_2_6769", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Subject, 2 female patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11147747_2_6770", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Subject, 2 female patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11147747_2_6771", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "paroxetine; sertraline; venlafaxine"}, {"id": "11147747_2_6772", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11147747_2_6773", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11147747_2_6774", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11147747_2_6775", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11147747_2_6776", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11147747_2_6777", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11147747_2_6778", "context": "In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.", "question": "adverse event. Treatment, the selective serotonin reuptake inhibitors paroxetine and sertraline. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "paroxetine; sertraline"}, {"id": "1680596_1_6779", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Subject, a woman with classical rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1680596_1_6780", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Subject, a woman with classical rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "1680596_1_6781", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Subject, a woman with classical rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1680596_1_6782", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Subject, a woman with classical rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1680596_1_6783", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Subject, a woman with classical rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1680596_1_6784", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulphasalazine"}, {"id": "1680596_1_6785", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1680596_1_6786", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1680596_1_6787", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1680596_1_6788", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1680596_1_6789", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1680596_1_6790", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "classical rheumatoid arthritis"}, {"id": "1680596_1_6791", "context": "Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine (SASP) therapy developed a severe and lasting psoriasis-like skin reaction.", "question": "adverse event. Treatment, during introduction of sulphasalazine (SASP) therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19112808_1_6792", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "darifenacin"}, {"id": "19112808_1_6793", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19112808_1_6794", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19112808_1_6795", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19112808_1_6796", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19112808_1_6797", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19112808_1_6798", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19112808_1_6799", "context": "Interstitial granulomatous dermatitis associated with darifenacin.", "question": "adverse event. Treatment, darifenacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_2_6800", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methanol"}, {"id": "11762672_2_6801", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_2_6802", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11762672_2_6803", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11762672_2_6804", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_2_6805", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11762672_2_6806", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_2_6807", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, methanol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11762672_2_6808", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fomepizole"}, {"id": "11762672_2_6809", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11762672_2_6810", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11762672_2_6811", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11762672_2_6812", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11762672_2_6813", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11762672_2_6814", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11762672_2_6815", "context": "Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.", "question": "adverse event. Treatment, fomepizole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_3_6816", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Proton-pump inhibitors (PPIs); antiplatelet"}, {"id": "20925534_3_6817", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_3_6818", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "20925534_3_6819", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "20925534_3_6820", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_3_6821", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "20925534_3_6822", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_3_6823", "context": "Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved this in patients receiving dual antiplatelet therapy.", "question": "potential therapeutic event. Treatment, Proton-pump inhibitors (PPIs). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10592946_4_6824", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "caffeine"}, {"id": "10592946_4_6825", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10592946_4_6826", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10592946_4_6827", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_4_6828", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_4_6829", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_4_6830", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_4_6831", "context": "The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.", "question": "adverse event. Treatment, caffeine, which is present in oolong tea. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_8_6832", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "11283125_8_6833", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_8_6834", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_8_6835", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_8_6836", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "increased-risk ALL or stage III and IV lymphoblastic lymphoma"}, {"id": "11283125_8_6837", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "MTX; MTX"}, {"id": "11283125_8_6838", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_8_6839", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_8_6840", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intrathecal injections; HD IV"}, {"id": "11283125_8_6841", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_8_6842", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_8_6843", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "CNS relapse"}, {"id": "11283125_8_6844", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, HD IV MTX and intrathecal injections of MTX. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "MTX; MTX"}, {"id": "11283125_8_6845", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "11283125_8_6846", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_8_6847", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_8_6848", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_8_6849", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Subject, children with increased-risk ALL or stage III and IV lymphoblastic lymphoma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "increased-risk ALL or stage III and IV lymphoblastic lymphoma"}, {"id": "11283125_8_6850", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11283125_8_6851", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11283125_8_6852", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11283125_8_6853", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11283125_8_6854", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_8_6855", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_8_6856", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "increased-risk ALL or stage III and IV lymphoblastic lymphoma"}, {"id": "11283125_8_6857", "context": "Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.", "question": "potential therapeutic event. Treatment, our BFM-based treatment protocol in which cranial irradiation was omitted. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17823522_1_6858", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha"}, {"id": "17823522_1_6859", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_1_6860", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_1_6861", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17823522_1_6862", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_1_6863", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_1_6864", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17823522_1_6865", "context": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment.", "question": "adverse event. Treatment, interferon alpha treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_2_6866", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "1422497_2_6867", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_2_6868", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1422497_2_6869", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1422497_2_6870", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_2_6871", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1422497_2_6872", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1422497_2_6873", "context": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy.", "question": "adverse event. Treatment, cyclophosphamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7212107_1_6874", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Subject, certain patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7212107_1_6875", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Subject, certain patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7212107_1_6876", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Subject, certain patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7212107_1_6877", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Subject, certain patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7212107_1_6878", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Subject, certain patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7212107_1_6879", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "7212107_1_6880", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7212107_1_6881", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7212107_1_6882", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7212107_1_6883", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7212107_1_6884", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7212107_1_6885", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7212107_1_6886", "context": "Secondary hyperparathyroidism in certain patients with lithium nephrotoxicity is also possible.", "question": "adverse event. Treatment, lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_2_6887", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18755414_2_6888", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18755414_2_6889", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18755414_2_6890", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18755414_2_6891", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18755414_2_6892", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aspirin"}, {"id": "18755414_2_6893", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "18755414_2_6894", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_2_6895", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_2_6896", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "16 months"}, {"id": "18755414_2_6897", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_2_6898", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_2_6899", "context": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose aspirin for 16 months.", "question": "adverse event. Treatment, low-dose aspirin for 16 months. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_3_6900", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, four out of six. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "589261_3_6901", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, four out of six. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "589261_3_6902", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, four out of six. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "589261_3_6903", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, four out of six. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "589261_3_6904", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, four out of six. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "589261_3_6905", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ouabain"}, {"id": "589261_3_6906", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "589261_3_6907", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "589261_3_6908", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "589261_3_6909", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_3_6910", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "589261_3_6911", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "589261_3_6912", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, ouabain. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_3_6913", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, five out of six patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "589261_3_6914", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, five out of six patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "589261_3_6915", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, five out of six patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "five"}, {"id": "589261_3_6916", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, five out of six patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "589261_3_6917", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Subject, five out of six patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "589261_3_6918", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cardiac glycoside"}, {"id": "589261_3_6919", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "589261_3_6920", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "589261_3_6921", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "589261_3_6922", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_3_6923", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "589261_3_6924", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "589261_3_6925", "context": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving digoxin.", "question": "adverse event. Treatment, cardiac glycoside. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19754002_4_6926", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pravastatin"}, {"id": "19754002_4_6927", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_4_6928", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_4_6929", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_4_6930", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_4_6931", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_4_6932", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_4_6933", "context": "The allergic reaction started to develop after co-administration of pravastatin.", "question": "adverse event. Treatment, co-administration of pravastatin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11202801_3_6934", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "11202801_3_6935", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_3_6936", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_3_6937", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_3_6938", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_3_6939", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_3_6940", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_3_6941", "context": "We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.", "question": "adverse event. Treatment, cyclophosphamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_2_6942", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-FU"}, {"id": "868978_2_6943", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_2_6944", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_2_6945", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_2_6946", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_2_6947", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_2_6948", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_2_6949", "context": "The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem.", "question": "adverse event. Treatment, 5-FU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_2_6950", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "eight-year old"}, {"id": "1966850_2_6951", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "1966850_2_6952", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1966850_2_6953", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1966850_2_6954", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1966850_2_6955", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatinum"}, {"id": "1966850_2_6956", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_2_6957", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_2_6958", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_2_6959", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_2_6960", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_2_6961", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1966850_2_6962", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, cisplatinum. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1966850_2_6963", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "eight-year old"}, {"id": "1966850_2_6964", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "1966850_2_6965", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1966850_2_6966", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1966850_2_6967", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Subject, an eight-year old boy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1966850_2_6968", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adriamycin"}, {"id": "1966850_2_6969", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1966850_2_6970", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1966850_2_6971", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1966850_2_6972", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1966850_2_6973", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1966850_2_6974", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "synovial sarcoma"}, {"id": "1966850_2_6975", "context": "Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and adriamycin cardiotoxicity.", "question": "adverse event. Treatment, adriamycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17504225_2_6976", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Subject, renal transplant recipients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17504225_2_6977", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Subject, renal transplant recipients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17504225_2_6978", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Subject, renal transplant recipients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17504225_2_6979", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Subject, renal transplant recipients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17504225_2_6980", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Subject, renal transplant recipients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "renal transplant"}, {"id": "17504225_2_6981", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "antimicrobial agents"}, {"id": "17504225_2_6982", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_2_6983", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_2_6984", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_2_6985", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_2_6986", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_2_6987", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_2_6988", "context": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents.", "question": "adverse event. Treatment, antimicrobial agents. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_12_6989", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Subject, patients with severe, persistent asthma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "16685007_12_6990", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Subject, patients with severe, persistent asthma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16685007_12_6991", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Subject, patients with severe, persistent asthma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16685007_12_6992", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Subject, patients with severe, persistent asthma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16685007_12_6993", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Subject, patients with severe, persistent asthma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16685007_12_6994", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "OCS; ciclesonide"}, {"id": "16685007_12_6995", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_12_6996", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16685007_12_6997", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16685007_12_6998", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_12_6999", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16685007_12_7000", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe, persistent asthma"}, {"id": "16685007_12_7001", "context": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe, persistent asthma, while maintaining asthma control.", "question": "potential therapeutic event. Treatment, ciclesonide. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14968106_1_7002", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxorubicin"}, {"id": "14968106_1_7003", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_1_7004", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_1_7005", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal administration"}, {"id": "14968106_1_7006", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_1_7007", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_1_7008", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_1_7009", "context": "CONCLUSION: This is, to our knowledge, the first report of severe myelopathy following accidental intrathecal administration of doxorubicin.", "question": "adverse event. Treatment, intrathecal administration of doxorubicin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_5_7010", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alpha interferon"}, {"id": "12854039_5_7011", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_5_7012", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_5_7013", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_5_7014", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_5_7015", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_5_7016", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_5_7017", "context": "Multiple sclerosis-like disease secondary to alpha interferon.", "question": "adverse event. Treatment, alpha interferon. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17921794_4_7018", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Subject, a patient with mild chronic renal insufficiency. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17921794_4_7019", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Subject, a patient with mild chronic renal insufficiency. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17921794_4_7020", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Subject, a patient with mild chronic renal insufficiency. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17921794_4_7021", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Subject, a patient with mild chronic renal insufficiency. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17921794_4_7022", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Subject, a patient with mild chronic renal insufficiency. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "mild chronic renal insufficiency"}, {"id": "17921794_4_7023", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin; colchicine"}, {"id": "17921794_4_7024", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_4_7025", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_4_7026", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_4_7027", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "over a year; 3 weeks"}, {"id": "17921794_4_7028", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_4_7029", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute gouty bursitis"}, {"id": "17921794_4_7030", "context": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.", "question": "adverse event. Treatment, taking simvastatin for over a year; 3 weeks after the start of treatment with colchicine for acute gouty bursitis. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "simvastatin; colchicine"}, {"id": "16603845_1_7031", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Subject, the patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16603845_1_7032", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Subject, the patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16603845_1_7033", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Subject, the patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16603845_1_7034", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Subject, the patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16603845_1_7035", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Subject, the patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16603845_1_7036", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegfilgrastim"}, {"id": "16603845_1_7037", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16603845_1_7038", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16603845_1_7039", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16603845_1_7040", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16603845_1_7041", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16603845_1_7042", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16603845_1_7043", "context": "Shortly after chemotherapy and an injection of pegfilgrastim, the patient developed poorly defined, rapidly progressive erythema, edema, and pain in his right forearm.", "question": "adverse event. Treatment, pegfilgrastim. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20628041_2_7044", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Subject, a polytrauma patient with Parkinson's disease (PD). Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "20628041_2_7045", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Subject, a polytrauma patient with Parkinson's disease (PD). Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "20628041_2_7046", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Subject, a polytrauma patient with Parkinson's disease (PD). Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20628041_2_7047", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Subject, a polytrauma patient with Parkinson's disease (PD). Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20628041_2_7048", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Subject, a polytrauma patient with Parkinson's disease (PD). Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "polytrauma"}, {"id": "20628041_2_7049", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "levodopa; enteral feeds"}, {"id": "20628041_2_7050", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20628041_2_7051", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20628041_2_7052", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20628041_2_7053", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20628041_2_7054", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20628041_2_7055", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Parkinson's disease (PD)"}, {"id": "20628041_2_7056", "context": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD).", "question": "adverse event. Treatment, interaction between enteral feeds and levodopa. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "enteral feeds; levodopa"}, {"id": "16978752_3_7057", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Subject, a schizophrenia patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16978752_3_7058", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Subject, a schizophrenia patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16978752_3_7059", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Subject, a schizophrenia patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16978752_3_7060", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Subject, a schizophrenia patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16978752_3_7061", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Subject, a schizophrenia patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16978752_3_7062", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine; thiazide"}, {"id": "16978752_3_7063", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16978752_3_7064", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16978752_3_7065", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16978752_3_7066", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16978752_3_7067", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16978752_3_7068", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "16978752_3_7069", "context": "Second, we report a case of neutropenia, which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide.", "question": "adverse event. Treatment, olanzapine and thiazide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "olanzapine; thiazide"}, {"id": "21658326_3_7070", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "TNF-alpha blockers"}, {"id": "21658326_3_7071", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_3_7072", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_3_7073", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_3_7074", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_3_7075", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_3_7076", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_3_7077", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, TNF-alpha blockers. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21658326_3_7078", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "imiquimod"}, {"id": "21658326_3_7079", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21658326_3_7080", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21658326_3_7081", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21658326_3_7082", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21658326_3_7083", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21658326_3_7084", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21658326_3_7085", "context": "While mild to moderate application site reactions (ASRs) are a well-known and common phenomenon associated with imiquimod, the potential of TNF-alpha blockers to elicit cutaneous inflammatory reactions has only recently been recognized.", "question": "adverse event. Treatment, imiquimod. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6239881_2_7086", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Subject, Nineteen cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6239881_2_7087", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Subject, Nineteen cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6239881_2_7088", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Subject, Nineteen cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Nineteen"}, {"id": "6239881_2_7089", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Subject, Nineteen cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6239881_2_7090", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Subject, Nineteen cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6239881_2_7091", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "benzoin"}, {"id": "6239881_2_7092", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6239881_2_7093", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6239881_2_7094", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6239881_2_7095", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6239881_2_7096", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6239881_2_7097", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6239881_2_7098", "context": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described.", "question": "adverse event. Treatment, compound tincture of benzoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8404753_3_7099", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Subject, 3 children with epilepsy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "8404753_3_7100", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Subject, 3 children with epilepsy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8404753_3_7101", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Subject, 3 children with epilepsy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "3"}, {"id": "8404753_3_7102", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Subject, 3 children with epilepsy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8404753_3_7103", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Subject, 3 children with epilepsy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8404753_3_7104", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CBZ"}, {"id": "8404753_3_7105", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8404753_3_7106", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8404753_3_7107", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8404753_3_7108", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8404753_3_7109", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8404753_3_7110", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "epilepsy"}, {"id": "8404753_3_7111", "context": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures.", "question": "adverse event. Treatment, CBZ. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_2_7112", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cadmium; zinc; cadmium; zinc"}, {"id": "11197767_2_7113", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1000 to 50000 microg/l"}, {"id": "11197767_2_7114", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11197767_2_7115", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11197767_2_7116", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_2_7117", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11197767_2_7118", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_2_7119", "context": "The toxicity of cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l were investigated against cercariae and metacercariae of Parorchis acanthus obtained from the dog whelk Nucella lapillus.", "question": "adverse event. Treatment, cadmium, zinc and cadmium/zinc mixtures at concentrations ranging from 1000 to 50000 microg/l. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "cadmium; zinc"}, {"id": "18354950_3_7120", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Subject, a 29-year Nigerian female patient with generalized tonic-elonic seizures. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "29-year"}, {"id": "18354950_3_7121", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Subject, a 29-year Nigerian female patient with generalized tonic-elonic seizures. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "18354950_3_7122", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Subject, a 29-year Nigerian female patient with generalized tonic-elonic seizures. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18354950_3_7123", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Subject, a 29-year Nigerian female patient with generalized tonic-elonic seizures. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": "Nigerian"}, {"id": "18354950_3_7124", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Subject, a 29-year Nigerian female patient with generalized tonic-elonic seizures. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18354950_3_7125", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "18354950_3_7126", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_3_7127", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_3_7128", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_3_7129", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "much earlier"}, {"id": "18354950_3_7130", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_3_7131", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "generalized tonic-elonic seizures"}, {"id": "18354950_3_7132", "context": "We report the syndrome of inappropriate antidiuresis as a much earlier side-effect of carbamazepine administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.", "question": "adverse event. Treatment, carbamazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11310527_2_7133", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A patient. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "11310527_2_7134", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A patient. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11310527_2_7135", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A patient. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11310527_2_7136", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A patient. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11310527_2_7137", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Subject, A patient. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11310527_2_7138", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin"}, {"id": "11310527_2_7139", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11310527_2_7140", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11310527_2_7141", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11310527_2_7142", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11310527_2_7143", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11310527_2_7144", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "atrial fibrillation"}, {"id": "11310527_2_7145", "context": "A patient was treated with warfarin for atrial fibrillation.", "question": "potential therapeutic event. Treatment, warfarin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19754002_1_7146", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Mood stabilizer; pravastatin"}, {"id": "19754002_1_7147", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19754002_1_7148", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19754002_1_7149", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19754002_1_7150", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19754002_1_7151", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19754002_1_7152", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19754002_1_7153", "context": "Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?", "question": "adverse event. Treatment, Mood stabilizer therapy and pravastatin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "Mood stabilizer; pravastatin"}, {"id": "1602800_1_7154", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "all-trans retinoic acid"}, {"id": "1602800_1_7155", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1602800_1_7156", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1602800_1_7157", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1602800_1_7158", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1602800_1_7159", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1602800_1_7160", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute promyelocytic leukemia in first relapse"}, {"id": "1602800_1_7161", "context": "Pulmonary leukostasis secondary to all-trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse.", "question": "adverse event. Treatment, all-trans retinoic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_1_7162", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Subject, A 74-year-old hypercholestrerolaemic woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "74-year-old"}, {"id": "15811174_1_7163", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Subject, A 74-year-old hypercholestrerolaemic woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15811174_1_7164", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Subject, A 74-year-old hypercholestrerolaemic woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_1_7165", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Subject, A 74-year-old hypercholestrerolaemic woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_1_7166", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Subject, A 74-year-old hypercholestrerolaemic woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_1_7167", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cerivastatin"}, {"id": "15811174_1_7168", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "0.15 mg/day"}, {"id": "15811174_1_7169", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_1_7170", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_1_7171", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_1_7172", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "22 days"}, {"id": "15811174_1_7173", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hypercholestrerolaemic"}, {"id": "15811174_1_7174", "context": "A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain.", "question": "adverse event. Treatment, cerivastatin (0.15 mg/day). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_3_7175", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cimetidine"}, {"id": "7081289_3_7176", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_3_7177", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_3_7178", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_3_7179", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_3_7180", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_3_7181", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_3_7182", "context": "There have been only two reports of cimetidine-induced hepatitis.", "question": "adverse event. Treatment, cimetidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3732375_2_7183", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline; viloxazine"}, {"id": "3732375_2_7184", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3732375_2_7185", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3732375_2_7186", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3732375_2_7187", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3732375_2_7188", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3732375_2_7189", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3732375_2_7190", "context": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.", "question": "adverse event. Treatment, concomitant administration of viloxazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "viloxazine; theophylline"}, {"id": "7639655_1_7191", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "7639655_1_7192", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_1_7193", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_1_7194", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_1_7195", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_1_7196", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_1_7197", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_1_7198", "context": "Anterior ischemic optic neuropathy secondary to interferon alfa.", "question": "adverse event. Treatment, interferon alfa. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_6_7199", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant and natural interferon alpha"}, {"id": "12854039_6_7200", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_6_7201", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_6_7202", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_6_7203", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12854039_6_7204", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_6_7205", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12854039_6_7206", "context": "PURPOSE: To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration.", "question": "adverse event. Treatment, recombinant and natural interferon alpha administration. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12234159_2_7207", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Rofecoxib"}, {"id": "12234159_2_7208", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12234159_2_7209", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12234159_2_7210", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12234159_2_7211", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12234159_2_7212", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12234159_2_7213", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "dysmenorrhea"}, {"id": "12234159_2_7214", "context": "Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.", "question": "adverse event. Treatment, Rofecoxib. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16609346_2_7215", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Subject, 4 cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16609346_2_7216", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Subject, 4 cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16609346_2_7217", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Subject, 4 cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "4"}, {"id": "16609346_2_7218", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Subject, 4 cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16609346_2_7219", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Subject, 4 cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16609346_2_7220", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Statin"}, {"id": "16609346_2_7221", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16609346_2_7222", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16609346_2_7223", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16609346_2_7224", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16609346_2_7225", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16609346_2_7226", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16609346_2_7227", "context": "Statin-associated myasthenia gravis: report of 4 cases and review of the literature.", "question": "adverse event. Treatment, Statin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4075534_3_7228", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Subject, Two reports. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4075534_3_7229", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Subject, Two reports. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4075534_3_7230", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Subject, Two reports. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "4075534_3_7231", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Subject, Two reports. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4075534_3_7232", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Subject, Two reports. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "4075534_3_7233", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alcohol; imipramine"}, {"id": "4075534_3_7234", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4075534_3_7235", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4075534_3_7236", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4075534_3_7237", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4075534_3_7238", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4075534_3_7239", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4075534_3_7240", "context": "Two reports of spindle coma are noted with alcohol and imipramine.", "question": "adverse event. Treatment, alcohol and imipramine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "alcohol; imipramine"}, {"id": "3003260_2_7241", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Decadron"}, {"id": "3003260_2_7242", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3003260_2_7243", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3003260_2_7244", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3003260_2_7245", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3003260_2_7246", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3003260_2_7247", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3003260_2_7248", "context": "Cataracts induced by intermittent Decadron used as an antiemetic.", "question": "adverse event. Treatment, Decadron. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "879939_2_7249", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Subject, two epileptic patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "879939_2_7250", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Subject, two epileptic patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "879939_2_7251", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Subject, two epileptic patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "879939_2_7252", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Subject, two epileptic patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "879939_2_7253", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Subject, two epileptic patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "879939_2_7254", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenytoin; phenobarbital; acetazolamide"}, {"id": "879939_2_7255", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "879939_2_7256", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "879939_2_7257", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "879939_2_7258", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "879939_2_7259", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "879939_2_7260", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "epileptic"}, {"id": "879939_2_7261", "context": "Severe osteomalacia was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide.", "question": "adverse event. Treatment, long-term treatment with congeners of phenytoin, phenobarbital, and acetazolamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenytoin; phenobarbital; acetazolamide"}, {"id": "3969689_4_7262", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acetaminophen; caffeine"}, {"id": "3969689_4_7263", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3969689_4_7264", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3969689_4_7265", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3969689_4_7266", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3969689_4_7267", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3969689_4_7268", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3969689_4_7269", "context": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "question": "adverse event. Treatment, acetaminophen; caffeine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_6_7270", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8912599_6_7271", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_6_7272", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_6_7273", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_6_7274", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_6_7275", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_6_7276", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_6_7277", "context": "Erosion of psoriatic plaques: an early sign of methotrexate toxicity.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11696132_1_7278", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "scopolamine"}, {"id": "11696132_1_7279", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11696132_1_7280", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11696132_1_7281", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "transdermal; patch"}, {"id": "11696132_1_7282", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11696132_1_7283", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11696132_1_7284", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "weaning off the opioid"}, {"id": "11696132_1_7285", "context": "After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.", "question": "adverse event. Treatment, transdermal scopolamine patch. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12851279_1_7286", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tifacogin (recombinant tissue factor pathway inhibitor)"}, {"id": "12851279_1_7287", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_1_7288", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12851279_1_7289", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12851279_1_7290", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_1_7291", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12851279_1_7292", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe sepsis"}, {"id": "12851279_1_7293", "context": "Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.", "question": "potential therapeutic event. Treatment, tifacogin (recombinant tissue factor pathway inhibitor). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15863610_5_7294", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Subject, a 64-year-old woman with a bicornuate uterus. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "64-year-old"}, {"id": "15863610_5_7295", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Subject, a 64-year-old woman with a bicornuate uterus. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "15863610_5_7296", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Subject, a 64-year-old woman with a bicornuate uterus. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15863610_5_7297", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Subject, a 64-year-old woman with a bicornuate uterus. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15863610_5_7298", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Subject, a 64-year-old woman with a bicornuate uterus. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "bicornuate uterus"}, {"id": "15863610_5_7299", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "raloxifene"}, {"id": "15863610_5_7300", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_5_7301", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_5_7302", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_5_7303", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_5_7304", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_5_7305", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "osteoporosis"}, {"id": "15863610_5_7306", "context": "CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.", "question": "adverse event. Treatment, raloxifene. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_1_7307", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegvisomant"}, {"id": "16728538_1_7308", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_1_7309", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_1_7310", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_1_7311", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within a few weeks"}, {"id": "16728538_1_7312", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_1_7313", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16728538_1_7314", "context": "After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.", "question": "adverse event. Treatment, pegvisomant. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "22372628_2_7315", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "lacosamide; antiepileptic drugs"}, {"id": "22372628_2_7316", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "22372628_2_7317", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "22372628_2_7318", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "22372628_2_7319", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22372628_2_7320", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "long-term (up to 5 years exposure)"}, {"id": "22372628_2_7321", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "uncontrolled partial-onset seizures"}, {"id": "22372628_2_7322", "context": "To evaluate the long-term (up to 5 years exposure) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open-label extension trial SP756 (NCT00522275).", "question": "potential therapeutic event. Treatment, long-term (up to 5 years exposure); lacosamide as adjunctive therapy; taking one to three concomitant antiepileptic drugs (AEDs). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "lacosamide; antiepileptic drugs"}, {"id": "7071645_3_7323", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "hydroxychloroquine"}, {"id": "7071645_3_7324", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7071645_3_7325", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7071645_3_7326", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "discontinuation"}, {"id": "7071645_3_7327", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7071645_3_7328", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7071645_3_7329", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "7071645_3_7330", "context": "Complete remission of the nephrosis occurred after discontinuation of hydroxychloroquine therapy.", "question": "potential therapeutic event. Treatment, discontinuation of hydroxychloroquine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18364401_1_7331", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Subject, elderly patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "elderly"}, {"id": "18364401_1_7332", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Subject, elderly patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18364401_1_7333", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Subject, elderly patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18364401_1_7334", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Subject, elderly patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18364401_1_7335", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Subject, elderly patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18364401_1_7336", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "18364401_1_7337", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18364401_1_7338", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18364401_1_7339", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18364401_1_7340", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18364401_1_7341", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18364401_1_7342", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18364401_1_7343", "context": "CONCLUSIONS: Clinicians treating elderly patients with olanzapine should be aware of the potential for rapidly developing hyperglycemia and monitor such patients accordingly.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18661248_2_7344", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Subject, a patient with collapsing focal glomeruloesclerosis (collapsing FGS). Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18661248_2_7345", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Subject, a patient with collapsing focal glomeruloesclerosis (collapsing FGS). Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18661248_2_7346", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Subject, a patient with collapsing focal glomeruloesclerosis (collapsing FGS). Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18661248_2_7347", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Subject, a patient with collapsing focal glomeruloesclerosis (collapsing FGS). Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18661248_2_7348", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Subject, a patient with collapsing focal glomeruloesclerosis (collapsing FGS). Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "collapsing focal glomeruloesclerosis"}, {"id": "18661248_2_7349", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "18661248_2_7350", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18661248_2_7351", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18661248_2_7352", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18661248_2_7353", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18661248_2_7354", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18661248_2_7355", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "PRES"}, {"id": "18661248_2_7356", "context": "We describe a case of PRES in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine (CSA).", "question": "potential therapeutic event. Treatment, withdrawal of cyclosporine (CSA). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12022905_3_7357", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Subject, our patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12022905_3_7358", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Subject, our patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_3_7359", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Subject, our patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_3_7360", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Subject, our patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_3_7361", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Subject, our patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_3_7362", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zuclopenthixol"}, {"id": "12022905_3_7363", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_3_7364", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_3_7365", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_3_7366", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_3_7367", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_3_7368", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_3_7369", "context": "DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.", "question": "adverse event. Treatment, zuclopenthixol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11202801_2_7370", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclophosphamide"}, {"id": "11202801_2_7371", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11202801_2_7372", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11202801_2_7373", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11202801_2_7374", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11202801_2_7375", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11202801_2_7376", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11202801_2_7377", "context": "Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.", "question": "adverse event. Treatment, cyclophosphamide therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11283125_3_7378", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Subject, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "children"}, {"id": "11283125_3_7379", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Subject, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "11283125_3_7380", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Subject, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "11283125_3_7381", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Subject, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "11283125_3_7382", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Subject, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "11283125_3_7383", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "HD MTX; MTX; HD IV Ara-C; MTX"}, {"id": "11283125_3_7384", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "5 g/m(2); 1 g/m(2)"}, {"id": "11283125_3_7385", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "over 24 hours every 2 weeks"}, {"id": "11283125_3_7386", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "bolus injection"}, {"id": "11283125_3_7387", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11283125_3_7388", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11283125_3_7389", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "lymphoblastic lymphoma"}, {"id": "11283125_3_7390", "context": "After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).", "question": "potential therapeutic event. Treatment, After completion of induction-consolidation phase; four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "MTX; HD IV Ara-C"}, {"id": "7756684_1_7391", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "KW-2149"}, {"id": "7756684_1_7392", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7756684_1_7393", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7756684_1_7394", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7756684_1_7395", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7756684_1_7396", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7756684_1_7397", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7756684_1_7398", "context": "The dose-limiting toxicity of KW-2149 is pulmonary toxicity.", "question": "adverse event. Treatment, KW-2149. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15773973_1_7399", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Flucloxacillin"}, {"id": "15773973_1_7400", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15773973_1_7401", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15773973_1_7402", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15773973_1_7403", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15773973_1_7404", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15773973_1_7405", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15773973_1_7406", "context": "Flucloxacillin-induced aplastic anaemia and liver failure.", "question": "adverse event. Treatment, Flucloxacillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_8_7407", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Subject, patients with cancer. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_8_7408", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Subject, patients with cancer. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_8_7409", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Subject, patients with cancer. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_8_7410", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Subject, patients with cancer. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_8_7411", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Subject, patients with cancer. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "cancer"}, {"id": "18855892_8_7412", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "18855892_8_7413", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_8_7414", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_8_7415", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_8_7416", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_8_7417", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_8_7418", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_8_7419", "context": "Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate-induced anaphylaxis.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_4_7420", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCNU"}, {"id": "15286697_4_7421", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_4_7422", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_4_7423", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_4_7424", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_4_7425", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_4_7426", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_4_7427", "context": "We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of BCNU-related pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2241449_1_7428", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfonamide"}, {"id": "2241449_1_7429", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_1_7430", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_1_7431", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_1_7432", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_1_7433", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_1_7434", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2241449_1_7435", "context": "Physicians using this \"new\" drug must be aware of the potential danger of sulfonamide-induced injury to the urinary tract.", "question": "adverse event. Treatment, sulfonamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_4_7436", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Brimonidine"}, {"id": "12504711_4_7437", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_4_7438", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_4_7439", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_4_7440", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_4_7441", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_4_7442", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_4_7443", "context": "RESULTS: Brimonidine was observed to cause IOP elevation, confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.", "question": "adverse event. Treatment, Brimonidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15507779_1_7444", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Subject, an HIV carrier. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15507779_1_7445", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Subject, an HIV carrier. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15507779_1_7446", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Subject, an HIV carrier. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15507779_1_7447", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Subject, an HIV carrier. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15507779_1_7448", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Subject, an HIV carrier. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15507779_1_7449", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nevirapine"}, {"id": "15507779_1_7450", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15507779_1_7451", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15507779_1_7452", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15507779_1_7453", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15507779_1_7454", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15507779_1_7455", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV carrier"}, {"id": "15507779_1_7456", "context": "Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.", "question": "adverse event. Treatment, nevirapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_2_7457", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Subject, 20 patients with hepatocellular carcinoma (HCC). Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "1711090_2_7458", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Subject, 20 patients with hepatocellular carcinoma (HCC). Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "1711090_2_7459", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Subject, 20 patients with hepatocellular carcinoma (HCC). Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "20"}, {"id": "1711090_2_7460", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Subject, 20 patients with hepatocellular carcinoma (HCC). Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "1711090_2_7461", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Subject, 20 patients with hepatocellular carcinoma (HCC). Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "hepatocellular carcinoma"}, {"id": "1711090_2_7462", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Lp-TAE; radiofrequency (RF) capacitive hyperthermia"}, {"id": "1711090_2_7463", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_2_7464", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "1711090_2_7465", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "1711090_2_7466", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_2_7467", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1711090_2_7468", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cirrhosis of the liver"}, {"id": "1711090_2_7469", "context": "The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver.", "question": "potential therapeutic event. Treatment, Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "Lp-TAE; radiofrequency (RF) capacitive hyperthermia"}, {"id": "3806824_1_7470", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phentolamine; papaverine"}, {"id": "3806824_1_7471", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3806824_1_7472", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3806824_1_7473", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intracavernous injection"}, {"id": "3806824_1_7474", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3806824_1_7475", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3806824_1_7476", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3806824_1_7477", "context": "Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.", "question": "adverse event. Treatment, intracavernous injection of phentolamine/papaverine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "phentolamine; papaverine"}, {"id": "440873_4_7478", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Subject, three children. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "440873_4_7479", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Subject, three children. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "440873_4_7480", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Subject, three children. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "440873_4_7481", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Subject, three children. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "440873_4_7482", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Subject, three children. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "440873_4_7483", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "440873_4_7484", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "440873_4_7485", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "440873_4_7486", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "440873_4_7487", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "440873_4_7488", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "440873_4_7489", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "440873_4_7490", "context": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use.", "question": "adverse event. Treatment, carbamazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17275666_1_7491", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Subject, Juvenile absence epilepsy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "Juvenile"}, {"id": "17275666_1_7492", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Subject, Juvenile absence epilepsy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17275666_1_7493", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Subject, Juvenile absence epilepsy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17275666_1_7494", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Subject, Juvenile absence epilepsy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17275666_1_7495", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Subject, Juvenile absence epilepsy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17275666_1_7496", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valproic acid"}, {"id": "17275666_1_7497", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17275666_1_7498", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17275666_1_7499", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17275666_1_7500", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17275666_1_7501", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17275666_1_7502", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "absence epilepsy"}, {"id": "17275666_1_7503", "context": "Juvenile absence epilepsy exacerbated by valproic acid.", "question": "adverse event. Treatment, valproic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_10_7504", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quetiapine"}, {"id": "15516308_10_7505", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_10_7506", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_10_7507", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_10_7508", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_10_7509", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_10_7510", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_10_7511", "context": "These cases were chosen for study because they were all deaths as a result of suicidal ingestion of drugs in which quetiapine was considered a significant factor.", "question": "adverse event. Treatment, quetiapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16599252_2_7512", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16599252_2_7513", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16599252_2_7514", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16599252_2_7515", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16599252_2_7516", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16599252_2_7517", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zafirlukast"}, {"id": "16599252_2_7518", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16599252_2_7519", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16599252_2_7520", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16599252_2_7521", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16599252_2_7522", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16599252_2_7523", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16599252_2_7524", "context": "We present a case of hypereosinophilia related to zafirlukast therapy.", "question": "adverse event. Treatment, zafirlukast therapy.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_3_7525", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Subject, In patients with methotrexate-induced anaphylaxis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18855892_3_7526", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Subject, In patients with methotrexate-induced anaphylaxis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18855892_3_7527", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Subject, In patients with methotrexate-induced anaphylaxis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18855892_3_7528", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Subject, In patients with methotrexate-induced anaphylaxis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18855892_3_7529", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Subject, In patients with methotrexate-induced anaphylaxis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18855892_3_7530", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "18855892_3_7531", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_3_7532", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_3_7533", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_3_7534", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_3_7535", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_3_7536", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "methotrexate-induced anaphylaxis"}, {"id": "18855892_3_7537", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_3_7538", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "18855892_3_7539", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_3_7540", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_3_7541", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_3_7542", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_3_7543", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_3_7544", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_3_7545", "context": "In patients with methotrexate-induced anaphylaxis, discontinuation of treatment may increase the risk of death due to cancer progression.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9737132_3_7546", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Pentazocine"}, {"id": "9737132_3_7547", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9737132_3_7548", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9737132_3_7549", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9737132_3_7550", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9737132_3_7551", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9737132_3_7552", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9737132_3_7553", "context": "Pentazocine-induced fibrous myopathy and localized neuropathy.", "question": "adverse event. Treatment, Pentazocine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11096051_1_7554", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": ""}, {"id": "11096051_1_7555", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11096051_1_7556", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11096051_1_7557", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11096051_1_7558", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11096051_1_7559", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11096051_1_7560", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "vancomycin toxicity"}, {"id": "11096051_1_7561", "context": "Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.", "question": "potential therapeutic event. Treatment, Intensive high-flux hemodiafiltration. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17823522_3_7562", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Subject, a patient with hepatitis C. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17823522_3_7563", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Subject, a patient with hepatitis C. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17823522_3_7564", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Subject, a patient with hepatitis C. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17823522_3_7565", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Subject, a patient with hepatitis C. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17823522_3_7566", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Subject, a patient with hepatitis C. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17823522_3_7567", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alpha; ribavirin"}, {"id": "17823522_3_7568", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17823522_3_7569", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17823522_3_7570", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "systemic"}, {"id": "17823522_3_7571", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17823522_3_7572", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17823522_3_7573", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "hepatitis C"}, {"id": "17823522_3_7574", "context": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin.", "question": "adverse event. Treatment, systemic treatment with interferon alpha and ribavirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "ribavirin; interferon alpha"}, {"id": "6810714_1_7575", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Subject, a woman with chronic schizophrenia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6810714_1_7576", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Subject, a woman with chronic schizophrenia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "6810714_1_7577", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Subject, a woman with chronic schizophrenia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6810714_1_7578", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Subject, a woman with chronic schizophrenia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6810714_1_7579", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Subject, a woman with chronic schizophrenia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6810714_1_7580", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol"}, {"id": "6810714_1_7581", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6810714_1_7582", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6810714_1_7583", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6810714_1_7584", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6810714_1_7585", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6810714_1_7586", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic schizophrenia"}, {"id": "6810714_1_7587", "context": "The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and photosensitivity after the addition of propranolol to her neuroleptic regimen.", "question": "adverse event. Treatment, propranolol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_2_7588", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Subject, an infant with complex congenital heart disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "infant"}, {"id": "16132305_2_7589", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Subject, an infant with complex congenital heart disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16132305_2_7590", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Subject, an infant with complex congenital heart disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16132305_2_7591", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Subject, an infant with complex congenital heart disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16132305_2_7592", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Subject, an infant with complex congenital heart disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16132305_2_7593", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "captopril"}, {"id": "16132305_2_7594", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_2_7595", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16132305_2_7596", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16132305_2_7597", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_2_7598", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16132305_2_7599", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "congenital heart disease"}, {"id": "16132305_2_7600", "context": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia.", "question": "adverse event. Treatment, captopril. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_1_7601", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valproic acid"}, {"id": "3084231_1_7602", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3084231_1_7603", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3084231_1_7604", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3084231_1_7605", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3084231_1_7606", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3084231_1_7607", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3084231_1_7608", "context": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "question": "adverse event. Treatment, valproic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19583682_3_7609", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19583682_3_7610", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19583682_3_7611", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19583682_3_7612", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19583682_3_7613", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19583682_3_7614", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "selective serotonin-reuptake inhibitors; ciprofloxacin"}, {"id": "19583682_3_7615", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19583682_3_7616", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19583682_3_7617", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19583682_3_7618", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19583682_3_7619", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19583682_3_7620", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19583682_3_7621", "context": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin.", "question": "adverse event. Treatment, interactions between three different selective serotonin-reuptake inhibitors (SSRI) and possibly ciprofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "ciprofloxacin; selective serotonin-reuptake inhibitors"}, {"id": "12218252_1_7622", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporin"}, {"id": "12218252_1_7623", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12218252_1_7624", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12218252_1_7625", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12218252_1_7626", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12218252_1_7627", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12218252_1_7628", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12218252_1_7629", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "adverse event. Treatment, cyclosporin a withdrawal. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12218252_1_7630", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "etanercept"}, {"id": "12218252_1_7631", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12218252_1_7632", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12218252_1_7633", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12218252_1_7634", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12218252_1_7635", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12218252_1_7636", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Generalised pustular psoriasis induced by cyclosporin a withdrawal"}, {"id": "12218252_1_7637", "context": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.", "question": "potential therapeutic event. Treatment, the tumour necrosis factor alpha inhibitor etanercept. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10592946_1_7638", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Subject, A 36-y-o patient with schizophrenia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "36-y-o"}, {"id": "10592946_1_7639", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Subject, A 36-y-o patient with schizophrenia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10592946_1_7640", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Subject, A 36-y-o patient with schizophrenia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10592946_1_7641", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Subject, A 36-y-o patient with schizophrenia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10592946_1_7642", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Subject, A 36-y-o patient with schizophrenia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "schizophrenia"}, {"id": "10592946_1_7643", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "oolong tea"}, {"id": "10592946_1_7644", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "15 L"}, {"id": "10592946_1_7645", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "each day"}, {"id": "10592946_1_7646", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10592946_1_7647", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10592946_1_7648", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10592946_1_7649", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10592946_1_7650", "context": "A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.", "question": "adverse event. Treatment, gradually increasing quantities of oolong tea that eventually reached 15 L each day. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3242521_1_7651", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Subject, a neonate. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "neonate"}, {"id": "3242521_1_7652", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Subject, a neonate. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3242521_1_7653", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Subject, a neonate. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3242521_1_7654", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Subject, a neonate. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3242521_1_7655", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Subject, a neonate. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3242521_1_7656", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nafcillin"}, {"id": "3242521_1_7657", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3242521_1_7658", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3242521_1_7659", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3242521_1_7660", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3242521_1_7661", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3242521_1_7662", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3242521_1_7663", "context": "Intraventricular nafcillin-induced seizures in a neonate.", "question": "adverse event. Treatment, nafcillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_4_7664", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cephalosporin"}, {"id": "6671350_4_7665", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_4_7666", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_4_7667", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_4_7668", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_4_7669", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_4_7670", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_4_7671", "context": "Nevertheless, the coagulopathy seemed to be most closely associated with the administration of the cephalosporin.", "question": "adverse event. Treatment, cephalosporin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_2_7672", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thiabendazole"}, {"id": "6873616_2_7673", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_2_7674", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_2_7675", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_2_7676", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_2_7677", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_2_7678", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_2_7679", "context": "Intrahepatic cholestasis and sicca complex after thiabendazole.", "question": "adverse event. Treatment, thiabendazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "748238_3_7680", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "748238_3_7681", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "748238_3_7682", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "748238_3_7683", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "748238_3_7684", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "748238_3_7685", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diphenylhydantoin"}, {"id": "748238_3_7686", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "748238_3_7687", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "748238_3_7688", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "748238_3_7689", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "748238_3_7690", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "748238_3_7691", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "748238_3_7692", "context": "We recommended periodic examination of the serum proteins in patients receiving diphenylhydantoin in order to detect development of monoclonal gammopathy.", "question": "adverse event. Treatment, diphenylhydantoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_3_7693", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Moxalactam"}, {"id": "6671350_3_7694", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_3_7695", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_3_7696", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_3_7697", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_3_7698", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_3_7699", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_3_7700", "context": "Moxalactam is more likely to be associated with platelet dysfunction.", "question": "adverse event. Treatment, Moxalactam. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_2_7701", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Subject, three AIDS patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_2_7702", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Subject, three AIDS patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_2_7703", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Subject, three AIDS patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "8151270_2_7704", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Subject, three AIDS patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_2_7705", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Subject, three AIDS patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_2_7706", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ddI"}, {"id": "8151270_2_7707", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_2_7708", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_2_7709", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_2_7710", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_2_7711", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_2_7712", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "AIDS"}, {"id": "8151270_2_7713", "context": "This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients.", "question": "adverse event. Treatment, ddI. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_3_7714", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Subject, Two patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_3_7715", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Subject, Two patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_3_7716", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Subject, Two patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "10573314_3_7717", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Subject, Two patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_3_7718", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Subject, Two patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "chronic atrial fibrillation"}, {"id": "10573314_3_7719", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tolterodine; warfarin"}, {"id": "10573314_3_7720", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_3_7721", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_3_7722", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_3_7723", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_3_7724", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_3_7725", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "stroke; urinary disorders"}, {"id": "10573314_3_7726", "context": "Two patients, each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation, developed adverse effects after the initiation of tolterodine for urinary disorders.", "question": "adverse event. Treatment, receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation; after the initiation of tolterodine for urinary disorders. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "tolterodine; warfarin"}, {"id": "16288069_2_7727", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Subject, A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness). Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "45-year-old"}, {"id": "16288069_2_7728", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Subject, A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness). Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16288069_2_7729", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Subject, A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness). Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16288069_2_7730", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Subject, A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness). Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16288069_2_7731", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Subject, A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness). Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "HIV-positive"}, {"id": "16288069_2_7732", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "penicillin G"}, {"id": "16288069_2_7733", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "an initial intravenous dose"}, {"id": "16288069_2_7734", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16288069_2_7735", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "16288069_2_7736", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16288069_2_7737", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16288069_2_7738", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "neurosyphilis"}, {"id": "16288069_2_7739", "context": "CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis.", "question": "adverse event. Treatment, an initial intravenous dose of penicillin G. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_6_7740", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Subject, second patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16393774_6_7741", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Subject, second patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16393774_6_7742", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Subject, second patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16393774_6_7743", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Subject, second patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16393774_6_7744", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Subject, second patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16393774_6_7745", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN-beta"}, {"id": "16393774_6_7746", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_6_7747", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_6_7748", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_6_7749", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "50 months"}, {"id": "16393774_6_7750", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_6_7751", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_6_7752", "context": "The second patient developed both autoimmune thyroid disease and a refractory pre-patellar bursitis after 50 months of IFN-beta therapy.", "question": "adverse event. Treatment, 50 months of IFN-beta therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_3_7753", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3156465_3_7754", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3156465_3_7755", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3156465_3_7756", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3156465_3_7757", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3156465_3_7758", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isotretinoin"}, {"id": "3156465_3_7759", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_3_7760", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_3_7761", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_3_7762", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_3_7763", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_3_7764", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_3_7765", "context": "We report an additional case of isotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.", "question": "adverse event. Treatment, isotretinoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "13680140_1_7766", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "isotretinoin"}, {"id": "13680140_1_7767", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "13680140_1_7768", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "13680140_1_7769", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "13680140_1_7770", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "13680140_1_7771", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "ong-term"}, {"id": "13680140_1_7772", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "13680140_1_7773", "context": "Reversible sclerotic changes of lumbar spine and femur due to long-term oral isotretinoin therapy.", "question": "adverse event. Treatment, long-term oral isotretinoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6725214_1_7774", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Subject, A case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6725214_1_7775", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Subject, A case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6725214_1_7776", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Subject, A case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6725214_1_7777", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Subject, A case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6725214_1_7778", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Subject, A case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6725214_1_7779", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trazodone"}, {"id": "6725214_1_7780", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6725214_1_7781", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6725214_1_7782", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6725214_1_7783", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6725214_1_7784", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6725214_1_7785", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6725214_1_7786", "context": "A case of priapism associated with trazodone is described.", "question": "adverse event. Treatment, trazodone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16678268_1_7787", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "16678268_1_7788", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16678268_1_7789", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16678268_1_7790", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "16678268_1_7791", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16678268_1_7792", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16678268_1_7793", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "16678268_1_7794", "context": "Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.", "question": "adverse event. Treatment, infliximab infusion. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6693840_3_7795", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "theophylline"}, {"id": "6693840_3_7796", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6693840_3_7797", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6693840_3_7798", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6693840_3_7799", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6693840_3_7800", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6693840_3_7801", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6693840_3_7802", "context": "No other endogenous or exogenous cause for the gynecomastia could be found except for the theophylline.", "question": "adverse event. Treatment, theophylline. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_5_7803", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Subject, a patient with an underlying vascular malformation. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16018164_5_7804", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Subject, a patient with an underlying vascular malformation. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16018164_5_7805", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Subject, a patient with an underlying vascular malformation. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16018164_5_7806", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Subject, a patient with an underlying vascular malformation. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16018164_5_7807", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Subject, a patient with an underlying vascular malformation. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "vascular malformation"}, {"id": "16018164_5_7808", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pseudoephedrine"}, {"id": "16018164_5_7809", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_5_7810", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_5_7811", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_5_7812", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_5_7813", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_5_7814", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_5_7815", "context": "This is a case of pseudoephedrine-induced intracerebral hemorrhage in a patient with an underlying vascular malformation.", "question": "adverse event. Treatment, pseudoephedrine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6651138_1_7816", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Subject, A 58-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "58-year-old"}, {"id": "6651138_1_7817", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Subject, A 58-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "6651138_1_7818", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Subject, A 58-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6651138_1_7819", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Subject, A 58-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6651138_1_7820", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Subject, A 58-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6651138_1_7821", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "scopolamine"}, {"id": "6651138_1_7822", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6651138_1_7823", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6651138_1_7824", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "patch"}, {"id": "6651138_1_7825", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "four days"}, {"id": "6651138_1_7826", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6651138_1_7827", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6651138_1_7828", "context": "A 58-year-old woman developed unilateral acute angle-closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V).", "question": "adverse event. Treatment, four days after the application of a patch of transdermal scopolamine delivery system (TRANSDERM-V). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12218252_2_7829", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Subject, a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "50-year-old"}, {"id": "12218252_2_7830", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Subject, a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "12218252_2_7831", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Subject, a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12218252_2_7832", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Subject, a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12218252_2_7833", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Subject, a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "psoriasis including mutilating psoriatic arthritis"}, {"id": "12218252_2_7834", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporin A"}, {"id": "12218252_2_7835", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12218252_2_7836", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12218252_2_7837", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12218252_2_7838", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12218252_2_7839", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12218252_2_7840", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12218252_2_7841", "context": "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.", "question": "adverse event. Treatment, the withdrawal of cyclosporin A. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8726608_2_7842", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Subject, she. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8726608_2_7843", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Subject, she. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "she"}, {"id": "8726608_2_7844", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Subject, she. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8726608_2_7845", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Subject, she. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8726608_2_7846", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Subject, she. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8726608_2_7847", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "acyclovir"}, {"id": "8726608_2_7848", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8726608_2_7849", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8726608_2_7850", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8726608_2_7851", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "Six days"}, {"id": "8726608_2_7852", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8726608_2_7853", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8726608_2_7854", "context": "Six days after starting acyclovir she exhibited signs of lithium toxicity.", "question": "adverse event. Treatment, Six days after starting acyclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11197767_1_7855", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "cadmium; zinc"}, {"id": "11197767_1_7856", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11197767_1_7857", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11197767_1_7858", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11197767_1_7859", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11197767_1_7860", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11197767_1_7861", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "11197767_1_7862", "context": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus (Digenea: Philophthalmidae).", "question": "potential therapeutic event. Treatment, cadmium and zinc. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2717661_1_7863", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "2717661_1_7864", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2717661_1_7865", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2717661_1_7866", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2717661_1_7867", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2717661_1_7868", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2717661_1_7869", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2717661_1_7870", "context": "The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT).", "question": "adverse event. Treatment, lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_5_7871", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Subject, One patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "589261_5_7872", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Subject, One patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "589261_5_7873", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Subject, One patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "One"}, {"id": "589261_5_7874", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Subject, One patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "589261_5_7875", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Subject, One patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "589261_5_7876", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ouabain"}, {"id": "589261_5_7877", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "589261_5_7878", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "589261_5_7879", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "589261_5_7880", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_5_7881", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "589261_5_7882", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "589261_5_7883", "context": "One patient on ouabain also developed cardiomyopathy.", "question": "adverse event. Treatment, ouabain. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15863610_3_7884", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "15863610_3_7885", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15863610_3_7886", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15863610_3_7887", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15863610_3_7888", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15863610_3_7889", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15863610_3_7890", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15863610_3_7891", "context": "Data suggest that tamoxifen is involved in the pathogenesis.", "question": "adverse event. Treatment, tamoxifen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6794018_2_7892", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "glibenclamide"}, {"id": "6794018_2_7893", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6794018_2_7894", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6794018_2_7895", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6794018_2_7896", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6794018_2_7897", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6794018_2_7898", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6794018_2_7899", "context": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.", "question": "adverse event. Treatment, glibenclamide therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_1_7900", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Subject, painful diabetic neuropathy patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18262450_1_7901", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Subject, painful diabetic neuropathy patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18262450_1_7902", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Subject, painful diabetic neuropathy patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "18262450_1_7903", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Subject, painful diabetic neuropathy patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18262450_1_7904", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Subject, painful diabetic neuropathy patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18262450_1_7905", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Prolonged-release oxycodone"}, {"id": "18262450_1_7906", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_1_7907", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_1_7908", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_1_7909", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_1_7910", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_1_7911", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "diabetic neuropathy"}, {"id": "18262450_1_7912", "context": "Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.", "question": "potential therapeutic event. Treatment, Prolonged-release oxycodone; gabapentin therapy. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14742791_3_7913", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pantoprazole"}, {"id": "14742791_3_7914", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_3_7915", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_3_7916", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_3_7917", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_3_7918", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_3_7919", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_3_7920", "context": "OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis (AIN) due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19555801_2_7921", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Subject, a patient of organic bipolar affective disorder. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19555801_2_7922", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Subject, a patient of organic bipolar affective disorder. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19555801_2_7923", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Subject, a patient of organic bipolar affective disorder. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19555801_2_7924", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Subject, a patient of organic bipolar affective disorder. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19555801_2_7925", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Subject, a patient of organic bipolar affective disorder. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19555801_2_7926", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aripiprazole"}, {"id": "19555801_2_7927", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19555801_2_7928", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19555801_2_7929", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19555801_2_7930", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19555801_2_7931", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19555801_2_7932", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "organic bipolar affective disorder"}, {"id": "19555801_2_7933", "context": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole.", "question": "adverse event. Treatment, the atypical antipsychotic aripiprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_2_7934", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Subject, A 28 year-old man with chronic hepatitis B. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "28 year-old"}, {"id": "10682234_2_7935", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Subject, A 28 year-old man with chronic hepatitis B. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "10682234_2_7936", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Subject, A 28 year-old man with chronic hepatitis B. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10682234_2_7937", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Subject, A 28 year-old man with chronic hepatitis B. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10682234_2_7938", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Subject, A 28 year-old man with chronic hepatitis B. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10682234_2_7939", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "interferon-alpha"}, {"id": "10682234_2_7940", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_2_7941", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "once a day"}, {"id": "10682234_2_7942", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "intramuscularly"}, {"id": "10682234_2_7943", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_2_7944", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_2_7945", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "chronic hepatitis B"}, {"id": "10682234_2_7946", "context": "A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days.", "question": "potential therapeutic event. Treatment, interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "21330680_2_7947", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21330680_2_7948", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21330680_2_7949", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21330680_2_7950", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21330680_2_7951", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21330680_2_7952", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "21330680_2_7953", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dosage"}, {"id": "21330680_2_7954", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21330680_2_7955", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21330680_2_7956", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21330680_2_7957", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21330680_2_7958", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21330680_2_7959", "context": "The case of a patient taking high-dosage olanzapine who experienced parkinsonism after smoking cessation is reported.", "question": "adverse event. Treatment, high-dosage olanzapine; smoking cessation. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4066620_1_7960", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Subject, A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "65-year-old"}, {"id": "4066620_1_7961", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Subject, A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "4066620_1_7962", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Subject, A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4066620_1_7963", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Subject, A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4066620_1_7964", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Subject, A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "bipolar disorder; cardiovascular disease"}, {"id": "4066620_1_7965", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trazodone; lithium"}, {"id": "4066620_1_7966", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high doses"}, {"id": "4066620_1_7967", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4066620_1_7968", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4066620_1_7969", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4066620_1_7970", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4066620_1_7971", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute depression"}, {"id": "4066620_1_7972", "context": "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression.", "question": "adverse event. Treatment, high doses of trazodone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "lithium; trazodone"}, {"id": "19354059_1_7973", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "19354059_1_7974", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19354059_1_7975", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19354059_1_7976", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19354059_1_7977", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19354059_1_7978", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19354059_1_7979", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19354059_1_7980", "context": "The most common complication of warfarin use is adverse bleeding.", "question": "adverse event. Treatment, warfarin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_2_7981", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylene blue"}, {"id": "18166746_2_7982", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_2_7983", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_2_7984", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18166746_2_7985", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_2_7986", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_2_7987", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_2_7988", "context": "To report a case of autonomic, neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy; to advance the argument for a diagnosis of serotonin syndrome; and to consider this diagnosis in previous, unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue.", "question": "adverse event. Treatment, methylene blue infusion for parathyroidectomy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15571949_2_7989", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "busulfan; HVOD"}, {"id": "15571949_2_7990", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15571949_2_7991", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15571949_2_7992", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15571949_2_7993", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15571949_2_7994", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15571949_2_7995", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15571949_2_7996", "context": "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.", "question": "adverse event. Treatment, intensive chemotherapy containing busulfan and to be associated with HVOD; HVOD. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "busulfan; HVOD"}, {"id": "11724089_3_7997", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ofloxacin"}, {"id": "11724089_3_7998", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_3_7999", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_3_8000", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_3_8001", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_3_8002", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_3_8003", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_3_8004", "context": "It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.", "question": "adverse event. Treatment, ofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21630612_1_8005", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21630612_1_8006", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "21630612_1_8007", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21630612_1_8008", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21630612_1_8009", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21630612_1_8010", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "simvastatin; amiodarone"}, {"id": "21630612_1_8011", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21630612_1_8012", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21630612_1_8013", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21630612_1_8014", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21630612_1_8015", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21630612_1_8016", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21630612_1_8017", "context": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature.", "question": "adverse event. Treatment, Concomitant use of simvastatin and amiodarone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "simvastatin; amiodarone"}, {"id": "9533061_10_8018", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clindamycin phosphate"}, {"id": "9533061_10_8019", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_10_8020", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9533061_10_8021", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "vaginal cream"}, {"id": "9533061_10_8022", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_10_8023", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9533061_10_8024", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9533061_10_8025", "context": "CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.", "question": "adverse event. Treatment, clindamycin phosphate vaginal cream. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_2_8026", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "8308951_2_8027", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_2_8028", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_2_8029", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_2_8030", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_2_8031", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_2_8032", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_2_8033", "context": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "question": "adverse event. Treatment, warfarin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_3_8034", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Subject, a patient with spinal cord astrocytoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_3_8035", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Subject, a patient with spinal cord astrocytoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_3_8036", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Subject, a patient with spinal cord astrocytoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_3_8037", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Subject, a patient with spinal cord astrocytoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_3_8038", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Subject, a patient with spinal cord astrocytoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_3_8039", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine"}, {"id": "3171334_3_8040", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_3_8041", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "a single dose"}, {"id": "3171334_3_8042", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_3_8043", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_3_8044", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_3_8045", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "spinal cord astrocytoma"}, {"id": "3171334_3_8046", "context": "Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma.", "question": "adverse event. Treatment, a single dose of vincristine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_5_8047", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Subject, his. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10682234_5_8048", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Subject, his. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "his"}, {"id": "10682234_5_8049", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Subject, his. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10682234_5_8050", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Subject, his. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10682234_5_8051", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Subject, his. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10682234_5_8052", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Clonazepam; thioridazine; beta-blockers; anticholinergics; bromocriptine"}, {"id": "10682234_5_8053", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_5_8054", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_5_8055", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10682234_5_8056", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_5_8057", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_5_8058", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "akathisia"}, {"id": "10682234_5_8059", "context": "Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia.", "question": "potential therapeutic event. Treatment, Clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7761316_1_8060", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Subject, four of 44 children (9%). Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "7761316_1_8061", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Subject, four of 44 children (9%). Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7761316_1_8062", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Subject, four of 44 children (9%). Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "four of 44"}, {"id": "7761316_1_8063", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Subject, four of 44 children (9%). Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7761316_1_8064", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Subject, four of 44 children (9%). Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7761316_1_8065", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "7761316_1_8066", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7761316_1_8067", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7761316_1_8068", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7761316_1_8069", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7761316_1_8070", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7761316_1_8071", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "relapsed Wilms' tumors"}, {"id": "7761316_1_8072", "context": "Musculoskeletal complaints were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of cyclophosphamide.", "question": "adverse event. Treatment, ifosfamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_1_8073", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8308951_1_8074", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8308951_1_8075", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8308951_1_8076", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8308951_1_8077", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8308951_1_8078", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin-like anticoagulant"}, {"id": "8308951_1_8079", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_1_8080", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_1_8081", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8308951_1_8082", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_1_8083", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_1_8084", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_1_8085", "context": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.", "question": "adverse event. Treatment, Cutaneous exposure to warfarin-like anticoagulant. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_2_8086", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Gemcitabine"}, {"id": "16317298_2_8087", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_2_8088", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_2_8089", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_2_8090", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_2_8091", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_2_8092", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_2_8093", "context": "Gemcitabine should be added to the list of drugs known to cause radiation recall.", "question": "adverse event. Treatment, Gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_1_8094", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "brimonidine"}, {"id": "12504711_1_8095", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_1_8096", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_1_8097", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12504711_1_8098", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_1_8099", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_1_8100", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_1_8101", "context": "A paradoxical ocular effect of brimonidine.", "question": "adverse event. Treatment, brimonidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12234159_1_8102", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "rofecoxib"}, {"id": "12234159_1_8103", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12234159_1_8104", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12234159_1_8105", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12234159_1_8106", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12234159_1_8107", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12234159_1_8108", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12234159_1_8109", "context": "Fixed drug eruption to rofecoxib.", "question": "adverse event. Treatment, rofecoxib. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9533061_8_8110", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Subject, patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "9533061_8_8111", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Subject, patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "9533061_8_8112", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Subject, patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "9533061_8_8113", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Subject, patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "9533061_8_8114", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Subject, patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "9533061_8_8115", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "clindamycin"}, {"id": "9533061_8_8116", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9533061_8_8117", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9533061_8_8118", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "vaginal cream"}, {"id": "9533061_8_8119", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9533061_8_8120", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9533061_8_8121", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "bacterial vaginosis"}, {"id": "9533061_8_8122", "context": "DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea.", "question": "potential therapeutic event. Treatment, receiving clindamycin vaginal cream. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "14742791_1_8123", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pantoprazole"}, {"id": "14742791_1_8124", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14742791_1_8125", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14742791_1_8126", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14742791_1_8127", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14742791_1_8128", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14742791_1_8129", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14742791_1_8130", "context": "Acute interstitial nephritis due to pantoprazole.", "question": "adverse event. Treatment, pantoprazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16515630_3_8131", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "taxanes"}, {"id": "16515630_3_8132", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16515630_3_8133", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16515630_3_8134", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16515630_3_8135", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16515630_3_8136", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16515630_3_8137", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16515630_3_8138", "context": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis.", "question": "adverse event. Treatment, taxanes such as paclitaxel. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1238016_1_8139", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Subject, Infant twins. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "Infant"}, {"id": "1238016_1_8140", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Subject, Infant twins. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1238016_1_8141", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Subject, Infant twins. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1238016_1_8142", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Subject, Infant twins. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1238016_1_8143", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Subject, Infant twins. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1238016_1_8144", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "benzalkonium (Zephiran) chloride"}, {"id": "1238016_1_8145", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1238016_1_8146", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1238016_1_8147", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1238016_1_8148", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1238016_1_8149", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1238016_1_8150", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "candidiasis"}, {"id": "1238016_1_8151", "context": "Infant twins sustained severe circumoral and pharyngeal burns from a concentrated solution of benzalkonium (Zephiran) chloride prescribed for treatment of candidiasis.", "question": "adverse event. Treatment, a concentrated solution of benzalkonium (Zephiran) chloride. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_2_8152", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Isotretinoin"}, {"id": "3156465_2_8153", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_2_8154", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_2_8155", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_2_8156", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_2_8157", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_2_8158", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3156465_2_8159", "context": "Isotretinoin teratogenicity.", "question": "adverse event. Treatment, Isotretinoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7081289_1_8160", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cimetidine"}, {"id": "7081289_1_8161", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7081289_1_8162", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7081289_1_8163", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7081289_1_8164", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7081289_1_8165", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7081289_1_8166", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7081289_1_8167", "context": "Hepatitis following cimetidine administration.", "question": "adverse event. Treatment, cimetidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_4_8168", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Subject, an 11-month-old female infant. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "11-month-old; infant"}, {"id": "10698143_4_8169", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Subject, an 11-month-old female infant. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "10698143_4_8170", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Subject, an 11-month-old female infant. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10698143_4_8171", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Subject, an 11-month-old female infant. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10698143_4_8172", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Subject, an 11-month-old female infant. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10698143_4_8173", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ibuprofen"}, {"id": "10698143_4_8174", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_4_8175", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10698143_4_8176", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "ingestion"}, {"id": "10698143_4_8177", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_4_8178", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10698143_4_8179", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10698143_4_8180", "context": "We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.", "question": "adverse event. Treatment, ingestion of ibuprofen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_5_8181", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "colchicine"}, {"id": "17619811_5_8182", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_5_8183", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_5_8184", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_5_8185", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_5_8186", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_5_8187", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_5_8188", "context": "Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomylysis.", "question": "adverse event. Treatment, colchicine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7526455_1_8189", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Subject, 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "73 year-old"}, {"id": "7526455_1_8190", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Subject, 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7526455_1_8191", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Subject, 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7526455_1_8192", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Subject, 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7526455_1_8193", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Subject, 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7526455_1_8194", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "flecainide"}, {"id": "7526455_1_8195", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7526455_1_8196", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7526455_1_8197", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7526455_1_8198", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "within 15 days"}, {"id": "7526455_1_8199", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7526455_1_8200", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Wolff-Parkinson-White syndrome; paroxysmic supraventricular tachycardia"}, {"id": "7526455_1_8201", "context": "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide.", "question": "adverse event. Treatment, flecainide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15522120_11_8202", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "sertraline"}, {"id": "15522120_11_8203", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_11_8204", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "15522120_11_8205", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "15522120_11_8206", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_11_8207", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "15522120_11_8208", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "depressive symptoms"}, {"id": "15522120_11_8209", "context": "Since the depressive symptoms returned sertraline medication was initiated.", "question": "potential therapeutic event. Treatment, sertraline. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8589490_1_8210", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CHOP"}, {"id": "8589490_1_8211", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8589490_1_8212", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8589490_1_8213", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "8589490_1_8214", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8589490_1_8215", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8589490_1_8216", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "a CD30 (Ki-1)-positive anaplastic large-cell lymphoma"}, {"id": "8589490_1_8217", "context": "Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.", "question": "adverse event. Treatment, CHOP chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11105373_1_8218", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Subject, A 33-year-old male. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "33-year-old"}, {"id": "11105373_1_8219", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Subject, A 33-year-old male. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "male"}, {"id": "11105373_1_8220", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Subject, A 33-year-old male. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11105373_1_8221", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Subject, A 33-year-old male. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11105373_1_8222", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Subject, A 33-year-old male. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11105373_1_8223", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroquinone; tretinoin"}, {"id": "11105373_1_8224", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "4%; 0.1%"}, {"id": "11105373_1_8225", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": "intermittently"}, {"id": "11105373_1_8226", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "cream; cream; face"}, {"id": "11105373_1_8227", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11105373_1_8228", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "9 months"}, {"id": "11105373_1_8229", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11105373_1_8230", "context": "A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.", "question": "adverse event. Treatment, 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2241449_3_8231", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Subject, two cases; patients with acquired immunodeficiency syndrome. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2241449_3_8232", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Subject, two cases; patients with acquired immunodeficiency syndrome. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2241449_3_8233", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Subject, two cases; patients with acquired immunodeficiency syndrome. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "2241449_3_8234", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Subject, two cases; patients with acquired immunodeficiency syndrome. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2241449_3_8235", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Subject, two cases; patients with acquired immunodeficiency syndrome. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2241449_3_8236", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sulfadiazine"}, {"id": "2241449_3_8237", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2241449_3_8238", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2241449_3_8239", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2241449_3_8240", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2241449_3_8241", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2241449_3_8242", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acquired immunodeficiency syndrome"}, {"id": "2241449_3_8243", "context": "We describe two cases of sulfadiazine-induced crystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.", "question": "adverse event. Treatment, sulfadiazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_2_8244", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium stearate"}, {"id": "17016002_2_8245", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_2_8246", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_2_8247", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "17016002_2_8248", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_2_8249", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_2_8250", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_2_8251", "context": "Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication.", "question": "adverse event. Treatment, calcium stearate, an additive agent for an oral antihistaminic medication. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11563738_1_8252", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "11563738_1_8253", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11563738_1_8254", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11563738_1_8255", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11563738_1_8256", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11563738_1_8257", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11563738_1_8258", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11563738_1_8259", "context": "The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2719905_1_8260", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine-6-glucuronide"}, {"id": "2719905_1_8261", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2719905_1_8262", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2719905_1_8263", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2719905_1_8264", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2719905_1_8265", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2719905_1_8266", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2719905_1_8267", "context": "Long lasting respiratory depression induced by morphine-6-glucuronide?", "question": "adverse event. Treatment, morphine-6-glucuronide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "623061_1_8268", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Subject, seven children, 5 years of age and younger. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children, 5 years of age and younger"}, {"id": "623061_1_8269", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Subject, seven children, 5 years of age and younger. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "623061_1_8270", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Subject, seven children, 5 years of age and younger. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "seven"}, {"id": "623061_1_8271", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Subject, seven children, 5 years of age and younger. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "623061_1_8272", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Subject, seven children, 5 years of age and younger. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "623061_1_8273", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentobarbital; pyrilamine maleate"}, {"id": "623061_1_8274", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "623061_1_8275", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "623061_1_8276", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "623061_1_8277", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "623061_1_8278", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "623061_1_8279", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "623061_1_8280", "context": "A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and pyrilamine maleate.", "question": "adverse event. Treatment, administration of an antiemetic combination of pentobarbital and pyrilamine maleate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "pentobarbital; pyrilamine maleate"}, {"id": "868978_1_8281", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-fluorouracil"}, {"id": "868978_1_8282", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_1_8283", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_1_8284", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "868978_1_8285", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_1_8286", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_1_8287", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "868978_1_8288", "context": "Oculomotor disturbances associated with 5-fluorouracil chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18258513_1_8289", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18258513_1_8290", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18258513_1_8291", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18258513_1_8292", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18258513_1_8293", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18258513_1_8294", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxorubicin"}, {"id": "18258513_1_8295", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18258513_1_8296", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18258513_1_8297", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18258513_1_8298", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18258513_1_8299", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18258513_1_8300", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18258513_1_8301", "context": "While doxorubicin was administered, the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.", "question": "adverse event. Treatment, doxorubicin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21802143_5_8302", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Subject, An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "18-year-old"}, {"id": "21802143_5_8303", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Subject, An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "man"}, {"id": "21802143_5_8304", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Subject, An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21802143_5_8305", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Subject, An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "Japanese"}, {"id": "21802143_5_8306", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Subject, An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21802143_5_8307", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "TAC"}, {"id": "21802143_5_8308", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "21802143_5_8309", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "21802143_5_8310", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "IV administration"}, {"id": "21802143_5_8311", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21802143_5_8312", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "21802143_5_8313", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "cell lymphoma"}, {"id": "21802143_5_8314", "context": "An 18-year-old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post-transplantation prophylaxis against graft-versus-host disease (GVHD) after an allogeneic bone marrow transplantation (BMT).", "question": "potential therapeutic event. Treatment, received continuous IV administration of TAC; allogeneic bone marrow transplantation (BMT). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10682234_1_8315", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "levodopa"}, {"id": "10682234_1_8316", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_1_8317", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_1_8318", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "Intravenous"}, {"id": "10682234_1_8319", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_1_8320", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_1_8321", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "a refractory akathisia case induced by interferon-alpha"}, {"id": "10682234_1_8322", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "potential therapeutic event. Treatment, Intravenous administration of levodopa. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10682234_1_8323", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon-alpha"}, {"id": "10682234_1_8324", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_1_8325", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_1_8326", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_1_8327", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_1_8328", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10682234_1_8329", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_1_8330", "context": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.", "question": "adverse event. Treatment, interferon-alpha.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12567347_1_8331", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Subject, Patients with lymphoblastic lymphoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12567347_1_8332", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Subject, Patients with lymphoblastic lymphoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12567347_1_8333", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Subject, Patients with lymphoblastic lymphoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12567347_1_8334", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Subject, Patients with lymphoblastic lymphoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12567347_1_8335", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Subject, Patients with lymphoblastic lymphoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12567347_1_8336", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "steroid; L-asparaginase"}, {"id": "12567347_1_8337", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12567347_1_8338", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12567347_1_8339", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12567347_1_8340", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12567347_1_8341", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12567347_1_8342", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "lymphoblastic lymphoma"}, {"id": "12567347_1_8343", "context": "Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.", "question": "adverse event. Treatment, L-asparaginase and steroid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "L-asparaginase; steroid"}, {"id": "7783891_1_8344", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sumatriptan"}, {"id": "7783891_1_8345", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7783891_1_8346", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7783891_1_8347", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7783891_1_8348", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7783891_1_8349", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7783891_1_8350", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7783891_1_8351", "context": "Because sumatriptan can cause coronary artery vasospasm, patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.", "question": "adverse event. Treatment, sumatriptan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11563738_2_8352", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Subject, 25-year-old man; schizophrenia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "25-year-old"}, {"id": "11563738_2_8353", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Subject, 25-year-old man; schizophrenia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "11563738_2_8354", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Subject, 25-year-old man; schizophrenia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11563738_2_8355", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Subject, 25-year-old man; schizophrenia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11563738_2_8356", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Subject, 25-year-old man; schizophrenia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11563738_2_8357", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "11563738_2_8358", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11563738_2_8359", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11563738_2_8360", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11563738_2_8361", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11563738_2_8362", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11563738_2_8363", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "11563738_2_8364", "context": "This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.", "question": "adverse event. Treatment, olanzapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7258204_1_8365", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Subject, A 67-year-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "67-year-old"}, {"id": "7258204_1_8366", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Subject, A 67-year-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "7258204_1_8367", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Subject, A 67-year-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "7258204_1_8368", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Subject, A 67-year-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7258204_1_8369", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Subject, A 67-year-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7258204_1_8370", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ampicillin"}, {"id": "7258204_1_8371", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7258204_1_8372", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7258204_1_8373", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "7258204_1_8374", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7258204_1_8375", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "10-day"}, {"id": "7258204_1_8376", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7258204_1_8377", "context": "A 67-year-old man developed diarrhea shortly after a 10-day course of oral ampicillin.", "question": "adverse event. Treatment, a 10-day course of oral ampicillin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16216617_1_8378", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenylephrine"}, {"id": "16216617_1_8379", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "16216617_1_8380", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16216617_1_8381", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "16216617_1_8382", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16216617_1_8383", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16216617_1_8384", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16216617_1_8385", "context": "Prominent positive U waves appearing with high-dose intravenous phenylephrine.", "question": "adverse event. Treatment, high-dose intravenous phenylephrine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16620273_2_8386", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16620273_2_8387", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16620273_2_8388", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16620273_2_8389", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16620273_2_8390", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16620273_2_8391", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "16620273_2_8392", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16620273_2_8393", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16620273_2_8394", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16620273_2_8395", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16620273_2_8396", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16620273_2_8397", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16620273_2_8398", "context": "Severe acidosis in patients taking metformin--rapid reversal and survival despite high APACHE score.", "question": "adverse event. Treatment, metformin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1868481_1_8399", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Subject, children with primary glomerulonephritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "children"}, {"id": "1868481_1_8400", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Subject, children with primary glomerulonephritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "1868481_1_8401", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Subject, children with primary glomerulonephritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1868481_1_8402", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Subject, children with primary glomerulonephritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1868481_1_8403", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Subject, children with primary glomerulonephritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1868481_1_8404", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylprednisolone"}, {"id": "1868481_1_8405", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1868481_1_8406", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1868481_1_8407", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "1868481_1_8408", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1868481_1_8409", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1868481_1_8410", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "primary glomerulonephritis"}, {"id": "1868481_1_8411", "context": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis.", "question": "adverse event. Treatment, intravenous pulse methylprednisolone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16728538_4_8412", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Subject, a patient with acromegaly. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "16728538_4_8413", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Subject, a patient with acromegaly. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16728538_4_8414", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Subject, a patient with acromegaly. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16728538_4_8415", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Subject, a patient with acromegaly. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16728538_4_8416", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Subject, a patient with acromegaly. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16728538_4_8417", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegvisomant; octreotide"}, {"id": "16728538_4_8418", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16728538_4_8419", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16728538_4_8420", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16728538_4_8421", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16728538_4_8422", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16728538_4_8423", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acromegaly"}, {"id": "16728538_4_8424", "context": "We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant.", "question": "adverse event. Treatment, long-acting somatostatin-analog octreotide; GH receptor antagonist pegvisomant. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "pegvisomant; octreotide"}, {"id": "12851279_6_8425", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Subject, 1754 patients (> or =18 years) with severe sepsis and a high INR. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "1754"}, {"id": "12851279_6_8426", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Subject, 1754 patients (> or =18 years) with severe sepsis and a high INR. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "12851279_6_8427", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Subject, 1754 patients (> or =18 years) with severe sepsis and a high INR. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "12851279_6_8428", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Subject, 1754 patients (> or =18 years) with severe sepsis and a high INR. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "12851279_6_8429", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Subject, 1754 patients (> or =18 years) with severe sepsis and a high INR. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "12851279_6_8430", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tifacogin"}, {"id": "12851279_6_8431", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_6_8432", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "12851279_6_8433", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "12851279_6_8434", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_6_8435", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "12851279_6_8436", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "severe sepsis"}, {"id": "12851279_6_8437", "context": "The primary efficacy population consisted of 1754 patients (> or =18 years) with severe sepsis and a high INR (> or =1.2) randomly assigned to intravenous infusion of either tifacogin (0.025 mg/kg per hour for 96 hours, n = 880) or placebo (arginine citrate buffer, n = 874), and 201 patients with a low INR (<1.2) randomly assigned to receive the same dose of either tifacogin or placebo.", "question": "potential therapeutic event. Treatment, tifacogin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20234160_3_8438", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Subject, a 23-year-old man. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "23-year-old"}, {"id": "20234160_3_8439", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Subject, a 23-year-old man. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "20234160_3_8440", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Subject, a 23-year-old man. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "20234160_3_8441", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Subject, a 23-year-old man. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "20234160_3_8442", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Subject, a 23-year-old man. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "20234160_3_8443", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vancomycin"}, {"id": "20234160_3_8444", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_3_8445", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_3_8446", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_3_8447", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_3_8448", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_3_8449", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "methicillin-resistant Staphylococcus aureus infection"}, {"id": "20234160_3_8450", "context": "We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.", "question": "adverse event. Treatment, vancomycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19884751_2_8451", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Amikacin"}, {"id": "19884751_2_8452", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "cessation"}, {"id": "19884751_2_8453", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "19884751_2_8454", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "19884751_2_8455", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "15 days"}, {"id": "19884751_2_8456", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "19884751_2_8457", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "tubular dysfunction"}, {"id": "19884751_2_8458", "context": "Recovery of the tubular dysfunction took 15 days following cessation of the offending drug, Amikacin.", "question": "potential therapeutic event. Treatment, 15 days following cessation of the offending drug, Amikacin. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "7139589_3_8459", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "7139589_3_8460", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7139589_3_8461", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7139589_3_8462", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7139589_3_8463", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7139589_3_8464", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7139589_3_8465", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7139589_3_8466", "context": "L-asparaginase-induced pancreatitis has been reported during or closely following administration of the drug.", "question": "adverse event. Treatment, L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15286697_3_8467", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "BCNU"}, {"id": "15286697_3_8468", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15286697_3_8469", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15286697_3_8470", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15286697_3_8471", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15286697_3_8472", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15286697_3_8473", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15286697_3_8474", "context": "These novel findings may offer specific therapeutic targets in the treatment of BCNU-associated pulmonary fibrosis.", "question": "adverse event. Treatment, BCNU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19212144_1_8475", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Subject, A 58-year-old man with advanced renal cell carcinoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "58-year-old"}, {"id": "19212144_1_8476", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Subject, A 58-year-old man with advanced renal cell carcinoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "19212144_1_8477", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Subject, A 58-year-old man with advanced renal cell carcinoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19212144_1_8478", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Subject, A 58-year-old man with advanced renal cell carcinoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19212144_1_8479", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Subject, A 58-year-old man with advanced renal cell carcinoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19212144_1_8480", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "temsirolimus"}, {"id": "19212144_1_8481", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19212144_1_8482", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19212144_1_8483", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "19212144_1_8484", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "five days"}, {"id": "19212144_1_8485", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19212144_1_8486", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "renal cell carcinoma"}, {"id": "19212144_1_8487", "context": "A 58-year-old man with advanced renal cell carcinoma developed grade 3 proteinuria (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion.", "question": "adverse event. Treatment, five days after temsirolimus infusion. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_1_8488", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Subject, A 2-year-old mentally retarded boy with frontal lobe epilepsy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "2-year-old"}, {"id": "9253492_1_8489", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Subject, A 2-year-old mentally retarded boy with frontal lobe epilepsy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "boy"}, {"id": "9253492_1_8490", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Subject, A 2-year-old mentally retarded boy with frontal lobe epilepsy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_1_8491", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Subject, A 2-year-old mentally retarded boy with frontal lobe epilepsy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_1_8492", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Subject, A 2-year-old mentally retarded boy with frontal lobe epilepsy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_1_8493", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zonisamide"}, {"id": "9253492_1_8494", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_1_8495", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_1_8496", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_1_8497", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_1_8498", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_1_8499", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "frontal lobe epilepsy"}, {"id": "9253492_1_8500", "context": "A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide.", "question": "adverse event. Treatment, zonisamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_1_8501", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylene blue"}, {"id": "18166746_1_8502", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_1_8503", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_1_8504", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "18166746_1_8505", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_1_8506", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_1_8507", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_1_8508", "context": "[Serotonin syndrome following methylene blue infusion during parathyroidectomy: a case report and literature review].", "question": "adverse event. Treatment, methylene blue infusion during parathyroidectomy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "868978_3_8509", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Subject, Two patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "868978_3_8510", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Subject, Two patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "868978_3_8511", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Subject, Two patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "868978_3_8512", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Subject, Two patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "868978_3_8513", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Subject, Two patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "868978_3_8514", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-fluorouracil"}, {"id": "868978_3_8515", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "868978_3_8516", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "868978_3_8517", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "868978_3_8518", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "868978_3_8519", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "868978_3_8520", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "disseminated adenocarcinoma of the colon"}, {"id": "868978_3_8521", "context": "Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity.", "question": "adverse event. Treatment, 5-fluorouracil (5-FU). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11510798_4_8522", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "corticosteroids"}, {"id": "11510798_4_8523", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "11510798_4_8524", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "11510798_4_8525", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "11510798_4_8526", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11510798_4_8527", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "11510798_4_8528", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "clinical and radiological abnormalities"}, {"id": "11510798_4_8529", "context": "Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved.", "question": "potential therapeutic event. Treatment, corticosteroids. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "9886213_1_8530", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "praziquantel"}, {"id": "9886213_1_8531", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9886213_1_8532", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9886213_1_8533", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9886213_1_8534", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9886213_1_8535", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9886213_1_8536", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9886213_1_8537", "context": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy.", "question": "adverse event. Treatment, praziquantel therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "172214_1_8538", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "adriamycin; actinomycin-D; mithramycin"}, {"id": "172214_1_8539", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "172214_1_8540", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "172214_1_8541", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "172214_1_8542", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "172214_1_8543", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "172214_1_8544", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "172214_1_8545", "context": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.", "question": "adverse event. Treatment, widely separated courses of adriamycin; actinomycin-D and mithramycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "adriamycin; actinomycin-D; mithramycin"}, {"id": "11485141_3_8546", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "11485141_3_8547", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11485141_3_8548", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11485141_3_8549", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11485141_3_8550", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11485141_3_8551", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11485141_3_8552", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11485141_3_8553", "context": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine.", "question": "adverse event. Treatment, gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_12_8554", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Subject, both patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_12_8555", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Subject, both patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_12_8556", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Subject, both patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "both"}, {"id": "10573314_12_8557", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Subject, both patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_12_8558", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Subject, both patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_12_8559", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tolterodine"}, {"id": "10573314_12_8560", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_12_8561", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_12_8562", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_12_8563", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_12_8564", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_12_8565", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_12_8566", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "adverse event. Treatment, tolterodine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_12_8567", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Subject, both patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10573314_12_8568", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Subject, both patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10573314_12_8569", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Subject, both patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "both"}, {"id": "10573314_12_8570", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Subject, both patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10573314_12_8571", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Subject, both patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10573314_12_8572", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tolterodine"}, {"id": "10573314_12_8573", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_12_8574", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10573314_12_8575", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10573314_12_8576", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_12_8577", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10573314_12_8578", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "elevated INR"}, {"id": "10573314_12_8579", "context": "The temporal association of the course of tolterodine with an elevated INR, the return to the previous warfarin dose-INR response relationship after tolterodine discontinuation, and the absence of other causes for the elevated INR were factors found in both patients.", "question": "potential therapeutic event. Treatment, tolterodine discontinuation. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "15461766_2_8580", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "prostaglandin E1"}, {"id": "15461766_2_8581", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15461766_2_8582", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15461766_2_8583", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15461766_2_8584", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15461766_2_8585", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15461766_2_8586", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15461766_2_8587", "context": "The harlequin color change and association with prostaglandin E1.", "question": "adverse event. Treatment, prostaglandin E1. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19336028_1_8588", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19336028_1_8589", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19336028_1_8590", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19336028_1_8591", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19336028_1_8592", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19336028_1_8593", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Efalizumab; Etanercept"}, {"id": "19336028_1_8594", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19336028_1_8595", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19336028_1_8596", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19336028_1_8597", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19336028_1_8598", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19336028_1_8599", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "refractory palmopustular psoriasis and psoriatic arthritis"}, {"id": "19336028_1_8600", "context": "A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.", "question": "adverse event. Treatment, Efalizumab and Etanercept. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "Efalizumab; Etanercept"}, {"id": "10225085_1_8601", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bupivacaine; lidocaine; metabolic acidosis; oxidants"}, {"id": "10225085_1_8602", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_1_8603", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_1_8604", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10225085_1_8605", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_1_8606", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_1_8607", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_1_8608", "context": "Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.", "question": "adverse event. Treatment, the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "metabolic acidosis; oxidants; bupivacaine; lidocaine"}, {"id": "6851259_1_8609", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6851259_1_8610", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6851259_1_8611", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6851259_1_8612", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6851259_1_8613", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6851259_1_8614", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tolmetin"}, {"id": "6851259_1_8615", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6851259_1_8616", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6851259_1_8617", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6851259_1_8618", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6851259_1_8619", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6851259_1_8620", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6851259_1_8621", "context": "Nephrotic range pseudoproteinuria in a tolmetin-treated patient.", "question": "adverse event. Treatment, tolmetin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "19318596_4_8622", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Subject, With. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "19318596_4_8623", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Subject, With. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_4_8624", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Subject, With. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_4_8625", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Subject, With. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_4_8626", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Subject, With. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "19318596_4_8627", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "19318596_4_8628", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_4_8629", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_4_8630", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "19318596_4_8631", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_4_8632", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_4_8633", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_4_8634", "context": "With the first cyclosporine dose, the patient complained of leg pain that was most severe during the cyclosporine infusion.", "question": "adverse event. Treatment, first cyclosporine dose. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15811174_3_8635", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15811174_3_8636", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15811174_3_8637", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15811174_3_8638", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15811174_3_8639", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15811174_3_8640", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cerivastatin"}, {"id": "15811174_3_8641", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15811174_3_8642", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15811174_3_8643", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15811174_3_8644", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15811174_3_8645", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15811174_3_8646", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15811174_3_8647", "context": "We report on a patient who developed acute rhabdomyolysis after taking cerivastatin.", "question": "adverse event. Treatment, cerivastatin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8124920_2_8648", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Subject, patient suffering from rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8124920_2_8649", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Subject, patient suffering from rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8124920_2_8650", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Subject, patient suffering from rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8124920_2_8651", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Subject, patient suffering from rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8124920_2_8652", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Subject, patient suffering from rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8124920_2_8653", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8124920_2_8654", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "8124920_2_8655", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8124920_2_8656", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8124920_2_8657", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8124920_2_8658", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8124920_2_8659", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "8124920_2_8660", "context": "In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose methotrexate: an acute megaloblastic anaemia and a pneumonitis.", "question": "adverse event. Treatment, low-dose methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11109149_3_8661", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Subject, a 57-year-old man with acral erythrocyanosis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "57-year-old"}, {"id": "11109149_3_8662", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Subject, a 57-year-old man with acral erythrocyanosis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "11109149_3_8663", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Subject, a 57-year-old man with acral erythrocyanosis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11109149_3_8664", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Subject, a 57-year-old man with acral erythrocyanosis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11109149_3_8665", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Subject, a 57-year-old man with acral erythrocyanosis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "acral erythrocyanosis"}, {"id": "11109149_3_8666", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bleomycin; methotrexate"}, {"id": "11109149_3_8667", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11109149_3_8668", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11109149_3_8669", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11109149_3_8670", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11109149_3_8671", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11109149_3_8672", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "metastatic squamous cell carcinoma of the hypopharynx"}, {"id": "11109149_3_8673", "context": "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.", "question": "adverse event. Treatment, combined chemotherapy (bleomycin and methotrexate). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "bleomycin; methotrexate"}, {"id": "2719905_2_8674", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Subject, a 7 year old girl with haemolytic uraemic syndrome. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "7 year old"}, {"id": "2719905_2_8675", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Subject, a 7 year old girl with haemolytic uraemic syndrome. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "girl"}, {"id": "2719905_2_8676", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Subject, a 7 year old girl with haemolytic uraemic syndrome. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2719905_2_8677", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Subject, a 7 year old girl with haemolytic uraemic syndrome. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2719905_2_8678", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Subject, a 7 year old girl with haemolytic uraemic syndrome. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "haemolytic uraemic syndrome"}, {"id": "2719905_2_8679", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "2719905_2_8680", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2719905_2_8681", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2719905_2_8682", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravenous"}, {"id": "2719905_2_8683", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2719905_2_8684", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2719905_2_8685", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2719905_2_8686", "context": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome.", "question": "adverse event. Treatment, intravenous administration of morphine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18071101_1_8687", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Subject, a case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18071101_1_8688", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Subject, a case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18071101_1_8689", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Subject, a case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18071101_1_8690", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Subject, a case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18071101_1_8691", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Subject, a case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18071101_1_8692", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quetiapine"}, {"id": "18071101_1_8693", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18071101_1_8694", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18071101_1_8695", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18071101_1_8696", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18071101_1_8697", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18071101_1_8698", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18071101_1_8699", "context": "Although adverse effects are usually mild, the author reports here a case of leucocytopenia and thrombocytopenia with quetiapine treatment that required its discontinuation.", "question": "adverse event. Treatment, quetiapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3720318_1_8700", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mono-octanoin"}, {"id": "3720318_1_8701", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3720318_1_8702", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3720318_1_8703", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrabiliary infusion"}, {"id": "3720318_1_8704", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3720318_1_8705", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3720318_1_8706", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3720318_1_8707", "context": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono-octanoin.", "question": "adverse event. Treatment, intrabiliary infusion of mono-octanoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "589261_1_8708", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "doxorubicin"}, {"id": "589261_1_8709", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "589261_1_8710", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "589261_1_8711", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "589261_1_8712", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "589261_1_8713", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "589261_1_8714", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "589261_1_8715", "context": "Cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.", "question": "potential therapeutic event. Treatment, Cardiac glycosides. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18262450_7_8716", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Subject, Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "18262450_7_8717", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Subject, Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "18262450_7_8718", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Subject, Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": "Three hundred and thirty eight"}, {"id": "18262450_7_8719", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Subject, Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "18262450_7_8720", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Subject, Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "18262450_7_8721", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "gabapentin; prolonged-release oxycodone; placebo"}, {"id": "18262450_7_8722", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "maximum tolerated dose"}, {"id": "18262450_7_8723", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_7_8724", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral; tablets"}, {"id": "18262450_7_8725", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": "for up to 12 weeks"}, {"id": "18262450_7_8726", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_7_8727", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "painful diabetic neuropathy"}, {"id": "18262450_7_8728", "context": "Three hundred and thirty eight patients with moderate to severe painful diabetic neuropathy despite receiving their maximum tolerated dose of gabapentin, had oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks.", "question": "potential therapeutic event. Treatment, gabapentin; oral prolonged-release oxycodone or placebo tablets added to their therapy for up to 12 weeks. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "22552763_4_8729", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "22552763_4_8730", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "22552763_4_8731", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "22552763_4_8732", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "22552763_4_8733", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "22552763_4_8734", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ASA; NSAID; dabigatran etexilate"}, {"id": "22552763_4_8735", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "22552763_4_8736", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "22552763_4_8737", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "22552763_4_8738", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "22552763_4_8739", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "22552763_4_8740", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "22552763_4_8741", "context": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA.", "question": "adverse event. Treatment, thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "dabigatran etexilate; NSAID; ASA"}, {"id": "2532694_2_8742", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Dapsone"}, {"id": "2532694_2_8743", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2532694_2_8744", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2532694_2_8745", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2532694_2_8746", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2532694_2_8747", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2532694_2_8748", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2532694_2_8749", "context": "Dapsone-induced erythroderma with Beau's lines.", "question": "adverse event. Treatment, Dapsone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_2_8750", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9870779_2_8751", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9870779_2_8752", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9870779_2_8753", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9870779_2_8754", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Subject, a patient with rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9870779_2_8755", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methotrexate"}, {"id": "9870779_2_8756", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_2_8757", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_2_8758", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_2_8759", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9870779_2_8760", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_2_8761", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "9870779_2_8762", "context": "Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis.", "question": "adverse event. Treatment, Methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15516308_3_8763", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quetiapine"}, {"id": "15516308_3_8764", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15516308_3_8765", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15516308_3_8766", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15516308_3_8767", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15516308_3_8768", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15516308_3_8769", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15516308_3_8770", "context": "We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal overdose deaths were associated with quetiapine.", "question": "adverse event. Treatment, quetiapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2830062_3_8771", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Subject, Both patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2830062_3_8772", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Subject, Both patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2830062_3_8773", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Subject, Both patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2830062_3_8774", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Subject, Both patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2830062_3_8775", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Subject, Both patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2830062_3_8776", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "o,p'-DDD; dexamethasone"}, {"id": "2830062_3_8777", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2830062_3_8778", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2830062_3_8779", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2830062_3_8780", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2830062_3_8781", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2830062_3_8782", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2830062_3_8783", "context": "Both patients developed hypoadrenalism while on o,p'-DDD and apparently adequate dexamethasone replacement therapy.", "question": "adverse event. Treatment, o,p'-DDD and apparently adequate dexamethasone replacement therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "o,p'-DDD; dexamethasone"}, {"id": "16046172_1_8784", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Subject, a 78-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "78-year-old"}, {"id": "16046172_1_8785", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Subject, a 78-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16046172_1_8786", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Subject, a 78-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16046172_1_8787", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Subject, a 78-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16046172_1_8788", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Subject, a 78-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16046172_1_8789", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sodium hyaluronate"}, {"id": "16046172_1_8790", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "single; injection"}, {"id": "16046172_1_8791", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16046172_1_8792", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "16046172_1_8793", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16046172_1_8794", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16046172_1_8795", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16046172_1_8796", "context": "In the other patient, a 78-year-old woman, Neisseria mucosa knee arthritis occurred after a single sodium hyaluronate injection.", "question": "adverse event. Treatment, a single sodium hyaluronate injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21729965_1_8797", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "21729965_1_8798", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "21729965_1_8799", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "21729965_1_8800", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "21729965_1_8801", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Subject, an HIV-positive woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "21729965_1_8802", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "21729965_1_8803", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21729965_1_8804", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21729965_1_8805", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21729965_1_8806", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21729965_1_8807", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21729965_1_8808", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV-positive"}, {"id": "21729965_1_8809", "context": "Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.", "question": "adverse event. Treatment, Implanon   failure; on antiretroviral therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16341621_1_8810", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium hydroxylapatite"}, {"id": "16341621_1_8811", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16341621_1_8812", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16341621_1_8813", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "periurethral injection"}, {"id": "16341621_1_8814", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16341621_1_8815", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16341621_1_8816", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "stress urinary incontinence"}, {"id": "16341621_1_8817", "context": "Massive prolapse of the urethral mucosa following periurethral injection of calcium hydroxylapatite for stress urinary incontinence.", "question": "adverse event. Treatment, periurethral injection of calcium hydroxylapatite. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "2532694_1_8818", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Subject, A 35-year-old female with borderline lepromatous (BL) leprosy. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "35-year-old"}, {"id": "2532694_1_8819", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Subject, A 35-year-old female with borderline lepromatous (BL) leprosy. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "2532694_1_8820", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Subject, A 35-year-old female with borderline lepromatous (BL) leprosy. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2532694_1_8821", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Subject, A 35-year-old female with borderline lepromatous (BL) leprosy. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2532694_1_8822", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Subject, A 35-year-old female with borderline lepromatous (BL) leprosy. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2532694_1_8823", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dapsone"}, {"id": "2532694_1_8824", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2532694_1_8825", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2532694_1_8826", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2532694_1_8827", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2532694_1_8828", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2532694_1_8829", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "borderline lepromatous (BL) leprosy"}, {"id": "2532694_1_8830", "context": "A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from dapsone-induced erythroderma is reported.", "question": "adverse event. Treatment, dapsone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8912599_8_8831", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "8912599_8_8832", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8912599_8_8833", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8912599_8_8834", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8912599_8_8835", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8912599_8_8836", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8912599_8_8837", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8912599_8_8838", "context": "Well-known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_1_8839", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aspirin"}, {"id": "18755414_1_8840", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low-dose"}, {"id": "18755414_1_8841", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_1_8842", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "internal"}, {"id": "18755414_1_8843", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_1_8844", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_1_8845", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "falx meningioma"}, {"id": "18755414_1_8846", "context": "Hemorrhage from a falx meningioma after internal use of low-dose aspirin.", "question": "adverse event. Treatment, internal use of low-dose aspirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9671138_2_8847", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9671138_2_8848", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9671138_2_8849", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9671138_2_8850", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9671138_2_8851", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9671138_2_8852", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fludarabine"}, {"id": "9671138_2_8853", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9671138_2_8854", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9671138_2_8855", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9671138_2_8856", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9671138_2_8857", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9671138_2_8858", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic lymphocytic leukemia"}, {"id": "9671138_2_8859", "context": "Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia.", "question": "adverse event. Treatment, fludarabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9149614_2_8860", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amiodarone"}, {"id": "9149614_2_8861", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9149614_2_8862", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9149614_2_8863", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9149614_2_8864", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9149614_2_8865", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9149614_2_8866", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "atrial fibrillation complicating cardiomyopathy"}, {"id": "9149614_2_8867", "context": "Nonsustained polymorphous ventricular tachycardia during amiodarone therapy for atrial fibrillation complicating cardiomyopathy.", "question": "adverse event. Treatment, amiodarone therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8316494_1_8868", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clofazimine"}, {"id": "8316494_1_8869", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low dosage"}, {"id": "8316494_1_8870", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8316494_1_8871", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8316494_1_8872", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8316494_1_8873", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8316494_1_8874", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8316494_1_8875", "context": "Severe abdominal pain in low dosage clofazimine.", "question": "adverse event. Treatment, low dosage clofazimine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12908837_1_8876", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clonazepam"}, {"id": "12908837_1_8877", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12908837_1_8878", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12908837_1_8879", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12908837_1_8880", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12908837_1_8881", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12908837_1_8882", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12908837_1_8883", "context": "Behavioral side effects associated with clonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and temper tantrums.", "question": "adverse event. Treatment, clonazepam. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6671350_2_8884", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cephalosporin; moxalactam"}, {"id": "6671350_2_8885", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_2_8886", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_2_8887", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_2_8888", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_2_8889", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_2_8890", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acute and chronic renal failure"}, {"id": "6671350_2_8891", "context": "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure.", "question": "adverse event. Treatment, cephalosporin or moxalactam antibiotics. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_2_8892", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vitamin D"}, {"id": "9865241_2_8893", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_2_8894", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9865241_2_8895", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9865241_2_8896", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_2_8897", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9865241_2_8898", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9865241_2_8899", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "adverse event. Treatment, vitamin D. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9865241_2_8900", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Pamidronate"}, {"id": "9865241_2_8901", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "9865241_2_8902", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "9865241_2_8903", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "9865241_2_8904", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9865241_2_8905", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "9865241_2_8906", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "hypercalcemia"}, {"id": "9865241_2_8907", "context": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning.", "question": "potential therapeutic event. Treatment, Pamidronate. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "17090724_3_8908", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17090724_3_8909", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17090724_3_8910", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17090724_3_8911", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17090724_3_8912", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17090724_3_8913", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "amphotericin B deoxycholate"}, {"id": "17090724_3_8914", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17090724_3_8915", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17090724_3_8916", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17090724_3_8917", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17090724_3_8918", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17090724_3_8919", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17090724_3_8920", "context": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient.", "question": "adverse event. Treatment, amphotericin B deoxycholate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_1_8921", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Subject, an infant with congenital heart disease. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "infant"}, {"id": "16132305_1_8922", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Subject, an infant with congenital heart disease. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "16132305_1_8923", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Subject, an infant with congenital heart disease. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16132305_1_8924", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Subject, an infant with congenital heart disease. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16132305_1_8925", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Subject, an infant with congenital heart disease. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "congenital heart disease"}, {"id": "16132305_1_8926", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Captopril"}, {"id": "16132305_1_8927", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_1_8928", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16132305_1_8929", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16132305_1_8930", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_1_8931", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16132305_1_8932", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16132305_1_8933", "context": "Captopril-induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease.", "question": "adverse event. Treatment, Captopril. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15836666_1_8934", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fentanyl"}, {"id": "15836666_1_8935", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15836666_1_8936", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15836666_1_8937", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15836666_1_8938", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15836666_1_8939", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "Chronic"}, {"id": "15836666_1_8940", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15836666_1_8941", "context": "Chronic fentanyl application induces adrenocortical insufficiency.", "question": "adverse event. Treatment, Chronic fentanyl. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16132305_5_8942", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "captopril; steroids"}, {"id": "16132305_5_8943", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16132305_5_8944", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16132305_5_8945", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16132305_5_8946", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16132305_5_8947", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16132305_5_8948", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "eosinophilia; radiographic abnormalities"}, {"id": "16132305_5_8949", "context": "After discontinuing captopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and radiographic abnormalities both resolved.", "question": "potential therapeutic event. Treatment, discontinuing captopril and starting systemic steroids. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12927328_1_8950", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Subject, a woman schizophrenic patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12927328_1_8951", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Subject, a woman schizophrenic patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12927328_1_8952", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Subject, a woman schizophrenic patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12927328_1_8953", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Subject, a woman schizophrenic patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12927328_1_8954", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Subject, a woman schizophrenic patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12927328_1_8955", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clozapine"}, {"id": "12927328_1_8956", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12927328_1_8957", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12927328_1_8958", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12927328_1_8959", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12927328_1_8960", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12927328_1_8961", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenic"}, {"id": "12927328_1_8962", "context": "We present a surprising case of a woman schizophrenic patient treated with clozapine suffering from EPS.", "question": "adverse event. Treatment, clozapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17016002_3_8963", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Subject, this patient's. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "17016002_3_8964", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Subject, this patient's. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "17016002_3_8965", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Subject, this patient's. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17016002_3_8966", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Subject, this patient's. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17016002_3_8967", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Subject, this patient's. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17016002_3_8968", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "calcium stearate"}, {"id": "17016002_3_8969", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17016002_3_8970", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17016002_3_8971", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17016002_3_8972", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17016002_3_8973", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17016002_3_8974", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17016002_3_8975", "context": "Therefore, we concluded that this patient's pulmonary disease was caused by calcium stearate, an additive for an antihistaminic drug.", "question": "adverse event. Treatment, calcium stearate; an additive for an antihistaminic drug. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3343188_2_8976", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Subject, man, dogs, and cats. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3343188_2_8977", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Subject, man, dogs, and cats. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3343188_2_8978", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Subject, man, dogs, and cats. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3343188_2_8979", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Subject, man, dogs, and cats. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3343188_2_8980", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Subject, man, dogs, and cats. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3343188_2_8981", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Benzocaine"}, {"id": "3343188_2_8982", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3343188_2_8983", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3343188_2_8984", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3343188_2_8985", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3343188_2_8986", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3343188_2_8987", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3343188_2_8988", "context": "Benzocaine-induced methemoglobinemia has been reported in man, dogs, and cats.", "question": "adverse event. Treatment, Benzocaine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8151270_3_8989", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Subject, HIV-1-infected patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8151270_3_8990", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Subject, HIV-1-infected patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8151270_3_8991", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Subject, HIV-1-infected patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "8151270_3_8992", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Subject, HIV-1-infected patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8151270_3_8993", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Subject, HIV-1-infected patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8151270_3_8994", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "didanosine"}, {"id": "8151270_3_8995", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8151270_3_8996", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8151270_3_8997", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8151270_3_8998", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8151270_3_8999", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8151270_3_9000", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "HIV-1"}, {"id": "8151270_3_9001", "context": "We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine (ddI).", "question": "adverse event. Treatment, didanosine (ddI). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11352235_2_9002", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "11352235_2_9003", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11352235_2_9004", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11352235_2_9005", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11352235_2_9006", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11352235_2_9007", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11352235_2_9008", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "11352235_2_9009", "context": "Leflunomide-associated weight loss in rheumatoid arthritis.", "question": "adverse event. Treatment, Leflunomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11450788_1_9010", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11450788_1_9011", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11450788_1_9012", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11450788_1_9013", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11450788_1_9014", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Subject, case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11450788_1_9015", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Antiretroviral"}, {"id": "11450788_1_9016", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11450788_1_9017", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11450788_1_9018", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11450788_1_9019", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11450788_1_9020", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11450788_1_9021", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11450788_1_9022", "context": "Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.", "question": "adverse event. Treatment, Antiretroviral. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1756352_1_9023", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Subject, A woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "1756352_1_9024", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Subject, A woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "1756352_1_9025", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Subject, A woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "1756352_1_9026", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Subject, A woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "1756352_1_9027", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Subject, A woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "1756352_1_9028", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenelzine"}, {"id": "1756352_1_9029", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1756352_1_9030", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1756352_1_9031", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1756352_1_9032", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1756352_1_9033", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1756352_1_9034", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1756352_1_9035", "context": "A woman developed delusional parasitosis when taking phenelzine.", "question": "adverse event. Treatment, phenelzine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8308951_4_9036", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "warfarin"}, {"id": "8308951_4_9037", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8308951_4_9038", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8308951_4_9039", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "Percutaneous absorption"}, {"id": "8308951_4_9040", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8308951_4_9041", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8308951_4_9042", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8308951_4_9043", "context": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "question": "adverse event. Treatment, Percutaneous absorption of warfarin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10752888_2_9044", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrofurantoin"}, {"id": "10752888_2_9045", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10752888_2_9046", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10752888_2_9047", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10752888_2_9048", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10752888_2_9049", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10752888_2_9050", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10752888_2_9051", "context": "We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.", "question": "adverse event. Treatment, nitrofurantoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17619811_4_9052", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Colchicine"}, {"id": "17619811_4_9053", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17619811_4_9054", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17619811_4_9055", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17619811_4_9056", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17619811_4_9057", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17619811_4_9058", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17619811_4_9059", "context": "Colchicine-induced rhabdomyolysis.", "question": "adverse event. Treatment, Colchicine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16678268_2_9060", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "16678268_2_9061", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16678268_2_9062", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16678268_2_9063", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16678268_2_9064", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "three weeks"}, {"id": "16678268_2_9065", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16678268_2_9066", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Crohn's disease"}, {"id": "16678268_2_9067", "context": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn's disease (CD).", "question": "adverse event. Treatment, infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_7_9068", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Subject, each patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "10573314_7_9069", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Subject, each patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "10573314_7_9070", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Subject, each patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10573314_7_9071", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Subject, each patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10573314_7_9072", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Subject, each patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10573314_7_9073", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tolterodine"}, {"id": "10573314_7_9074", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_7_9075", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10573314_7_9076", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10573314_7_9077", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "10-14 days later."}, {"id": "10573314_7_9078", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10573314_7_9079", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_7_9080", "context": "In each patient, the initiation of tolterodine was associated with a significant increase in the patient's INR measured 10-14 days later.", "question": "adverse event. Treatment, the initiation of tolterodine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_4_9081", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Subject, Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9007910_4_9082", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Subject, Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9007910_4_9083", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Subject, Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "3% or more"}, {"id": "9007910_4_9084", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Subject, Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9007910_4_9085", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Subject, Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "Genetic deficiencies in DPD"}, {"id": "9007910_4_9086", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-FU"}, {"id": "9007910_4_9087", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "standard doses"}, {"id": "9007910_4_9088", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_4_9089", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9007910_4_9090", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_4_9091", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_4_9092", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "cancer"}, {"id": "9007910_4_9093", "context": "DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for 5-FU catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.", "question": "adverse event. Treatment, standard doses of 5-FU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_11_9094", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "moxifloxacin; acetaminophen"}, {"id": "21515865_11_9095", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "21515865_11_9096", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "21515865_11_9097", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "21515865_11_9098", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_11_9099", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "21515865_11_9100", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_11_9101", "context": "According to the Drug Interaction Probability Scale, the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use.", "question": "adverse event. Treatment, concomitant acetaminophen and moxifloxacin use. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "acetaminophen; moxifloxacin"}, {"id": "17921794_1_9102", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "colchicine; statin"}, {"id": "17921794_1_9103", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17921794_1_9104", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17921794_1_9105", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17921794_1_9106", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17921794_1_9107", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17921794_1_9108", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17921794_1_9109", "context": "Both colchicine and statin therapy may be associated with myopathy, which usually occurs after several months of therapy.", "question": "adverse event. Treatment, colchicine and statin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "colchicine; statin"}, {"id": "6671350_1_9110", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cephalosporins"}, {"id": "6671350_1_9111", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6671350_1_9112", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6671350_1_9113", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6671350_1_9114", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6671350_1_9115", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6671350_1_9116", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6671350_1_9117", "context": "Cephalosporins are most likely associated with Vitamin K deficiency.", "question": "adverse event. Treatment, Cephalosporins. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18042092_2_9118", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "glatiramer acetate"}, {"id": "18042092_2_9119", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18042092_2_9120", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18042092_2_9121", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "subcutaneous injection"}, {"id": "18042092_2_9122", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18042092_2_9123", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18042092_2_9124", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18042092_2_9125", "context": "Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate.", "question": "adverse event. Treatment, subcutaneous injection of glatiramer acetate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_3_9126", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Subject, a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "21-year-old"}, {"id": "3084231_3_9127", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Subject, a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "3084231_3_9128", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Subject, a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3084231_3_9129", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Subject, a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3084231_3_9130", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Subject, a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "insidious progressive decline in global cognitive abilities"}, {"id": "3084231_3_9131", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valproic acid"}, {"id": "3084231_3_9132", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3084231_3_9133", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3084231_3_9134", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3084231_3_9135", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3084231_3_9136", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3084231_3_9137", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "epilepsy"}, {"id": "3084231_3_9138", "context": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "question": "adverse event. Treatment, valproic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "17316891_1_9139", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Subject, a 50-year-old woman with advanced non-small cell lung cancer. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "50-year-old"}, {"id": "17316891_1_9140", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Subject, a 50-year-old woman with advanced non-small cell lung cancer. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "17316891_1_9141", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Subject, a 50-year-old woman with advanced non-small cell lung cancer. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "17316891_1_9142", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Subject, a 50-year-old woman with advanced non-small cell lung cancer. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "17316891_1_9143", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Subject, a 50-year-old woman with advanced non-small cell lung cancer. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "17316891_1_9144", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cisplatin; gemcitabine"}, {"id": "17316891_1_9145", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17316891_1_9146", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17316891_1_9147", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "17316891_1_9148", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17316891_1_9149", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17316891_1_9150", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "lung cancer"}, {"id": "17316891_1_9151", "context": "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy.", "question": "adverse event. Treatment, cisplatin and gemcitabine chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "cisplatin; gemcitabine"}, {"id": "18628507_3_9152", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "VRC"}, {"id": "18628507_3_9153", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18628507_3_9154", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18628507_3_9155", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18628507_3_9156", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18628507_3_9157", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18628507_3_9158", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18628507_3_9159", "context": "Here, we report a case of angio-oedema associated with VRC therapy.", "question": "adverse event. Treatment, VRC therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_2_9160", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thalidomide"}, {"id": "18037876_2_9161", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_2_9162", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_2_9163", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_2_9164", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_2_9165", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "during"}, {"id": "18037876_2_9166", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18037876_2_9167", "context": "Multiple syncopal episodes started to occur during thalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.", "question": "adverse event. Treatment, during thalidomide treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9413296_1_9168", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Subject, A 25-year-old woman; she. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "25-year-old"}, {"id": "9413296_1_9169", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Subject, A 25-year-old woman; she. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "9413296_1_9170", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Subject, A 25-year-old woman; she. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9413296_1_9171", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Subject, A 25-year-old woman; she. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9413296_1_9172", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Subject, A 25-year-old woman; she. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9413296_1_9173", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methysergide"}, {"id": "9413296_1_9174", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9413296_1_9175", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9413296_1_9176", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9413296_1_9177", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9413296_1_9178", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9413296_1_9179", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9413296_1_9180", "context": "A 25-year-old woman sought medical attention because of iliocaval manifestations of retroperitoneal fibrosis while she was taking methysergide.", "question": "adverse event. Treatment, methysergide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18569796_2_9181", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "alendronate"}, {"id": "18569796_2_9182", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18569796_2_9183", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18569796_2_9184", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18569796_2_9185", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18569796_2_9186", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18569796_2_9187", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18569796_2_9188", "context": "Nodular scleritis following alendronate therapy.", "question": "adverse event. Treatment, alendronate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10573314_8_9189", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Subject, both patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "10573314_8_9190", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Subject, both patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "10573314_8_9191", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Subject, both patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "10573314_8_9192", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Subject, both patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "10573314_8_9193", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Subject, both patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "10573314_8_9194", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "tolterodine"}, {"id": "10573314_8_9195", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10573314_8_9196", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10573314_8_9197", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10573314_8_9198", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10573314_8_9199", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10573314_8_9200", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "10573314_8_9201", "context": "Thus, tolterodine was ineffective in both patients and was discontinued one to two days before the elevated INRs were determined during routine clinic visits.", "question": "potential therapeutic event. Treatment, tolterodine. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "2022118_1_9202", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Subject, patient who is purging. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "2022118_1_9203", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Subject, patient who is purging. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "2022118_1_9204", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Subject, patient who is purging. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "2022118_1_9205", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Subject, patient who is purging. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "2022118_1_9206", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Subject, patient who is purging. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "2022118_1_9207", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "lithium"}, {"id": "2022118_1_9208", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "2022118_1_9209", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "2022118_1_9210", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "2022118_1_9211", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "2022118_1_9212", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "2022118_1_9213", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "2022118_1_9214", "context": "However, the use of lithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of cardiac toxicity.", "question": "adverse event. Treatment, lithium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "681921_2_9215", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "disulfiram"}, {"id": "681921_2_9216", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "681921_2_9217", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "681921_2_9218", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "681921_2_9219", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "681921_2_9220", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "681921_2_9221", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "681921_2_9222", "context": "Neurophysiological mechanisms which aid in elucidating the role of disulfiram in the etiology of catatonia are discussed.", "question": "adverse event. Treatment, disulfiram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10717401_1_9223", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "10717401_1_9224", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10717401_1_9225", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10717401_1_9226", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10717401_1_9227", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10717401_1_9228", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10717401_1_9229", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10717401_1_9230", "context": "Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.", "question": "adverse event. Treatment, L-asparaginase treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4063627_3_9231", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Subject, This case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "4063627_3_9232", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Subject, This case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "4063627_3_9233", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Subject, This case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "4063627_3_9234", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Subject, This case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "4063627_3_9235", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Subject, This case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "selective IgA deficiency"}, {"id": "4063627_3_9236", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fenclofenac; aurothiomalate; sulphasalazine"}, {"id": "4063627_3_9237", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4063627_3_9238", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4063627_3_9239", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4063627_3_9240", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4063627_3_9241", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4063627_3_9242", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4063627_3_9243", "context": "This case demonstrates the association of selective IgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and sulphasalazine.", "question": "adverse event. Treatment, fenclofenac; aurothiomalate; sulphasalazine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18262450_14_9244", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "oxycodone; gabapentin"}, {"id": "18262450_14_9245", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_14_9246", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "18262450_14_9247", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "18262450_14_9248", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_14_9249", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "18262450_14_9250", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "painful diabetic neuropathy"}, {"id": "18262450_14_9251", "context": "This study provides the first evidence that co-administration of prolonged-release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy.", "question": "potential therapeutic event. Treatment, co-administration of prolonged-release oxycodone and existing gabapentin therapy. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": "oxycodone; gabapentin"}, {"id": "17504225_4_9252", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clarithromycin; sirolimus"}, {"id": "17504225_4_9253", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "17504225_4_9254", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "17504225_4_9255", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "17504225_4_9256", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "17504225_4_9257", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "17504225_4_9258", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "17504225_4_9259", "context": "In the present case report, the concomitant administration of clarithromycin and sirolimus determined impressive increase of sirolimus trough blood concentrations from 6.2 up to 54 ng/mL and this increase was associated with an acute impairment of renal function, almost completely reversed upon both drugs discontinuation.", "question": "adverse event. Treatment, the concomitant administration of clarithromycin and sirolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "clarithromycin; sirolimus"}, {"id": "10190739_1_9260", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "riluzole"}, {"id": "10190739_1_9261", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10190739_1_9262", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10190739_1_9263", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10190739_1_9264", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10190739_1_9265", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10190739_1_9266", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10190739_1_9267", "context": "In one case, the readministration of riluzole was followed by the relapse of hepatitis.", "question": "adverse event. Treatment, riluzole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16018164_3_9268", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Pseudoephedrine"}, {"id": "16018164_3_9269", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16018164_3_9270", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16018164_3_9271", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16018164_3_9272", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16018164_3_9273", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16018164_3_9274", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16018164_3_9275", "context": "Pseudoephedrine-induced hemorrhage associated with a cerebral vascular malformation.", "question": "adverse event. Treatment, Pseudoephedrine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16490518_1_9276", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Subject, a 34-year-old man without a history of glaucoma. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "34-year-old"}, {"id": "16490518_1_9277", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Subject, a 34-year-old man without a history of glaucoma. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "16490518_1_9278", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Subject, a 34-year-old man without a history of glaucoma. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16490518_1_9279", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Subject, a 34-year-old man without a history of glaucoma. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16490518_1_9280", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Subject, a 34-year-old man without a history of glaucoma. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "16490518_1_9281", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "corticosteroid; triamcinolone acetate"}, {"id": "16490518_1_9282", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16490518_1_9283", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16490518_1_9284", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravitreal injection"}, {"id": "16490518_1_9285", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16490518_1_9286", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16490518_1_9287", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16490518_1_9288", "context": "PURPOSE: To report a case of severe corticosteroid-induced glaucoma after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.", "question": "adverse event. Treatment, intravitreal injection of triamcinolone acetate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7369302_2_9289", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "quinine"}, {"id": "7369302_2_9290", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7369302_2_9291", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7369302_2_9292", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7369302_2_9293", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7369302_2_9294", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7369302_2_9295", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7369302_2_9296", "context": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "question": "adverse event. Treatment, quinine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_6_9297", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "levomepromazine"}, {"id": "10682234_6_9298", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "100 mg"}, {"id": "10682234_6_9299", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10682234_6_9300", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10682234_6_9301", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_6_9302", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "Two days"}, {"id": "10682234_6_9303", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10682234_6_9304", "context": "Two days' administration of levomepromazine 100 mg led him to a coma for 2 days.", "question": "adverse event. Treatment, Two days' administration of levomepromazine 100 mg. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9777751_1_9305", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Methimazole; granulocyte colony-stimulating factor"}, {"id": "9777751_1_9306", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9777751_1_9307", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9777751_1_9308", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9777751_1_9309", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9777751_1_9310", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9777751_1_9311", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9777751_1_9312", "context": "Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.", "question": "adverse event. Treatment, Methimazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18751717_2_9313", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "triamcinolone acetonide (IVTA)"}, {"id": "18751717_2_9314", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18751717_2_9315", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18751717_2_9316", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "18751717_2_9317", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18751717_2_9318", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18751717_2_9319", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18751717_2_9320", "context": "BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis (ASPPC) that developed after intravitreal triamcinolone acetonide (IVTA) injection.", "question": "adverse event. Treatment, intravitreal triamcinolone acetonide (IVTA) injection. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14522628_2_9321", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ganciclovir"}, {"id": "14522628_2_9322", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14522628_2_9323", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14522628_2_9324", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14522628_2_9325", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14522628_2_9326", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14522628_2_9327", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14522628_2_9328", "context": "Skin rash and splinter hemorrhages from ganciclovir.", "question": "adverse event. Treatment, ganciclovir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_5_9329", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Subject, pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "pediatric"}, {"id": "15368548_5_9330", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Subject, pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15368548_5_9331", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Subject, pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15368548_5_9332", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Subject, pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15368548_5_9333", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Subject, pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "leukemia"}, {"id": "15368548_5_9334", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": ""}, {"id": "15368548_5_9335", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_5_9336", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_5_9337", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_5_9338", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_5_9339", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_5_9340", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "L-asparaginase-induced necrotizing pancreatitis"}, {"id": "15368548_5_9341", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, percutaneous drainage. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_5_9342", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "15368548_5_9343", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_5_9344", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_5_9345", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_5_9346", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_5_9347", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_5_9348", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15368548_5_9349", "context": "We present a pediatric patient with leukemia and a severe, L-asparaginase-induced necrotizing pancreatitis, treated successfully with percutaneous drainage used to flush the infected necrotic parts.", "question": "adverse event. Treatment, L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11804071_3_9350", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "INH"}, {"id": "11804071_3_9351", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11804071_3_9352", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11804071_3_9353", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11804071_3_9354", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11804071_3_9355", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11804071_3_9356", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11804071_3_9357", "context": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.", "question": "adverse event. Treatment, INH. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_3_9358", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ifosfamide"}, {"id": "10646879_3_9359", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_3_9360", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10646879_3_9361", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10646879_3_9362", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_3_9363", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10646879_3_9364", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10646879_3_9365", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "adverse event. Treatment, ifosfamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10646879_3_9366", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "MB"}, {"id": "10646879_3_9367", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10646879_3_9368", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10646879_3_9369", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10646879_3_9370", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10646879_3_9371", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10646879_3_9372", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "ifosfamide-induced encephalopathy"}, {"id": "10646879_3_9373", "context": "We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.", "question": "potential therapeutic event. Treatment, MB. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18354950_2_9374", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "low-dose carbamazepine"}, {"id": "18354950_2_9375", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_2_9376", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_2_9377", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_2_9378", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_2_9379", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_2_9380", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_2_9381", "context": "Hyponatraemia during low-dose carbamazepine therapy.", "question": "adverse event. Treatment, low-dose carbamazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16697705_1_9382", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "capecitabine"}, {"id": "16697705_1_9383", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16697705_1_9384", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16697705_1_9385", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16697705_1_9386", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16697705_1_9387", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16697705_1_9388", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16697705_1_9389", "context": "Acute coronary syndrome induced by capecitabine therapy.", "question": "adverse event. Treatment, capecitabine therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_1_9390", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Subject, A case. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "3171334_1_9391", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Subject, A case. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "3171334_1_9392", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Subject, A case. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "3171334_1_9393", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Subject, A case. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "3171334_1_9394", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Subject, A case. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "3171334_1_9395", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine"}, {"id": "3171334_1_9396", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "a single dose"}, {"id": "3171334_1_9397", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_1_9398", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_1_9399", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_1_9400", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_1_9401", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_1_9402", "context": "A case of severe visual loss following a single dose of vincristine is described.", "question": "adverse event. Treatment, a single dose of vincristine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_3_9403", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Subject, young woman with SLE and thrombocytopenia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "16357738_3_9404", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Subject, young woman with SLE and thrombocytopenia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "16357738_3_9405", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Subject, young woman with SLE and thrombocytopenia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "16357738_3_9406", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Subject, young woman with SLE and thrombocytopenia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "16357738_3_9407", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Subject, young woman with SLE and thrombocytopenia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "thrombocytopenia"}, {"id": "16357738_3_9408", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine"}, {"id": "16357738_3_9409", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_3_9410", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_3_9411", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_3_9412", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_3_9413", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_3_9414", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "SLE"}, {"id": "16357738_3_9415", "context": "We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and seizure after receiving cyclosporine.", "question": "adverse event. Treatment, cyclosporine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12507063_1_9416", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Subject, patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12507063_1_9417", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Subject, patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12507063_1_9418", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Subject, patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12507063_1_9419", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Subject, patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12507063_1_9420", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Subject, patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12507063_1_9421", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gabapentin"}, {"id": "12507063_1_9422", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "withdrawal"}, {"id": "12507063_1_9423", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12507063_1_9424", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12507063_1_9425", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12507063_1_9426", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12507063_1_9427", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12507063_1_9428", "context": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.", "question": "adverse event. Treatment, secondary to gabapentin withdrawal. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "4014301_2_9429", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "insulin"}, {"id": "4014301_2_9430", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "4014301_2_9431", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "4014301_2_9432", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "4014301_2_9433", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "4014301_2_9434", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "4014301_2_9435", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "4014301_2_9436", "context": "Self-limited edema is a well-recognized complication of insulin therapy.", "question": "adverse event. Treatment, insulin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15061230_1_9437", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Subject, these patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "15061230_1_9438", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Subject, these patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "15061230_1_9439", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Subject, these patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "15061230_1_9440", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Subject, these patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "15061230_1_9441", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Subject, these patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "15061230_1_9442", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "dexamethasone"}, {"id": "15061230_1_9443", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15061230_1_9444", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15061230_1_9445", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15061230_1_9446", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15061230_1_9447", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15061230_1_9448", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15061230_1_9449", "context": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients.", "question": "adverse event. Treatment, dexamethasone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12397859_1_9450", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12397859_1_9451", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12397859_1_9452", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12397859_1_9453", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12397859_1_9454", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12397859_1_9455", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nefazodone"}, {"id": "12397859_1_9456", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12397859_1_9457", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12397859_1_9458", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12397859_1_9459", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12397859_1_9460", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12397859_1_9461", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12397859_1_9462", "context": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone, an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.", "question": "adverse event. Treatment, nefazodone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3156465_1_9463", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Isotretinoin"}, {"id": "3156465_1_9464", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3156465_1_9465", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3156465_1_9466", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3156465_1_9467", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3156465_1_9468", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3156465_1_9469", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "acne"}, {"id": "3156465_1_9470", "context": "Isotretinoin, a drug used for the treatment of acne, has been shown to have teratogenic effects.", "question": "adverse event. Treatment, Isotretinoin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_6_9471", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zuclopenthixol"}, {"id": "12022905_6_9472", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_6_9473", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_6_9474", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12022905_6_9475", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_6_9476", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_6_9477", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12022905_6_9478", "context": "The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.", "question": "adverse event. Treatment, zuclopenthixol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6572542_4_9479", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Subject, Two patients; chronic myeloid leukemia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6572542_4_9480", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Subject, Two patients; chronic myeloid leukemia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6572542_4_9481", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Subject, Two patients; chronic myeloid leukemia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "6572542_4_9482", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Subject, Two patients; chronic myeloid leukemia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6572542_4_9483", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Subject, Two patients; chronic myeloid leukemia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6572542_4_9484", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CCNU"}, {"id": "6572542_4_9485", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "1100 mg/m2; 1240 mg/m2"}, {"id": "6572542_4_9486", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_4_9487", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_4_9488", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_4_9489", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_4_9490", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic myeloid leukemia"}, {"id": "6572542_4_9491", "context": "Two patients treated for chronic myeloid leukemia with high doses of CCNU (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.", "question": "adverse event. Treatment, CCNU (1100 mg/m2 and 1240 mg/m2, respectively). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11724089_1_9492", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ofloxacin"}, {"id": "11724089_1_9493", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11724089_1_9494", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11724089_1_9495", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11724089_1_9496", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11724089_1_9497", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11724089_1_9498", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11724089_1_9499", "context": "CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.", "question": "adverse event. Treatment, ofloxacin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18755414_3_9500", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Subject, Our case is the second one. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18755414_3_9501", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Subject, Our case is the second one. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18755414_3_9502", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Subject, Our case is the second one. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "second"}, {"id": "18755414_3_9503", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Subject, Our case is the second one. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18755414_3_9504", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Subject, Our case is the second one. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18755414_3_9505", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "aspirin"}, {"id": "18755414_3_9506", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18755414_3_9507", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18755414_3_9508", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18755414_3_9509", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18755414_3_9510", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18755414_3_9511", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18755414_3_9512", "context": "Our case is the second one in which hemorrhage from a meningioma may have been induced by aspirin prophylaxis.", "question": "adverse event. Treatment, aspirin prophylaxis. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10225085_2_9513", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "bupivacaine; lidocaine"}, {"id": "10225085_2_9514", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10225085_2_9515", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10225085_2_9516", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "10225085_2_9517", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10225085_2_9518", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10225085_2_9519", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10225085_2_9520", "context": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.", "question": "adverse event. Treatment, axillary block with bupivacaine and additional injection of lidocaine in the operative field. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "lidocaine; bupivacaine"}, {"id": "10812579_3_9521", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "morphine"}, {"id": "10812579_3_9522", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10812579_3_9523", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10812579_3_9524", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10812579_3_9525", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10812579_3_9526", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10812579_3_9527", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10812579_3_9528", "context": "Nonconvulsive status epilepticus: the role of morphine and its antagonist.", "question": "adverse event. Treatment, morphine and its antagonist. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8579054_1_9529", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Subject, two patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8579054_1_9530", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Subject, two patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8579054_1_9531", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Subject, two patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "8579054_1_9532", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Subject, two patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8579054_1_9533", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Subject, two patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8579054_1_9534", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "hydroxyurea"}, {"id": "8579054_1_9535", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8579054_1_9536", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8579054_1_9537", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8579054_1_9538", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8579054_1_9539", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8579054_1_9540", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "essential thrombocythemia"}, {"id": "8579054_1_9541", "context": "Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.", "question": "adverse event. Treatment, hydroxyurea. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10698143_1_9542", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "ibuprofen; naloxone"}, {"id": "10698143_1_9543", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10698143_1_9544", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10698143_1_9545", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "10698143_1_9546", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10698143_1_9547", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10698143_1_9548", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "Central nervous system manifestations"}, {"id": "10698143_1_9549", "context": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.", "question": "potential therapeutic event. Treatment, naloxone. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "20465622_2_9550", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sirolimus"}, {"id": "20465622_2_9551", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20465622_2_9552", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20465622_2_9553", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20465622_2_9554", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20465622_2_9555", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20465622_2_9556", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20465622_2_9557", "context": "BACKGROUND: Aphthous stomatitis, a common mucocutaneous disorder, is a well accepted complication of sirolimus therapy.", "question": "adverse event. Treatment, sirolimus. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_4_9558", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propafenone; citalopram; propafenone"}, {"id": "18675768_4_9559", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_4_9560", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_4_9561", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_4_9562", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_4_9563", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_4_9564", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_4_9565", "context": "The goal of this article was to describe a potential drug-drug interaction between propafenone and citalopram, which caused symptoms of propafenone adverse effects.", "question": "adverse event. Treatment, drug-drug interaction between propafenone and citalopram. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "propafenone; citalopram"}, {"id": "7949255_1_9566", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Subject, one out of 23 patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "7949255_1_9567", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Subject, one out of 23 patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7949255_1_9568", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Subject, one out of 23 patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "one out of 23"}, {"id": "7949255_1_9569", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Subject, one out of 23 patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7949255_1_9570", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Subject, one out of 23 patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7949255_1_9571", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "7949255_1_9572", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "high-dose"}, {"id": "7949255_1_9573", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7949255_1_9574", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "7949255_1_9575", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7949255_1_9576", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7949255_1_9577", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "osteogenic sarcoma"}, {"id": "7949255_1_9578", "context": "Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high-dose methotrexate (HD-MTX) for osteogenic sarcoma.", "question": "adverse event. Treatment, chemotherapy with high-dose methotrexate (HD-MTX). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18675768_13_9579", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propafenone; citalopram; propafenone"}, {"id": "18675768_13_9580", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18675768_13_9581", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18675768_13_9582", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18675768_13_9583", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18675768_13_9584", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18675768_13_9585", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18675768_13_9586", "context": "This is the first report of a possible interaction between propafenone and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked coronary artery disease.", "question": "adverse event. Treatment, propafenone and citalopram; propafenone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "propafenone; citalopram"}, {"id": "1082426_1_9587", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vasopressin"}, {"id": "1082426_1_9588", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1082426_1_9589", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1082426_1_9590", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intraarterial"}, {"id": "1082426_1_9591", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1082426_1_9592", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1082426_1_9593", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1082426_1_9594", "context": "Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.", "question": "adverse event. Treatment, intraarterial vasopressin therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16685007_1_9595", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Subject, adult patients. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "adult"}, {"id": "16685007_1_9596", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Subject, adult patients. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "16685007_1_9597", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Subject, adult patients. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "16685007_1_9598", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Subject, adult patients. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "16685007_1_9599", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Subject, adult patients. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "16685007_1_9600", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Ciclesonide; steroid"}, {"id": "16685007_1_9601", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16685007_1_9602", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16685007_1_9603", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "oral"}, {"id": "16685007_1_9604", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16685007_1_9605", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16685007_1_9606", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "asthma"}, {"id": "16685007_1_9607", "context": "Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma.", "question": "potential therapeutic event. Treatment, Ciclesonide. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "8250714_1_9608", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Subject, Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "8250714_1_9609", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Subject, Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "8250714_1_9610", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Subject, Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Five"}, {"id": "8250714_1_9611", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Subject, Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "8250714_1_9612", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Subject, Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "8250714_1_9613", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "nitrous oxide"}, {"id": "8250714_1_9614", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8250714_1_9615", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8250714_1_9616", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8250714_1_9617", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8250714_1_9618", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8250714_1_9619", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "vitamin B12 deficiency"}, {"id": "8250714_1_9620", "context": "Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia.", "question": "adverse event. Treatment, nitrous oxide anesthesia. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12022905_1_9621", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Subject, a 31-year-old patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "31-year-old"}, {"id": "12022905_1_9622", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Subject, a 31-year-old patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12022905_1_9623", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Subject, a 31-year-old patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12022905_1_9624", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Subject, a 31-year-old patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12022905_1_9625", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Subject, a 31-year-old patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12022905_1_9626", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zuclopenthixol"}, {"id": "12022905_1_9627", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12022905_1_9628", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12022905_1_9629", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "12022905_1_9630", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12022905_1_9631", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12022905_1_9632", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "behavioral alterations"}, {"id": "12022905_1_9633", "context": "CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.", "question": "adverse event. Treatment, oral zuclopenthixol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6401771_2_9634", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Subject, patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6401771_2_9635", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Subject, patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6401771_2_9636", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Subject, patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6401771_2_9637", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Subject, patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6401771_2_9638", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Subject, patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6401771_2_9639", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mitomycin C; 5-fluorouracil"}, {"id": "6401771_2_9640", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6401771_2_9641", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6401771_2_9642", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6401771_2_9643", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6401771_2_9644", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6401771_2_9645", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6401771_2_9646", "context": "Three cases of acute renal toxicity in patients receiving long-term therapy with mitomycin C and 5-fluorouracil are reported.", "question": "adverse event. Treatment, mitomycin C and 5-fluorouracil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9870779_1_9647", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Subject, A 40-year-old man with a long standing history of rheumatoid arthritis. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "40-year-old"}, {"id": "9870779_1_9648", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Subject, A 40-year-old man with a long standing history of rheumatoid arthritis. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "9870779_1_9649", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Subject, A 40-year-old man with a long standing history of rheumatoid arthritis. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9870779_1_9650", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Subject, A 40-year-old man with a long standing history of rheumatoid arthritis. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9870779_1_9651", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Subject, A 40-year-old man with a long standing history of rheumatoid arthritis. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9870779_1_9652", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "MTX"}, {"id": "9870779_1_9653", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9870779_1_9654", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9870779_1_9655", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9870779_1_9656", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "6 month"}, {"id": "9870779_1_9657", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9870779_1_9658", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "rheumatoid arthritis"}, {"id": "9870779_1_9659", "context": "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis.", "question": "adverse event. Treatment, MTX over a 6 month period. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9627209_1_9660", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Subject, In case 1. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9627209_1_9661", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Subject, In case 1. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9627209_1_9662", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Subject, In case 1. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9627209_1_9663", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Subject, In case 1. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9627209_1_9664", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Subject, In case 1. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9627209_1_9665", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "sertraline"}, {"id": "9627209_1_9666", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "daily dose of 25 mg"}, {"id": "9627209_1_9667", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9627209_1_9668", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9627209_1_9669", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9627209_1_9670", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9627209_1_9671", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9627209_1_9672", "context": "In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.", "question": "adverse event. Treatment, a total daily dose of 25 mg sertraline. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7355327_3_9673", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "propranolol; propranolol"}, {"id": "7355327_3_9674", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7355327_3_9675", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7355327_3_9676", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7355327_3_9677", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7355327_3_9678", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7355327_3_9679", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7355327_3_9680", "context": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.", "question": "adverse event. Treatment, propranolol. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6362443_2_9681", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Subject, A depressed woman with no history of bipolar illness. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6362443_2_9682", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Subject, A depressed woman with no history of bipolar illness. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "6362443_2_9683", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Subject, A depressed woman with no history of bipolar illness. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6362443_2_9684", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Subject, A depressed woman with no history of bipolar illness. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6362443_2_9685", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Subject, A depressed woman with no history of bipolar illness. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6362443_2_9686", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "fluoxetine"}, {"id": "6362443_2_9687", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6362443_2_9688", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6362443_2_9689", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6362443_2_9690", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6362443_2_9691", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6362443_2_9692", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "depressed"}, {"id": "6362443_2_9693", "context": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine.", "question": "adverse event. Treatment, fluoxetine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6725214_2_9694", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "trazodone"}, {"id": "6725214_2_9695", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6725214_2_9696", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6725214_2_9697", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6725214_2_9698", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6725214_2_9699", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6725214_2_9700", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6725214_2_9701", "context": "Priapism associated with trazodone therapy: case report.", "question": "adverse event. Treatment, trazodone therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_3_9702", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "7639655_3_9703", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_3_9704", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_3_9705", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_3_9706", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_3_9707", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_3_9708", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "7639655_3_9709", "context": "OBJECTIVE: To report the occurrence of anterior ischemic optic neuropathy as a complication of treatment with interferon alfa and to consider the possible underlying mechanisms for this association.", "question": "adverse event. Treatment, interferon alfa. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8850251_4_9710", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "mequitazine"}, {"id": "8850251_4_9711", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "low dosage"}, {"id": "8850251_4_9712", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8850251_4_9713", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8850251_4_9714", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8850251_4_9715", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8850251_4_9716", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8850251_4_9717", "context": "Mequitazine seemed to play a part similar to chlorpromazine, and absence of mequitazine-induced photosensitivity may be due to a relatively low dosage of the drug.", "question": "adverse event. Treatment, mequitazine; due to a relatively low dosage of the drug. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_2_9718", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentamidine"}, {"id": "15927910_2_9719", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_2_9720", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_2_9721", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_2_9722", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_2_9723", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_2_9724", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_2_9725", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15927910_2_9726", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pentamidine"}, {"id": "15927910_2_9727", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15927910_2_9728", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15927910_2_9729", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15927910_2_9730", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15927910_2_9731", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15927910_2_9732", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15927910_2_9733", "context": "Although various manifestations of pentamidine-induced cardiotoxicity have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.", "question": "adverse event. Treatment, pentamidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23115227_6_9734", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Subject, the patient. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "23115227_6_9735", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Subject, the patient. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "23115227_6_9736", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Subject, the patient. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23115227_6_9737", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Subject, the patient. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "23115227_6_9738", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Subject, the patient. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "23115227_6_9739", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin; emtricitabine"}, {"id": "23115227_6_9740", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "13.3 mg"}, {"id": "23115227_6_9741", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "weekly"}, {"id": "23115227_6_9742", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "23115227_6_9743", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23115227_6_9744", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23115227_6_9745", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "23115227_6_9746", "context": "The mean weekly warfarin dose while the patient was receiving emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8), with a mean international normalized ratio (INR) of 2.8 (95% CI 2.5 to 3.1).", "question": "potential therapeutic event. Treatment, The mean weekly warfarin dose; emtricitabine monotherapy was 13.3 mg (95% CI 12.7 to 13.8). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "3806824_2_9747", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phentolamine; papaverine"}, {"id": "3806824_2_9748", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3806824_2_9749", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3806824_2_9750", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intracavernous self-injection"}, {"id": "3806824_2_9751", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3806824_2_9752", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3806824_2_9753", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3806824_2_9754", "context": "We report a case of penile fibrosis after intracavernous self-injection of a combination of phentolamine and papaverine.", "question": "adverse event. Treatment, intracavernous self-injection of a combination of phentolamine and papaverine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "phentolamine; papaverine"}, {"id": "6865827_3_9755", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Subject, the same patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6865827_3_9756", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Subject, the same patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6865827_3_9757", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Subject, the same patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6865827_3_9758", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Subject, the same patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6865827_3_9759", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Subject, the same patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6865827_3_9760", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methimazole; propylthiouracil"}, {"id": "6865827_3_9761", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6865827_3_9762", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6865827_3_9763", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6865827_3_9764", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6865827_3_9765", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6865827_3_9766", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6865827_3_9767", "context": "This is, to the best of our knowledge, the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient.", "question": "adverse event. Treatment, both propylthiouracil and methimazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "propylthiouracil; methimazole"}, {"id": "15522120_1_9768", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chocolate; fluoxetine; sertraline"}, {"id": "15522120_1_9769", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15522120_1_9770", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15522120_1_9771", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15522120_1_9772", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15522120_1_9773", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15522120_1_9774", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15522120_1_9775", "context": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment: case report.", "question": "adverse event. Treatment, chocolate during fluoxetine and sertraline treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "fluoxetine; chocolate; sertraline"}, {"id": "18262450_11_9776", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gabapentin; Oxycodone"}, {"id": "18262450_11_9777", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18262450_11_9778", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18262450_11_9779", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18262450_11_9780", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18262450_11_9781", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18262450_11_9782", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18262450_11_9783", "context": "Oxycodone-gabapentin co-administration was associated with less escape medication use (P = 0.03) and fewer nights of disturbed sleep (P < 0.05).", "question": "adverse event. Treatment, Oxycodone-gabapentin co-administration. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "Oxycodone; gabapentin"}, {"id": "6618859_2_9784", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenobarbital; phenytoin; fluoresone"}, {"id": "6618859_2_9785", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6618859_2_9786", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6618859_2_9787", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6618859_2_9788", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6618859_2_9789", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6618859_2_9790", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "epileptics"}, {"id": "6618859_2_9791", "context": "Gynecomastia in epileptics treated with phenobarbital, phenytoin and fluoresone: two case reports.", "question": "adverse event. Treatment, phenobarbital, phenytoin and fluoresone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "phenobarbital; phenytoin; fluoresone"}, {"id": "3542612_1_9792", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Captopril"}, {"id": "3542612_1_9793", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3542612_1_9794", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3542612_1_9795", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3542612_1_9796", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3542612_1_9797", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3542612_1_9798", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3542612_1_9799", "context": "Captopril-induced lichen planus pemphigoides with pemphigus-like features.", "question": "adverse event. Treatment, Captopril. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6873616_3_9800", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thiabendazole"}, {"id": "6873616_3_9801", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6873616_3_9802", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6873616_3_9803", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6873616_3_9804", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6873616_3_9805", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6873616_3_9806", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6873616_3_9807", "context": "The literature on thiabendazole-induced cholestasis and its association with sicca complex is reviewed.", "question": "adverse event. Treatment, thiabendazole. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8523340_2_9808", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Subject, patients with mucocutaneous reactions. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "8523340_2_9809", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Subject, patients with mucocutaneous reactions. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "8523340_2_9810", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Subject, patients with mucocutaneous reactions. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "8523340_2_9811", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Subject, patients with mucocutaneous reactions. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "8523340_2_9812", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Subject, patients with mucocutaneous reactions. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "mucocutaneous reactions"}, {"id": "8523340_2_9813", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "gold"}, {"id": "8523340_2_9814", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "very low dosage"}, {"id": "8523340_2_9815", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "8523340_2_9816", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "8523340_2_9817", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8523340_2_9818", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "8523340_2_9819", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "8523340_2_9820", "context": "How low can you go? Use of very low dosage of gold in patients with mucocutaneous reactions.", "question": "potential therapeutic event. Treatment, very low dosage of gold. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "23970584_3_9821", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Subject, A 55-year-old HIV-positive African woman. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "55-year-old"}, {"id": "23970584_3_9822", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Subject, A 55-year-old HIV-positive African woman. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": "woman"}, {"id": "23970584_3_9823", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Subject, A 55-year-old HIV-positive African woman. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "23970584_3_9824", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Subject, A 55-year-old HIV-positive African woman. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": "African"}, {"id": "23970584_3_9825", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Subject, A 55-year-old HIV-positive African woman. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": "HIV"}, {"id": "23970584_3_9826", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "triamcinolone"}, {"id": "23970584_3_9827", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_3_9828", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "23970584_3_9829", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "injection"}, {"id": "23970584_3_9830", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_3_9831", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "23970584_3_9832", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "pain relief of postherpetic neuralgia"}, {"id": "23970584_3_9833", "context": "A 55-year-old HIV-positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia.", "question": "potential therapeutic event. Treatment, a single epidural triamcinolone injection. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6731466_2_9834", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Subject, a patient; toothache. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6731466_2_9835", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Subject, a patient; toothache. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6731466_2_9836", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Subject, a patient; toothache. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6731466_2_9837", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Subject, a patient; toothache. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6731466_2_9838", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Subject, a patient; toothache. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6731466_2_9839", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zomepirac sodium"}, {"id": "6731466_2_9840", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6731466_2_9841", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6731466_2_9842", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6731466_2_9843", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6731466_2_9844", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6731466_2_9845", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "toothache"}, {"id": "6731466_2_9846", "context": "Anaphylactoid shock, disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache.", "question": "adverse event. Treatment, zomepirac sodium. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11341670_1_9847", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, three of six young female volunteers. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "11341670_1_9848", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, three of six young female volunteers. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "11341670_1_9849", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, three of six young female volunteers. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "11341670_1_9850", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, three of six young female volunteers. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11341670_1_9851", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, three of six young female volunteers. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11341670_1_9852", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "omeprazole"}, {"id": "11341670_1_9853", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11341670_1_9854", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11341670_1_9855", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11341670_1_9856", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11341670_1_9857", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11341670_1_9858", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11341670_1_9859", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, omeprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11341670_1_9860", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, two young female volunteers. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "young"}, {"id": "11341670_1_9861", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, two young female volunteers. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "female"}, {"id": "11341670_1_9862", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, two young female volunteers. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "two"}, {"id": "11341670_1_9863", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, two young female volunteers. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11341670_1_9864", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Subject, two young female volunteers. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11341670_1_9865", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pantoprazole"}, {"id": "11341670_1_9866", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11341670_1_9867", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11341670_1_9868", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11341670_1_9869", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11341670_1_9870", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11341670_1_9871", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11341670_1_9872", "context": "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.", "question": "adverse event. Treatment, pantoprazole; high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10682234_7_9873", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "levodopa"}, {"id": "10682234_7_9874", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "10682234_7_9875", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "10682234_7_9876", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "Intravenous"}, {"id": "10682234_7_9877", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10682234_7_9878", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "10682234_7_9879", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "akathisia"}, {"id": "10682234_7_9880", "context": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically.", "question": "potential therapeutic event. Treatment, Intravenous levodopa 25 mg. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "19318596_1_9881", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Subject, a child undergoing hematopoietic stem cell transplant. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "19318596_1_9882", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Subject, a child undergoing hematopoietic stem cell transplant. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "19318596_1_9883", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Subject, a child undergoing hematopoietic stem cell transplant. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "19318596_1_9884", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Subject, a child undergoing hematopoietic stem cell transplant. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "19318596_1_9885", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Subject, a child undergoing hematopoietic stem cell transplant. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "hematopoietic stem cell transplant"}, {"id": "19318596_1_9886", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Cyclosporine"}, {"id": "19318596_1_9887", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "19318596_1_9888", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "19318596_1_9889", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "19318596_1_9890", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "19318596_1_9891", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "19318596_1_9892", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "19318596_1_9893", "context": "Cyclosporine-induced pain syndrome in a child undergoing hematopoietic stem cell transplant.", "question": "adverse event. Treatment, Cyclosporine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_5_9894", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine"}, {"id": "3171334_5_9895", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "small dose"}, {"id": "3171334_5_9896", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_5_9897", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_5_9898", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_5_9899", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": "dose; single"}, {"id": "3171334_5_9900", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_5_9901", "context": "Visual loss after a single small dose of vincristine has never been reported.", "question": "adverse event. Treatment, a single small dose of vincristine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12786839_2_9902", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "salazosulfapyridine"}, {"id": "12786839_2_9903", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12786839_2_9904", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12786839_2_9905", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12786839_2_9906", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12786839_2_9907", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12786839_2_9908", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12786839_2_9909", "context": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.", "question": "adverse event. Treatment, salazosulfapyridine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "23970584_8_9910", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "raltegravir"}, {"id": "23970584_8_9911", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "23970584_8_9912", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "23970584_8_9913", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "23970584_8_9914", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "23970584_8_9915", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "23970584_8_9916", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "23970584_8_9917", "context": "Clinicians should be aware of raltegravir-induced DRESS syndrome as well as the potential for drug-drug interactions due to protease inhibitor-based therapy.", "question": "adverse event. Treatment, raltegravir. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12504711_2_9918", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Subject, patients on topical brimonidine. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12504711_2_9919", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Subject, patients on topical brimonidine. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12504711_2_9920", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Subject, patients on topical brimonidine. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12504711_2_9921", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Subject, patients on topical brimonidine. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12504711_2_9922", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Subject, patients on topical brimonidine. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12504711_2_9923", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "brimonidine"}, {"id": "12504711_2_9924", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12504711_2_9925", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12504711_2_9926", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "topical"}, {"id": "12504711_2_9927", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12504711_2_9928", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12504711_2_9929", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12504711_2_9930", "context": "CONCLUSION: Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow-up of patients on topical brimonidine.", "question": "adverse event. Treatment, topical brimonidine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12659609_9_9931", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Subject, the patient's. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12659609_9_9932", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Subject, the patient's. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12659609_9_9933", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Subject, the patient's. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12659609_9_9934", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Subject, the patient's. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12659609_9_9935", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Subject, the patient's. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12659609_9_9936", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chloroquine"}, {"id": "12659609_9_9937", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": "902 micro g/L"}, {"id": "12659609_9_9938", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12659609_9_9939", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12659609_9_9940", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12659609_9_9941", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12659609_9_9942", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "12659609_9_9943", "context": "Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.", "question": "adverse event. Treatment, chloroquine (902 micro g/L). Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20925534_15_9944", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "PPI"}, {"id": "20925534_15_9945", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20925534_15_9946", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20925534_15_9947", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20925534_15_9948", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20925534_15_9949", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20925534_15_9950", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "20925534_15_9951", "context": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole, but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI.", "question": "adverse event. Treatment, PPI. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18855892_2_9952", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methotrexate"}, {"id": "18855892_2_9953", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18855892_2_9954", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18855892_2_9955", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18855892_2_9956", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18855892_2_9957", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18855892_2_9958", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18855892_2_9959", "context": "Anaphylactic/anaphylactoid reactions to methotrexate are rare.", "question": "adverse event. Treatment, methotrexate. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1422497_3_9960", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "1% alum"}, {"id": "1422497_3_9961", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "1422497_3_9962", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "Continuous"}, {"id": "1422497_3_9963", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": "bladder irrigation"}, {"id": "1422497_3_9964", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1422497_3_9965", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "1422497_3_9966", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "bleeding urothelium"}, {"id": "1422497_3_9967", "context": "Continuous bladder irrigation of a 1% alum solution is a simple and generally safe method of chemical cautery to treat the bleeding urothelium.", "question": "potential therapeutic event. Treatment, Continuous bladder irrigation of a 1% alum solution. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "10759907_3_9968", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zolmitriptan"}, {"id": "10759907_3_9969", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10759907_3_9970", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10759907_3_9971", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "10759907_3_9972", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "10759907_3_9973", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10759907_3_9974", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "10759907_3_9975", "context": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.", "question": "adverse event. Treatment, zolmitriptan. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1756352_2_9976", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "phenelzine"}, {"id": "1756352_2_9977", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1756352_2_9978", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1756352_2_9979", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1756352_2_9980", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1756352_2_9981", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1756352_2_9982", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1756352_2_9983", "context": "Delusional parasitosis associated with phenelzine.", "question": "adverse event. Treatment, phenelzine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "8610807_2_9984", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tissue plasminogen activator"}, {"id": "8610807_2_9985", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "8610807_2_9986", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "8610807_2_9987", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "8610807_2_9988", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "8610807_2_9989", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "8610807_2_9990", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "8610807_2_9991", "context": "CONCLUSION: The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.", "question": "adverse event. Treatment, tissue plasminogen activator. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9007910_1_9992", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "5-fluorouracil"}, {"id": "9007910_1_9993", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9007910_1_9994", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9007910_1_9995", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "9007910_1_9996", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9007910_1_9997", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9007910_1_9998", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Dihydropyrimidine dehydrogenase deficiency"}, {"id": "9007910_1_9999", "context": "Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.", "question": "adverse event. Treatment, 5-fluorouracil-based chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_2_10000", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "Interferon-beta (IFN-beta); type I interferon"}, {"id": "16393774_2_10001", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_2_10002", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "16393774_2_10003", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "16393774_2_10004", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_2_10005", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "16393774_2_10006", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "multiple sclerosis"}, {"id": "16393774_2_10007", "context": "Interferon-beta (IFN-beta) is a type I interferon used in the management of multiple sclerosis.", "question": "potential therapeutic event. Treatment, Interferon-beta (IFN-beta) is a type I interferon. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "18071101_2_10008", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Quetiapine"}, {"id": "18071101_2_10009", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18071101_2_10010", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18071101_2_10011", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18071101_2_10012", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18071101_2_10013", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18071101_2_10014", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18071101_2_10015", "context": "Quetiapine-induced leucopenia and thrombocytopenia.", "question": "adverse event. Treatment, Quetiapine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_2_10016", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ranibizumab"}, {"id": "18425523_2_10017", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_2_10018", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_2_10019", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intravitreal"}, {"id": "18425523_2_10020", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_2_10021", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_2_10022", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_2_10023", "context": "CONCLUSION: Severe and sustained ocular hypertension may occur after intravitreal ranibizumab.", "question": "adverse event. Treatment, intravitreal ranibizumab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18425523_1_10024", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Subject, four patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18425523_1_10025", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Subject, four patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18425523_1_10026", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Subject, four patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "four"}, {"id": "18425523_1_10027", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Subject, four patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18425523_1_10028", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Subject, four patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18425523_1_10029", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ranibizumab"}, {"id": "18425523_1_10030", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18425523_1_10031", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18425523_1_10032", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18425523_1_10033", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18425523_1_10034", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18425523_1_10035", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18425523_1_10036", "context": "BACKGROUND: To describe the occurrence of ocular hypertension in four patients following injection of ranibizumab intravitreally.", "question": "adverse event. Treatment, ranibizumab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "20234160_2_10037", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Vancomycin"}, {"id": "20234160_2_10038", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "20234160_2_10039", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "20234160_2_10040", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "20234160_2_10041", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "20234160_2_10042", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "20234160_2_10043", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "methicillin-resistant Staphylococcus aureus infections"}, {"id": "20234160_2_10044", "context": "Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as \"red man syndrome\" and anaphylaxis.", "question": "adverse event. Treatment, Vancomycin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15093850_2_10045", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pilocarpine"}, {"id": "15093850_2_10046", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15093850_2_10047", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15093850_2_10048", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "oral"}, {"id": "15093850_2_10049", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15093850_2_10050", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15093850_2_10051", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "15093850_2_10052", "context": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.", "question": "adverse event. Treatment, pilocarpine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16357738_1_10053", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cyclosporine; cisplatin; tacrolimus; interferon-alpha"}, {"id": "16357738_1_10054", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16357738_1_10055", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16357738_1_10056", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16357738_1_10057", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16357738_1_10058", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16357738_1_10059", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16357738_1_10060", "context": "Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling RPLS.", "question": "adverse event. Treatment, immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and interferon-alpha. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12854039_2_10061", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Subject, a 62-year-old woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "62-year-old"}, {"id": "12854039_2_10062", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Subject, a 62-year-old woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12854039_2_10063", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Subject, a 62-year-old woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12854039_2_10064", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Subject, a 62-year-old woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12854039_2_10065", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Subject, a 62-year-old woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12854039_2_10066", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "recombinant interferon alpha-2a"}, {"id": "12854039_2_10067", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12854039_2_10068", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12854039_2_10069", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12854039_2_10070", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "a seven-month"}, {"id": "12854039_2_10071", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12854039_2_10072", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "chronic active hepatitis C"}, {"id": "12854039_2_10073", "context": "Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.", "question": "adverse event. Treatment, a seven-month use of recombinant interferon alpha-2a for chronic active hepatitis C.. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9550246_1_10074", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "9550246_1_10075", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9550246_1_10076", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9550246_1_10077", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9550246_1_10078", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Subject, patients with schizophrenia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9550246_1_10079", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "risperidone"}, {"id": "9550246_1_10080", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9550246_1_10081", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9550246_1_10082", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9550246_1_10083", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9550246_1_10084", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9550246_1_10085", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "schizophrenia"}, {"id": "9550246_1_10086", "context": "A syndrome of increased affect in response to risperidone among patients with schizophrenia.", "question": "adverse event. Treatment, risperidone. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16393774_3_10087", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "IFN-beta"}, {"id": "16393774_3_10088", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16393774_3_10089", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16393774_3_10090", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16393774_3_10091", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16393774_3_10092", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16393774_3_10093", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16393774_3_10094", "context": "Therapy with IFN-beta has rarely been associated with the development of autoimmune disorders.", "question": "adverse event. Treatment, IFN-beta. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18977778_1_10095", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "low-molecular-weight heparin"}, {"id": "18977778_1_10096", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18977778_1_10097", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18977778_1_10098", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18977778_1_10099", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18977778_1_10100", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18977778_1_10101", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18977778_1_10102", "context": "Despite these antithrombotic effects, the patient developed repeated venous thromboembolism during treatment with low-molecular-weight heparin.", "question": "adverse event. Treatment, treatment with low-molecular-weight heparin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18354950_1_10103", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "carbamazepine"}, {"id": "18354950_1_10104", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18354950_1_10105", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18354950_1_10106", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18354950_1_10107", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18354950_1_10108", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18354950_1_10109", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18354950_1_10110", "context": "Hyponatraemia developed after rechallenge with controlled release carbamazepine.", "question": "adverse event. Treatment, rechallenge with controlled release carbamazepine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18505911_1_10111", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Azathioprine"}, {"id": "18505911_1_10112", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18505911_1_10113", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18505911_1_10114", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18505911_1_10115", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18505911_1_10116", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18505911_1_10117", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18505911_1_10118", "context": "Azathioprine-induced warfarin resistance.", "question": "adverse event. Treatment, Azathioprine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3084231_2_10119", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "valproic acid"}, {"id": "3084231_2_10120", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3084231_2_10121", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3084231_2_10122", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3084231_2_10123", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3084231_2_10124", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3084231_2_10125", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3084231_2_10126", "context": "Reversible valproic acid-induced dementia: a case report.", "question": "adverse event. Treatment, valproic acid. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6697887_1_10127", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "verapamil"}, {"id": "6697887_1_10128", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6697887_1_10129", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6697887_1_10130", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "Parenteral"}, {"id": "6697887_1_10131", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6697887_1_10132", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6697887_1_10133", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6697887_1_10134", "context": "Parenteral-verapamil-induced sustained hypotension.", "question": "adverse event. Treatment, Parenteral-verapamil. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "1711090_6_10135", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Lp-TAE; HT"}, {"id": "1711090_6_10136", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1711090_6_10137", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1711090_6_10138", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1711090_6_10139", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1711090_6_10140", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1711090_6_10141", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1711090_6_10142", "context": "The main side-effects of Lp-TAE combined with HT were low-grade fever, localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.", "question": "adverse event. Treatment, Lp-TAE combined with HT. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "Lp-TAE; HT"}, {"id": "6738830_2_10143", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "cinepazide"}, {"id": "6738830_2_10144", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6738830_2_10145", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6738830_2_10146", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6738830_2_10147", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6738830_2_10148", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6738830_2_10149", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "parkinsonism"}, {"id": "6738830_2_10150", "context": "Unique behavioral change with cinepazide in parkinsonism.", "question": "adverse event. Treatment, cinepazide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "3171334_4_10151", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "vincristine"}, {"id": "3171334_4_10152", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "3171334_4_10153", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "3171334_4_10154", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "3171334_4_10155", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "3171334_4_10156", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "3171334_4_10157", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "3171334_4_10158", "context": "The literature of vincristine optic nerve toxicity is reviewed.", "question": "adverse event. Treatment, vincristine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7639655_4_10159", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Subject, Two patients, ages 40 and 51 years. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "ages 40 and 51 years"}, {"id": "7639655_4_10160", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Subject, Two patients, ages 40 and 51 years. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "7639655_4_10161", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Subject, Two patients, ages 40 and 51 years. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "Two"}, {"id": "7639655_4_10162", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Subject, Two patients, ages 40 and 51 years. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "7639655_4_10163", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Subject, Two patients, ages 40 and 51 years. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "7639655_4_10164", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "interferon alfa"}, {"id": "7639655_4_10165", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "7639655_4_10166", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "7639655_4_10167", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "7639655_4_10168", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7639655_4_10169", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "7639655_4_10170", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "malignant neoplasms"}, {"id": "7639655_4_10171", "context": "PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with interferon alfa for malignant neoplasms experienced sudden bilateral, sequential visual loss with disc-related field defects and segmental optic disc edema.", "question": "adverse event. Treatment, interferon alfa. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14968106_2_10172", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "doxorubicin"}, {"id": "14968106_2_10173", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14968106_2_10174", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14968106_2_10175", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "intrathecal injection"}, {"id": "14968106_2_10176", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14968106_2_10177", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14968106_2_10178", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14968106_2_10179", "context": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin.", "question": "adverse event. Treatment, intrathecal injection of doxorubicin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "14522628_1_10180", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "ganciclovir"}, {"id": "14522628_1_10181", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "14522628_1_10182", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "14522628_1_10183", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "14522628_1_10184", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "14522628_1_10185", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "14522628_1_10186", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "14522628_1_10187", "context": "Generalised cutaneous rash associated with ganciclovir therapy has rarely been reported in literature.", "question": "adverse event. Treatment, ganciclovir therapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "129501_1_10188", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Subject, cases. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "129501_1_10189", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Subject, cases. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "129501_1_10190", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Subject, cases. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "129501_1_10191", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Subject, cases. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "129501_1_10192", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Subject, cases. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "129501_1_10193", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "chymopapain"}, {"id": "129501_1_10194", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "129501_1_10195", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "129501_1_10196", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "injection"}, {"id": "129501_1_10197", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "129501_1_10198", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "129501_1_10199", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "129501_1_10200", "context": "Anaphylaxis after the injection of chymopapain occurs in about 1% of such cases.", "question": "adverse event. Treatment, the injection of chymopapain. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "9253492_3_10201", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Subject, a child. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "child"}, {"id": "9253492_3_10202", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Subject, a child. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "9253492_3_10203", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Subject, a child. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "9253492_3_10204", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Subject, a child. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "9253492_3_10205", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Subject, a child. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "9253492_3_10206", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "zonisamide"}, {"id": "9253492_3_10207", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "9253492_3_10208", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "9253492_3_10209", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "9253492_3_10210", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "9253492_3_10211", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "9253492_3_10212", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "9253492_3_10213", "context": "Heat stroke-like episode in a child caused by zonisamide.", "question": "adverse event. Treatment, zonisamide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18166746_7_10214", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "methylene blue; serotonergic agents"}, {"id": "18166746_7_10215", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18166746_7_10216", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18166746_7_10217", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18166746_7_10218", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18166746_7_10219", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18166746_7_10220", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18166746_7_10221", "context": "An interaction between methylene blue and serotonergic agents may give rise to the serotonin syndrome.", "question": "adverse event. Treatment, methylene blue and serotonergic agents. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "serotonergic agents; methylene blue"}, {"id": "11236070_2_10222", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Subject, in some patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "11236070_2_10223", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Subject, in some patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "11236070_2_10224", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Subject, in some patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "11236070_2_10225", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Subject, in some patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "11236070_2_10226", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Subject, in some patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "11236070_2_10227", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "olanzapine"}, {"id": "11236070_2_10228", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11236070_2_10229", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11236070_2_10230", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11236070_2_10231", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11236070_2_10232", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11236070_2_10233", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11236070_2_10234", "context": "These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.", "question": "adverse event. Treatment, olanzapine treatment. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18371508_1_10235", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "pegylated interferon alpha-2a; ribavirin"}, {"id": "18371508_1_10236", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18371508_1_10237", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18371508_1_10238", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18371508_1_10239", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18371508_1_10240", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18371508_1_10241", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18371508_1_10242", "context": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.", "question": "adverse event. Treatment, pegylated interferon alpha-2a and ribavirin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "pegylated interferon alpha-2a; ribavirin"}, {"id": "16620273_1_10243", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "metformin"}, {"id": "16620273_1_10244", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16620273_1_10245", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16620273_1_10246", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16620273_1_10247", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16620273_1_10248", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16620273_1_10249", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "Type 2 diabetes"}, {"id": "16620273_1_10250", "context": "CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis.", "question": "adverse event. Treatment, metformin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18037876_3_10251", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Subject, patient with primary plasma-cell leukemia. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18037876_3_10252", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Subject, patient with primary plasma-cell leukemia. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18037876_3_10253", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Subject, patient with primary plasma-cell leukemia. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18037876_3_10254", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Subject, patient with primary plasma-cell leukemia. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18037876_3_10255", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Subject, patient with primary plasma-cell leukemia. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18037876_3_10256", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "thalidomide"}, {"id": "18037876_3_10257", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18037876_3_10258", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18037876_3_10259", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18037876_3_10260", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "18037876_3_10261", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18037876_3_10262", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "primary plasma-cell leukemia"}, {"id": "18037876_3_10263", "context": "Sustained ventricular tachycardia in a thalidomide-treated patient with primary plasma-cell leukemia.", "question": "adverse event. Treatment, thalidomide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "10579985_3_10264", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Subject, a 29-year-old man with CD. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "29-year-old"}, {"id": "10579985_3_10265", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Subject, a 29-year-old man with CD. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "man"}, {"id": "10579985_3_10266", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Subject, a 29-year-old man with CD. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "10579985_3_10267", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Subject, a 29-year-old man with CD. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "10579985_3_10268", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Subject, a 29-year-old man with CD. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "10579985_3_10269", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "infliximab"}, {"id": "10579985_3_10270", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "10579985_3_10271", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "10579985_3_10272", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "infusion"}, {"id": "10579985_3_10273", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "3 weeks"}, {"id": "10579985_3_10274", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "10579985_3_10275", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "CD"}, {"id": "10579985_3_10276", "context": "The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.", "question": "adverse event. Treatment, 3 weeks after infusion with infliximab. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "16317298_6_10277", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "gemcitabine"}, {"id": "16317298_6_10278", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "16317298_6_10279", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "16317298_6_10280", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "16317298_6_10281", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "16317298_6_10282", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "16317298_6_10283", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "16317298_6_10284", "context": "We suggest discontinuing gemcitabine if radiation recall is observed.", "question": "adverse event. Treatment, discontinuing gemcitabine. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "18523232_4_10285", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Subject, a patient. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "18523232_4_10286", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Subject, a patient. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "18523232_4_10287", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Subject, a patient. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "18523232_4_10288", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Subject, a patient. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "18523232_4_10289", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Subject, a patient. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "18523232_4_10290", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "itraconazole"}, {"id": "18523232_4_10291", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "18523232_4_10292", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "18523232_4_10293", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "18523232_4_10294", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "24 weeks"}, {"id": "18523232_4_10295", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "18523232_4_10296", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "18523232_4_10297", "context": "OBJECTIVE: To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.", "question": "adverse event. Treatment, pulse itraconazole therapy for 24 weeks. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "7712052_6_10298", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Subject, patients with PTSD. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": ""}, {"id": "7712052_6_10299", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Subject, patients with PTSD. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "7712052_6_10300", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Subject, patients with PTSD. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "7712052_6_10301", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Subject, patients with PTSD. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "7712052_6_10302", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Subject, patients with PTSD. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "7712052_6_10303", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "lithium"}, {"id": "7712052_6_10304", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": ""}, {"id": "7712052_6_10305", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": ""}, {"id": "7712052_6_10306", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "7712052_6_10307", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "7712052_6_10308", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": ""}, {"id": "7712052_6_10309", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": "PTSD"}, {"id": "7712052_6_10310", "context": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD.", "question": "potential therapeutic event. Treatment, lithium. Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "6928097_1_10311", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Subject, She. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6928097_1_10312", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Subject, She. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "She"}, {"id": "6928097_1_10313", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Subject, She. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "6928097_1_10314", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Subject, She. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6928097_1_10315", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Subject, She. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6928097_1_10316", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "Adriamycin"}, {"id": "6928097_1_10317", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6928097_1_10318", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6928097_1_10319", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": "chemotherapy"}, {"id": "6928097_1_10320", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": "6 months"}, {"id": "6928097_1_10321", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6928097_1_10322", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6928097_1_10323", "context": "She was placed on adjuvant Adriamycin (doxorubicin) chemotherapy, but 6 months later died of Adriamycin toxicity.", "question": "adverse event. Treatment, adjuvant Adriamycin (doxorubicin) chemotherapy. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "12477460_2_10324", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": "postmenopausal"}, {"id": "12477460_2_10325", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": "woman"}, {"id": "12477460_2_10326", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12477460_2_10327", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12477460_2_10328", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Subject, a postmenopausal woman. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "12477460_2_10329", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tamoxifen"}, {"id": "12477460_2_10330", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12477460_2_10331", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12477460_2_10332", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12477460_2_10333", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12477460_2_10334", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12477460_2_10335", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "an endometriotic cyst"}, {"id": "12477460_2_10336", "context": "BACKGROUND: Ovarian cancer arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy is rare.", "question": "adverse event. Treatment, tamoxifen. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "15368548_1_10337", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "L-asparaginase"}, {"id": "15368548_1_10338", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "15368548_1_10339", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "15368548_1_10340", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "15368548_1_10341", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "15368548_1_10342", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "15368548_1_10343", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "leukemia"}, {"id": "15368548_1_10344", "context": "L-asparaginase-induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia.", "question": "adverse event. Treatment, L-asparaginase. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "21515865_3_10345", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Subject, An 89-year-old man. Subject.Age?", "question_type": "Potential_therapeutic_event.Subject.Age", "answers": "89-year-old"}, {"id": "21515865_3_10346", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Subject, An 89-year-old man. Subject.Gender?", "question_type": "Potential_therapeutic_event.Subject.Gender", "answers": ""}, {"id": "21515865_3_10347", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Subject, An 89-year-old man. Subject.Population?", "question_type": "Potential_therapeutic_event.Subject.Population", "answers": ""}, {"id": "21515865_3_10348", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Subject, An 89-year-old man. Subject.Race?", "question_type": "Potential_therapeutic_event.Subject.Race", "answers": ""}, {"id": "21515865_3_10349", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Subject, An 89-year-old man. Subject.Disorder?", "question_type": "Potential_therapeutic_event.Subject.Disorder", "answers": ""}, {"id": "21515865_3_10350", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Treatment.Drug?", "question_type": "Potential_therapeutic_event.Treatment.Drug", "answers": "warfarin sodium"}, {"id": "21515865_3_10351", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Treatment.Dosage?", "question_type": "Potential_therapeutic_event.Treatment.Dosage", "answers": "19 mg"}, {"id": "21515865_3_10352", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Treatment.Freq?", "question_type": "Potential_therapeutic_event.Treatment.Freq", "answers": "weekly"}, {"id": "21515865_3_10353", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Treatment.Route?", "question_type": "Potential_therapeutic_event.Treatment.Route", "answers": ""}, {"id": "21515865_3_10354", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Treatment.Time_elapsed?", "question_type": "Potential_therapeutic_event.Treatment.Time_elapsed", "answers": ""}, {"id": "21515865_3_10355", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Treatment.Duration?", "question_type": "Potential_therapeutic_event.Treatment.Duration", "answers": "long-term"}, {"id": "21515865_3_10356", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Treatment.Disorder?", "question_type": "Potential_therapeutic_event.Treatment.Disorder", "answers": ""}, {"id": "21515865_3_10357", "context": "An 89-year-old man receiving long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg) arrived at the anticoagulation clinic for his monthly visit.", "question": "potential therapeutic event. Treatment, long-term anticoagulation with warfarin sodium (total weekly dosage of 19 mg). Combination.Drug?", "question_type": "Potential_therapeutic_event.Combination.Drug", "answers": ""}, {"id": "12851279_14_10358", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Subject, patients with severe sepsis and high INR. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "12851279_14_10359", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Subject, patients with severe sepsis and high INR. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "12851279_14_10360", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Subject, patients with severe sepsis and high INR. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": ""}, {"id": "12851279_14_10361", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Subject, patients with severe sepsis and high INR. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "12851279_14_10362", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Subject, patients with severe sepsis and high INR. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": "high INR"}, {"id": "12851279_14_10363", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "tifacogin"}, {"id": "12851279_14_10364", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "12851279_14_10365", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "12851279_14_10366", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "12851279_14_10367", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "12851279_14_10368", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "12851279_14_10369", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": "sepsis"}, {"id": "12851279_14_10370", "context": "Treatment with tifacogin had no effect on all-cause mortality in patients with severe sepsis and high INR.", "question": "adverse event. Treatment, tifacogin. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "6572542_1_10371", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Subject, three patients. Subject.Age?", "question_type": "Adverse_event.Subject.Age", "answers": ""}, {"id": "6572542_1_10372", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Subject, three patients. Subject.Gender?", "question_type": "Adverse_event.Subject.Gender", "answers": ""}, {"id": "6572542_1_10373", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Subject, three patients. Subject.Population?", "question_type": "Adverse_event.Subject.Population", "answers": "three"}, {"id": "6572542_1_10374", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Subject, three patients. Subject.Race?", "question_type": "Adverse_event.Subject.Race", "answers": ""}, {"id": "6572542_1_10375", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Subject, three patients. Subject.Disorder?", "question_type": "Adverse_event.Subject.Disorder", "answers": ""}, {"id": "6572542_1_10376", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "CCNU"}, {"id": "6572542_1_10377", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "6572542_1_10378", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "6572542_1_10379", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "6572542_1_10380", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "6572542_1_10381", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "6572542_1_10382", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "6572542_1_10383", "context": "Although lung specimens were lacking from these three patients, it is suggested that the pulmonary toxicity of CCNU may be dose-related.", "question": "adverse event. Treatment, CCNU. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}, {"id": "11452245_11_10384", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "clarithromycin; potent inhibitors of CYP3A4; repaglinide"}, {"id": "11452245_11_10385", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "11452245_11_10386", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "11452245_11_10387", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "11452245_11_10388", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "11452245_11_10389", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "11452245_11_10390", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "11452245_11_10391", "context": "Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.", "question": "adverse event. Treatment, Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": "clarithromycin; repaglinide; potent inhibitors of CYP3A4"}, {"id": "1888256_1_10392", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Drug?", "question_type": "Adverse_event.Treatment.Drug", "answers": "diltiazem"}, {"id": "1888256_1_10393", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Dosage?", "question_type": "Adverse_event.Treatment.Dosage", "answers": ""}, {"id": "1888256_1_10394", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Freq?", "question_type": "Adverse_event.Treatment.Freq", "answers": ""}, {"id": "1888256_1_10395", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Route?", "question_type": "Adverse_event.Treatment.Route", "answers": ""}, {"id": "1888256_1_10396", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Time_elapsed?", "question_type": "Adverse_event.Treatment.Time_elapsed", "answers": ""}, {"id": "1888256_1_10397", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Duration?", "question_type": "Adverse_event.Treatment.Duration", "answers": ""}, {"id": "1888256_1_10398", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Treatment.Disorder?", "question_type": "Adverse_event.Treatment.Disorder", "answers": ""}, {"id": "1888256_1_10399", "context": "Drug-induced fever due to diltiazem.", "question": "adverse event. Treatment, diltiazem. Combination.Drug?", "question_type": "Adverse_event.Combination.Drug", "answers": ""}]}